Molecular Biology of Cancer

This page intentionally left blank





Molecular Biology of Cancer

Mechanisms, Targets, and Therapeutics

THIRD EDITION

Lauren Pecorino

University of Greenwich

1

1

Great Clarendon Street, Oxford, OX2 6DP,

United Kingdom

Oxford University Press is a department of the University of Oxford.

It furthers the University’s objective of excellence in research, scholarship, and education by publishing worldwide. Oxford is a registered trade mark of Oxford University Press in the UK and in certain other countries

© Lauren Pecorino 2012

The moral rights of the author have been asserted

First Edition copyright 2005

Second Edition copyright 2008

Impression: 1

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of Oxford University Press, or as expressly permitted by law, by licence or under terms agreed with the appropriate reprographics rights organization. Enquiries concerning reproduction outside the scope of the above should be sent to the Rights Department, Oxford University Press, at the address above

You must not circulate this work in any other form

and you must impose this same condition on any acquirer

British Library Cataloguing in Publication Data

Data available

Library of Congress Cataloging in Publication Data

Library of Congress Control Number: 2012932747

ISBN 978–0–19–957717–0

Printed in Italy on acid-free paper by

L.E.G.O. S.p.A.—Lavis TN

Links to third party websites are provided by Oxford in good faith and for information only. Oxford disclaims any responsibility for the materials contained in any third party website referenced in this work.

This book is dedicated to my mentors:

Raffaela and Joseph Pecorino

Professor Frank Erk

Professor Sidney Strickland

Professor Jeremy Brockes

In memory of:

Marie Favia

Mildred Maiello

Kerry O’Neill

This page intentionally left blank

■ PREFACE

Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics is intended for both undergraduate and graduate-level students (including medical students) and employees in the pharmaceutical industry interested in learning about how a normal cell becomes transformed into a cancer cell. Signaling pathways of a cell detect and respond to changes in the environment and regulate normal cellular activities. Cells contain many receptors on their membrane that allow a signal from outside the cell (e.g. growth factors) to be transmitted to the inside of the cell. Signaling pathways are composed of molecules that interact with other molecules, whereby one triggers the next in a sequence, in a way similar to the actions of team members in a relay race. The relay of information may cause a change in cell behavior or in gene expression, and results in a cellular response (e.g. cell growth). Interference in these signal transduction pathways has grave consequences (e.g. unregulated cell growth) and may lead to the transformation of a normal cell into a cancer cell. The identifi -

cation of the malfunctions of specifi c pathways involved in carcinogenesis provides scientists with molecular targets that can be used to generate new cancer therapeutics. I have chosen to present the biology of cancer together with a promise for its application towards designing new cancer drugs. Therefore, for most chapters in the text, the fi rst half discusses the cell and molecular biology of a specifi c hallmark of cancer and the last half of the chapter discusses therapeutic strategies. To help form a link between particular molecular targets discussed in the fi rst half of the chapter and the therapeutic strategies discussed in the last half of the chapter, a target symbol () is shown in the margin. I hope that this presentation stimulates interest and motivates learning of the subject matter.

Several new topics have been added to this third edition. They include: an update on the hallmarks of cancer, chromothripsis, strategies that target DNA repair, microRNAs, and reprogramming energy metabolism.

Deservedly, a section on the immune system has been added to the chapter on infection and infl ammation and a section on pharmacogenetics has been added to the discussion about the cancer industry in Chapter 12, a chapter that may be valuable for special career interests and supplementary for some cancer courses. The fi nal chapter, “Cancer in the future”, focuses on cancer vaccines and technology.

Personally, I believe that the use of diagrams and illustrations is an extremely powerful tool of learning. A picture paints a thousand words . . .

and more. I strongly suggest that the reader studies and enjoys the fi gures, artistically created by Joseph Pecorino. Major points and new cancer

viii

P R E FAC E

therapeutics are illustrated in red, and the target symbol () is used to identify molecular targets. Detailed descriptions of the fi gures are found in the body of the text. This edition contains the inclusion of additional color plates of experimental data.

Several features that are used throughout the text to facilitate learning and interest are described below:

Pause and think

These features are often presented in the margins of the text and are designed to engage the reader in thought and to present additional perspectives of core concepts. Many times questions are posed; sometimes they are answered and other times they encourage the rereading of particular sections of text.

How do we know that?

These features examine experimental evidence from the scientifi c literature and ask the reader to analyze raw data or understand the details of an experimental protocol.

Special interest boxes

Shaded boxes are used to highlight special topics of interest such as the box entitled “Skin cancer” in Chapter 2. They are also used to provide additional explanation of more complex subjects such as “A little lesson about ROS . . .” in Chapter 2, and “A little lesson about the MAP kinase family . . .” in Chapter 4.

Lifestyle tips

These are suggestions about lifestyle choices and habits to minimize cancer risk, based on our current knowledge.

Leaders in the fi eld of . . .

Scientists around the world have made contributions to the concepts presented in this text. Short biographies of several leading scientists, including their major contributions to a particular fi eld of cancer biology, are presented. This feature is meant to give a human touch to the text. It may also be used as a tool for professional use and for following a continuing interest in the research literature. It may be of interest to listen to leading scientists in a particular subject area by attending scientifi c conferences.

P R E FAC E ix

Analysis of . . .

Specifi c molecular techniques used to analyze particular biological and cellular events are described. It is important that science and medical professionals ask themselves “How do we know that?”. Each of the major concepts underlying our current state of knowledge is the result of numerous experiments that generate data, suggesting possible explanations and mechanisms of cellular events. The information retrieved is governed by the techniques that are used for analysis.

Chapter highlights: refresh your memory

Summary points are listed in order to consolidate major concepts and provide a brief overview of the chapter. These may be particularly useful for revising for examinations.

Self tests and activities

Several features are included to strengthen your understanding of particular concepts presented in the chapter: Self tests presented within the text ask you to immediately reinforce material just presented and often refer to a fi gure. This causes a break from reading and engages you, the student, in

“active” learning. Activities that are aimed at strengthening your understanding of particular concepts and encouraging additional self-centered learning are presented towards the end of a chapter. Some require web-based research, while others are more refl ective. Multiple choice questions can be found on the companion website.

Further reading is a list of general references found at the end of each chapter. These references consist mostly of reviews and support the contents of the chapter. They are not referenced in the main body of the text.

Selected special topics mainly lists specifi c primary research papers that are referenced in the main body of the text and may be pursued for further interest. Several relevant web sites are also included.

Appendix 1 is a summary diagram that links key molecular pathways to the cell cycle.

Appendix 2 lists centers of cancer research as a starting point for search-ing for research posts and employment in the fi eld. Entries are separated by location (USA and UK).

x

P R E FAC E

Glossary

Over 160 entries are defi ned in a clear and concise manner in order to provide students with a handy reference point for fi nding explanations of unfamiliar words.

It is my hope that the readers of this text will learn something new, become interested in something molecular, and ultimately, somehow, contribute to the fi eld of cancer biology. This fi eld is evolving at a tremendous rate, and so by the time of printing the information contained within these pages will need to be updated! This does not concern me because my aim is to present a process of how the pieces of science are put together and how we may attempt to apply our knowledge to cancer therapies. Many new drugs will fail but a select few will not. These select few will make marked improvements in the quality of life for many.

New to this edition

• Updates on the hallmarks of cancer and metastasis.

• New topics covered, including chromothripsis, the therapeutic potential of gene signatures, microRNAs, and reprogramming energy metabolism.

• Additional background information and enhanced explanation of immunology.

■ ACKNOWLEDGMENTS

First, I would like to express my deepest gratitude to Jonathan Crowe, Commissioning Editor, at Oxford University Press (OUP). I am indebted to him for his faith that I could turn a one-page proposal into a complete textbook for the fi rst edition and for his continued support during the writing of the following editions. He nurtured the synthesis of the book with special care, and provided a wealth of helpful suggestions and advice.

With love, I thank my father, Joseph Pecorino, for his never-ending encouragement and I acknowledge his artistic talent used to translate doz-ens of my stick drawings into precise illustrations for the book during our visits across the Atlantic Ocean over the years. Stephen Crumly kindly reproduced the illustrations using his fi ne skills in computer graphics under tight deadlines. Thanks to Philippa Hendry, Production Editor, and her production staff, and Dewi Jackson and Sarah Broadly for additional assistance at Oxford University Press. I also thank Jayne MacArthur for her careful proofreading of the book.

Kind appreciation is expressed for the precise and critical comments given by my offi cial reviewers for the fi rst edition: Tony Bradshaw, Oxford Brookes University, UK; Moira Galway, St Francis Xavier University, Canada; Maria Jackson, University of Glasgow, UK; Helen James, University of East Anglia (UEA), UK; and Ian Judson, Cancer Research UK, London, UK. The value added to the text by these scientists cannot be underestimated. Their comments have had tremendous impact and provided a foundation for the second edition. Special thanks is expressed for the critical comments given by my offi cial reviewers for new chapters of the second edition—Michael Carty, NUI Galway, Irish Republic; from the UK: Joanna Wilson, Glasgow, Jonathan Bard, Edinburgh, Phillipa Dar-bre, Reading, Stephanie McKeown, Ulster, Penka Nikolova, KCL, Elana Klenova, Essex; from the USA: Annemarie Bettica, Manhattanville College, Nancy Bachman, Oneonta, and James Olesen, Ball State University.

Kind appreciation is expressed to my most recent set of reviewers: Roger Barraclough, University of Liverpool; Helen Coley, University of Surrey; Meg Duroux, Aalborg University; Paula M. Checchi, University of California, Davis; Jill Johnston, The University of Sydney; Tapas K. Sengupta, Indian Institute of Science Education and Research (IISER), Kolkata; Paola Marignani, Dalhousie University; Andrew Sharrocks, University of Manchester; and Alicia F. Paulson, University of South Dakota.

I thank Rita Canipari, Ken Douglas, Dario Tuccinardi, Ricky Rickles, Anne Schuind, and Sarah Thurston for providing unoffi cial scientifi c

xii

AC K N O W L E D G M E N T S

critical comments to previous editions and Dylan Edwards, UEA, Nicole Bournias-Vardiabasis, University of Californa at San Bernadino, and Young-Joon Surh, Seoul National University, for suggestions to previous editions.

Many improvements in the third edition are a result of casual feedback from many people from different places—so many thanks to all of you and apologies to those I have not named. I thank my colleagues, Babs Chowdhry, Mark Edwards, John Spencer, and Laurence Harbige for suggestions and communicating cancer news. Special thanks also to the Dean of School, Martin Snowden, for his support of this project. I am thankful for suggestions and literature reviews from former students of the University of Greenwich, Kenny Pratt, and Stephen O’Grady.

I acknowledge the fi nancial support of the School of Science, University of Greenwich, and The Biochemical Society to attend the American

Association of Cancer Research (AACR) Annual Meetings over the last few years. The information gained and contacts made were important

resources for this edition. Appreciation for their kind gestures of support of this textbook is given to Samuel Adunyah, Meharry Medical College; David Axelrod, Rutgers; Michael Caligiuri, Ohio State University; Jules Harris, University of Arizona; and Candace Ritchie, Merck, who I met at these conferences.

Many fellow scientists have made suggestions or other contributions to the book, including: Jeremy Griggs, several members of the Kuriyan

Laboratory, David Lyden, Weil Cornell Medical College, Gerd Pfeifer, Mariann Rand-Weaver, and Jerry Shay. Special thanks are expressed to Andrea Cossarizza, Sarah Cowan, Xiuhuai Liu, M.-A. Shibata, and Kelly Dobben-Annis for helping me to obtain electronic fi gures. The Royal Society of Medicine Library, London, provided an ideal scientifi c sanctuary.

I am especially grateful to the support that came from my family, especially Raffaela Pecorino and Teresa Rapillo, and from friends. I am grateful for the tremendous support given by Marcus Gibson.

I admire and acknowledge the work of all those scientists whose

research efforts have contributed to the fi eld of cancer research.

■ OUTLINE CONTENTS



1 Introduction

1



2

DNA structure and stability: mutations versus repair 21



3

Regulation of gene expression 53



4

Growth factor signaling and oncogenes 77



5

The cell cycle 103



6

Growth inhibition and tumor suppressor genes 123



7 Apoptosis 149



8

Stem cells and differentiation 173



9 Metastasis 197

10

The immune system, infections, and infl ammation 225

11

Nutrients, hormones, and gene interactions 253

12

The cancer industry: drug development, pharmacogenomics,

and clinical trial design 283

13

Cancer in the future: focus on cancer vaccines and technology 299

APPENDIX 1: CELL CYCLE REGULATION

321

APPENDIX 2: CENTERS FOR CANCER RESEARCH

323

GLOSSARY

327

INDEX

337

This page intentionally left blank





■ DETAILED CONTENTS



1 Introduction

1

1.1 What is cancer?

2

1.2 Evidence suggests that cancer is a disease of the genome

at the cellular level

5

1.3 Infl uential factors in human carcinogenesis 10

1.4 Principles of conventional cancer therapies 13

1.5 Clinical

trials 15

1.6 The role of molecular targets in cancer therapies 16



2

DNA structure and stability: mutations versus repair 21

2.1 Gene structure—two parts of a gene: the regulatory region and

the coding region 22

2.2 Mutations 23

2.3 Carcinogenic

agents 25

2.4 DNA repair and predispositions to cancer 38

Therapeutic strategies

42

2.5 Conventional therapies: chemotherapy and radiation therapy 42

2.6 Strategies that target DNA repair pathways 47



3

Regulation of gene expression 53

3.1 Transcription factors and transcriptional regulation 53

3.2 Chromatin

structure 59

3.3 Epigenetic regulation of transcription 60

3.4 Evidence of a role for epigenetics in carcinogenesis 63

3.5 Telomeres and telomerase 66

3.6 MicroRNAs (miRNAs) and regulation of mRNA expression 69

Therapeutic strategies

70

3.7 Epigenomic and histonomic drugs 70

3.8 Telomerase

inhibitors 72



4

Growth factor signaling and oncogenes 77

4.1 Epidermal growth factor signaling: an important paradigm 77

4.2 Oncogenes 86

xvi

D E TA I L E D C O N T E N T S

Therapeutic strategies

95

4.3 Kinases as drug targets 95



5

The cell cycle 103

5.1 Cyclins and cyclin-dependent kinases (cdks) 104

5.2 Mechanisms of cdk regulation 107

5.3 Progression through the G1 checkpoint 109

5.4 The

G2 checkpoint 111

5.5 The mitotic checkpoint 112

5.6 The cell cycle and cancer 114

Therapeutic strategies

117

5.7 Cyclin-dependent kinase inhibitors 117

5.8 Other cell cycle kinase targets 118

5.9 Inhibitors of the mitotic spindle 118



6

Growth inhibition and tumor suppressor genes 123

6.1 Defi nitions of tumor suppressor genes 123

6.2 The retinoblastoma gene 127

6.3 Mutations in the RB pathway and cancer 129

6.4 The p53 pathway 129

6.5 Mutations in the p53 pathway and cancer 137

6.6 Interaction of DNA viral protein products with RB and p53 139

Therapeutic strategies

141

6.7 Targeting of the p53 pathway 141



7 Apoptosis 149

7.1 Molecular mechanisms of apoptosis 150

7.2 Apoptosis and cancer 160

7.3 Apoptosis and chemotherapy 164

Therapeutic strategies

165

7.4 Apoptotic

drugs 165



8

Stem cells and differentiation 173

8.1 Stem cells and cancer 174

8.2 Differentiation and the regulation of transcription 184

Therapeutic strategies

189

8.3 Inhibitors of the Wnt pathway 190

8.4 Inhibitors of the Hh pathway 191

8.5 Leukemia and differentiation therapies 192

D E TA I L E D C O N T E N T S xvii



9 Metastasis 197

9.1

The process of metastasis 198

9.2

Tools of cell invasion: cell adhesion molecules, integrins, and proteases 199

9.3 Intravasation 203

9.4 Transport 203

9.5 Extravasation 204

9.6 Metastatic

colonization 205

9.7 Angiogenesis 206

9.8

Other means of tumor neovascularization 212

Therapeutic strategies

212

9.9

Metalloproteinase inhibitors (MPIs) 213

9.10 Strategies for restoring metastasis suppressors 214

9.11 Anti-angiogenic therapy and vascular targeting 214

9.12 Targeting several steps of metastasis at once 220

10

The immune system, infections, and infl ammation 225

10.1 The immune system and cancer 226

10.2 Identifying infectious agents as carcinogens 230

10.3 Infl ammation and cancer 237

Therapeutic strategies

243

10.4 A national vaccination program against hepatitis B virus in Taiwan 244

10.5 Eradication

of

H. pylori and the relationship to prevention





of gastric cancer

244

10.6 Cancer vaccines to prevent cervical cancer 245

10.7 Inhibition of infl ammation 246

11

Nutrients, hormones, and gene interactions 253

11.1 Causative

factors 255

11.2 Preventative factors: microconstituents of fruits and vegetables 259

11.3 Reprogramming energy metabolism in tumor cells—an emerging

hallmark of cancer 265

11.4 Genetic polymorphisms and diet 268

11.5 Vitamin D: a link between nutrients and hormone action 269

11.6 Hormones and cancer 271

Therapeutic strategies

274

11.7 “Enhanced” foods and dietary supplements for chemoprevention 274

11.8 Drugs that target energy pathways 276

11.9 Drugs that target estrogen 276

xviii

D E TA I L E D C O N T E N T S

12

The cancer industry: drug development, pharmacogenomics,

and clinical trial design 283

12.1 Strategies of drug development 283

12.2 Development of imatinib 287

12.3 Second- and third-generation therapeutics 288

12.4 Pharmacogenomics 290

12.5 Improved clinical trial design 292

12.6 A career in cancer research 295

13

Cancer in the future: focus on cancer vaccines and technology

299

13.1 Cancer

vaccines 300

13.2 Microarrays and gene expression profi ling 306

13.3 Diagnostics and prognostics 308

13.4 Imaging 310

13.5 Personalized medicine and bioinformatics 311

13.6 Cancer

nanotechnology 313

13.7 Treating cancer symptoms 314

13.8 Are we making progress? 315

APPENDIX 1: CELL CYCLE REGULATION

321

APPENDIX 2: CENTERS FOR CANCER RESEARCH

323

GLOSSARY

327

INDEX

337





Chapter 1

Introduction

Introduction

The aim of this text is to provide a foundation in the molecular biology of cancer and to demonstrate the conceptual process that is being pursued in order to design more specifi c cancer drugs. Common threads are woven throughout the different chapters so that the terminology becomes familiar and the mechanisms of cellular processes become clear.

The text also provides guidance for everyday decisions that may lead to a decrease in cancer risk. The translation of the knowledge of molecular pathways into clinically important therapies (linked throughout the text by the target symbol, ““) will be communicated and will breathe excitement into learning. Academically, you will gain a foundation in the cell and molecular biology of cancer. More importantly, you will develop an intellectual framework upon which you can add new discoveries that will interest you throughout your lifetime. My goal in writing this book is to inspire. It would be most gratifying for me if, by reading this book, you, the reader, will be compelled to contribute to the cancer research fi eld directly. Knowledge is powerful.

Cancer statistics are shocking. One in three people is likely to suffer from cancer during their lifetime. Siegel et al. (2011) estimated that 571, 950 Americans would die from cancer in 2011, and the mortality rate (number of cancer deaths per year per 100 000 people) was over 200 for men in the UK in 2008 (Summary June 2011, Cancer Research, UK). The worldwide incidence (number of new cases) was estimated to be about 12.7 million cases in 2008 (Jemal et al. , 2011). These numbers are cold, stark, and impersonal. Hidden behind them are tears, fears, pain, and loss. No one is excluded from the risk. There is a need to understand the disease and to translate our knowledge into effective therapies. In order to understand the process of carcinogenesis, whereby a normal cell is transformed into a cancer cell, we must know the intricacies of cell function and the molecular pathways that underlie it. We must consider the cell in the context of the entire body. We have a lot to learn! However, knowledge of the molecular details in important cellular and biochemical pathways can be applied to a new wave of cancer therapies. What better reward for these efforts?





2 1: INTRODUCTION

1.1 What is cancer?

Cancer is a group of diseases characterized by unregulated cell growth and the invasion and spread of cells from the site of origin, or primary site, to other sites in the body. Several points within this defi nition need to be emphasized. First, cancer is considered to be a group of diseases. Over 100

types of cancer have been classifi ed. The tissue of origin gives the distinguishing characteristics of the cancer. Approximately 85% of cancers occur in epithelial cells and are classifi ed as carcinomas. Cancers derived from mesoderm cells (e.g. bone, muscle) are called sarcomas, and cancers of glandular tissue (e.g. breast) are called adenocarcinomas. Cancers of different origins have distinct features. For example, skin cancer has many characteristics that differ from lung cancer. The major factor that causes cancer in each target tissue is different: ultraviolet (UV) radiation from the sun can easily target the skin, while inhalation of cigarette smoke can target the lungs. In addition, as will be examined in detail later, there are differences in the molecular mechanisms involved in carcinogenesis within each cell type and the pattern of spread of cells from the primary site.

Treatment must be applied differently. Surgical removal of a cancerous growth is more amenable for the skin than the lungs. This initial view presents layers of complexity which may seem insurmountable to dissect in order to improve the conventional therapeutic approaches. However, even though the underlying cellular and molecular routes may be different, the end result is the same. In the year 2000, upon fi ne analysis, Hanahan and Weinberg defi ned six hallmarks of most, if not all, cancers. They proposed Growth signal

Evasion of growth

autonomy

inhibitory signals

Avoiding immune

Reprogramming

destruction

energy metabolism

Unlimited replicative

Evasion of cell death

potential

Figure 1.1 The hallmarks of

cancer. Reprinted and modifi ed

Genome instability

Tumor-promoting

from Hanahan, D. and Weinberg,

and mutation

inflammation

R.A. (2011) Hallmarks of cancer:

the next generation. Cell 100,

p. 646, copyright (2011), with

Invasion and

permission from Elsevier Science.

Angiogenesis

metastasis

See box on page 3.

1 . 1 W H AT I S C A N C E R ? 3

that acquiring the capability for autonomous growth signals, evasion of growth inhibitory signals, evasion of apoptotic cell death, unlimited replicative potential, angiogenesis (the formation of new blood vessels), and invasion and metastasis are essential for carcinogenesis. More recently, they have modifi ed their concept to include two enabling characteristics, genome instability and tumor-promoting infl ammation, that are crucial for acquiring the six hallmarks of cancer and they highlight two emerging hallmarks, reprogramming energy metabolism and avoiding immune

destruction (Hanahan and Weinberg, 2011). The last two processes are considered as emerging hallmarks because their relationship to the established six hallmarks mentioned previously requires further research, although there is evidence of their importance in carcinogenesis. Established hallmarks and emerging hallmarks, along with enabling characteristics (Figure 1.1) will be examined in detail in this text and each is a potential target pathway for the design of new therapeutics.

The hallmarks of cancer (see Figure 1.1)

• Growth signal autonomy:

– Normal cells need external signals from growth factors to divide

– Cancer cells are not dependent on normal growth factor signaling

– Acquired mutations short-circuit growth factor pathways leading to unregulated growth.

• Evasion of growth inhibitory signals:

– Normal cells respond to inhibitory signals to maintain homeostasis (most cells of the body are not actively dividing)

– Cancer cells do not respond to growth inhibitory signals

– Acquired mutations or gene silencing interfere with the inhibitory pathways.

• Avoiding immune destruction (emerging hallmark):

– There is evidence to support the theory of immune surveillance that states the immune system can recognize and eliminate cancer cells.

– Successful cancer cells may be those that do not stimulate an immune response or can interfere with the immune response so as to avoid immune destruction.

• Unlimited replicative potential:

– Normal cells have an autonomous counting device to defi ne a fi nite number of cell doublings after which they become senescent. This cellular counting device is the shortening of chromosomal ends, telomeres, that occurs during every round of DNA replication

– Cancer cells maintain the length of their telomeres

– Altered regulation of telomere maintenance results in unlimited replicative potential.

¼

4

1 : I N T R O D U C T I O N

•

¼

Tumor-promoting infl ammation (an enabling characteristic):

– Virtually all tumors contain infl ammatory immune cells

– Infl ammation is an immune response that can facilitate the ability of acquiring the core hallmarks of cancer. For example, infl ammatory cells can provide growth factors and enzymes that promote angiogenesis and invasion

– In addition, infl ammatory cells can release oxygen species that are mutagenic.

• Invasion and metastasis:

– Normal cells maintain their location in the body and generally do not migrate

– The movement of cancer cells to other parts of the body is a major cause of cancer deaths

– Alterations of the genome may affect the activity and/or levels of enzymes involved in invasion or molecules involved in cell–cell or cellular–extracellular adhesion.

• Angiogenesis (formation of new blood vessels):

– Normal cells depend on blood vessels to supply oxygen and nutrients but the vascular architecture is more or less constant in the adult

– Cancer cells induce angiogenesis, the growth of new blood vessels, needed for tumor survival and expansion

– Altering the balance between angiogenic inducers and inhibitors can activate the angiogenic switch.

• Genome instability and mutation (an enabling characteristic):

– Acquiring the core hallmarks of cancer usually depends on genomic alterations

– Faulty DNA repair pathways can contribute to genomic instability.

• Evasion of cell death:

– Normal cells are removed by apoptosis, often in response to DNA damage

– Cancer cells evade apoptotic signals.

• Reprogramming energy metabolism (emerging hallmark):

– Uncontrolled cell division demands increases in fuel and biosynthetic precursors that is obtained by adjusting energy metabolism

– Unlike normal cells, cancer cells carry out glycolysis even in the presence of oxygen. Glycolysis intermediates can be used in biosynthetic pathways.

PAUSE AND THINK

Cancer is characterized by unregulated cell growth and the invasion Why are malignant tumors life

and spread of cells from their site of origin. This leads to the distinction threatening? They are physical

between a benign tumor and a malignant tumor. A benign tumor is not obstructions and as they invade

evidence of cancer. Benign tumors do not spread throughout the body other organs they compromise

function. They also compete

(that is, they do not metastasize), although some can be life threatening fi ercely with healthy tissues for

because of their location (e.g. a benign brain tumor that may be diffi cult nutrients and oxygen.

to remove). Malignant tumors, on the other hand, do not remain encapsu-lated, show features of invasion, and metastasize.





1 . 2 E V I D E N C E S U G G E S T S T H AT C A N C E R I S A D I S E A S E O F T H E G E N O M E AT T H E C E L L U L A R L E V E L 5

Cancer cells can be distinguished from normal cells in cell culture conditions Normally, cells grow as a single layer, or monolayer, in a Petri dish due to a property called contact inhibition; contact with neighboring cells inhibits growth.

Transformed cells (cells that have become cancer cells) acquire the following phenotypes:

• they fail to exhibit contact inhibition and instead grow as piles of cells or “foci”

against a monolayer of normal cells

• they can grow in conditions of low serum

• they adopt a round morphology rather than a fl at and extended one

• they are able to grow without attaching to a substrate (e.g. the surface of a Petri dish), exhibiting “anchorage independence.”

1.2 Evidence suggests that cancer is a disease of the

genome at the cellular level

Interestingly, most agents that cause cancer (carcinogens) are agents that cause alterations to the DNA sequence or mutations (mutagens). Thus, similarly to all genetic diseases, cancer results from alterations in DNA. A large amount of evidence indicates that the DNA of tumor cells contains many alterations ranging from subtle point mutations (changes in a single base pair) to large chromosomal aberrations, such as deletions and chromosomal translocations. The accumulation of mutations in cells over time represents a multi-step process that underlies carcinogenesis. The requirement for an accumulation of mutations over time explains why there is an increased risk of cancer with age and why cancer has become more prevalent over the centuries as human lifespan has increased. There have been more cases of cancer in recent years because we are living longer. World life expectancy more than doubled over the past two centuries, from roughly 25 years to about 65 for men and 70 for women, and some populations, such as Japanese women, currently enjoy life expectancies of almost 85 years (data within Oeppen and Vaupel, 2002). The longer we live the more time there is for our DNA to accumulate mutations which may lead to cancer. There is evidence, however, that in a small percentage of tumors, a single catastrophic event in a cell can lead immediately to many mutations and cause cancer (described further in the next chapter). Interestingly, only 5–10% of the mutations observed are thought to be directly involved in causing cancer based upon mathematical modeling. This estimate provides the basis for the current optimism in the fi eld of molecular therapies. Almost all of the mutations identifi ed in tumor cells are somatic mutations whereby the DNA of a somatic (body) cell has been damaged. These mutations are not passed on to the next generation of offspring, and therefore cannot be inherited, but they are passed to daughter cells after cell division. Inheritable modifi cations of the genome and chromatin structure also play a role in

6

1 : I N T R O D U C T I O N

carcinogenesis (discussed in Chapter 3). Thus, cancer is considered to be a disease of the genome at the cellular level. Only alterations in the DNA of sperm or egg cells, called germline mutations, will be passed on to offspring. Some germline mutations can cause an increased risk of developing cancer but are rarely involved in causing cancer immediately.

Cancer cells continue to change their behavior as they progress. The progressive changes of a cell resulting from an accumulation of genetic mutations that confer a growth advantage over its neighbors proceeds in a fashion analogous to Darwinian evolution: chance events give rise to mutations that confer changes in phenotype and allow adaptation to the environment, resulting in the selection and survival of the fi ttest. This classifi es the mechanism of cancer as obeying “natural order” and being statistically inevitable, and is discussed at length by Mel Greaves in his book Cancer: The Evolutionary Legacy (2001). The accumulation of mutations occurs only after the cell’s defense mechanisms (e.g. DNA repair) have been evaded. Any alterations of DNA that are not repaired before the next cell division are passed on to the daughter cells and are perpetuated. The cell relies on several processes to repair damaged DNA.

In cases of severe DNA damage, cell suicide is induced in order to protect the whole body from cell transformation. The molecular details of these processes and the mutations that compromise them will be described in Chapters 2 and 7. Thus, many mechanisms exist for blocking carcinogenic events, but over-burdening the system increases the probability that a cell carrying a deleterious mutation will escape surveillance.

Growth, apoptosis, and differentiation regulate cell numbers

There are three important processes that contribute to the overall net cell number in an individual. First, cell proliferation (cell division, cell growth) is the most obvious. Cell division results in two daughter cells.

Second, the elimination of cells by programmed cell death also affects the net cell number. Last, during the process of differentiation cells can enter an inactive phase of cell growth and thus differentiation can affect net cell numbers. DNA mutations that alter the function of normal genes involved in growth, apoptosis, or differentiation can affect the balance of cell numbers in the body and lead to unregulated growth. Examine the simplistic model shown in Figure 1.2. If four of the nine cells shown in Figure 1.2(a) divide , and four are programmed to die by apoptosis , and one differentiates (so the cell neither dies nor divides) the cell number will remain the same (Figure 1.2b; remaining cells shown in red).

However, if apoptosis is blocked in one cell and that cell divides instead, the total number of cells will increase to 11 (Figure 1.2c). Similarly, if differentiation in a cell is blocked and that cell divides, as is the case in some leukemias, the number of cells will also increase. Thus, an alteration in

1 . 2 E V I D E N C E S U G G E S T S T H AT C A N C E R I S A D I S E A S E O F T H E G E N O M E AT T H E C E L L U L A R L E V E L 7

(a)

(b)

(c)

Figure 1.2 Growth, apoptosis,

and differentiation affect cell

number (see text for explanation).

the processes of growth, apoptosis, or differentiation can alter cell num-PAUSE AND THINK

bers. Normal genes that can be activated by mutation to be oncogenic are called proto-oncogenes. Proto-oncogenes play functional roles in normal So, is a mutation in the hemo-cells. The term reminds us that all normal cells have genes that have the globin gene likely to cause cancer? No, because the function of

potential to become oncogenic.

hemoglobin does not affect cell

growth, differentiation, or death

Oncogenes and tumor suppressor genes

and does not lead to unregu-

lated growth of blood cells. The

Growth is regulated by both positive and negative molecular factors.

hemoglobin gene is not a proto-

Thus, to increase growth, enhancement of positive factors or depletion of oncogene.

negative factors is required. Note these factors are products of genes and all cells, except egg and sperm cells, contain two alleles of every gene.

There are two major types of mutated genes that contribute to carcinogenesis: oncogenes and tumor suppressor genes (Figure 1.3). A general description of an oncogene is a gene mutated such that its protein product is produced in higher quantities, or has increased activity and therefore acts in a dominant manner to initiate tumor formation. “Dominant”

refers to the characteristic that a mutation in only one allele is suffi cient for an effect. For example, one oncogene produces increased quantities of a specifi c growth factor (e.g. platelet-derived growth factor) which stimulates growth inappropriately. Another example is an oncogene that produces a growth factor receptor with increased activity because it has been altered so that it is always in the “on” state and does not require growth factor to transduce a signal into the cell.

Tumor suppressor genes code for proteins that play a role in inhibiting both growth and tumor formation. Loss of growth inhibition occurs when

8

1 : I N T R O D U C T I O N

Dominant

Oncogene

Abnormal growth

(e.g. growth inducer)

Growth without

regulation

M

Recessive

Tumor suppressor gene

Abnormal growth

(e.g. growth inhibitor)

Loss of growth

inhibitor

M

M

Tumor suppressor gene

Haploinsufficient

Abnormal growth

(e.g. DNA repair protein)

Lower gene dose

Figure 1.3 Oncogenes and tumor

M

suppressor genes.

Identifi cation of oncogenes by cell transformation assays

The prototypical experiment used to demonstrate the presence of an oncogene is to test for cell transformation in culture. The DNA of interest is isolated and introduced into a standard cell line called NIH/3T3 (mouse fi broblast cells) by calcium phosphate precipitation or electroporation. If the test DNA contains an oncogene, foci (mentioned earlier) will form and will be easily identifi able against a monolayer of untransformed NIH/3T3 cells.

mutations cause a loss of function of these genes. Consequently, growth is permitted. Tumor suppressor mutations are mainly recessive in nature because one intact allele is usually suffi cient to inhibit growth; thus both alleles of the gene must be mutated before the loss of function is actually seen phenotypically. Recessive mutations support Knudson’s two-hit

hypothesis, the classical model used to explain the mechanism behind tumor suppressor action (see Chapter 6 and Figure 6.2). It states that both alleles need to be mutated (recessive) to trigger carcinogenesis. This model has been used to explain the mechanism behind conditions that predispose individuals to an increased risk of cancer. Patients inherit one mutated tumor suppressor allele and may acquire a second somatic mutation over time. Therefore, these patients have a “head start” towards a cancer phenotype in the race for accumulation of mutations. Recent evidence suggests there is an alternative mechanism for particular tumor suppressor genes, called haploinsuffi ciency, whereby only one mutated allele can lead to the cancer phenotype. As the term suggests, one normal allele produces half (“haplo-”) of the quantity of protein product produced by normal cells and this is not enough to suppress tumor formation in these

1 . 2 E V I D E N C E S U G G E S T S T H AT C A N C E R I S A D I S E A S E O F T H E G E N O M E AT T H E C E L L U L A R L E V E L 9

cases. This has been demonstrated for genes that regulate DNA repair and the DNA-damage response, such that reduced activity leads to genetic instability. Gene dosage may also affect the spectrum of tumors observed; haploinsuffi ciency may cause cancer in some cell types and recessive mutations may cause cancer in other cell types (Fodde and Smits, 2002).

Other exceptions to Knudson’s two-hit hypothesis will be discussed in Chapter 6.

All of the cancer cells in a patient arise from a single cell that contains an accumulation of initiating mutations; in other words, the development of cancer is clonal. It is generally assumed that only one of the 1014 cells in the body needs to be transformed in order to create a tumor. However, studies of adult stem cells have made recent contributions to our understanding of carcinogenesis. Stem cells are undifferentiated cells that have the ability to self-renew and produce differentiated progeny. Normal stem cells may be a main starting point for carcinogenesis in some cancers as both cancer cells and stem cells utilize, and rely on, self-renewal molecular programs. Also, cancer is more likely to develop in cells that are actively proliferating as there is a greater chance for mutations to accumulate; normal stem cells continue to proliferate over long periods of time. These concepts will be discussed further in Chapter 8.

The concepts described in this section suggest that cancer is a disease of the genome at the cellular level.

? HOW DO WE KNOW THAT?

Types of evidence

Gain-of-function evidence (“move it” evidence) is the

strongest type of evidence and is obtained when your factor of

Like all science, cancer biology depends on evidence. Gilbert’s

interest is moved to a new location and triggers a causative

textbook, Developmental Biology, classifi es evidence into three event at a time or place where it normally does not occur. This is

types: correlative evidence, loss-of-function evidence, and strong evidence. Recombinant DNA plasmids may be con-gain-of-function evidence.

structed whereby the coding region of a gene of interest is

Correlative evidence (“show it” evidence) documents obser-

placed under the control of a promoter that directs expression

vations between two events and weakly intimates that one may

of the gene in a different tissue or at a different time. DNA

cause the other. For example, a gene from a tumor sample has a

transfection of cells in culture and the production of transgenic

mutation compared with the same gene isolated from healthy

animals with such recombinant plasmids are important experi-

tissue. This type of evidence provides a good starting point but is mental techniques used to demonstrate gain-of-function.

not particularly strong evidence and may even be coincidental.

As you read the scientifi c literature, try to classify the evi-

Loss-of-function evidence (“block it” evidence), uses differdence presented into “show it,” “block it,” or “move it” types

ent techniques to inhibit the function of a gene, gene product,

in order to develop your ability to critically analyze the data

or other factor of interest. Antibodies that block protein func-

(Adams, 2003). Overall, the fi eld of cancer biology relies on the

tion and knock-out mice are common experimental techniques

sum of many types of experimental techniques that must be

used to investigate loss-of-function. Appropriate controls must

critically evaluated.

be in place to ensure that only the target is affected.





10

1 : I N T R O D U C T I O N

1.3 Infl uential factors in human carcinogenesis

Environment, reproductive life, diet, and smoking are four factors that play an important role in carcinogenesis. These lifestyle factors can, in principle, be altered to prevent most cancers. Exposure to carcinogens, hormonal modifi cations infl uenced by childbirth and birth control, and exposure to viruses, underlie these lifestyle factors. Epidemiology, the study of disease in the population, has been instrumental in elucidating the contributions of these factors towards different cancers. Although molecular details will be discussed in later chapters, a brief introduction of each factor is given in the following sections.

Environment

Observations by a British surgeon in 1775 resulted in the fi rst correlation between an environmental agent and specifi c cancers. Percival Pott concluded that the high incidence of nasal and scrotal cancer in chimney sweeps was due to chronic exposure to soot. Not only where you work, but also the choice of where you relax can contribute to your risk of cancer. Unprotected exposure to the sun exposes your skin to UVB radiation which can directly alter your DNA by forming pyrimidine dimers and cause mutations. Sun blocks that have UV-absorbing ingredients have been developed to protect your skin from UV radiation and are a good defense if you do decide to relax in the sun.

Reproductive life

Another early observation was that nuns are more likely to develop

breast cancer than other women. We now know that having children

reduces breast cancer risk for women compared with not having chil-

dren. The age of a woman at the time of giving birth for the fi rst time and the age of a woman at the initiation and termination of her menstrual cycles also infl uences cancer risk. Hormonal contraception and fertility treatments also affect cancer risk because they alter a women’s ovulation schedule (active ingredients prevent and promote ovulation, respectively). Sexual promiscuity can also contribute to increased risk of cancer. Sexually transmitted human papillomaviruses can be found in all cervical cancers worldwide. It is not surprising, therefore, that nuns have a low incidence of cervical cancer. Barrier methods of contraception and vaccination can help protect against this infectious pathogen. One can see in Figure 1.4 that Kaposi’s sarcoma is a predominant cancer in

Kenyan males, which correlates with the AIDS epidemic in Africa. The causative virus of Kaposi’s sarcoma, human herpesvirus type 8, generally requires immunosuppressive conditions created by HIV infection.

1 . 3 I N F L U E N T I A L FAC TO R S I N H U M A N C A R C I N O G E N E S I S 11

USA female

Italian male

Kenyan male

Japanese female

11.2% esophagus

14.5% lung

10.4% lung

26.4% breast

15.4% lung

18.1% breast

6.1% non-Hodgkin’s

4.4% non-Hodgkin’s

5.0% stomach

lymphoma

lymphoma

6.1% liver

5.2% liver

12.8% stomach

7.5% Kaposi’s

16.6% colorectal

15.6% colorectal

sarcoma

10.8% colorectal

7.0% bladder

8.6% prostate

5.8 uterus

21.8% prostate

Diet

Figure 1.4 Leading new cases of

cancers differ among different

The incidence of a specifi c cancer varies greatly between different popula-populations. Data from Globocan

tions in different geographical locations. Observation of immigration pat-2008, IARC (Ferlay et al. , 2010).

The percentage of new cases of a

terns has revealed that local cancer rates strongly infl uence cancer risk, specifi c cancer is refl ected in the with diet being one of the most infl uential factors. Figure 1.4 shows a degree of red shading.

comparison of cancer prevalence between US females and Japanese

females (Ferlay et al. , 2010). Stomach cancer is a predominant cancer in the Japanese population and a minor cancer in the population of the USA.

Interestingly, the risk of stomach cancer in Japanese people who have migrated to the USA decreases only if they adopt the American diet, but not if they retain a Japanese diet. The Mediterranean diet, which is rich in fresh fruit and vegetables, has been promoted to be benefi cial in reducing cancer risks. Recently, studies of the molecular interactions of individual dietary constituents (e.g. polyphenols, carotenoids, and allium compounds) with cellular signaling pathways have begun and some will be examined in Chapter 11.

Alcohol

Alcohol was classifi ed as a carcinogen by the International Agency for Research on Cancer in 2007. There is convincing evidence that chronic alcohol drinking increases the risk of cancer of the mouth, esophagus, and breast, and probable evidence for increased risk of liver cancer. Chronic alcohol drinking accounts for 389,000 cases of cancer worldwide. Alcohol and smoking have a synergistic effect meaning that the risk of cancer

12

1 : I N T R O D U C T I O N

from both alcohol and smoking combined is greater than the sum of each risk alone (think of 2 + 2 = 5). Current guidelines recommend a maximum daily alcohol intake of 28g (approximately a quarter of a bottle of wine) in men and half this amount in women. Molecular mechanisms involved in alcohol-mediated carcinogenesis are discussed in Chapter 11.

Smoking

The clearest example of lifestyle factors underlying a specifi c cancer is the discovery that smoking causes lung cancer (it is also implicated in pancreatic, bladder, kidney, mouth, stomach, and liver cancer). Since 1985, lung cancer has remained the main cancer worldwide. Smoking accounts for 40% of all cancer deaths: 1.18 million deaths. At least 81 carcinogens have been identifi ed in cigarette smoke. Smoking became particularly fashionable in Europe and the USA during World War I and World War II and resulted in an epidemic of lung carcinoma. After vast public education campaigns and a subsequent reduction of smoking, lung cancer death rates have fallen dramatically in the USA (Figure 1.5). Unfortunately, lung cancer rates are still rising in other parts of the world, such as China. It may be a good idea for these countries to consider implementing restric-tions on smoking in public places and imposing tobacco taxes.

It is clear that some future cancer deaths can be avoided by changes in lifestyle factors.

100

Lung and bronchus

90

80

70

60

50

Stomach

Prostate

40

Colon and rectum

Rate per 100 000 males

30

Figure 1.5 Annual age-adjusted

20

Pancreas

cancer death rates among males

for selected cancers, USA, 1930–

10

Liver

2007. From Siegel, R. et al.

Leukemia

(2011). Cancer Statistics, 2011.

0

CA Cancer J. Clin. 61: 212–236,

with permission from John Wiley

1930

1935

1940

1945

1950

1955

1960

1965

1970

1975

1980

1985

1990

1995

2000

2005

and Sons.

Year of death





1 . 4 P R I N C I P L E S O F C O N V E N T I O N A L C A N C E R T H E R A P I E S 13

Additional infl uences

In addition to lifestyle factors, there are risk factors inherent in our own physiology. By-products of our metabolism and errors that occur during DNA replication contribute to carcinogenesis. Aerobic metabolism produces by-products of oxygen radicals that are mutagenic. Several inherited metabolic diseases also produce mutagenic by-products. For example, tyrosinemia type I patients have a defect in the enzyme fumarylacetoacetate hydrolase which is involved in tyrosine breakdown. As a result of this block, the by-products fumarylacetoacetate and maleylacetate accumulate and increase the risk of cancer owing to their ability to covalently modify DNA and cause mutations. During DNA replication and repair,

polymerases can introduce mutations directly in DNA because of their associated error rates. There is a perpetual inherent risk of mutation during the lifespan of a cell by the nature of cell processes.

1.4 Principles of conventional cancer therapies

The earliest therapeutic strategy used against cancer was surgically to PAUSE AND THINK

remove as much of the cancer as possible. Obviously this is relatively easy in some types of cancer and impossible in other types. It is not a precise Let us “create” an example

procedure at the cellular level and does not address the question of cells purely to illustrate the concept

of the MTD. Two aspirins may be

that have spread from the primary site (metastasized cells). Therefore, the minimum for an effective

chemotherapy and radiotherapy have been used to inhibit or eradicate dose against a headache and 30

metastasized cells. The objectives of cancer therapies are to prevent prolif-may be the dose that can be tol-

eration (cytostatic effect) and to kill the cancer cells (cytotoxic effect). The erated before harmful side-aim with all drugs is to achieve an effective result with the minimum side-effects are observed. However, if

effects. This is indicated by the therapeutic index. This is the value of the harmful side-effects were seen

difference between the minimum effective dose and the maximum tolerafter three aspirins the thera-

ated dose (MTD) (Figure 1.6). The larger the value, the safer the drug.

peutic index would decrease

Many conventional cancer treatments are administered at MTDs.

and the drug would be much

less favorable.

Chemotherapy

Conventional chemotherapy uses chemicals that target DNA, RNA, and

protein to disrupt the cell cycle in rapidly dividing cancer cells and thus has broad specifi city. The ultimate goal of cytotoxic chemotherapy is to cause severe DNA damage and to trigger apoptosis in the rapidly dividing cancer cells. The side-effects of chemotherapy, which we are all too aware of, such as alopecia (loss of hair), ulcers, and anemia, are due to the fact that hair follicles, stomach epithelia, and hematopoietic cells are also rapidly dividing and therefore they too are greatly affected by these drugs.

14

1 : I N T R O D U C T I O N

(a)

Maximum

tolerated

effect

fectEf

Aspirin

Minimum

effect

Therapeutic

index

Minimum

Maximum

effective

tolerated

dose

dose

Dose

(b)

Maximum

tolerated

effect

Most chemotherapies

Minimum

effect

Therapeutic

index

fect

Figure 1.6 The therapeutic index

Ef

is the value of the difference

between the minimum effective

dose and the maximum tolerated

dose (MTD). (a) The value for the

therapeutic index of aspirin is

Minimum Maximum

higher than that of (b) the

effective

tolerated

therapeutic index of most

dose

dose

chemotherapies.

Dose

Often, prescribed MTDs induce toxicity in sensitive tissues and require a pause in drug administration so that normal cells can recover. We must appreciate that conventional chemotherapies (e.g. cisplatin and methotrexate, discussed in Chapter 2) have had results in treating cancers and continue to extend lives but at the same time we must desire drugs with better effi ciencies and less severe and debilitating side-effects. We must strive to develop drugs that rise to these expectations.





1 . 5 C L I N I C A L T R I A L S 15

1.5 Clinical trials

Testing of new drugs in humans must progress through staged clinical trials (Table 1.1). Phase I trials examine dose responses for assessing drug safety, using a small number (20–80) of healthy volunteers or

patients. Many parameters of the metabolism of the drug in humans

(e.g. How long does the drug remain in the body?) are obtained at this time. About 70% of drugs tested in Phase I will progress to Phase II studies. Phase II trials are designed to examine effi cacy in a larger group of people (100–300). Phase III trials should not be initiated prior to knowing the effective drug dosage. Phase III trials are large-scale studies (1000–3000 people) to confi rm drug effectiveness, monitor side-effects, and also to compare the effi cacy of the new drug with conventional treatments. Only terminally ill patients may be recruited for clinical trials, by law, in many countries. This has implications for the outcome of testing particular drugs and will be discussed later in the text. About 30% of drugs tested successfully complete Phase III studies. Drugs are also tested against control populations. These people either receive no treatment or receive a placebo, or inactive substance. In order to reduce the risk of bias, trials can be randomized. That is, patients are randomly assigned to either a treatment group or a control group, guaranteeing that the two groups are similar. In addition, the trial may be conducted as a single-blind study, whereby patients do not know which group they are in, or as a double-blind study, whereby neither patients nor investigators know who has received the treatment or placebo until after a code is broken that identifi es the people in the two groups. Unlike con-PAUSE AND THINK

ventional chemotherapies, targeted therapy may not require MTDs.

Is tumor shrinkage a suitable

Experience is teaching us that the design of trials for molecularly tar-assessment criterion for cyto-

geted drugs needs to be well thought out. It is important to consider the static drugs? No, because direct

stage and type of cancer to be treated, patient populations with the cor-cell death is not anticipated with

rect molecular profi les (that is, does the patient carry mutations in genes this class of drugs. Cytotoxic

of interest), assessment of the compound in inhibiting its molecular tar-drugs are expected to kill tumor

get, and assessment of the relationship between molecular inhibition cells.

and clinical response.

Table 1.1 Clinical trials

Purpose

Number of patients

Phase I

Safety

20–100

Phase II

Effi cacy

Up to several hundred

Phase III

Effi cacy often tested against conventional treatments

Several hundred to several thousand





16

1 : I N T R O D U C T I O N

1.6 The role of molecular targets in cancer therapies

The major fl aw in the rationale of most conventional therapies is the lack of selectivity against tumor cells versus normal cells. As a result, the side-effects of most therapies are very harsh, as mentioned earlier. There is a need to learn about the differences between normal and transformed

cells at the molecular level in order to identify cancer-specifi c molecular targets. In this way, we can design drugs that will be specifi c for the cancer cells, have increased effi cacy, and cause fewer side-effects.

Molecules of fame

As we examine the molecular pathways that underlie carcinogenesis we must keep in mind that the pathways do not act in isolation but are inter-connected (see Appendix 1). Despite the many hundreds of molecules

involved in carcinogenesis, there are several families of “star players” in the story of carcinogenesis. Many of these “star players” act as nodes that receive signals from many pathways and can exert several effects in response to a specifi c signal.

The family of protein kinases, one of the largest families of genes in eukaryotes, must be included in any introduction to cancer biology. Protein kinases phosphorylate (add a phosphate group to) a hydroxyl group on specifi c amino acids in proteins. Tyrosine kinases phosphorylate tyrosine residues while serine/threonine kinases phosphorylate serine and threonine residues. Phosphorylation results in a conformational change and is an important mechanism for regulating the activity of a protein. Kinases can be found at the cell surface as transmembrane receptors, inside the cell as intracellular transducers, or inside the nucleus. Kinases play a critical role in major cell functions, including cell cycle progression, signal transduction, and transcription, and are important molecular targets for the design of cancer drugs. Phosphorylation is also regulated by phosphatases—

enzymes that remove phosphate groups. Mutational analysis of all known human protein tyrosine phosphatases suggests that several of these act as tumor suppressors in some types of cancer (see Chapter 6).

The Ras family is another “star” set of genes which are found mutated in over 50% of certain cancers (e.g. colon cancer). Ras is an intracellular transducer protein that acts subsequently to binding of a growth factor to its receptor and is involved in transmitting the signal from the receptor through the cell. As G proteins, they reside on the intracellular side of the plasma membrane and are activated by the exchange of GDP for GTP.

Tumor protein p53 (TP53; p53) and its related family members hold

pivotal positions in guarding the integrity of the genome by coordinating responses of the cell (e.g. cell cycle arrest, DNA repair, apoptosis) to different types of stress (e.g. DNA damage, hypoxia). The p53 gene is a

1 . 6 T H E R O L E O F M O L E C U L A R TA R G E T S I N C A N C E R T H E R A P I E S 17

tumor suppressor gene that has a key role in inhibiting carcinogenesis. It is mutated in more than half of all cancers and over a thousand different mutations have been identifi ed. It acts as a transcription factor and induces the expression of genes required to carry out its functions.

The retinoblastoma gene ( Rb) is also a tumor suppressor gene that plays a central role in regulating the cell cycle. It is commonly mutated in several cancers. The retinoblastoma protein normally functions as an inhibitor of cell proliferation by binding to and suppressing an essential transcription factor of cell cycle progression. Its activity is regulated by phosphorylation by cyclin D and the cyclin-dependent kinases (4/6).

The introduction of cancer genomics

The completion of the Human Genome Project, whereby every nucleotide of a human genome has been sequenced and mapped, has paved the way

for cancer genomics. Learning about the details of the genome of a cancer cell and how it differs from a normal cell will provide us with the fi ne distinctions needed to design more powerful and specifi c drugs (Stratton, 2011). Both alterations that are common for specifi c cancers and alterations that are different among individuals with the same specifi c cancer are important to understand. One of the most signifi cant fi ndings from examining the cancer genome has been that the genomic profi le of an individual’s tumor is unique and “personal.” This understanding is leading us into the era of personalized medicine where a patient’s tumor genome will inform doctors of the best treatment for that individual.

Since the Human Genome Project, new sequencing technologies have

developed and greatly advanced the speed at which genomes can be

sequenced and this has encouraged different approaches. The International Cancer Genome Consortium (ICGC) has been organized to co-

ordinate large genomic studies across the globe to characterize at least 50 classes of cancer, including the sequencing of several hundreds of tumors for each type, and to make the data available to the entire research community. The information gathered from these efforts promises to yield important insights into the understanding of cancer and will lead to better molecular classifi cations that will inform drug discovery strategies.

Results from specifi c projects under the ICGC, such as the whole-genome sequencing of four cases of chronic lymphocytic leukemia, have already been published (Puente et al. , 2011). Furthermore, the human genome has recently been subdivided into functional categories such as the “kinome”

by the mapping of the complete set of 518 protein kinase genes in the genome (Manning et al. , 2002). As aberrant regulation and mutation of these genes are involved in carcinogenesis, this will be an important tool for the design of new molecular therapies. The International SNP Map Working Group is analyzing single nucleotide polymorphisms (SNPs) to

18

1 : I N T R O D U C T I O N

identify mutations within the genome that may be linked with cancer. A recent demonstration of a genome-wide analysis of SNPs in one type of leukemia revealed frequent targets of somatic mutations (e.g. PAX5

altered in 32% of cases), many of which code for regulators of differentiation (Mullighan et al. , 2007). Discoveries about the functional role of small RNAs in gene regulation have led to new tools (e.g. RNA interference) to help elucidate the function of genes in an organism. The fi ndings from studies of functional genomics promise to provide insights into cancer biology.

Analysis of gene function by small interfering RNAs (siRNAs)

Gene function is often determined by abolishing the expression of a gene product and observing the resulting phenotype. RNA interference is a cellular mechanism for regulating gene expression in most eukaryotes. Short RNA duplexes (approximately 21 nucleotides long with two nucleotide 3′ overhangs) called small interfering RNAs (siRNAs) mediate the expression of genes by causing the degradation of homologous single-stranded target RNAs. Experimentally, we can use siRNAs to target endogenous genes in mammalian cells.

Using the known sequence of a segment of target mRNA, sense and antisense RNAs are designed, synthesized, and annealed to produce siRNA duplexes. The siRNAs are delivered to cells by classical gene transfer methods (e.g. electroporation). Specifi c antibodies against the targeted protein are often used to ensure that target protein levels have been diminished.

(See Kamath et al. (2003) as an example of the use of this approach.) Good news

The nature of the “now” generation of drugs is small molecules and antibodies targeted against selective gene products. Soon it is likely that methods to prevent expression of specifi c target genes (e.g. antisense RNA, siRNAs) will also enter the clinic. Several therapies based on these designs that can treat specifi c cancers will be described later in the text. The good news is that in the USA the cancer death rates have decreased in both men and women from 1998–2007 (Jemal et al. , 2011; Siegel et al. , 2011) and similar progress can be seen in other countries in the world. Progress is beginning to show.

■ CHAPTER HIGHLIGHTS—REFRESH YOUR MEMORY

•

Cancer is a common disease that will affect

•

There are ten hallmarks of cancer. They are:

one out of three people over their lifetime,

– Growth signal autonomy

worldwide.

– Evasion of growth

•

Cancer is a group of diseases that results in the spreading

inhibitory signals

of mutated cells throughout the body.

– Avoiding immune destruction

1 . 6 T H E R O L E O F M O L E C U L A R TA R G E T S I N C A N C E R T H E R A P I E S 19

– Unlimited replicative potential

•

A gene containing a dominant mutation that results in

– Tumor-promoting infl ammation

inappropriate activation of growth is an oncogene.

– Invasion and metastasis

•

Tumor suppressor genes are usually inactivated by muta-

– Angiogenesis

tions in both alleles (recessive) and this results in inactiva-

– Genomic instability and mutation

tion of growth inhibition.

– Evasion of cell death

•

Haploinsuffi ciency, whereby only one allele of a tumor

– Reprogramming energy metabolism.

suppressor gene is inactivated, also contributes to

•

Most carcinogens are mutagens.

carcinogenesis.

•

Most often, carcinogenesis is a multi-step process that

•

Changes in lifestyle factors can affect cancer risk.

requires the accumulation of several mutations. However,

•

Many conventional therapies are broad-acting drugs

there is evidence that in a small percentage

administered at MTDs resulting in severe side-effects.

of tumors, a single catastrophic event in a cell can

•

Protein kinases, enzymes that phosphorylate proteins, are

lead immediately to many mutations and cause cancer.

important molecules in carcinogenesis.

•

Cancer is a genomic disease at the cellular level.

•

Cancer genomics is being used to defi ne molecular

•

Genes that are involved in growth, differentiation, or

targets for tumor-specifi c effects.

cell death when deregulated can give rise to the cancer

•

Some cancers can already be treated by specifi c molecular

phenotype.

approaches.

■ ACTIVITY

1. Become familiar with the Globocan 2008 web site and see how epidemiological data can be formatted in different ways (go to http://globocan.iarc.fr/). On the left-hand side,

select Tables, then select by populations. Try different parameters. Then examine the data for different countries under Graphs and Maps then Pie chart by Cancers. How do the cancer profi les differ between continents? Select to run a cancer map for lung cancer.

What are your conclusions?

■ FURTHER READING

Alison, M.R. (2007) The Cancer Handbook, 2nd edn. John Wiley and Sons, Inc., New York.

Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C., and Parkin, D.M. (2010) Globocan 2008v1.2. Cancer Incidence and Mortality Worldwide. IARC CancerBase No.10, International Agency for Research on Cancer, Lyon, France.

Gilbert, S.F. (2010) Developmental Biology, 9th edn. Sinauer Associates, Inc., Sunderland, MA.

Greaves, M. (2001) Cancer: The Evolutionary Legacy. Oxford University Press, Oxford.

Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation.

Cell 144: 646–674.

Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., and Forman, D. (2011) Global Cancer Statistics, 2011. CA Cancer J. Clin. 61: 69–90.

Peto, J. (2001) Cancer epidemiology in the last century and the next decade. Nature 411: 390–395.

20

1 : I N T R O D U C T I O N

Siegel, R., Ward, E., Brawley, O., and Jemal, A. (2011) Cancer statistics, 2011. CA Cancer J. Clin. 61: 212–236.

■ WEB SITES

American Cancer Society. Cancer Facts and Figures http://www.cancer.org/Research/

CancerFactsFigures/index

Globocan 2008 http://globocan.iarc.fr/

Latest UK Cancer Incidence and Mortality (2008) Summary (2011). http://info.

cancerresearchuk.org/prod_consump/groups/cr_common/@nre/@sta/documents/

generalcontent/cr_072108.pdf

The Food and Drug Administration. Running Clinical Trials http://www.fda.gov/

ScienceResearch/SpecialTopics/RunningClinicalTrials/default.htm

The International Cancer Genome Consortium http://www.icgc.org/

■ SELECTED SPECIAL TOPICS

Adams, D.S. (2003) Teaching critical thinking in a developmental biology course at an American liberal arts college. Int. J. Dev. Biol. 47: 145–151.

Fodde, R. and Smits, R. (2002) A matter of dosage. Science 298: 761–763.

Kamath, R., Fraser, A., Dong, Y., Poulin, G., Durbin, R., Gotta, M., et al. (2003) Systemic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 421: 231–237.

Manning, G., Whyte, D., Martinez, R., Hunter, T., and Sudarsanam, S. (2002) The protein kinase complement of the human genome. Science 298: 1912–1934.

Mullighan, C.G., Goorha, S., Radtke, I., Miller, C.B., Coustan-Smith, E., Dalton, J.D., et al. (2007) Genome-wide analysis of genetic alterations in acute lymphoblastic leukemia. Nature 446: 758–764.

Oeppen, J. and Vaupel, J.W. (2002) Broken limits to life expectancy. Science 296: 1029–1030.

Puente, X.S., Pinyol, M., Quesada, V., Conde, L., Ordóñez, G.R., Villamor, N., et al.

(2011) Whole-genome sequencing identifi es recurrent mutations in chronic lymphocytic leukemia. Nature 427: 101–105.

Stratton, M.R. (2011) Exploring the genomes of cancer cells: progress and promise.

Science 331: 1553–1558.





Chapter 2

DNA structure and stability:

mutations versus repair

Introduction

Genetic information, coded within DNA, requires stability. DNA directs the production of proteins, needed for the structure and function of cells over a lifetime, through an adaptor molecule, RNA. Unlike RNA and protein, which have a limited existence before they are degraded and/or recycled, DNA must maintain its integrity over that lifetime. However, our genes are subject to a myriad of attacks by both environmental agents and endogenous processes that result in mutation and scission. Changes to the DNA sequence may have severe consequences for the cell and its progeny. Cancer is a disease that involves alterations to gene structure and gene expression at the cellular level. The role of the accumulation of mutations gradually over time is well established for the process of carcinogenesis but recent evidence shakes this conventional view and suggests that for a small number of cancers, one-off cell catastrophic events may also generate mutations that underlie carcinogenesis (Stephens et al. , 2011). A one-off cell crisis that shatters chromosomes and results in tens to hundreds of genomic rearrangements is called chromothripsis (“chromo” meaning chromosome and “thripsis” meaning breaking into small pieces). In this chapter we will review the structure of a gene and describe the mutations that occur during carcinogenesis.

When considering the process of carcinogenesis we must be aware that cells are equipped with defense mechanisms against mutations, such as the detection and repair of DNA damage. Detection and repair of DNA damage is particularly crucial in the time before a cell divides as errors existing during replication will be passed on to daughter cells. Pausing the cell cycle is sometimes coupled to the repair of DNA damage. Apoptosis, a more hard-line defense, can be triggered as a last resort; thus, cell suicide is the ultimate price to be paid to prevent perpetuation of DNA damage and to protect the individual from carcinogenesis (see Chapter 7). In this chapter, we will also examine how, on one hand, mutations in DNA occur as a consequence of exposure to carcinogens and, on the other hand, examine the DNA repair systems that are in place to maintain the integrity of the genome and suppress tumorigenesis.





22 2: DNA STRUCTURE AND STABILITY: MUTATIONS VERSUS REPAIR

2.1 Gene structure—two parts of a gene: the regulatory

region and the coding region

We have about 20,000 genes! They are encoded in our DNA, an impres-

sively simplistic double-helical molecule made up of two chains of nucleotides. A nucleotide is made up of a sugar, phosphate, and a nitrogenous base (adenine, guanine, cytosine, or thymine) and it is the sequence of the bases that holds the instructional information of our genes. The central dogma of molecule biology states that DNA is transcribed into RNA and RNA is translated into protein. Gene expression refers to the transcription of a gene. For the purpose of simplicity, keep in mind that there are two distinct functional parts to a gene (Figure 2.1). The 5′ end of a gene contains nucleotide sequences that make up the promoter region, and this region is involved in regulating the expression of the gene. These 5′ nucleotide sequences interact with proteins that affect the activity of RNA polymerase and determine when and where a gene is expressed. (Note, however, there are exceptions; for many genes, some regulatory regions can be located elsewhere, such as downstream (the direction along the DNA molecule towards the 3′ end) of the gene or within introns.) The TATA box (TATAAAA), located near the start site of transcription, is one of the most important regulatory elements for most genes. Binding of the TATA box-binding protein (TBP) to the TATA box is crucial for the initiation of transcription. A short sequence of DNA within a promoter that is recognized by a specifi c protein and contributes to the regulation of the gene is called a response element (RE). Common response elements identify genes under a common type of regulation. For example, the sequence CCATATTAGG is

referred to as the serum response element (SRE) and is found in genes that are responsive to serum. Also, it is not surprising that the response element for a protein that is essential for the regulation of the cell cycle, the transcription factor E2F, is found in the promoters of the cyclin E and cyclin A genes, the products of which are major players in the cell cycle. Enhancer elements are additional regulatory DNA sequences that are position- and orientation-independent relative to a promoter and are important for tissue-specifi c and stage-specifi c expression. Downstream of the promoter 5¢

3¢

Promoter region

Start of site

Coding sequences

transcription

mRNA

Figure 2.1 A simplistic

representation: two functional

parts of a gene.

Protein





2 . 2 M U TAT I O N S 23

are the nucleotides that will be transcribed into RNA and those coding for exons will be translated into protein. These downstream nucleotide

sequences represent the coding region of the gene.

2.2 Mutations

As stated previously, most carcinogens are mutagens. These agents induce mutations either by modifying DNA (e.g. forming DNA adducts) or by

causing chromosomal damage (e.g. DNA strand breaks). Several types of mutations are illustrated in Figure 2.2: transitions, transversions, insertions, deletions, and chromosomal translocations. Transitions and transversions are two types of base substitutions. A transition is the substitution for one purine for another purine and a transversion is the substitution of a purine for a pyrimidine or vice versa. Base substitutions during replication may occur for several reasons. First, DNA polymerase is not always 100%

accurate. The enzyme may make an error and insert a wrong nucleotide during DNA synthesis. Also, modifi cations of bases owing to oxidation or covalent additions and alterations of chromatin structure can cause mis-reading of the DNA template by DNA polymerase. Remember that the

genetic code is a triplet code read in a sequential but non-overlapping manner. An insertion or deletion of a base can alter the reading frame (marked by a “,” in Figure 2.2) and thus can also be referred to as a frameshift mutation. In most cases this leads to a non-functional or truncated protein product. A chromosomal translocation is the exchange of one part of one chromosome for another part of a different chromosome and results in changes of the base sequence of DNA. Gene amplifi cation, whereby the copy number of a gene increases from the two copies present in the normal diploid genome to sometimes hundreds of copies, may also occur in cancer cells (not shown).

A T G , A G C,TA T

original

A T G , G G C,T A T

transition

A T G , T G C,TA T

transversion

A T G,A A G,C TA,T

insertion

A

G

A,G C T,A T

–

deletion

Chromosomal

translocation

Figure 2.2 Types of mutations.

24 2: DNA STRUCTURE AND STABILITY: MUTATIONS VERSUS REPAIR

As we will see in later chapters, there are many examples of these

types of mutations in genes regulating growth, differentiation, and apoptosis that are involved in carcinogenesis. For most cancers, different types of mutations accumulate over time within an individual cell and cause the cell to be transformed into a cancer cell. But for 2–3% of cancers, particularly bone cancer (up to 25%), recent evidence suggests that a single event of chromothripsis involving one or a few chromosomes leads to multiple gene rearrangements (in some cases tens to hundreds) that can disrupt tumor suppressor genes and/or produce oncogenic fusion genes. In simple terms, a chromosome shatters and the attempt to repair the damage results in many incorrect junctions (Plate 1). The pattern of localized re arrangements is highly unlikely to have occurred by a gradual process.

? HOW DO WE KNOW THAT?

Sequencing strategies had shown, for example, that a kidney

hybridization). The probes were each labeled with a different

cancer cell line called TK10 contained 55 rearrangements color dye and hybridized to the TK10 cells. As can be seen in involving chromosome 5. (Note: TK10 is a hyperdiploid cell line

Plate 1, there were several wild-type copies of chromosome 5

and contains more than 46 chromosomes.) In order to investi-

showing the expected arrangement of the chromosomal

gate the genomic rearrangements of a single chromosome in a

regions of interest (white, yellow, red, purple, green) and two

cell line that showed evidence of chromothripsis, Stephens and

copies of a chromosome derived from chromosome 5 in which

colleagues (2011) designed fluorescent i n s itu hybridization all fi ve FISH probes were closely juxtaposed and rearranged

(FISH) probes to fi ve widely separated regions of chromosome 5

(purple, red, yellow, green, white). This is strong evidence for

and analyzed TK10 cells (see page 115 for details about FISH

chromothripsis.

Although the cause of chromothripsis is still unknown, three suggestions have been proposed: ionizing radiation that leads to chromosome breaks; telomere dysfunction which may lead to end–end chromosome

fusions (both suggested by Stephens et al. , 2011); or aborted apoptosis such that cells which have initiated DNA fragmentation survive (suggested by Tubio and Estivill, 2011). This area promises to be an area of future research.

In theory, mutations may occur anywhere across a particular gene but the location will determine whether some of these mutations give rise to a growth advantage and contribute to carcinogenesis. For example, a

mutation may alter the conformation of a cyclin protein and result in unregulated progression of the cell cycle, whereas another mutation may have no effect on protein conformation or function. “Driver mutations”

are located in cancer genes by defi nition and confer a growth advantage on cells, whereas “passenger mutations” do not confer a growth advantage and “are there for the ride.” Some calculations predict that 5–7

driver mutations are required in most cancers, whereas other calculations





2 . 3 C A R C I N O G E N I C AG E N T S 25

predict as many as 20 driver mutations are required in some cancers.

Some mutations may give rise to a cell that has an increased rate of mutation as a result of for example, defective DNA repair and these cells are said to have a “mutator phenotype.”

The consequence of a mutation in a gene is determined by its location with respect to the two functional parts of a gene. Mutations occurring in the promoter region may alter the regulation of the gene and affect the levels or temporal/spatial expression of the gene product. The consequence of such mutations may be over- or under-expression of the protein product or the appearance of the protein product at the wrong time or in the wrong place (i.e. the wrong cell type), respectively. Alternatively, mutations occurring in the coding region of genes may affect the structure and thus alter the function of the gene product or cause a truncation (e.g.

the introduction of a stop codon) that abolishes the protein’s function completely.

2.3 Carcinogenic agents

PAUSE AND THINK

The backbone of cancer biology has been the identifi cation of carcinogens Although the discussion in this

section is directed at nuclear

responsible for cancer-causing mutations, and the identifi cation of specifi c DNA, it is interesting to think

mutations as causative factors of carcinogenesis along with the elucida-about a possible link between

tion of the pathways they affect. Several classes of carcinogens will now mitochondrial DNA and cancer.

be described, including radiation, chemicals, infectious pathogens, and Mitochondrial DNA lacks his-particular endogenous reactions.

tones and has a lower capacity

for DNA repair, making it suscep-

Radiation as a carcinogen

tible to mutation. Currently the

role of mitochondrial DNA muta-

Radiation is energy. There are two forms of radiation: energy traveling in tions in cancer initiation is contro-waves or as a stream of atomic particles. Energy waves include gamma (γ) versial, but one report published

rays, high-energy electromagnetic radiation that is similar to X-rays.

in Science presents evidence that

Atomic particles include alpha (α) and beta (β) particles that are emitted specifi

c mitochondrial DNA

mutations can increase the ability

by radioactive atoms. (Alpha particles comprise two protons and two of cancer cells to spread (see Ishi-neutrons, while beta particles comprise electrons.)

kawa et al. , 2008).

Electromagnetic radiation is naturally occurring radiation which possesses a broad range of energies. Electromagnetic radiation moves as waves of energy, which have peaks and troughs (in a manner analogous to waves at sea). The distance between successive peaks (or troughs) is termed the wavelength. High-energy electromagnetic radiation, such as cosmic radiation, has a short wavelength, while low-energy radiation, such as radio waves, has a long wavelength. The electromagnetic spectrum spans electromagnetic radiation of varying wavelengths, as shown in Figure 2.3. The electromagnetic spectrum extends from long-wavelength radiation (not

26 2: DNA STRUCTURE AND STABILITY: MUTATIONS VERSUS REPAIR

IR

Light

UV

X-rays

Gamma rays

Ionizing

radiation

Heat

The electromagnetic spectrum

10–3

100

103

Photon energy (in electron volts)

1012

1015

1018

Frequency (in Hz)

Figure 2.3 The electromagnetic

300 μm

300 nm

300 pm

spectrum and corresponding

Wavelength

characteristics.

shown) to extremely short-wavelength radiation, such as X-rays and

gamma radiation. The visible spectrum spans those wavelengths that we can detect with our eyes as visible light. Ultraviolet (UV) radiation is emitted from the sun and has a higher energy (and so a shorter wavelength) than visible light.

Several types of radiation (including both energy waves and atomic particles) can damage DNA and act as carcinogens. The amount of energy released by a particular radiation source affects the mechanism and extent of damage to DNA. The amount of energy released by a particular radiation source and absorbed by the body tissue is measured in grays (Gy).

One gray is the release to the body tissue of 1 joule (J) of energy per 1 kg of tissue. The real issue is not how much radiation is absorbed by the body tissue, however, but how much damage is done when the radiation has been absorbed. The amount of damage caused depends on the rate at

which a particular radiation source releases energy. If a radiation source releases energy at a high rate, then it causes more damage than a source that releases energy more slowly.

Linear energy transfer (LET) is used to help describe the rate at which energy is released. Specifi cally, it describes the amount of energy released by a radiation source as it travels a fi xed distance. High-LET radiation emits more energy than low-LET radiation over the same distance. Therefore, high-LET radiation (such as alpha particles) causes more biological damage than low-LET radiation (such as X-rays). The quantity and type of DNA damage caused by a particular radiation source depends on

whether it is high- or low-LET radiation. Double-stranded DNA breaks

2 . 3 C A R C I N O G E N I C AG E N T S 27

are more commonly caused by high-LET radiation, and lead to chromo-

somal translocations and deletions.

The amount of biological damage caused by a particular source of radiation is measured in sieverts (Sv). (The numerical value of these units is determined by multiplying the gray units by a factor relating to the LET

value of a particular type of radiation.)

Two classes of radiation, ionizing radiation and UV radiation, have been demonstrated to act as carcinogens and damage DNA. Let us examine both types of radiation next.

Ionizing radiation

Ionizing radiation includes both alpha and beta particles (atomic particles) and gamma rays (energy waves). When high-energy radiation, such as gamma rays, strikes molecules in its path, electrons may be displaced from atoms within the molecule. The loss of one or more electrons converts the molecule from being electrically neutral to carrying an electrical charge. The charged molecule is called an ion, and hence the radiation causing the formation of an ion is called ionizing radiation.

Ionizing radiation can damage DNA directly by causing ionization of the atoms comprising DNA, or indirectly by the interaction with water molecules (a process known as radiolysis) to generate dangerous intermediates called reactive oxygen species (ROS) (see Box “A little lesson about ROS . . .”). These reactive oxygen species may react with DNA, or with other biomolecules, to cause damage within the cell.

A little lesson about ROS . . .

Some radiation exerts its biological effect by the generation of damaging intermediates through the interaction of radiation with water, or radiolysis. As our body comprises 55–60% water, radiation is most likely to strike water than any other matter. The striking of water by radiation causes it to lose an electron and become highly reactive. This sets off a chain reaction in which water is converted to oxygen, O , through a three-step process.

2

Radiation interacts with a single molecule of water and thus it cannot split directly into the diatomic gases H and O . Equation (1) is

2

2

not possible because this equation is not bal-

anced.

H O → H + O

(1)



2

2

2

The balanced equation (Equation 2) does not apply to radiation as radiation interacts with only a single molecule of water, and not the two molecules required in Equation (2): 2H O → 2H + O

(2)



2

2

2

¼

28 2: DNA STRUCTURE AND STABILITY: MUTATIONS VERSUS REPAIR

¼ Instead, radiolysis results in the sequential generation of three dangerous reactive oxygen species (ROS) as an electron (e–) is lost at each step. The three ROS, formed in sequence, are the hydroxyl radical (–OH), hydrogen peroxide (H O ), and the superoxide 2

2

radical (O−):

2

e−

e−

e−

e−

H O→

O

⋅ H →

H O

→

O−⋅

→O

2

2

2

2

2

hydroxyl radical

hydrogen peroxide

superroxide radical

The hydroxyl radical is an extremely reactive molecule; in fact, it is one of the most reactive (and therefore dangerous) molecules known! It immediately removes electrons from any molecule in its path, turning that molecule into a free radical and so propagating a chain reaction. (A free radical is a highly unstable, reactive molecule that possesses an unpaired electron. Both the hydroxyl radical and the superoxide radical shown earlier are free radicals.)

Neither hydrogen peroxide nor the superoxide radical are as reactive as the hydroxyl radical. Hydrogen peroxide is actually more dangerous to DNA than the hydroxyl radical however. The slower reactivity of hydrogen peroxide (compared with the hydroxyl radical) gives the hydrogen peroxide molecule time to travel into the nucleus of a cell, where it is free to interact with, and wreak havoc upon, DNA.

Oxidation of DNA (the removal of electrons, by species such as the free radicals mentioned here) is one of the main causes of mutation, and explains why free radicals are such potent carcinogens. Oxidation can produce several types of DNA damage, including oxidized bases. Among the variety of oxidized nitrogenous bases observed, 8-oxoguanine is the most abundant. DNA polymerase mispairs 8-oxoguanine with adenine during DNA replication leading to a G→T transversion mutation. The presence of iron can exacerbate the consequences of hydrogen peroxide production. If it encounters iron and receives an electron from it, hydrogen peroxide can be reconverted into the hydroxyl radical that may attack DNA. The Fenton reaction (Equation 3) illustrates this:

H O

Fe2+

OH−

OH

Fe3

+

→

+ ⋅

+

+

(3)



2

2



O−

Fe3+

O

Fe2+

⋅ +

→

+

(4)



2

2



The superoxide radical is the third intermediate before the formation of oxygen. It is not very reactive but acts more as a catalyst for the generation of the other two intermediates mentioned because it helps regenerate iron (Equation 4) in the form needed for the earlier-mentioned Fenton reaction. Thus, the ROS intermediates affect one another.

(Lane, 2002)

People are exposed to varying amounts of ionizing radiation. Expo-

sure to gamma rays from cosmic radiation depends on the altitude at which you live or travel. The average exposure for high-altitude fl ights is about 0.005–0.01 mSv h−1. A chest X-ray required for medical diagnosis

2 . 3 C A R C I N O G E N I C AG E N T S 29

of some conditions exposes patients to 0.1 mSv. The contribution of the accumulation of these varying daily exposures towards cancer risk is relatively unknown.

Studies of the victims of the atomic bombing in Japan continue to contribute to our knowledge of ionizing radiation as a carcinogen. Evidence suggests that the most important damage associated with ionizing

radiation-induced carcinogenesis is double-strand DNA breaks. A long-term and comprehensive study of 80,000 atomic bomb survivors called The Life Span Study (latest report Preston et al. , 2003) has revealed three important points: (1) leukemia is the most frequent ionizing radiation-PAUSE AND THINK

induced cancer, (2) age is an important risk factor, whereby those exposed as children are most affected, and (3) the risks of solid cancer increase Marie Curie, who worked with

with dose in a linear fashion. People exposed at 30 years of age have a risk radioactivity all of her adult life,

of solid cancer that is elevated by 47% per Sv at the age of 70. These stud-died of leukemia at the age of

67. The multi-stage process of

ies have helped guide recommendations for radiation limits. The US

carcinogenesis is manifested by

National Council on Radiation Protection and Measurements (NCRP)

the fairly long incubation peri-

and the International Commission on Radiological Protection recom-

ods needed to develop cancer

mends an annual radiation dose limit of 1 mSv (100 mrem) for members after exposure to carcinogens.

of the public.

Ultraviolet radiation

Ultraviolet radiation (UV) from the sun is also carcinogenic and is a prin-LIFESTYLE TIP

cipal cause of skin cancer. Of the three types of UV light—UVA (wavelength 320–380

nm), UVB (wavelength 290–320

nm), and UVC In 2009, The International

(wavelength 200–290 nm)—UVB is the most effective carcinogen. The

Agency for Research on Cancer

(IARC) raised the classifi cation

conjugated double bonds in the rings of the nitrogenous bases of DNA of ultraviolet emitting tanning

absorb UV radiation. UVB directly and uniquely causes characteristic devices to “carcinogenic to

UV photoproducts: cyclobutane pyrimidine dimers and pyrimidine–

humans”—the highest risk cat-

pyrimidone photoproducts (Figure 2.4a,b). Cyclobutane pyrimidine

egory—based on evidence of

dimers are the most prevalent, formed at least 20–40 times more fre-increased risk of melanoma for

quently than other UV photoproducts. The formation of a pyrimidone

regular users (El Ghissassi et al.,

(6–4) photoproduct mimics an abasic site (a nucleotide minus a base) and 2009). Even short-term tanning

is more effi ciently repaired than cyclobutane pyrimidine dimers. The for-salon exposure (10 treatments

mation of a pyrimidine dimer causes a bend in the DNA helix and, as a in 2 weeks) results in the forma-result, DNA polymerase cannot read the DNA template. Under these con-tion of cyclobutane pyrimidine

ditions DNA polymerase preferentially incorporates an “A” residue.

dimers. A natural look is less

Consequently, TT dimers are often restored but TC and CC dimers result taxing for your DNA!

in transitions (TC→TT and CC→TT) (Figure 2.4c). Results from a mam-

malian cell system showed that cyclobutane pyrimidine dimers are responsible for at least 80% of UVB-induced mutations. The precise class of mutations resulting from pyrimidine dimers is a unique molecular signature of skin cancer (see Box “Skin cancer”)—they are not found in any other types of cancer.

30 2: DNA STRUCTURE AND STABILITY: MUTATIONS VERSUS REPAIR

(a)

(b)

P

O

H

O

C

N

N

C O

TT Cyclobutane

TC (6 – 4) pyrimidine-

C

C

pyrimidine dimer

pyrimidone photoproduct

H

CH3

P

H

O

O

O

C

N

CH

N O

3

5

O

N

C O

C

C

N

CH

CH

3

N

3

O

H

H

P

O

5

6

NH

C

N

CH3

N

2

O

6

6

N

C O

O

N

O

O

N

N

C

C

4

N

H

CH3

5

6

P

O

H

O

C

N

N

C O

C

C

H

CH

P

3

G G

(c)

C C

DNA

UV radiation

polymerase

G G

G G

C C

C C

DNA

A A

polymerase

T T

Pyrimidine

A A

Figure 2.4 (a) UV photoproducts.

dimer

C C

(b) A pyrimidine dimer in the

G G

context of a polynucleotide chain.

C C

(c) Steps involved in UV-induced

transitions.

C C

T T

Transition

UVA indirectly damages DNA via free radical-mediated damage. Water

is fragmented by UVA, generating electron-seeking ROS (such the hydroxyl radical as mentioned earlier) that cause DNA damage (e.g. oxidation of bases). G→T transversions are characteristic of UVA damage.

Skin cancer

UV light is specifi cally carcinogenic to the skin because it does not penetrate the body any deeper than the skin. The skin is made up of squamous cells, basal cells, and melanocytes, and skin cancers are classifi ed by the cell type they affect: squamous cell carcinoma (SCC), basal cell carcinoma (BCC), and melanoma, respectively. The depth of transmission of each type of UV light is dependent on the wavelength: UVC only penetrates into the superfi cial layer of the skin, UVB penetrates into the basal level of the epidermis, and UVA penetrates into the more acellular dermis level. Sunscreens work on the basis of including UV-absorbing organic chemicals (e.g. cinnamates), inorganic zinc-containing pigments, or titanium oxides in their ingredients to minimize UV absorption by the skin. (Note ¼

2 . 3 C A R C I N O G E N I C AG E N T S 31

¼ that melanin formation, known to most people as tanning, is a natural defense mechanism against UV absorption.) Additional ingredients in sunscreens must be used with care as we have learned that some compounds may be photosensitized carcinogens, chemicals that can be activated by UV to become carcinogenic. Ironically, some early sunscreens included bergamot oil which contains 5-methoxy psoralen, a photosensitized carcinogen! Some drugs, such as fl uoroquinolone antibiotics, are also photosensitized carcinogens, which explains the reasons for the precautions from doctors to stay out of the sun during their administration.

A cellular mechanism for the elimination of UV-damaged skin cells is to initiate apoptosis. This phenomenon is familiar to us as the peeling of the skin after a sunburn. The tumor suppressor p53 protein (introduced in Chapter 1 and discussed in detail in Chapter 6) is an important regulator of apoptosis. Mutation of the p53 gene is important for the initiation of squamous cell and basal cell carcinoma, but not melanoma. The characteristic mutations (CC→TT transitions) caused only by UV and no other carcinogen were identifi ed in the p53 gene. Mutations in the p53 gene which disrupt normal p53 function and provide cells with a growth advantage, may induce the formation of tumor cells. The pattern of mutation is not random but rather tends to be localized to nine places, called hot spots.

This suggests that p53 mutations are causal for skin cancer. Further investigation of why there are so few hotspots within the context of hundreds of sites with adjacent pyrimidine dimers in the p53 gene yielded an explanation. The hot spots in p53 are not repaired effi -

ciently. Removal of cyclobutane pyrimidine dimers is particularly slow at these sites. The resulting loss of p53 function causes a block in apoptosis and consequently allows the proliferation of mutated p53 cells. Thus, UV radiation not only induces p53 mutations but also selects for the clonal expansion of the p53 mutated cells, by inducing apoptosis in normal cells with wild-type p53.

Different pathways seem to be central for melanoma. The elucidation of one of these pathways was one of the fi rst successes of the Cancer Genome Project. It identifi ed mutations in the BRAF gene in 66% of malignant melanomas (Davies et al. , 2002).

BRAF is a serine/threonine kinase that functions in the signal transduction pathway downstream of a melanocyte-stimulating hormone and may explain why there is a high frequency of BRAF mutations in melanoma relative to other cancers. Surprisingly, the major mutation identifi ed (T→A) in the kinase domain is not characteristic of UV-induced mutations (CC→TT). See Chapter 4 for a newly approved drug designed to target BRAF.

Chemical carcinogens

Many chemicals in our environment and in our diet play a role in human carcinogenesis. The common mechanism of action of chemical carcinogens is that an electrophilic (electron-defi cient) form reacts with nucleo-philic sites (sites that can donate electrons) in the purine and pyrimidine rings of nucleic acids. Some chemical carcinogens can act directly on DNA but others become active only after they are metabolized in the body, forming what are called ultimate carcinogens, the molecules that execute the damage. A family of enzymes called the cytochrome P450 enzymes is

32 2: DNA STRUCTURE AND STABILITY: MUTATIONS VERSUS REPAIR

involved in the metabolism of chemicals in the liver and is important in the activation of carcinogens to ultimate carcinogens. Genetic polymorphisms and variable expression account for differences in responses to chemical carcinogens among individuals. For example, the expression of one of the P450 enzymes called CYP1A1 (aryl hydrocarbon hydroxylase) can vary 50-fold in human lung tissue and may be responsible for the delivery of varying doses of ultimate carcinogens among smokers (Alexandrov et al. , 2002).

Carcinogens can be segregated into 10 groups:

(i)

polycyclic aromatic hydrocarbons

(ii) aromatic

amines

(iii) azo

dyes

(iv) nitrosamines and nitrosamides

(v)

hyrazo and azoxy compounds

(vi) carbamates

(vii) halogenated compounds

(viii) natural products

(ix) inorganic

carcinogens

(x)

miscellaneous compounds (alkylating agents, aldehydes, phenolics).

Four major classes of carcinogens are described in the following sections: polycyclic aromatic hydrocarbons (PAHs), aromatic amines,

nitrosamines, and alkylating agents. These carcinogens exert their

effects by adding functional groups covalently to DNA. Chemically

modifi ed bases, called DNA adducts, distort the DNA helix causing

errors to be made during replication. The resulting mutations initiate cell carcinogenesis.

LIFESTYLE TIP

Polycyclic aromatic hydrocarbons (PAHs)

The International Agency for

Research on Cancer (IARC) has

The fi rst demonstration that chemicals could be used to induce cancer in classifi

ed 81 compounds in

animals was carried out in 1915. Coal tar, containing carcinogenic PAHs, mainstream cigarette smoke as

induced skin carcinomas on the ears of rabbits. Carcinogenic PAHs are carcinogens (Smith et al., 2003).

derived from phenanthrene (Figure 2.5a). Additional rings and/or methyl Benzo[a]pyrene (BP) ranks high

groups in the bay region of the three aromatic rings can convert inactive in the measure of lipophilicity (a

phenanthrene into an active carcinogen. Benzo[a]pyrene (BP), the most feature that allows easy entry

well known carcinogen in cigarette smoke, and 7,12-dimethyl benz[a]

into cells) and associated carci-

anthracene (DMBA), one of the most potent carcinogens, are examples of nogenicity. The presence of nico-PAHs. PAHs must be metabolized further in order to give the ultimate car-tine makes smoking addictive.

cinogen that will form adducts with purine bases of DNA. The P450

Smoking is a cause of cancer;

not smoking prevents illness.

enzyme, CYP1A1, is the predominant enzyme that metabolizes BP to the Don’t choose to smoke.

highly reactive mutagenic BP diol epoxides (Figure 2.5b). BP results mainly in G→T transversions.

2 . 3 C A R C I N O G E N I C AG E N T S 33

(a)

O

O

Bay region

12

1

Bay region

Bay region

OH

OH

3

2

11

2

4

H

1

3

2

3C

O

11

5

12

4

1

3

6

OH

10

10

OH

9

4

8

9

10

5

7

7

HO

6

5

8

7

6

8

9

OH

CH3

Phenanthrene

Benzo[a]pyrene

7,12-dimethyl-

benz[a]anthracene

O

HO

(b)

OH

P-450

(+)-BP 7,8-diol-9,10-epoxide-2

O

Epoxide hydrolase

P-450

8

HO

12

1

7

HO

P-450

2

11

O

OH

OH

10

(-)-BP 7,8-diol-9,10-epoxide-1

3

(+)-BP 7,8-oxide

(-)-BP 7,8-dihydrodiol

9

O

4

8

P-450

P-450

7

6

5

Epoxide hydrolase

HO

8

OH

BP

7

HO

(+)-BP 7,8-diol-9,10-epoxide-1

O

P-450

O

OH

(-)-BP 7,8-oxide

(+)-BP 7,8-dihydrodiol

HO

OH

(-)-BP 7,8-diol-9,10-epoxide-2

Aromatic amines

Figure 2.5 (a) Examples of

polycyclic aromatic amines.

Heterocyclic amines (HCAs) are carcinogens produced by cooking meat, (b) Metabolic activation of BP.

formed from heating amino acids and proteins. About 20 HCAs have

been identifi ed. Three examples, Phe-P-1, IQ, and Mel Q, are shown in Figure 2.6. It is important to be aware of these as they illustrate an example of carcinogens to which we may be exposed daily and which are produced in our own kitchens.

A LEADER IN THE FIELD . . . of molecular carcinogenesis: Gerd Pfeifer Gerd Pfeifer has made important contributions to determining the molecular mechanisms of cancer. Investigations into skin and lung cancer provided strong evidence that UV radiation and carcinogens in cigarette smoke are causative agents for each cancer, respectively.

Pfeifer and his colleagues demonstrated that the mutational hotspots of the p53 gene ¼

34 2: DNA STRUCTURE AND STABILITY: MUTATIONS VERSUS REPAIR

¼observed in skin cancer cells are due to low-effi ciency repair of DNA at these sites as discussed in the Box “Skin cancer.” By mapping DNA adducts of the p53 gene that are formed after exposure to benzo[a]pyrene diol epoxide (a potent cigarette carcinogen), Pfeifer and colleagues showed that the locations of these adducts matched the distribution of p53 gene mutations in lung tumors from smokers. This seminal work, reported in Science in 1996, provided a direct causal link between a defi ned carcinogen and lung cancer.

Gerd Pfeifer received his PhD from the University of Frankfurt, Germany. He has crossed the Atlantic and is currently a Professor and Chair at the City of Hope, Beckman Research Institute in California. His research group is continuing to study the mechanisms of mutagenesis in cancer and is also currently investigating epigenetic mechanisms of gene regulation in cancer (discussed in Chapter 3).

Nitrosamines and nitrosamides

Many nitrosamines and nitrosamides are found in tobacco or are formed when preservative nitrites react with amines in fi sh and meats during PAUSE AND THINK

smoking. The structure of alkylnitrosoureas, examples of nitrosamines, is What is the structural difference

shown in Figure 2.7(a). Their principal carcinogenic product is alkylated between IQ and Mel Q?

O6 guanine derivatives, as shown in Figure 2.7(b) (guanine is depicted next to it for comparison).

NH2

N

N

CH3

N

Ph

2-Amino-3 methylimidazo

[4,5-f] quinoline (IQ)

N

NH2

NH2

2 Amino-5 phenylpyridine

(PHe-P-1)

N

N

CH3

N

CH3

2-Amino-3,4 dimethylimidazo

[4,5-f] quinoline (Mel Q)

Figure 2.6 Heterocyclic amines.

2 . 3 C A R C I N O G E N I C AG E N T S 35

(a)

NO

O

R

N

C

NH2

R = CH3 or C2H5 or C3H7

Alkylnitrosoureas

(b)

O

CH3

O

N

N

N

HN

Figure 2.7 (a) An example of

N

N

N

H

H

nitrosamines: alkylnitrosoureas.

2N

N

2N

(b) A potential carcinogenic

DNA

DNA

product of nitrosamines: O6

adduct of guanine. Guanine is

O6 adduct of Guanine

Guanine

shown for comparison.

Alkylating agents

C2H4Cl

Mustard gas (sulfur mustard, Figure 2.8) is the most well known exam-S

ple of an alkylating agent because of its use and consequences observed C2H4Cl

during World War I. It is a bi-functional (having two reactive groups) Figure 2.8 Structure of mustard carcinogen that is able to form intra- and inter-chain cross-links on DNA gas.

directly.

Fibrous minerals: asbestos and erionite

Asbestos and erionite are naturally occurring fi brous minerals that act as LIFESTYLE TIP

chemical/physical carcinogens and mutagens. In 2009, IARC concluded from a study of women heavily exposed to asbestos in the workplace, It has been suggested that

that asbestos induced mutagenicity, chromosomal aberrations, aneu-

changes in the way we prepare

ploidy, polyploidy, and epigenetic alterations in the disease process.

food can reduce the amounts of

HCAs produced. Oven-roasting,

Asbestos is a group of fi brous silicate minerals that was used extensively marinating, and coating food

in building materials because of its insulating properties but is now pro-with breadcrumbs before frying

hibited in several countries (but is still used in the developing world) are modifi

cations that may

because of its association with several diseases of the lung, including lung reduce the formation of HCAs.

cancer and mesothelioma. Erionite is a fi brous zeolite mineral formed from volcanic rock. Although the exact mechanisms of carcinogenesis remain unclear, they may include generation of ROS, physical interaction with the mitotic machinery, and induction of a chronic infl ammatory response (see Chapter 10), in addition to genetic and epigenetic alterations. Genetics may predispose some people to the carcinogenic effects of fi brous materials.

36 2: DNA STRUCTURE AND STABILITY: MUTATIONS VERSUS REPAIR

? HOW DO WE KNOW THAT?

Family pedigrees

X-ray diffraction, showed that there was no difference

between the type of erionite in villages that exhibited the

Malignant mesothelioma is a rare cancer that is linked to

epidemic and those that did not. However, malignant meso-

fi brous minerals. It is rare in the USA and the UK; however,

thelioma was prevalent in some families and absent in others

there is an epidemic of malignant mesothelioma in several

and marriages between these two groups led to some off-

small villages of Turkey that has been linked to exposure to

spring developing the disease. Thus, the data demonstrate

erionite. Fifty per cent of all deaths in these regions are due

that a genetic predisposition can infl uence mineral fi ber car-

to malignant mesothelioma! Pedigree studies of families that

cinogenesis.

live in these villages uncovered a link between genetics and

Dogan et al. (2006) and family pedigree data within: available fi ber carcinogenesis. Chemical and physical analysis, includ-

online at http://cancerres.aacrjournals.org/cgi/reprint/66/10/5063

ing scanning electron microscopy, mass spectrometry, and

Infectious pathogens as carcinogens

Early in the 20th century, viruses were shown to cause tumors in animals.

As we will see in Chapter 4, they have been invaluable tools for investigating the molecular events of cell transformation. Viruses that are oncogenic can be classifi ed as DNA tumor viruses or RNA tumor viruses (also called retroviruses), depending on the nucleic acid that defi nes their genome. The mechanisms of carcinogenesis for these two classes of virus differ. DNA tumor viruses encode viral proteins that block tumor suppressor genes, often by protein–protein interactions (discussed in Chapter 6). Many retroviruses cause cancers in animals by encoding mutated forms of normal genes (i.e. oncogenes) that have a dominant effect in host cells (discussed in Chapter 4). Mechanisms of replication between DNA and RNA viruses

also differ. Some DNA viruses, such as human papilloma and Epstein–Barr viruses, replicate strictly as episomes within host cells. Retroviruses replicate by integration of the viral genome into the host DNA and utilize the host’s translational machinery to produce viral proteins. Integration may lead to deregulated gene expression.

Direct causation of cancer by specifi c viruses and bacteria has been demonstrated and will be discussed in detail in Chapter 10. However, a few named examples are given below. The International Agency for

Research on Cancer (IARC) has classifi ed human papillomavirus (type 16 and 18) as a human carcinogen and a causative agent of cervical

cancer. In addition, Kaposi’s sarcoma-associated herpesvirus (KSHV) causes Kaposi’s sarcoma, hepatitis B virus is associated with liver cancer, and Epstein–Barr virus (EBV) with nasopharyngeal carcinoma. The human T-cell lymphotropic virus type 1 (HTLV-1) is the only retrovirus known to cause cancer in humans. It causes acute T-cell leukemia

(ATL). Helicobacter pylori, a Gram-negative spiral bacterium, establishes chronic infection and ulcers in the stomach and alters host cell

2 . 3 C A R C I N O G E N I C AG E N T S 37

function, which is associated with carcinogenesis. The IARC has classifi ed H. pylori as a human carcinogen and one of the causative agents of gastric cancer. The typhoid pathogen, Salmonella enterica serovar Typhi ( S. typhi), establishes chronic infection in the gallbladder and has been linked to hepatobiliary and gallbladder carcinoma. The molecular events behind the mechanism of bacteria-induced transformation are

the subject of current studies. The promotion of host cell proliferation, the generation of oxygen free radicals and subsequent DNA damage,

and the activation of oncogenes are areas of investigation (Lax and Thomas, 2002).

Endogenous carcinogenic reactions

In addition to carcinogens, endogenous cellular reactions generate mutations. Oxidative respiration and lipid peroxidation, two processes of normal cell metabolism, produce ROS that can react with DNA and lipids to produce oxidized products (e.g. 8-oxoguanine) also seen by exposure to radiation (see Box “A little lesson about ROS . . .”). During respiration, the initiating radical, superoxide anion (O−⋅

2 ) is produced upon reduction

of NADH and formation of ubisemiquinone during oxidative phospho-

rylation. Therefore, breathing generates the same ROS intermediates as those generated by radiation! However, the dose of these intermediates differs between the two sources: radiation produces extremely reactive hydroxy radicals immediately and randomly within a cell, while respiration produces the less reactive superoxide radical immediately and only at specifi c locations within the cell.

Spontaneous chemical reactions (e.g. hydrolysis of the glycosidic

bond between a base and deoxyribose producing an abasic site) also

contribute to the formation of mutations. Deamination of cytosine to form uracil is the most common. Errors during DNA replication and

DNA recombination contribute to the formation of mutations, although the DNA polymerases used possess proofreading ability to help minimize the number of mutations caused in this way. The proofreading

function is dependent on the 3′–5′ exonuclease activity of the polymerase. If an incorrect nucleotide is added to the growing 3′ end of the newly synthesized strand the DNA double helix exhibits melting; that is, the strands remain separated at this point. Melting causes the polymerase to pause and the strand is transferred to the exonuclease site. Here, the incorrect nucleotide is removed, the strand is transferred back to the original polymerase binding site, and DNA synthesis reoccurs. Overall, it is estimated that 104–106 mutations occur in a single human cell per day. By and large, under normal circumstances, this immense error burden is successfully dealt with by the highly effi cient cellular DNA repair mechanisms.





38 2: DNA STRUCTURE AND STABILITY: MUTATIONS VERSUS REPAIR

2.4 DNA repair and predispositions to cancer

DNA repair is an important line of defense against mutations caused by carcinogens and by endogenous mechanisms. If DNA lesions are not

repaired before a cell replicates, they may contribute to carcinogenesis.

Repair of the various types of mutation is accomplished by several different DNA repair mechanisms. Five types of DNA repair systems are

described in the following sections: one-step repair, nucleotide excision repair, base excision repair, mismatch repair, and recombinational

repair. Defects in most of these pathways result in a predisposition to cancer.

One-step repair

One-step repair involves the direct reversal of DNA damage. The repair enzyme alkyltransferase directly removes an alkyl group from the O6

atom of guanine after exposure of DNA to alkylating carcinogens such as N-methylnitrosourea. In this case, a methyl group is transferred to a cysteine residue on the alkyltransferase and the alkyltransferase becomes inactive.

Nucleotide excision repair (NER)

Nucleotide excision repair is specifi c for helix-distorting lesions such as pyrimidine dimers and bulky DNA adducts induced by environmental

agents (UVB and PAHs, respectively). This damage interferes with

transcription and replication as described earlier. Two subpathways exist: global genome NER surveys the genome for helix distortion and transcription-coupled repair identifi es damage that interferes with transcription. The lesion, along with some (24–32) adjacent nucleotides, is excised out by endonucleases, and DNA polymerase δ/ε is used to fi ll in the gap using the opposite strand as a template. Proliferating cell nuclear factor is part of the polymerase holoenzyme and physically forms a ring that encircles and binds the damaged region. Xeroderma pigmentosum

(XP) is an inherited disorder characterized by a defect in NER. Affected individuals are hypersensitive to the sun and have a 1000-fold increased risk of skin cancer. Seven XP gene products (XPA–XPG) have been identifi ed out of the 25 proteins involved in NER.

Base excision repair (BER)

Base excision repair targets chemically altered bases (e.g. 8-oxoguanine) induced mostly by endogenous mechanisms; in the absence of such

2 . 4 D N A R E PA I R A N D P R E D I S P O S I T I O N S TO C A N C E R 39

repair the damage will cause a point mutation. The 8-oxoguanine lesion can functionally mimic T and form a stable 8-oxoguanine: A base pair, often bypassing detection by replicative DNA polymerases. Failure to remove 8-oxoguanine before replication results in a G→T transversion mutation. The fi rst step of base excision repair is carried out by a family of DNA-damage-specifi c glycosylases (such as OGG1 and MUTYH)

which scan millions of base pairs per second for 8-oxoguanine lesions.

These glycosylases then fl ip the lesion outside of the helix and cleave the base from the DNA backbone, creating an abasic site. Subsequently, an endonuclease cleaves the DNA strand at the abasic site and DNA

polymerase β replaces the nucleotide and ligase fi lls the gap. Poly (ADP-ribose) polymerase (PARP) interacts with single strand break

intermediates formed during BER. Mutations in the OGG1 gene that codes for the principal glycosylase responsible for the repair of 8-oxoguanine: C base pairs have not been identifi ed in tumors to date. No inherited defects in BER had been identifi ed in humans until recently—

mutations in the MUTYH (formerly hMYH) gene that encodes a DNA glycosylase responsible for the removal of mismatched adenines paired with 8-oxoguanine may be the principal cause of multiple colorectal adenoma syndrome (David et al. , 2007).

Mismatch repair

Mismatch repair corrects replication errors that have escaped editing by polymerases. It includes repair of insertions and deletions produced as a result of slippage during the replication of repetitive sequences, as well as nucleotide mismatches. The molecular events can be described in brief as follows:

• recognition of the mismatch is carried out by proteins HMSH2/6 and hMSH2/3

• hMLH1/hPMS2 and hMHL1/hPMS1 are recruited

• the newly synthesized strand is identifi ed (fl agged by the replication machinery)

• endonucleases and exonucleases remove the nucleotides around and including the mismatch

• DNA polymerases resynthesize a newly replicated strand.

Hereditary non-polyposis colorectal cancer (HNPCC) is one of the

most common cancer syndromes in humans. Half of all patients with

HNPCC carry a germline mutation in hMLH1 or hMSH2. Loss of function of the protein products encoded by these genes is responsible for complete loss of mismatch repair. Thus, cells are vulnerable to mutations.

40 2: DNA STRUCTURE AND STABILITY: MUTATIONS VERSUS REPAIR

Recombinational repair

Homologous recombination and non-homologous end-joining are two

types of recombinational repair that mend double-strand DNA breaks.

Homologous recombination depends on the presence of sister chromatids formed during DNA synthesis as a template for recombining severed ends.

Many members of the same protein family make up a complex that per-

forms what has been nicknamed DNA gymnastics. The molecular events

shown in Figure 2.9 are described in brief:

(a) A double-strand break activates the ataxia telangiectasia mutated (ATM) kinase.

(b) The RAD50/MRE11/NBS1 complex (a substrate of ATM) uses its 5′–3′

exonuclease activity (depicted by scissors in Figure 2.9) to create single-stranded 3′ ends.

(c) BRCA1/2 aids in the nuclear transport of RAD51 (shown as gray

circles).

(d) RAD52 facilitates RAD51 binding to these exposed ends to form a nucleoprotein fi lament.

(e) RAD51 can exchange a homologous sequence from a single strand

within a double-stranded molecule (shown in red; e.g. a sister

chromatid), with a single-stranded sequence.

(f) The sequences from the double-stranded molecule are then used as a template sequence for repair.

(g) Resolvases restore the junctions formed as a result of homologous recombination, called Holliday junctions.

(h) Two copies of intact DNA molecules are produced with rarely any errors.

Ataxia telangiectasia is an inherited syndrome whereby patients have a mutation in the ataxia telangiectasia mutated (ATM) kinase. Patients are sensitive to X-rays and have an increased risk of lymphoma. Germline mutations in the BRCA1 and BRCA2 genes give rise to an increased risk of breast and ovarian cancers. Those who develop cancer show that they acquired a second mutation later in life and illustrate that BRCA1 and BRCA2 act as tumor suppressor genes. Loss of homologous recombination leads to genomic instability and carcinogenesis. Note that loss of function of these genes also occurs in sporadic tumors.

Suffi ce it to say that the other type of recombinational repair, end-joining, links non-homologous ends and is therefore error prone, and can possibly result in chromosomal translocations.

One of the main molecular players involved in carcinogenesis is p53

and should be mentioned here. p53, “the guardian of the genome,” is a

2 . 4 D N A R E PA I R A N D P R E D I S P O S I T I O N S TO C A N C E R 41

(a)

5′

3′

ATM

(b)

5′

RAD50

MRE11

NBS1

BRCA1

RAD52

(c)

BRCA2

RAD51 ( )

(d)

Homologous sequence

(e)

Double-stranded DNA

DNA

synthesis

(f)

DNA

synthesis

(g)

Holliday junction

resolvases

(h)

Figure 2.9 Recombinational

Homologous recombination complete

repair.

protein that plays an important role in the molecular events that protect the integrity of DNA; it is central in the orchestration of DNA repair. The details of this important tumor suppressor protein will be discussed in Chapter 6.





42 2: DNA STRUCTURE AND STABILITY: MUTATIONS VERSUS REPAIR

Therapeutic strategies

2.5 Conventional therapies: chemotherapy and

radiation therapy

Conventional therapies continue to extend and save lives. It is important to understand their rationale before moving to more molecular approaches discussed later in the text. Several conventional therapies aim to induce extensive DNA damage in order to trigger apoptosis and paradoxically include agents classifi ed as carcinogens. Other conventional therapies inhibit DNA metabolism in order to block DNA synthesis in the rapidly dividing cancer cells. DNA synthesis is essential to produce a new set of chromosomes for the daughter cells produced by cell division. Still other drugs interfere with the mechanics of cell division. Both chemotherapies and radiotherapy will be discussed.

Chemotherapy

A brief description and examples of the three main types of classical chemotherapy are given in the following sections.

Alkylating agents and platinum-based drugs

Alkylating agents and platinum-based drugs work by a similar mode of action. Alkylating agents have the ability to form DNA adducts by covalent bonds via an alkyl group. They may act during all phases of the cell cycle. Chlorambucil (Figure 2.10a) is one example of a member of the nitrogen mustard family of drugs. Its usual target is the N7 position of guanine residues. Bi-functional alkylating agents (compounds with two reactive groups) form intra-strand and inter-strand cross-links in DNA that alter the conformation of the double helix or prevent separation of the DNA strands and interfere with DNA replication. They are much

more potent than monofunctional analogs, indicating that cross-linking is the basis of their function as monofunctional analogs cannot cross-link.

Some drugs require metabolic activation within the body. The alkylat-PAUSE AND THINK

ing agent cyclophosphamide (Figure 2.10b) is one example. Oxidases in Do you recall a similar mecha-the liver produce an aldehyde form that decomposes to yield phosphoranism of action for any carcino-

mide mustard, the biologically active molecule.

gens?

The platinum-based drugs, such as cisplatin [cis Pt(II)(NH3)2Cl2] and carboplatin (Figure 2.10c and 2.10d, respectively), form covalent bonds via the platinum atom. Cisplatin is a water-soluble molecule that contains

2 . 5 C O N V E N T I O N A L T H E R A P I E S : C H E M OT H E R A P Y A N D R A D I AT I O N T H E R A P Y 43

CH2CH2Cl

(a)

CH2CH2

N

Chlorambucil

CH2CH2Cl

COOH

NH

CH

(b)

2CH2Cl

O

P

N

Cyclophosphamide

CH

O

2CH2Cl

(c)

H3N

Cl

Pt

Cisplatin

H3N

Cl

O

(d)

H

O

C

3N

Pt

Carboplatin

Figure 2.10 Examples of

H3N

O

C

alkylating agents and platinum-

O

based drugs.

a Pt atom bound to four functional groups. The Pt–N bond has a covalent character and is essentially irreversible, whereas that with Cl is more labile. Cl is replaced with water in the plasma and cytosol before the molecule binds to the N7 position of guanine and adenine in its DNA target.

The GG, AG, and GXG (where X can be any base) adducts comprise over 90% of the total. The resulting DNA damage triggers apoptosis. Although cisplatin had a major impact on some cancers, such as ovarian cancer, it was associated with irreversible kidney damage. Later, carboplatin was identifi ed as a less toxic platinum analog.

Antimetabolites

Antimetabolites are compounds that are structurally similar to endogenous molecules (e.g. nitrogenous bases of DNA) and therefore can mimic their role and inhibit nucleic acid synthesis. Two examples, fl uorodeoxyuridylate (F-dUMP) and methotrexate, are shown alongside similar endogenous molecules, deoxyuridylate and dihydrofolate, respectively, in Figure 2.11. 5-Fluorouracil (5-FU) is a derivative of uracil and is converted into F-dUMP. F-dUMP competes with the natural substrate dUMP for the catalytic site of thymidylate synthase, the enzyme that produces thymidylate (dTMP) (Figure 2.12). F-dUMP forms a covalent complex with the enzyme and acts as a suicide inhibitor, generating an intermediate that inactivates the thymidylate synthase through covalent modifi cation. As a result, the dTMP and dTTP pools are depleted, dUMP and dUTP accumulate, and

44 2: DNA STRUCTURE AND STABILITY: MUTATIONS VERSUS REPAIR

O

O

F

H

HN

HN

(a)

N

O

H

N

O

H

deoxyribose-P

deoxyribose-P

Fluorodeoxyuridylate

Deoxyuridylate

(F-dUMP)

dUMP

H2N

N

N

(b)

O –

N

O

N

H

N

N

NH2

H3C

O O

O

–

Methotrexate

H

H2N

N

N

O –

HN

O

N

H

Figure 2.11 Antimetabolites: (a)

O

HN

N

fl uorodeoxyuridylate (F-dUMP)

and (b) methotrexate. Structural

differences between the

O O

O

antimetabolite and endogenous

–

molecule are shown in red.

Dihydrofolate

DNA synthesis in rapidly dividing cells is severely compromised. Another important antimetabolite, methotrexate, targets an accessory enzyme of the same reaction. As an analog of dihydrofolate, methotrexate is a competitive inhibitor of dihydrofolate reductase, the enzyme used to regenerate tetrahydrofolate that is required in the thymidylate synthase reaction (Figure 2.12; see Chapter 11 for further discussion of tetrahydrofolate).

Organic drugs

Doxorubicin is a fungal anthracycline antibiotic that inhibits topoisomerase II, an enzyme that releases torsional stress during DNA replication, by

2 . 5 C O N V E N T I O N A L T H E R A P I E S : C H E M OT H E R A P Y A N D R A D I AT I O N T H E R A P Y 45

Fluorouracil

Figure 2.12 Action of

antimetabolites

fl uorodeoxyuridylate (F-dUMP)

and methotrexate (both shaded

dUMP

F-dUMP

red). The enzyme thymidylate

synthetase uses N5N10

methylenetetrahydrofolate as a

dTMP DNA

methyl donor and catalyzes the

methylation of dUMP to form

Thymidylate

N5N10 Methylene-

synthase

dTMP. The cancer drug

tetrahydrofolate

fl uorouracil is converted into the

antimetabolite F-dUMP (red

Methotrexate

rectangular shape), which

Dihydrofolate

competes (////) with dUMP and

targets thymidylate synthetase

NADPH

(target symbol, , shown).

Glycine

Methotrexate (red triangle) is an

NADP+

antimetabolite that competes (////)

+ H+

Serine

Dihydrofolate

with dihydrofolate and

reductase

methotrexate targets the enzyme

dihydrofolate reductase (target

Tetrahydrofolate

symbol, , shown).

trapping single-strand and double-strand DNA intermediates. Doxo-

rubicin diffuses across cell membranes and accumulates in most cell types.

Cardiac damage is its most severe side-effect, but new compounds (e.g.

ICRF-187) that can block the cardiac toxicity are being investigated. These drugs are primarily used to treat solid tumors (e.g. of the breast or lung).

The plant alkaloids vincristine and vinblastine (from the Madagascar periwinkle plant) bind to tubulin and prevent microtubule assembly in contrast to the drug paclitaxel (taxol) which binds to the β-tubulin subunit in polymers and stabilizes the microtubules against depolymerization.

Thus, two opposing strategies can be used to disrupt the mitotic spindle.

Radiation therapy

Radiation therapy, either alone or in combination with other therapies, is received by approximately 60% of cancer patients in the USA. Ionizing radiation is usually delivered to the tumor by electron linear accelerators.

Radiation reacts with water inside cells to generate ROS that damage DNA. Apoptosis will be induced in cells that contain large amounts of DNA damage. The supply of oxygen affects the potency of ionizing

radiation and is thought to be caused by the generation of ROS. Oxygen can assist in making radiation-induced damage permanent. More

double-strand breaks occur in cells irradiated in the presence of oxygen

46 2: DNA STRUCTURE AND STABILITY: MUTATIONS VERSUS REPAIR

than in cells irradiated in the absence of oxygen. Therefore, the number of zones of hypoxia within a solid tumor infl uences the outcome of radiation treatment. Targeting of the tumor has been made more precise by modern techniques such as magnetic resonance imaging (MRI) and computed

tomography (CT) which produce three-dimensional images of the tumor within the body.

Heterogeneous cell sensitivity and drug resistance: obstacles to these treatments

In addition to the severe side-effects that result, there are also practical PAUSE AND THINK

problems with conventional therapies. Cancer cells, as part of a large We are familiar with the con-tumor mass, will receive different doses of treatment depending on the cept that overuse of antibiotics

location of individual cells within the mass. Cells deep within the tumor can lead to the creation of

and therefore furthest from the blood supply will receive lower doses than resistant bacteria. Their rapid

cells on the surface of the tumor. Cells within the same tumor may have division and high frequency of

acquired different mutations and some cells may have become resistant to mutation allows for the selec-the drug.

tion of bacterial strains that can

Anticancer drugs impose a strong force for the selection of cells that can evolve to survive in the presence

of the drug. Rapidly dividing

acquire drug resistance. There are several mechanisms that a cancer cell human cells that are genetically

may utilize to become resistant to chemotherapy (Figure 2.13). Cells may unstable can acquire resistance

become resistant by increasing the effl ux of the drug, decreasing the intake in a similar manner.

= drug

Modify drug

metabolism

Gene

Increase

amplification

drug target

*

Increase DNA repair

Figure 2.13 Mechanisms of drug

P-glycoprotein

resistance. Based on a diagram

Efflux

Influx

printed in Annu. Rev. Med. 53,

Copyright (2002) by Annual

Reviews (http://www.

annualreviews.org/).





2 . 6 S T R AT E G I E S T H AT TA R G E T D N A R E PA I R PAT H WAYS 47

of the drug, increasing the number of target molecules within the cell, or altering drug metabolism or DNA repair processes. Increasing the effl ux of a drug is regulated at the cell surface. There is a family of ATP-dependent transporters that are involved in the movement of nutrients and other molecules across membranes. The multi-drug resistance gene ( MDR1) codes for one member of this family called P-glycoprotein (P-gp) or the multi-drug transporter. This protein, normally a chloride ion effl ux pump, can bind a variety of chemotherapeutic drugs, including doxorubicin, vinblastine, and taxol. Upon binding, ATP is hydrolyzed and causes a conformational change of P-gp. As a result, the drug is released extracellularly.

The transporter can be recycled by a second hydrolysis of ATP and continue to increase the effl ux of the drug. Some drugs utilize specifi c transporters to enter cells. Mutations in these receptors may render them non-functional and decrease infl ux of the drug. Resistance to methotrexate commonly occurs by mutation of the folate transporter. An increase in the number of drug target molecules by gene amplifi cation is another means of developing resistance against methotrexate. The DHFR gene is amplifi ed in some cancer cells. An increase in the effi ciency of DNA repair, such as increased alkyltransferase activity, can give rise to resistance from alkylating agents such as doxorubicin. Levels of this enzyme are found to be highly variable in different tumors.

2.6 Strategies that target DNA repair pathways

Synthetic lethal strategies

The name “synthetic lethal strategies” sounds like it was used in a James Bond fi lm. It involves interactions whereby inhibiting the function of one gene is cytotoxic only in the presence of an additional mutation. Let’s look at the development of poly (ADP-ribose) polymerase (PARP) inhibitors for use in tumors with BRCA1/2 mutations as an example of a synthetic lethal strategy. PARPs are enzymes that are key in base excision repair, a pathway that repairs DNA single-strand

breaks. Inhibition of PARP causes impaired base excision repair and the accumulation of single-strand breaks that can lead to double-strand breaks, normally repaired by homologous recombination pathways.

The synthetic lethal strategy takes advantage of the characteristic DNA repair defect caused by mutations in tumors in some cases of inherited breast cancer. Some of these patients carry a germline mutation in either tumor suppressor gene, BRCA1 or BRCA2, and acquire a somatic mutation in the other BRCA1/2 allele later in life. This results in a

48 2: DNA STRUCTURE AND STABILITY: MUTATIONS VERSUS REPAIR

BRCA1/BRCA2

PARP

Homologous

Base excision repair (BER): SS breaks

recombination (HR)

BRCA1/BRCA2 mutations

PARP inhibitors

Impaired HR

Impaired BER ds breaks HR

(normal cell survives)

BRCA1/BRCA2 mutations

and

PARP inhibitors

Impaired HR

Impaired BER

Figure 2.14 The rationale of

synthetic lethal interactions:

Synthetic lethal in tumor cells

PARP inhibitors.

tumor that is defi cient in homologous recombination and double-strand repair; the non-tumor cells in the patient do not carry the homozygous BRCA1/2 mutated genotype and retain the homologous recombination DNA repair pathway. Tumors cells that lack BRCA1/2 function and are treated with PARP inhibitors have impaired homologous recombination and base excision repair pathways, and these characteristics are lethal; healthy cells treated with PARP inhibitors have a functional homologous recombination pathway and are viable (Figure 2.14).

Administration of the PARP inhibitor called olaparib in a Phase I trial showed an anti-tumor effect in BRCA1 or BRCA2 defi cient tumors

(Fong et al. , 2009). Note that this trial tested olaparib as a single agent, in the absence of DNA-damaging chemotherapy and showed less

adverse effects. Additional PARP inhibitors are being tested in clinical trials.

Combination therapies

Inhibition of DNA repair pathways promises to be an important strategy to maximize a tumor’s sensitivity to chemotherapy and radiotherapy, as they rely on damaging DNA to exert their effect. Many clinical trials are testing combinations of PARP inhibitors with conventional DNA-damaging chemotherapies, such as platinum-based drugs and

alkylating agents, and also with radiotherapy. The therapeutic index of drug cocktails is important to monitor so as not to increase toxicity in healthy cells.

2 . 6 S T R AT E G I E S T H AT TA R G E T D N A R E PA I R PAT H WAYS 49

■ CHAPTER HIGHLIGHTS—REFRESH YOUR MEMORY

•

In simplistic terms, a gene consists of a regulatory region

•

Many chemical carcinogens add functional groups cova-

and a coding region. Mutations in the former may alter

lently to DNA.

gene expression, while mutations in the latter may affect

•

Both viruses and bacteria have been classifi ed as carcino-

the gene product.

gens for specifi c cancers.

•

Most carcinogens are mutagens.

•

One-step repair, nucleotide excision repair, base excision

•

Several types of mutations include: base substitutions

repair, mismatch repair, and recombinational repair are

(transitions and transversions), frameshift mutations

fi ve systems for repairing damaged DNA.

(insertions or deletions), and chromosomal transloca-

•

Patients with xeroderma pigmentosum have an inherited

tions.

defect in NER and have a 1000-fold increased risk of skin

•

An accumulation of mutations over time is responsible for

cancer.

transforming a normal cell into a cancer cell for most can-

•

Many patients with hereditary non-polyposis colorectal

cers, but a single event of chromothripsis may underlie a

cancer (HNPCC) have an inherited defect in mismatch

small number of cancers.

repair.

•

Mutations in the promoter region of a gene may alter its

•

The major types of chemotherapies are:

regulation.

– alkylating agents—two examples are clorambucil and

•

Mutations in the coding region of a gene may alter the

cisplatin;

function of the gene product.

– antimetabolites—two examples are 5-FU and metho-

•

Carcinogens include radiation, chemicals, and infectious

trexate;

pathogens.

– organic drugs—two examples are vincristine and vin-

•

Radiation can damage DNA directly or indirectly through

blastine.

the formation of reactive oxygen species (ROS).

•

The development of drug resistance is a major problem

•

Three intermediate ROS formed from the radiolysis of

for chemotherapy.

water are the hydroxyl radical, hydrogen peroxide, and

•

Targeting DNA repair pathways can help sensitize tumors

the superoxide radical.

to chemotherapy and has also been used to create syn-

•

The hydroxyl radical is one of the most reactive sub-

thetic lethal interactions.

stances.

•

Many carcinogens need to be metabolized to form an

ultimate carcinogen that covalently binds to DNA.

■ ACTIVITY

1. Make a list of fi ve carcinogens and the mutations they cause. Describe the method of DNA repair used to correct each type of mutation.

■ FURTHER READING

Chabner, B.A. and Roberts, T.G. (2005) Chemotherapy and the war on cancer. Nature Rev. Cancer 5: 65–72.

Evers, B., Helleday, T., and Jonkers, J. (2010) Targeting homologous recombination repair defects in cancer. Trends Pharmacol. Sci. 31: 372–380.

Gottesman, M.M. (2002) Mechanisms of cancer drug resistance. Annu. Rev. Med. 53: 615–627.

50 2: DNA STRUCTURE AND STABILITY: MUTATIONS VERSUS REPAIR

Hecht, S.S. (2003) Tobacco carcinogens, their biomarkers and tobacco-induced cancer.

Nature Rev. Cancer 3: 733–737.

Huang, S.X.L., Jaurand, M.-C., Kamp, D.W., Whysner, J., and Hei, T.K. (2011) Role of mutagenicity in asbestos fi ber-induced carcinogenicity and other diseases. J. Toxicol. Environ. Health Part B 14: 179–245.

Ichihashi, M., Ueda, M., Budiyanto, A., Bito, T., Oka, M., Fukunaga, M., et al. (2003) UV-induced skin damage. Toxicology 189: 21–39.

Jackson, S.P. and Bartek, J. (2009) The DNA-damage response in human biology and disease. Nature 461: 1071–1078.

Pfeifer, G.P., You, Y.-H., and Besaratinia, A. (2005) Mutations induced by ultraviolet light. Mutation Res./Fund. Mol. Mech. Mutagenesis 571: 19–31.

Stratton, M.R. (2009) The cancer genome Nature 458: 719–724.

Williams, G.M. and Jeffrey, A.M. (2000) Oxidative DNA damage: endogenous and chemically induced. Regulatory Toxicol. Pharmacol. 32: 283–292.

■ SELECTED SPECIAL TOPICS

Alexandrov, K., Cascorbi, I., Rojas, M., Bouvier, G., Kriek, E., and Bartsch, H. (2002) CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers’

lung: comparison with aromatic/hydrophobic adduct formation. Carcinogenesis 23: 1969–1977.

David, S.S., O’Shea, V.L., and Kundu, S. (2007) Base-excision repair of oxidative DNA damage. Nature 447: 941–950.

Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949–954.

Dogan, A.U., Baris, Y.I., Dogan, M., Emri, S., Steele, I., Elmishad, A.G., et al. (2006) Genetic predisposition to fi ber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res. 66: 5063–5068.

El Ghissassi, F., Baan, R., Straif, K., Grosse, Y., Secretan, B., Bouvard, V., et al. (2009).

A review of human carcinogens- Part D: radiation. Lancet Oncol. 10: 751–752.

Fong, P.C., Boss, D.S., Yap, T.A., Tutt, A., Wu, P., Mergui-Roelvink, M., et al. (2009) Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361: 123–134.

Ishikawa, K., Takenaga, K., Akimoto, M., Koshikawa, N., Yamaguchi, A., Imanishi, H., et al. (2008) ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 320: 661–664.

Lane, N. (2002) Oxygen—the molecule that made the world. Oxford University Press, Oxford.

Lax, A.J. and Thomas, W. (2002) How bacteria could cause cancer: one step at a time.

Trends Microbiol. 10: 293–299.

Preston, D.L., Shimizu, Y., Pierce, D.A., Suyama, A., and Mabuchi, K. (2003) Studies of mortality of atomic bomb survivors. Report 13: solid cancer and noncancer disease mortality; 1950–1997. Radiat. Res. 160: 381–407.

Smith, C.J., Perfetti, T.A., Garg, R., and Hansch, C. (2003) IARC carcinogens reported in cigarette mainstream smoke and their calculated log P values. Food Chem. Toxicol. 41: 807–817.

2 . 6 S T R AT E G I E S T H AT TA R G E T D N A R E PA I R PAT H WAYS 51

Stephens, P.J., Greenman, C.D., Fu, B., Yang, F., Bignell, G.R., Mudie, L.J., et al.

(2011) Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144: 27–40.

Tubio, J.M.C. and Estivill, X. (2011) Cancer: When catastrophe strikes a cell. Nature 470: 476–477.

This page intentionally left blank





Chapter 3

Regulation of gene expression

Introduction

Cancer is a disease of the genome at the cellular level that may be manifested by alterations in gene expression. Gene expression may be modulated in various ways, particularly through the regulation of transcription. In this chapter we will review the molecular components involved in transcriptional regulation, and how they can contribute to the processes underpinning cancer. As mentioned in Chapter 2, mutations in the promoter region of genes can alter the regulation of gene expression and lead to carcinogenesis. Accumulating evidence suggests an additional mechanism of regulating gene expression, called epigenetics (Greek for “upon” the genome), to be important for carcinogenesis. It involves PAUSE AND THINK

heritable alterations in gene expression encoded by modifi cations of the genome and its chromatin components, but not by changes in the DNA sequence. The structure of a gene To illustrate how a domain

within the context of chromatin is described in order to elucidate how gene and chromatin works, let us look at an analogy

structure affects gene expression. Throughout this chapter there is a focus on DNA–protein in which an electrical plug represents a domain. There are many

interactions in transcriptional regulation, chromatin confi guration, and telomere exten-different household appliances

sion. In addition, the role of the small non-coding RNAs called micro RNAs (miRNAs) in the with vastly different functions,

regulation of post-transcriptional gene expression is presented.

such as a toaster, an iron, and a

television. However, each appli-

ance contains a plug that has a

function independent of the rest

3.1 Transcription factors and transcriptional regulation

of the appliance. It has a specifi c

conformation that fi ts into an

Transcription factors are proteins that bind to gene promoters and regu-electrical socket and conducts

late transcription. About 3000 transcription factors regulate the 23,000

electricity to power the appli-

genes or so encoded in the human genome. Transcription factors contain a ance. A DNA-binding domain is

set of independent protein modules or domains, each having a specifi c that part of the transcription fac-role important for the function of transcription factors. They include tor whose function is to recog-DNA-binding domains, transcriptional activation domains, dimerization nize specifi

c DNA promoter

domains, and ligand-binding domains.

sequences and bind DNA. There

Four common types of DNA-binding domains are the helix-turn-helix

is some variety in the structure of

motif, the leucine zipper motif, the helix-loop-helix motif, and the zinc fi n-a domain in the same way that

there are US, UK, and Continen-

ger motif. These domains are characteristic protein conformations that tal European plugs.

enable a transcription factor to bind DNA. It is the conformation of these protein domains that facilitates binding to DNA. Take the helix-turn-helix

54 3: REGULATION OF GENE EXPRESSION

and zinc fi nger domains as examples. The amino acid side-chains of the alpha helix portions of the helix-turn-helix motif lie in the major groove of the DNA helix and hydrogen bond to specifi c DNA base pairs. The zinc fi nger domain (approximately 30 amino acids long; Figure 3.1a) is confi gured around a zinc atom that links two cysteines and two histidines (shown in red) (or two cysteines and two cysteines). It consists of a simple ββα fold (Figure 3.1b). The side-chains of specifi c amino acids recognize a specifi c DNA sequence (about fi ve nucleotide pairs). Transactivation domains function by binding to other components of the transcriptional apparatus in order to induce transcription by RNA polymerase, the main enzyme required for transcription. Some transcription factors work in pairs (forming what we call a “dimer”) and require a dimerization domain

which facilitates protein–protein interactions between the two molecules.

Interactions between transcription factors are a common theme in transcriptional regulation. Some transcription factors only function upon binding of a ligand and therefore require a ligand-binding domain (this is analogous to the space for a coin in a pinball machine). The activity of a transcription factor can be regulated by several means: synthesis in particular cell types only, covalent modifi cation such as phosphorylation, (a)

H

H

C

C

Zn

Zn

H

H

C

C

NH2

COOH

(b)

NH2

C

H

Zn

C

Figure 3.1 The zinc fi nger DNA-

binding domain: (a) primary and

(b) secondary structure.

H

3 . 1 T R A N S C R I P T I O N FAC TO R S A N D T R A N S C R I P T I O N A L R E G U L AT I O N 55

? HOW DO WE KNOW THAT?

Experimental methods used to examine transcription

Another technique that is used to examine protein–DNA

factor binding

interactions is DNase footprinting. DNase, an enzyme that

cleaves DNA, is used to probe a promoter region. Protein bound

The interactions of transcription factors and their DNA

to a DNA fragment will protect the DNA from DNase cleavage.

response elements can be examined by several methods of

The DNA is end-labeled and, after enzymatic treatment, is ana-

molecular biology. These protein–DNA interactions are often

lyzed using gel electrophoresis and autoradiography. Areas of

fi rst detected by gel/band shift assays (also called electropho-

DNA that have been protected by protein binding will result in a

retic mobility shift assays or EMSAs). This assay involves the

clear region referred to as a “footprint” (Figure 3.2b).

incubation of a protein, usually within a cell or nuclear extract,

A third method of investigating transcription is to construct

with a labeled DNA fragment containing the promoter

deletions or point mutations in the promoter fragment, clone

sequences of interest. The products of the incubation reaction

them into a reporter plasmid (e.g. luciferase, whose activity can

are analyzed on a non-denaturing polyacrylamide gel. DNA

easily be detected), and examine the effects of the mutations

that has bound protein will be observed as a band that has

upon transfection into cells in culture or using in vitro transcrip-migrated more slowly (been retarded) than unbound DNA

tion assays (Figure 3.2c). Deletion or mutation of a promoter

(Figure 3.2a). Competition experiments that use irrelevant

region that is important for transcription is indicated by a

DNA fragments or known irrelevant proteins can be used to

decrease in transcription.

establish specifi city.

ligand binding, cell localization, and/or if dimeric, by exchange of partner proteins.

As we will see in the coming chapters, many oncogenic signaling pathways leading to uncontrolled growth, evasion of apoptosis, or aberrant differentiation converge on a single transcription factor that regulates a set of genes to produce a transformed phenotype. Thus, misregulation of a single transcription factor can cause cancer.

Many of the key points of transcriptional regulation can be demon-

strated by two examples: the AP-1 transcription factor family and the steroid hormone receptors. The AP-1 transcription factor is important for the processes of growth, differentiation, and death, and therefore plays a role in carcinogenesis. AP-1 binds either to the 12- O-tetradecanoylphorbol-13-acetate (TPA) response element or the cAMP response element in the promoter region of their target genes.

The AP-1 transcription factor is actually composed of two components and can be produced by dimers of proteins from the Jun and Fos families (Jun, Jun B, Jun D, Fos, Fos B, FRA1, and FRA 2) (Figure 3.3). Eighteen possible combinations are possible. Both Jun and Fos members contain a basic leucine zipper dimerization domain. Because the processes of

growth, differentiation, and apoptosis need to be carefully regulated, AP-1 is itself activated in response to specifi c signals such as growth factors, ROS, and radiation. The specifi c combination of dimers infl uences the biological response. The antagonism displayed between Jun and Jun B





56 3: REGULATION OF GENE EXPRESSION

(a)

(b)

μg

μg

μg

μg

μg

μg

μg

μg

μg

μg

μg

μg

μg

μg

μg

0

0.3125

0.625

1.25

2.5

0

0.3125

0.625

1.25

2.5

0

0.3125

0.625

1.25

2.5

Hela

Hela 2hr

Hela 4hr

Serum Response

Serum Response

(c)

Promoter of interest

Wild type

Reporter

3’ deletion

Reporter

5’ deletion 1

Reporter

ol

∅

GA

TC

50

25

∅

200

100

contr protein (nM)

5’ deletion 2

Reporter

Figure 3.2 Methods used to examine transcription factor binding. (a) EMSA was used to visualize the changes in AP-1 binding following different treatments of HeLa cells: HeLa (control), HeLa 2 h serum response, and HeLa 4 h serum response nuclear extracts were serially diluted and assayed using an infrared dye (IRDyeR700) end-labeled DNA fragment containing the AP-1 response element. Gel electrophoresis and imaging followed. Courtesy of LI-COR Biosciences. (b) A sample DNase footprinting autoradiograph. Courtesy of George P. Munson. (c) A schematic diagram of possible mutant promoter constructs linked to a reporter gene to be used for promoter analysis. The effects of promoter sequence alterations may be indicated by changes in transcriptional activity.

The constructs are transfected into cells and reporter enzyme activity is used as an indicator of transcriptional activity.

3 . 1 T R A N S C R I P T I O N FAC TO R S A N D T R A N S C R I P T I O N A L R E G U L AT I O N 57

AP-1

Jun

Fos

Jun B

FosB

Jun D

FRA1

or

FRAZ

Figure 3.3 Members of the Jun

and Fos transcription factor

Jun family

Fos family

family.

with regard to cell proliferation in some cell types supports this: Jun acts as a positive regulator of proliferation while Jun B acts as a negative regulator in the presence of Jun.

Both the Fos and Jun family of transcription factors that make up the AP-1 complex play a role in tumorigenesis (see references in Milde-Langosch, 2005). As TPA is a tumor promoter and the AP-1 complex

binds to the TPA response element, an association of AP-1 with car-

cinogenesis was implicated early after this property was characterized.

The fi rst members of AP-1 identifi ed, c-jun and c-Fos, were able to transform normal cells in culture to cancer cells and are frequently over-expressed in tumor cells.

Steroid hormones are lipid-soluble signaling molecules that exert their effects by regulating the transcription of sets of genes via specifi c receptors (Table 3.1). The superfamily of steroid hormone receptors acts as ligand-dependent transcription factors. There are currently 48 members Table 3.1 Examples of members of the steroid hormone receptor superfamily Class: steroid receptors

TR/RAR/PPAR/VDR-like receptors

Androgen receptor (AR)

Peroxisome proliferator activated receptor (PPAR)

Estrogen receptor (α/βER)

Retinoic acid receptor (RAR)

Glucocorticoid receptor (GR)

Thyroid hormone receptor (TR)

Mineralocorticoid receptor (MR)

Vitamin D receptor (VDR)

Progesterone (PR)

58 3: REGULATION OF GENE EXPRESSION

of the nuclear receptor family (see the Nuclear Receptor Signaling Atlas web site http://www.nursa.org/). They contain a zinc fi nger type of DNA-binding domain, a ligand-binding domain for a specifi c steroid hormone, and a dimerization domain as they activate transcription as a dimer. Each domain functions independently and in a manner that is specifi c for a particular steroid hormone receptor. This feature has been utilized as a molecular tool by scientists in so-called domain swap experiments which produce chimeric receptors. For example if the ligand-binding domain of the thyroid hormone receptor is swapped with the ligand-binding domain of the retinoic acid receptor, the newly formed chimeric receptor (Figure 3.4) will retain the DNA-binding domain of the thyroid hormone receptor and will activate thyroid hormone-responsive genes. However, these genes will be activated by retinoic acid via the retinoic acid ligand-binding domain, and not by thyroid hormone. Such experiments clearly demonstrate the functional independence of these domains.

Steroid hormones pass through the cell membrane and bind to their

particular intracellular receptors in the cytoplasm (note: some members of the steroid hormone receptor superfamily bind to their ligands in the nucleus). Upon binding, the receptors move into the nucleus and activate transcription of their target genes through specifi c DNA response elements (see Figure 3.5).

The retinoic acid receptor (RAR), as a member of the steroid hormone receptor family, acts as a retinoic acid (RA)-dependent transcriptional regulator and is important during differentiation. Retinoic acid is derived from vitamin A. The RAR is constitutively located in the nucleus and acts as a transcriptional repressor in the absence of RA. It binds to the RA response element (RARE) in target genes as a heterodimer with another Retinoic acid

Retinoic acid

DNA-binding

receptor

Ligand-binding

domain

domain

Retinoic acid RE

Thyroid hormone

Thyroid hormone

DNA-binding

Ligand-binding

receptor

domain

domain

Thyroid RE

Retinoic acid

Chimeric

thyroid hormone/

DNA-binding

Ligand-binding

retinoic acid

domain

domain

receptor

Figure 3.4 A chimeric steroid

hormone receptor is shown below

its two parental receptors.

Thyroid RE





3 . 2 C H R O M AT I N S T R U C T U R E 59

Glucocorticoid

GR

Cell membrane

GR

GR

GRE

Target

gene

Nucleus

Figure 3.5 Mechanism of action

of the glucocorticoid receptor

(GR, red) (GRE, glucocorticoid

response element).

member of the family called RXR. Aberrant forms of RARs are characteristic of several leukemias. As we will see throughout the text, members of the steroid hormone receptor superfamily (e.g. estrogen receptor, vitamin D receptor) play an important role in many different types of cancer.

3.2 Chromatin structure

Human DNA is present in the nucleus of cells in the form of 46 chromosomes. Chromosomes are made of chromatin: a thread of DNA (60%)

plus associated RNA (5%) and protein (35%). It is astonishing to think that the actual length of DNA in the nucleus of a cell is over a meter when fully extended. A high level of packaging (Figure 3.6) is required to neatly organize the DNA to fi t into the nucleus of a cell and to allow it to assume necessarily organized conformations for transcription and replication.

PAUSE AND THINK

Both of these processes involve unwinding of the double helix and reading of template strands.

How would you organize long

pieces of thread in a sewing

The simplest or primary level of organization of chromatin is the wrap-box? Most thread is wrapped

ping of DNA around a protein “spool” and is referred to as the “beads around a spool for orderly and

on a string” array. The beads represent the nucleosome, which contains easy unwinding. Few people

147 base pairs (bp) of DNA wrapped 1.7 times around a core of histone would just leave a disorganized

proteins. The histone core is an octomer of histones containing two cop-bunch of thread for fear of get-

ies of histones H2A, H2B, H3, and H4. Each histone contains domains ting tangles and knots.

for histone–histone and histone–DNA interactions and NH2-terminal





60 3: REGULATION OF GENE EXPRESSION

Radial loops

Linker histones

Long range

fiber–fiber

Short range

interactions

internucleosomal

30 nm fiber

interactions

G1 chromatid

Figure 3.6 Multiple levels of

Beads-on-a-string

chromatin structure. Reprinted,

with permission, from Annu. Rev.

Biophys. Biomolec. Struct. 3, p.

Nucleosome

362, Copyright 2002 by Annual

Reviews (http://www.

Core histone

DNA

tail domain

annualreviews.org).

lysine-rich and COOH-terminal “tail” domains which can be post-translationally modifi ed (e.g. acetylated, methylated, or phosphorylated). Histone H1 is a linker histone and binds to DNA located outside the core.

Ten to sixty base pairs of DNA separate the “beads.” The secondary level of organization is the formation of 30 nm fi bers, and these can associate to form a tertiary structure of radial loops.

Chromatin has an important role beyond being a structural scaffold.

The degree of compaction or relaxation of chromatin determines how

readily the DNA in a portion of chromatin can be transcribed: highly-compact chromatin cannot be transcribed (it is transcriptionally “silent”), whereas more relaxed chromatin is accessible for transcription. The structure of chromatin—from compacted to relaxed—can change, and it is this feature that enables it to have a regulatory role in transcription. Chromatin conformation is encoded by heritable (that is, they can be passed on from one cell generation to the next) epigenetic modifi cations as we will examine in the following section.

3.3 Epigenetic regulation of transcription

Epigenetics refers to heritable information that is encoded by modifi cations of the genome and chromatin components. These modifi cations

affect the structure and conformation of chromatin and, consequently, transcriptional regulation. Epigenetic alterations in gene expression do not cause a change in the nucleotide sequence of the DNA and therefore

3 . 3 E P I G E N E T I C R E G U L AT I O N O F T R A N S C R I P T I O N 61

are not mutations. Stable epigenetic switches are important during normal cell differentiation. For example, stem cells are maintained in a stem cell state by epigenetic silencing of genes important for differentiation.

(Note: it is differential gene expression that makes one cell type different from another.) Two types of epigenetic mechanisms will be discussed in the following sections: histone modifi cations and DNA methylation. Both can be acquired or inherited and both affect transcriptional activity by regulating the access of transcription factors to appropriate nucleotide sequences in gene promoters. It is important to keep in mind that all epigenetic processes work together to regulate open and closed states of chromatin, and that regulation of transcription factor binding links genetic and epigenetic mechanisms.

Histone modifi cation

Histone proteins are subject to diverse post-translational modifi cations such as acetylation, methylation, phosphorylation, and ubiquination. The histone code hypothesis predicts that the pattern of these multiple histone modifi cations helps to specify the components and activity of the transcription regulatory molecular machinery. Let us focus on acetylation.

The acetylation pattern of histones alters chromatin structure and

affects gene expression (Figure 3.7). Acetylation acts as a docking signal for the recruitment or the repulsion of chromatin-modifying factors. Histone acetyltransferases (HATs; add acetyl groups) and histone deacetylases (HDACs; remove acetyl groups) are two families of enzymes that

produce the pattern. HATs acetylate specifi c histone-tail lysines and other non-histone proteins, including transcription factors (e.g. E2F and p53).

Acetylation of histones relaxes chromatin folding and this correlates with enhanced transcriptional elongation by RNA polymerase II. HDACs

remove acetyl groups and restore a positive charge to lysine residues of the histone tails which stabilize chromatin compaction and higher-level packaging. This confi guration of chromatin limits the accessibility of transcription factors and results in the repression of transcription.

In addition, transcriptional activators often recruit HATs and other chromatin-remodeling enzymes to the promoter region. The retinoblas-PAUSE AND THINK

toma tumor suppressor protein, mentioned as a “molecule of fame” in In general, HATs activate tran-Chapter 1, exerts its effects, in part, by recruiting HDACs to specifi c gene scription and HDACs repress

promoters (see Chapter 5). Thus, a signaling network seems to underlie transcription.

chromatin modeling.

DNA methylation

Another epigenetic process that affects transcriptional regulation is DNA methylation. DNA methylation is the addition of a methyl group to posi-

62 3: REGULATION OF GENE EXPRESSION

Lys A

HATs

Lys+

Lys+

HDACs

Lys A

Repression

Lys+

Activation

H2A

H2B

Lys A

H3

H4

Nucleosome core

Figure 3.7 Histone acetylation

affects gene expression.

tion 5 of cytosine. Only 3–4% of all cytosines in DNA are methy lated.

Methylation only occurs at cytosine nucleotides which are situated 5′ to guanine nucleotides (CpGs). Methylcytosine deaminates spontaneously and results in C→T transitions (Figure 3.8). It is thought that evolution has selected against this dinucleotide as a result of the high rate of mutation, as CpG is under-represented and unequally distributed in the genome. CpG

clusters, called CpG islands, are located in the promoter region of 50% of human genes. In general, the CpG islands found in gene promoter regions are not methylated in normal tissues and transcription may occur. Methylated cytosines are found mainly in repetitive sequences and in the CpG

islands found in the promoter region of repressed genes such as X-chromosome inactivated genes, imprinted genes, and some tissue-specifi c genes. In these cases, methylation is a heritable signal that is associated with a compacted chromatin structure and maintains gene silencing.



Enzymes called DNA methyltransferases (DNMTs) mediate the covalent

addition of a methyl group from the methyl carrier, S-adenosyl-methionine.





3 . 4 E V I D E N C E O F A R O L E F O R E P I G E N E T I C S I N C A R C I N O G E N E S I S 63

NH2

NH2

O

CH3

CH3

N

N

HN

methylation

deamination

N

O

N

O

N

O

cytosine

5 methylcytosine

thymine

Figure 3.8 Spontaneous

deamination of methylcytosine

C

T

Transition

leads to a C→T transition.

Three methyltransferases are known: DNMT1, DNMT3a, and DNMT3b.

DNMT1 is involved in the conversion of hemi-methylated DNA to fully methylated DNA during replication. This mechanism allows methylation patterns to be inheritable; if only one strand remained methylated the signal would be lost in half of its daughter cells after replication. The other two methyltransferases are mainly involved in de novo methyltransferase activity (methylation of new sites).

It has been suggested that the mechanism by which methylation results in silencing is by recruiting methyl binding domain (MBD) proteins, which have been shown to interact with HDACs and chromatin-remodeling

enzymes. Therefore, epigenetic regulation of transcription includes cross-talk between methylation, chromatin-remodeling enzymes, and histone modifi cation.

3.4 Evidence of a role for epigenetics in carcinogenesis

Misregulated epigenetic silencing plays an important role in cancer.

Abnormal epigenetic programs may inactivate large groups of genes. Epigenetic events can cause other epigenetic events, leading to genome-wide alterations and genomic instability. Recent work suggests that hundreds of epigenetically-silenced genes may exist in individual tumors. Epigenetic inactivation and the inactivation of genes by mutation cooperate during carcinogenesis. On one hand, mutations can disable enzymes that are crucial for epigenetic regulation and, on the other hand, epigenetic silencing can provide the second “hit” (discussed further in Section 6.1) required for a tumor suppressor gene to be inactivated in a recessive manner (Figure 1.3). A brief examination of some of the accumulating supporting evidence is described next.

64 3: REGULATION OF GENE EXPRESSION

Histone modifi cation and cancer

Altered HAT or HDAC activity has been observed in several cancers.

Interestingly, one gene, EP300, which codes for a HAT has been found to be mutated in epithelial cancers. Several of the mutations predicted a truncated protein, and inactivation of the second allele was observed in fi ve out of six cases, suggesting that it functions as a tumor suppressor.

Genomic sequencing of tumor DNA from specifi c types of lymphoma

identifi ed frequent mutations of histone-modifying genes suggesting that epigenetic alterations play an important role in lymphoma development (Morin et al. , 2011).

Acute promyelocytic leukemia is characterized by a chromosomal

translocation that produces a fusion protein called PML–RAR. This novel fusion protein retains the DNA-binding domain and ligand-binding

PAUSE AND THINK

domain of the RAR in addition to PML sequences. PML–RAR recruits

HDAC to the promoter region of RA target genes and represses the

RAR is a member of which fam-

ily of transcription factors? See

expression of these genes. The lack of activation of RAR target genes Section 3.1.

causes the block of differentiation that characterizes the leukemia. Other tumors have also been associated with aberrant recruitment of HDACs.

Methylation and cancer

Cancer-specifi c changes in DNA methylation have been recognized, and many studies have focused on hypermethylation observed in normally

unmethylated CpG islands of gene promoters (see “Analysis of DNA

methylation by sodium bisulfate treatment and methylation-specifi c PCR” box). Gene silencing by methylation may be an important mechanism of carcinogenesis whereby critical genes normally involved in tumor suppression may be switched off. Inactivation of gene expression by methylation of the promoter regions of such genes has been observed in cancer cell lines and human tumors. For example, estrogen receptor protein is present in normal ovarian epithelial cells but is frequently lost in ovarian cancer. Hypermethylation of the estrogen receptor-α gene promoter was observed in three out of four human ovarian cell lines that lacked estrogen receptor protein (O’Doherty et al. , 2002). This indicates that hypermethylation may be responsible for this phenotype in ovarian tumors. As another example, the breast cancer susceptibility gene, BRCA1, is often mutated in a recessive manner in inherited breast cancer. Thus, the loss of function of the gene product suggests that normal BRCA1 acts to suppress breast cancer. Mutation of BRCA1 is very rarely observed in non-inherited breast cancer. However, interestingly, hypermethylation is associated with the inactivation of BRCA1 in non-inherited breast cancer and therefore this may be another way of accomplishing loss of function.

These fi ndings support the view that epigenetics may be an additional

3 . 4 E V I D E N C E O F A R O L E F O R E P I G E N E T I C S I N C A R C I N O G E N E S I S 65

mechanism for carcinogenesis. Additional examples of some key target genes affected by methylation include the retinoblastoma ( Rb) gene; inhibitor of the cell cycle p16 INK4a; pro-apoptotic death-associated protein kinase ( DAPK); APC; and the estrogen receptor gene. Evidence also indicates that abnormal methylation occurs in a subset of pre-malignant cells, and it has been suggested that this may “addict” cells to altered signaling pathways and facilitate subsequent mutational events that provide the cell with a selective advantage and promote tumorigenesis.

Analysis of DNA methylation by sodium bisulfate treatment and

methylation-specifi c PCR

Molecular biology procedures used for standard genetic analysis erase DNA methylation information, and so specialized methods for methylation analysis were developed. Sodium bisulfate treatment of genomic DNA converts unmethylated cytosine residues to uracil by deamination. 5-Methylcytosines are converted to thymine under these same conditions.

Treated DNA is no longer complementary and PCR amplifi cation requires specially designed primers. There are several possible designs for PCR amplifi cation primers of the resulting DNA but, most commonly, primers are designed to hybridize specifi cally with the sodium bisulfate modifi ed sequences. PCR that uses these types of primers is called methylation-specifi c PCR. Methylation-specifi c PCR provides information about particular methylation patterns in single gene candidates. This approach is now complemented by current comprehensive genome-scale approaches that generate DNA methylation maps.

Sites of methylated DNA interact with additional epigenetic regula-

tory proteins such as histone-modifying enzymes (described earlier), methyl cytosine-binding proteins, and DNMTs. These proteins collaborate to defi ne the structure of chromatin. In addition to recruiting HDAC (discussed previously), PML–RAR has also been shown to

recruit methyltransferase resulting in the DNA methylation of a promoter region of a specifi c gene (Di Croce et al. , 2002). The RARβ2 gene has a RARE in its promoter and is one of the target genes of PML–

RAR. It has been demonstrated that PML–RAR forms stable complexes

with DNMTs at the RARβ2 promoter and that the resulting hyper-

methylation contributes to carcinogenesis. It has been suggested that DNMTs, in addition to mediating methylation, may act as a platform

for the assembly of chromatin-modifying factors.

As not all carcinogens are mutagens, it may be possible that some non-genotoxic carcinogens (agents that do not mutate genes) are epigenetic carcinogens. Hypermethylation has been observed in tumor-sensitive mice treated with phenobarbital, a non-genotoxic carcinogen in rodents (Watson and Goodman, 2002). The data suggest that a disruption to normal methylation patterns is related to tumor susceptibility and that non-genotoxic carcinogens may act via methylation. In addition, nutritional defi ciencies





66 3: REGULATION OF GENE EXPRESSION

(methionine, choline) seem to affect the cellular level of S-adenosylmethionine, an important methyl group donor. This suggests that perturbation of methylation can be produced through the diet (see Chapter 11). It has also been suggested that epigenetic gene silencing that is characteristic of normal stem cells and progenitor cells may be “locked in” during chronic injury and infl ammation (see Chapter 8 for stem cells and Chapter 10 for infl ammation) and contribute to carcinogenesis.

Mutation of DNA methyltransferases has been demonstrated in several cancers and leads directly to altered methylation. Another role of methylation in transformation may be to promote mutation. Methylated cytosine residues have a tendency to deaminate spontaneously causing C→T transitions. This may account for the increased mutation rate observed in methylated CpG islands.

Paradoxically, the genome of a cancer cell overall can have 20–60% less methylation than a normal cell. This global hypomethylation, mainly in the coding region of genes and of repetitive DNA sequences, occurs in the cancer cell at the same time as the hypermethylation of specifi c genes described earlier. This results in the activation of genes not normally expressed. Although this phenomenon has not been vigorously studied, one report points to a causal role of DNA hypomethylation in tumor formation (Gaudet et al. , 2003). Mice bred to have reduced levels of DNA methyltransferase 1 exhibited genome-wide hypomethylation and developed T-cell lymphomas. Overall, misregulation of many epigenetic processes is intimately involved in cancer development.

3.5 Telomeres and telomerase

One of the hallmarks of cancer cells is that they acquire a limitless replicative potential (see Figure 1.1). Normal cells have an autonomous program that allows for a fi nite number of replication cycles. This phenomenon is well known in that cells in culture only undergo a certain number of doublings before they stop dividing and enter senescence (permanent growth arrest). Telomeres, repetitive DNA sequences and

specialized proteins at the ends of chromosomes, have been shown to function as a molecular counter of the cell’s replicative potential (see Verdun and Karlseder, 2007 for review). Telomeres protect the ends of chromosomes from digestion by nuclear enzymes and also prevent

induction of mechanisms that repair DNA double-stranded breaks. Telomeres are composed of several thousand repeats of the sequence

TTAGGG bound by a set of associated proteins called the shelterin complex, which functions to control telomere length and protect the chromosomal ends. Telomeres shorten by 100–200 bases with each round of DNA replication owing to the limits of DNA polymerases during DNA

3 . 5 T E L O M E R E S A N D T E L O M E R A S E 67

replication (see Box “A little lesson about DNA replication”, see page 68). DNA polymerases proceed only in the 5′–3′ direction and require an RNA primer to initiate DNA synthesis. The RNA primers are

removed after replication is complete. As a result, the 3′ end of the parental chromosomal DNA is not replicated and thus chromosomes

progressively erode during each round of replication (Figure 3.9). When the chromosomes reach a threshold length, cells enter a stable and irreversible state of growth arrest called cellular senescence. If cells bypass this stage because of mutation and telomeres become critically short, chromosomal instability results and apoptosis (or cell transformation discussed later) is induced. Maintaining telomere length in stem cells of renewal tissue (e.g. the basal layer of the epidermis) is important for providing a longer replicative potential. Telomerase, a ribonucleoprotein

containing human telomerase reverse transcriptase activity (hTERT) and a human telomerase RNA (hTR) maintain telomere length in certain cell types, such as stem cells. Reverse transcriptases are enzymes that synthesize DNA from RNA—an exception to the central dogma of molecular

biology which states that RNA is synthesized from DNA. The hTR con-

tains 11 complementary base pairs to the TTAGGG repeats and acts as a template for the reverse transcriptase to add new repeats (shown in red) to telomeric DNA on the 3′ ends of chromosomes (Figure 3.10).

It has been shown in vitro that the telomere ends are not linear but rather complicated structures forming t-loops and may form four-stranded DNA conformations called G quadruplexes. It is important that chromosome ends are distinguishable from DNA double-stranded breaks.

If they were not, the DNA repair processes would produce chromosomal fusions and other aberrations in an attempt to repair the damage.

Several lines of evidence have linked telomerase activity with cancer.

The maintenance of telomeres seems to be important for tumor growth and approximately 90% of tumors accomplish this by upregulating telomerase. Telomerase activity was clearly a distinguishing feature in one classical study where it was detectable in cultured immortal cell lines (98

of 100) and tumor tissue biopsies (90 of 101) but undetectable in cultured normal somatic cells (22) or benign tissue samples (50). It has been found that telomerase, in addition to two oncogenes, is essential in the protocol to transform normal fi broblasts to cancer cells in vitro, thus 3’

5’

Leading

5

strand

5’ 3’

Okasaki

fragment

3’

Chromosomal

shortening

Chromosomal

Lagging

RNA primers

Figure 3.9 Chromosomal

shortening

5’

strand

shortening after DNA replication.

68 3: REGULATION OF GENE EXPRESSION

T T A G G G T T A G G G T T A G G G T T A G

Telomeric

5’

ends

A A T C C C A A T C C C A A T

3’

T T A G G G T T A G G G T T A G G G T T A G G G T T A G

5

Extension

C A A U C C C A A U C

of telomere

A A T C C C A A T C C C A A T

3’

ends

Telomerase

T T A G G G T T A G G G T T A G G G T T A G G G T T A G G G T T A G

5

Extension

C A A U C C C A A U C

of telomere

A A T C C C A A T C C C A A T

3’

ends

Telomerase

Figure 3.10 Telomere extension by

telomerase.

A little lesson about DNA replication . . .

DNA replication proceeds in a semi-conservative manner: each of the two parental strands acts as a template for the synthesis of a newly replicated strand (Figure 3.11; new DNA strand synthesis is shown in red). Each of the polynucleotide strands that make up the DNA helix has a sense of direction; that is each has a 5′ end and a 3′ end. The two strands are arranged in an antiparallel manner. As DNA polymerases only work in a 5′–3′ direction each strand is replicated differently as the DNA helix unwinds. For one strand, the leading strand, replication proceeds in a continuous manner from the 5′–3′ end. For the other strand, the lagging strand, replication occurs in a discontinuous manner through the 5′–3′

synthesis of short Okazaki fragments. After removing the RNA primers and fi lling in the gaps, these fragments are ligated together by the enzyme DNA ligase to form one continuous strand. The requirement of DNA polymerase for a RNA primer and the subsequent removal of this primer causes the strands to shorten at the extreme chromosomal ends during each round of replication.

providing a strong link between telomerase and tumorigenesis. Several oncogenes have been demonstrated to regulate the expression of telomerase. For example, the transcription factor c-myc (an oncogene discussed in later chapters) increases the expression of the hTERT gene via specifi c response elements in the promoter region. As mentioned earlier, if cells bypass the replicative senescence stage because of mutation, telomeres become critically short and chromosomal instability results. This genetic catastrophe may lead to the loss of tumor suppression mechanisms, and evasion of apoptosis. Subsequently, transformed cells emerge. Most

transformed cells have upregulated telomerase activity that helps establish cell immortality.





3 . 6 M I C R O R N A S ( M I R N A S ) A N D R E G U L AT I O N O F M R N A E X P R E S S I O N 69

3’

5’

5’

Leading strand

Okazaki

fragment Lagging strand

Figure 3.11 Semiconservative and

RNA

RNA

RNA

3’

semidiscontinuous DNA

3’

5’

replication.

Interestingly, modifi cations of the telomere hypothesis of senescence described previously have recently been suggested and have strong implications for cancer. The telomere hypothesis would predict that telomeres shorten at a constant rate, yet great heterogeneity of replicative lifespan exists among cells within a clonally derived population (i.e. some cells arrest after a few divisions and some after many divisions). It has been reported that telomere shortening is accelerated by oxidative stress (von Zglinicki, 2002), which suggests that the problem of replicating the ends of chromosomes is not the only determining factor for telomere length and replicative potential. Telomeric DNA is repaired less profi ciently compared with the bulk of the genome in response to oxidative damage. Unrepaired single-strand breaks accelerate telomere shortening, although the mechanism by which this occurs is unclear. These observations suggest that telomeric DNA may act as a sensor for DNA damage and may explain why there is great heterogeneity in the rate of telomeric shortening among individual cells. Therefore, telomere shortening may act as a tumor suppression mechanism by limiting replicative potential in response to genome damage.

3.6 MicroRNAs (miRNAs) and regulation of mRNA

expression

MicroRNAs (miRNAs) are small, non-protein-coding RNAs (18–25

nucleotides in length) that regulate the expression of mRNAs. Each miRNA may be able to repress hundreds of gene targets post-transcriptionally.

Therefore, they are powerful regulators of gene expression.

Mature miRNAs require several steps of processing. After they are transcribed by RNA polymerase II from intergenic regions or from regions that code for introns, the primary transcript is processed by ribonucleases Dro-sha and DGCR8 in the nucleus. This processing produces pre-miRNAs,

hairpin-shaped intermediates of 70–100 nucleotides. Exportin-5 transports pre-miRNAs into the cytosplasm where they are further processed by ribonuclease Dicer into a double-stranded miRNA. The strands separate and a mature single-stranded molecule joins a RNA-induced silencing complex (RISC). This effector complex of the miRNA pathway is made up of miRNAs and specifi c proteins.





70 3: REGULATION OF GENE EXPRESSION

The repression of gene targets by miRNAs happens in one of two ways.

Under the fi rst scenario, the miRNA hybridizes perfectly to the 3′ untranslated region (UTR) of their target mRNA. The formation of this complex in the RISC leads to mRNA cleavage and subsequent degradation. Alternatively, miRNAs may bind to imperfect complementary sites in the 3′

UTR of their target mRNAs. The formation of this complex in the RISC

blocks translation. The net result for both scenarios is a decrease in the amount of the protein encoded by the gene from which the mRNA has

been transcribed.

miRNAs are involved in regulating a diverse set of biological pro-

cesses including growth, differentiation, and apoptosis. Not surprisingly, some miRNAs may play a role in cancer as oncogenes (miRNAs

that are oncogenic are called oncomirs) and others as tumor suppressors. Amplifi ed or upregulated miRNAs that suppress tumor suppres-

sor mRNAs can act as oncomirs. It has been demonstrated that

over- expression of a single miRNA, called mir-155, can lead to cancer in mice. However, miRNAs that normally repress the expression of oncogenes act as tumor suppressors and are lost in tumor cells. Endogenous miRNAs have also been implicated in suppressing metastasis (Tavazoie et al. , 2007).

Some of the mechanisms of miRNA deregulation are common with tra-

ditional oncogenes, such as base pair substitutions, deletions, and aberrant epigenetic modifi cations (see Section 3.3). However, miRNA

expression can also be altered at the level of processing, adding another layer of regulation. The products of oncogenes have been shown to regulate transcription of miRNAs illustrating that the interplay of oncogenes and miRNAs can be complex.

Selected groups of specifi c miRNAs are commonly altered in particular cancers and recent data have shown that miRNA expression profi les of tumors are able to discriminate between different types of cancer. Thus, miRNA profi les will be useful for cancer diagnosis and prognosis

(Esquela-Kerscher and Slack, 2006; Yanaihara et al., 2006) whereas

mRNA profi les have been proven to be unreliable.

Therapeutic strategies

3.7 Epigenomic and histonomic drugs

It is a fairly recent view that epigenetic silencing may be as important as mutation as a mechanism for carcinogenesis. Currently, the concept of

3 . 7 E P I G E N O M I C A N D H I S TO N O M I C D R U G S 71

reversing somatic mutations is diffi cult to envisage because mutations are not reversible. However, the concept is conceivable for epigenetic changes as these are modifi cations that are reversible. A large number of genes known to play important roles in carcinogenesis have been shown to display hypermethylation of their promoter regions. As the increased methylation seen in tumor cells is not observed in normal cells, it provides a tumor-specifi c target for DNA methylation inhibitors. Similarly, enzymes that alter chromatin structure, such as HDACs that modify histones, provide other molecular targets. As described earlier, several forms of leukemia and lymphoma are associated with transcriptional repression due to recruitment of HDACs. Reversal of epigenetic silencing is an approach that may lead to new therapeutics.

DNA methylation inhibitors

Drugs that block DNA methylation are predicted to show anti-tumor

effects as inactivation of tumor suppressor genes by methylation may be an important mechanism in carcinogenesis. Recall that DNA methylation occurs at position 5 on cytosine. Two 5′-modifi ed analogs of deoxycytidine, 5-azacytidine (5-azaC) and 5-aza-2′-deoxycytidine,

have been used to target DNA methyltransferases (Figure 3.12). These drugs are incorporated into DNA and/or RNA. They covalently link

with DNA methyltransferases (DNMT, left red target in Figure 3.12)

and sequester its action such that there is signifi cant demethylation after several rounds of replication. These drugs may result in DNA

instability that parallels antimetabolite chemotherapeutic agents. A potential hindrance is that aberrant methylation and gene repression return after treatment is stopped, dictating that administration of the drug must be prolonged. Both of these drugs showed anti-leukemic

activity in clinical trials but were not successful in solid tumors. 5-AzaC

(azacitidine; Vidaza™) and 5-aza-2′-deoxycytidine (decitabine) has

been approved by the US Food and Drug Administration (FDA) for the

treatment of leukemia.

DNMT

5-azaC

Lys A

Romidepsin

decitabine

SAHA

Figure 3.12 Drugs designed to

A

G

C

G

HDAC

target epigenetic mechanisms

(shown in red).





72 3: REGULATION OF GENE EXPRESSION

Inhibitors of histone deacetylases

Histone-modifying enzymes have been targeted for the development of new cancer drugs (Figure 3.12). Recall that HDACs generally repress gene transcription and that aberrant recruitment is characteristic of some cancers, such as leukemias. Reactivation of silenced genes involved in growth, differentiation, or apoptosis provides the rationale for treating such cancers, with inhibitors of HDACs. Several classes of drugs that bind to the catalytic site of HDACs (right red target in Figure 3.12) and block the binding to their substrates (acetylated lysines of histone proteins) are being tested in clinical trials: short-chain fatty acids such as sodium n-butyrate; hydroxamic acids such as SAHA; cyclic peptides such as

romidepsin (formerly FK-228); and benzamide derivatives such as entinostat. In general, these drugs are well tolerated and many can be administered orally. Alteration of gene expression appears to be selective.

Interestingly, many HDAC inhibitors induce p21WAF1, a cyclin-dependent kinase inhibitor important for growth arrest. These drugs seem to have little, or no, effect on normal cells. Molecular effectiveness was demonstrated by the detection of acetylated histones in particular white blood cells and tumor cells and this was associated with clinical improvement.

Romidepsin (FK-228) and SAHA (vorinostat; Zolinza™) have been

approved by the FDA for use in the clinic.

3.8 Telomerase inhibitors

The relatively tumor-specifi c expression of telomerase and its pivotal role in the ability of a cancer cell to divide indefi nitely suggest that it may be a valuable molecular target for new cancer therapies. However, several parameters need to be examined when considering the inhibition of telomerase as a cancer therapy. Effectiveness may depend on initial telomere length and, thus, this should be assessed from tumor biopsies prior to treatment. Also the response may be slow owing to the time needed for the telomeres of cancer cells to shorten enough to trigger senescence or apoptosis, and long-term treatment may be necessary. In general, long-term treatment increases the probability of drug resistance. Several different strategies, targeting either the RNA component or the catalytic protein component, have been explored in pre-clinical studies. As telomerase is dependent on its functional RNA molecule, antisense oligonucleotides and ribozymes have been popular agents used to target hTR. Antisense oligonucleotides are complementary to part of the target RNA and hybridize by Watson–Crick base-pairing. Hybridization can inhibit function directly or trigger degradation by the

3 . 8 T E L O M E R A S E I N H I B I TO R S 73

recruitment of RNases. Hammerhead ribozymes contain antisense

sequences for target recognition and an internal endonuclease activity that cleaves the target RNA. Reverse transcriptase inhibitors against the catalytic domain of hTERT and nucleoside analogs have also been investigated. BIBR1532 is a synthetic small molecule inhibitor that directly binds hTERT non-competitively and has been shown to induce telomere-driven senescence. G-quadruplex binding molecules that prevent interaction between the enzyme and substrate have also been developed (e.g. telomestatin). High-throughput screening has identifi ed several natural compounds as telomerase inhibitors, such as components of

mistletoe and a green tea catechin.

One anti-telomerase drug candidate that has entered Phase II clinical trials is Imetelstat (GRN 163L; Geron). Imetelstat, a modifi ed 13-mer oligonucleotide, binds directly to the template region of the RNA component of human telomerase (hTR), which lies in the catalytic site of hTERT.

Imetelstat binding to hTR results in direct, competitive inhibition of telomerase enzymatic activity. It is promising that pre-clinical studies of this drug suggest that it may be effective against pediatric brain tumors, a group of cancers with high mortality in children (Castelo-Branco et al. , 2011).

■ CHAPTER HIGHLIGHTS—REFRESH YOUR MEMORY

•

Transcription factors recognize DNA response elements

•

Methylation at CpG islands represses transcription.

and are essential for the regulation of gene expression.

•

Epigenetic alterations are genome-wide in

•

Steroid hormone receptors act as ligand-dependent tran-

carcinogenesis.

scription factors.

•

Telomeres play a role in the replicative potential of a cell.

•

Chromatin has several levels of DNA packaging: the

•

Telomeres shorten with each round of replication but the

nucleosome, the 30 nm fi ber, and radial loops.

rate of shortening may also be infl uenced by oxidative

•

Epigenetic changes also regulate gene expression. These

stress.

involve modifi cation of nucleotides or chromatin

•

Telomerase is an enzyme that maintains telomere length.

components.

•

Telomerase activity is increased in 90% of tumors.

•

Histone modifi cation and methylation are two types of

•

MicroRNA expression is deregulated in cancer.

epigenetic mechanism.

•

Strategies for the design of new drugs target DNMTs,

•

HATs add acetyl groups to histones and activate

HDACs, telomerase, and miRNAs. Some new drugs that

transcription.

target epigenetics have been approved and others are in

•

HDACs remove acetyl groups and repress transcription.

clinical trials.

■ ACTIVITY

1. Formulate evidence for your view on the statement that epigenetics is as important as mutation for carcinogenesis. Include an examination of epigenetic diseases that lead to an increased risk of cancer (see Feinberg, 2007). Contribute to a class debate on this issue.

74 3: REGULATION OF GENE EXPRESSION

2. Look at the evidence supporting the role of oncomirs in cancer. Start with Esquela-Kerscher and Slack (2006) and Yanaihara et al. (2006). Critically discuss strategies and challenges for designing drugs that target miRNAs in cancer (see Garzon et al. , 2010).

■ FURTHER READING

Baylin, S.B. and Ohm, J.E. (2006) Epigenetic silencing in cancer—a mechanism for early oncogenic pathway addiction? Nature Rev. Cancer 6: 107–116.

Brown, R. and Strathdee, G. (2002) Epigenomics and epigenetic therapy of cancer.

Trends Mol. Med. 8(Suppl.): S43–S48.

Buseman, C.M., Wright, W.E., and Shay, J.W. (2012) Is telomerase a viable target in cancer? Mut. Res. 730: 90–97.

Chen, H., Li, Y., and Tollefsbol, T.O. (2009) Strategies targeting telomerase inhibition.

Mol. Biotechnol. 41: 194–199.

Feinberg, A.P. (2007) Phenotypic plasticity and the epigenetics of human disease.

Nature 447: 433–440.

Goffi n, J. and Eisenhauer, E. (2002) DNA methyltransferase inhibitors—state of the art. Ann. Oncol. 13: 1699–1716.

Herman, J.G. and Baylin, S.B. (2003) Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349: 2042–2054.

Jones, P.A. and Baylin, S.B. (2007) The epigenomics of cancer. Cell 128: 683–692.

Laird, P.W. (2003) The power and the promise of DNA methylation markers. Nature 3: 253–266.

Marks, P.A., Richon, V.M., Breslow, R., and Rifkind, R.A. (2001) Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13: 477–483.

Milde-Langosch, K. (2005) The Fos family of transcription factors and their role in tumourigenesis. Eur. J. Cancer 41: 2449–2461.

Rodriguez-Paredes, M. and Esteller, M. (2011) Cancer epigenetics reaches mainstream oncology. Nature Med. 17: 330–339.

Schreiber, S.L. and Bernstein, B.E. (2002) Signaling network model of chromatin. Cell 111: 771–778.

Shaulian, E. and Karin, M. (2002) AP-1 as a regulator of cell life and death. Nature Cell Biol. 4: E131–E136.

Thorne, J.L., Campbell, M.J., and Turner, B.M. (2009) Transcription factors, chromatin, and cancer. Internat. J. Biochem. Cell Biol. 41: 164–175.

Verdun, R.E. and Karlseder, J. (2007) Replication and protection of telomers. Nature 447: 924–931.

■ WEB SITES

HDAC inhibitor in clinical trials http://www.methylgene.com

Nuclear Receptor Signaling Atlas http://www.nursa.org/

3 . 8 T E L O M E R A S E I N H I B I TO R S 75

■ SELECTED SPECIAL TOPICS

Castelo-Branco, P., Zhang, C., Lipman, T., Fujitani, M., Hansford, L., Clarke, I., et al. (2011) Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition. Clin. Cancer Res. 17: 111–121.

Di Croce, L., Raker, V.A., Corsaro, M., Fazi, F., Fanelli, M., Faretta, M., et al. (2002) Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295: 1079–1082.

Esquela-Kerscher, A. and Slack, F.J. (2006) Oncomirs—microRNAs with a role in cancer. Nature Rev. Cancer 6: 259–269.

Garzon, R., Marcucci, G., and Croce, C.M. (2010) Targeting microRNAs in cancer: rationale, strategies and challenges. Nature Rev. Drug Discov. 9: 775–789.

Gaudet, F., Hodgson, J.G., Eden, A., Jackson-Grusby, L., Dausman, J., Gray, J.W., et al. (2003) Induction of tumors in mice by genomic hypomethylation. Science 300: 489–492.

Morin, R.D., Mendez-Lago, M., Mungall, A.J., Goya, R., Mungall, K.L., Corbett, R.D., et al. , (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476: 298–303.

O’Doherty, A.M., Church, S.W., Russell, S.E.H., Nelson, J., and Hickey, I. (2002) Methylation status of oestrogen receptor—a gene promoter sequence in human ovarian epithelial cell lines. Br. J. Cancer 86: 282–284.

Tavazoie, S.F., Alarcon, C., Oskarsson, T., Padua, D., Wang, Q., Bos, P.D., et al.

(2007) Endogenous human microRNAs that suppress breast cancer metastasis.

Nature 451: 147–152.

von Zglinicki, T. (2002) Oxidative stress shortens telomeres. Trends Biochem. Sci. 27: 339–344.

Watson, R.E. and Goodman, J.I. (2002) Effects of phenobarbital on DNA methylation in GC-rich regions of hepatic DNA from mice that exhibit different levels of susceptibility to liver tumorigenesis. Toxicol. Sci. 68: 51–58.

Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., Stephens, R.M., et al. (2006) Unique microRNA molecular profi les in lung cancer diagnosis and prognosis . Cancer Cell 9: 189–198.

This page intentionally left blank





Chapter 4

Growth factor signaling

and oncogenes

Introduction

One of the fundamental characteristics of cells is their ability to self-reproduce. The process of cell division (also known as cell proliferation or cell growth) must be carefully regulated and DNA replication must be precisely coordinated in order to maintain the integrity of the genome for each cell generation. As emphasized earlier in this volume, unregulated growth is a quintessential characteristic of cancer.

PAUSE AND THINK

Normally, cell division is only initiated in response to a signal from outside of the cell. An extracellular growth factor stimulates cell growth by transmitting a signal into the cell, Let us scale up from molecules

and ultimately to the nucleus, to regulate gene expression in order to produce proteins to people to simplify the conse-that are essential for cell division. There are four types of proteins involved in the transduc-quence of phosphorylation. tion of a growth factor signal: growth factors, growth factor receptors, intracellular signal People often use additions or

transducers, and nuclear transcription factors which elicit the mitogenic effect through accessories to increase their rec-the regulation of gene expression. Examining the normal mechanism of growth will allow ognition by others; tour guides

a better understanding of the abnormalities that occur during carcinogenesis.

may hold up umbrellas so that

It is important to identify a common thread in many growth factor signal transduction their group easily recognizes

pathways: many growth factor receptors are tyrosine kinases. All kinases catalyze the them. Other additions may alter

transfer of the γ phosphate group from ATP/GTP to hydroxyl groups on a specifi c amino the activity of a person; the

acid in a target protein. Tyrosine kinases phosphorylate tyrosine residues in target proteins wearing of a heavy backpack

(Figure 4.1). Serine/threonine kinases phosphorylate serine and threonine residues. The may limit one’s activity. The

addition of the phosphate group, a bulky charged molecule, may serve as a recognition addition of phosphate residues

can have analogous effects on

site for new protein–protein interactions and/or may cause a conformational change proteins.

resulting in the activation or inactivation of an enzymatic activity. Specifi c examples will be described in the following sections.

4.1 Epidermal growth factor signaling: an important

paradigm

Epidermal growth factor (EGF) and its family of receptor tyrosine kinases serves as an important paradigm for how a signal from an extracellular

78

4: G R O W T H FAC TO R S I G N A L I N G A N D O N C O G E N E S

growth factor can be transduced through a cell, regulate gene expression, and trigger cell proliferation. It is a model that we know a great deal

about. The EGF receptor (EGFR; also known as ErbB1 or HER1), is a tyrosine kinase receptor and was the fi rst to be discovered. Three additional family members have since been identifi ed: ErbB2 (HER2), ErbB3

(HER3), and ErbB4 (HER4). As members of the receptor tyrosine kinase receptor family, these receptors contain an extracellular ligand-binding domain, a single transmembrane domain, and a cytoplasmic protein

tyrosine kinase domain (Figure 4.1), with two exceptions: HER2 does not bind to a known ligand but acts as a co-factor for the other members of the family and HER3 does not contain a tyrosine kinase domain. Getting the signal from a growth factor outside the cell to inside the nucleus where gene expression is regulated requires several steps: binding of the growth factor to the receptor, receptor dimerization, autophosphorylation, activation of intracellular transducers (including the “star player”

RAS) and a cascade of serine/threonine kinases, and regulation of transcription factors for gene expression. Each of the steps involved in the signal transduction pathway of EGF is illustrated in Figure 4.2 and described in the following sections. For ease of learning, the complete pathway has been divided into two parts: early steps of the pathway which occur at the cell membrane (Figure 4.4) and later steps of the EGF

pathways that occur away from the cell membrane (Figure 4.5). It is essential that you learn this model system because it will enable you to understand many other signal transduction pathways and it will be the basis for illustrating the mechanisms of carcinogenesis. Most interestingly, the components of this pathway have been targets for the design of new cancer therapeutics, some of which will be described at the end of the chapter.

EGF

Extracellular binding domain

EGFR

Transmembrane domain

Cytoplasmic domain

OH

OH

2–

Figure 4.1 Tyrosine kinase

O

PO

Ty

Ty

3

Ty

r

r

receptors phosphorylate tyrosine

AA3

AA3

AA3 r

AA5

AA5

residues on target proteins.

AA5

AA2

AA2

AA2

Phosphorylation usually results in

AA6

AA6

AA6

a conformational change of the

AA1

AA1

AA1

...

...

protein target.

...

4 . 1 E P I D E R M A L G R O W T H FAC TO R S I G N A L I N G : A N I M P O R TA N T PA R A D I G M 79

EGF

EGF

EGFR

EGFR

SOS

RAS

RAS

P

P

GRB2

SOS

GAPS

Active

GDP

GTP

Autophosphorylation

Inactive

RAF

Figure 4.2 The signal transduction

MEK

pathway of EGF. This pathway is

characterized by the sequential

steps of growth factor binding,

MAPK

MAPK

receptor dimerization,

P

autophosphorylation, activation

of an intracellular kinase cascade,

Transcription

activation of transcription factors,

factor

and regulation of gene expression.

Details are described in the text.

Growth factor binding

The fi rst step in the EGF signal transduction pathway is the binding of EGF to its receptor, EGFR. Extracellular domains (I and III) of EGFR

form a binding pocket for the ligand.

Dimerization

Dimerization is the process of two EGFR monomers interacting to form a dimer. The mechanism for receptor dimerization as suggested from

structural studies is described here and illustrated in Figure 4.3. The binding of one EGF molecule to one receptor causes a conformational EGF

EGF

EGF

EGF

EGF

EGF

EGFR

Cell membrane

P

P

Autophosphorylation

Figure 4.3 EGF receptor dimerization. Growth factor binding causes a conformational change that unmasks a dimerization domain required for receptor dimerization.

80

4: G R O W T H FAC TO R S I G N A L I N G A N D O N C O G E N E S

EGF

EGF

EGF

EGF

EGFR

EGFR

EGFR

EGFR

Cell membrane

GAPS

RAS

RAS

Active

GDP

GTP

SOS

Inactive

P

P

GRB2

SOS

Autophosphorylation

Figure 4.4 The early steps of the EGF pathway. The EGF growth factor binds to its receptor and causes the receptor to change shape. The change in shape allows two receptors to come together. They undergo autophosphorylation shown by a “P.” The phosphorylated receptor recruits GRB and SOS proteins to the membrane. SOS activates RAS. Activation occurs by the exchange of GDP with GTP. Note the SH2 domain of GRB2 that interacts with “P” and the SH3 domains at the interface of GRB2 and SOS are shaded in red.

Cell membrane

RAS

Active

GTP

RAF

RAF

ACTIVE

MEK

MEK

P

ACTIVE

MAPK

MAPK P

ACTIVE

MAPK P

ACTIVE

P

Transcription

Transcription

Gene expression

factor

factor

ACTIVE

Figure 4.5 The later steps of the EGF pathway. Activated RAS activates signal transducer RAF. RAF phosphorylates and activates MEK. MEK phosphorylates and activates MAPK.

Activated MAPK enters the nucleus and phosphorylates and activates transcription factors (TF) that turn on specifi c sets of genes needed for cell growth.

4 . 1 E P I D E R M A L G R O W T H FAC TO R S I G N A L I N G : A N I M P O R TA N T PA R A D I G M 81

change that reveals an extracellular receptor dimerization domain (shown in red). This facilitates the binding to a similar domain in another EGF-bound receptor monomer resulting in a receptor dimer. It is important to note that EGFR can also form heterodimers with other members of the ErbB family.

Autophosphorylation

The close proximity of two receptors, facilitated by dimerization, enables the kinase domain of one receptor of the dimer to phosphorylate the other receptor of the dimer and vice versa (see Plate 2). This intermolecular (between molecules) autophosphorylation on the cytoplasmic domain of the receptors (shown by red crossed lines in Figures 4.2, 4.3, and 4.4) occurs at tyrosine residues in the activation loop and results in a conformational change. The change in receptor conformation permits access of ATP and substrate to the catalytic kinase domain. Autophosphorylation is also crucial for the recruitment of cytoplasmic proteins, as we will see later in this chapter. At this stage a signal from outside the cell has been transduced to inside the cell.

Note that activation of the tyrosine kinase receptor needs to be turned off after a particular length of time. Mechanisms for the termination of kinase activity include additional phosphorylation triggering a conformational change that inhibits extracellular ligand binding and kinase activity, dephosphorylation of regulatory phosphorylated tyrosine residues by tyrosine phosphatases, binding of negative regulators (e.g. RALT) to the kinase domain, and receptor endocytosis and degradation. However,

recent data suggest that internalization of the receptor may also play a role in the transport of the receptor to the nucleus and the induction of specifi c genes (see Linggi and Carpenter, 2006).

Translocation of specifi c proteins to the membrane

Activation of the tyrosine kinase catalytic domain facilitates further phosphorylation. Some phosphorylated tyrosine residues create high-affi nity binding sites for proteins that contain Src homology 2 (SH2) domains and act as docking sites for the recruitment of specifi c intracellular proteins.

SH2 domains (approximately 100 amino acids long) and Src homology

PAUSE AND THINK

3 (SH3) domains (approximately 50 amino acids long) mediate protein–

Remember that a domain is a

protein interactions in pathways activated by tyrosine kinases. SH2

part of a protein with a specifi c

domains recognize and bind to distinct amino acid sequences (1–6 resi-confi guration that has a specifi c

dues) C terminal to phosphorylated tyrosine residues and SH3 domains function analogous to an elec-recognize and bind to proline and hydrophobic amino acid residues on trical plug (see Chapter 3).

partner proteins. Both SH2 and SH3 domains are frequently found in the

82

4: G R O W T H FAC TO R S I G N A L I N G A N D O N C O G E N E S

same protein. Proteins mentioned later in the text that contain SH2 and SH3 domains include SRC, ABL, Grb2, and PI3-K.

Grb2, an intracellular protein that contains SH2 and SH3 domains, recognizes the phosphorylated EGF receptor via its SH2 domains and facilitates the recruitment of specifi c proteins to the membrane via its SH3

domains. Specifi cally, the two SH3 domains of Grb2 interact with the exchange protein SOS (son of sevenless), which facilitates the activation of the pivotal intracellular transducer RAS. Thus, SOS, the activator of RAS is translocated from the cytoplasm to the membrane in response to growth factor stimulation (Figure 4.4).

RAS activation

The RAS proteins are “star players” in regulating cell growth because of their position in the signal transduction pathway; they act as a pivotal point for the integration of a growth factor signal initiating from the membrane with a number of crucial signaling pathways that carry the signal through the cytoplasm and into the nucleus. N-, H-, and K-RAS are the three members of the family. They are GTP-binding proteins such that when they are bound to GDP they are inactive and when they are bound to GTP they are active. Nucleotide exchange factors, such as SOS mentioned earlier, catalyze the exchange of GDP with GTP. GTPase activating proteins (GAPs) catalyze the hydrolysis of GTP to GDP to terminate the signal, although RAS proteins possess some intrinsic GTPase activity which allows for self-regulation.

In the EGFR pathway, the protein–protein interactions facilitated by the SH3 domains of Grb2 with the SH3 domains of SOS bring SOS to the membrane where RAS is located. SOS facilitates the exchange of GDP for GTP, and results in RAS activation (Figure 4.4).

RAS proteins undergo a series of post-translational modifi cations that direct their traffi cking in the cell. Farnesylation, the addition of the C15

farnesyl isoprenoid lipid to the C-terminal CAAX motif (where C represents cysteine, A represents an aliphatic amino acid, and X represents any amino acid), is one modifi cation that is required for localizing RAS to the cell membrane. It is interesting to note that it has recently been demonstrated that endogenous RAS is capable of activating downstream signaling pathways from subcellular membrane compartments (endoplasmic

reticulum and Golgi) upon EGF stimulation (Hingorani and Tuveson,

2003). This adds a new dimension to our knowledge as it was previously thought that localization to the plasma membrane was essential for RAS

activity. Furthermore, it has been demonstrated that RAS can transform cells from their subcellular compartments, as well as from the membrane.

These new observations must be considered in the rationale for designing new cancer therapies.

4 . 1 E P I D E R M A L G R O W T H FAC TO R S I G N A L I N G : A N I M P O R TA N T PA R A D I G M 83

Raf activation

RAS–GTP binds to and contributes to the activation of the serine/threonine kinase Raf, one of its main effectors. The recruitment of Raf to the

cell membrane is necessary for its activation by RAS-GTP. Activation involves the relief of a Raf auto-inhibitory mechanism. Activated Raf is a signal transducer that carries the signal away from the membrane (Figure 4.5). As a kinase, it phosphorylates mitogen-activated protein kinase kinase (MAPKK; MEK).

A little lesson about the MAP kinase family: MAP kinase kinase kinases, MAP

kinase kinases, and MAP kinases

The nomenclature may seem confusing at fi rst but it is because of the fact that a series of phosphorylation steps is necessary for signal transduction: a kinase (MAPKKK) phosphorylates another kinase (MAPKK), which itself phosphorylates yet another kinase (MAPK; originally called ERK). A unique feature of MAP kinase activation is that it requires both tyrosine and threonine phosphorylation. MAPKK is a dual-specifi city kinase that phosphorylates both tyrosine and threonine residues. Raf is a MAPKKK and MEK is a MAPKK.

The MAP kinase cascade

The activated MAPKKs (MEK), dual tyrosine and serine/threoine kinases,

go on to phosphorylate the mitogen-activated protein kinases (MAPKs) (also known as extracellular signal-regulated kinases; ERKs). The MAPKs are a family of serine/threonine kinases that provide the cytoplasmic link between the activated RAS on the plasma membrane and regulation of

gene expression, as activated MAPKs can enter the nucleus. The activity of many transcription factors is regulated by phosphorylation and thus MAPKs can affect the activity of transcription factors via phosphorylation (Figure 4.5).

Although this discussion focuses on MAPK, there are actually three distinct, but parallel, MAP kinase pathways: MAPK, JNK, and p38. As

noted in this section, MAPK is activated by growth factors. JNK and p38

are activated by a various environmental stress signals such as ultraviolet and ionizing radiation. The JNK and p38 pathways usually trigger apoptosis. All three MAPK pathways act as a common mechanism that serves multiple signaling pathways and results in various cellular responses.

Regulation of transcription factors

The AP1 transcription factor is an important target of the MAPK cascade.

As a transcription factor, it binds to DNA and regulates the expression of genes involved in growth, differentiation, and death. One mechanism,

84

4: G R O W T H FAC TO R S I G N A L I N G A N D O N C O G E N E S

whereby AP-1 induces cell cycle progression, is by binding to and activating the cyclin D gene, a critical regulator of the cell cycle. AP-1 is not a single protein but rather is made up of the products of two gene families, jun and fos. These proteins contain basic leucine zipper domains that facilitate their binding as dimers to either the cAMP response element (CRE) or the 12- O-tetradecanoylphorbol-13-acetate (TPA) response element in a target gene. AP-1 activity is induced by two mechanisms. First, direct phosphorylation of members of the Fos family by MAPK affects their DNA-binding activity. Secondly, MAPK phosphorylation and subsequent activation of other transcription factors increases the expression of both fos and jun genes. As a result, AP1 activity increases and subsequent transcriptional regulation proceeds.

The Myc family of transcription factors (Myc, Max, Mad, Mxi) can

dimerize in different ways and lead to distinct biological effects of growth, differentiation, and death. Several seem to be targets of MAPKs. Myc is a short-lived protein that promotes proliferation by regulating the expression of specifi c target genes. Gene targets of myc include N-Ras and p53, but the identifi cation of additional targets is the subject of ongoing research. Myc requires the constitutively expressed family member Max to function. Myc and Max form heterodimers via basic helix-loop-helix leucine zipper domains and bind to a regulatory sequence called the E-box in their target genes. Heterodimer formation and DNA binding are crucial for the oncogenic, mitogenic, and apoptotic effects of Myc. Other heterodimers, such as Max and Mad/Mxi, are inhibitory for Myc function. They can also bind to PAUSE AND THINK

the E-box in gene promoters but they repress transcription. Thus, the Myc family of transcription factors forms a network of interacting basic helix-The three-letter language of

loop-helix leucine zipper proteins and the identity of the members within a molecular terms sounds pecu-heterodimer determines the biological effect elicited.

liar at fi rst but with practice

will become familiar and allow

you to build your molecular

Self-test Close this book and try to redraw Figure 4.2. Check your answer. Correct your vocabulary.

work. Close the book once more and try again.

Good! Now let us backtrack to illustrate how you can build levels of complexity on the foundation you have learned. RAS has been noted to be a “major player” for the integration of a growth factor signal with a number of crucial signaling pathways. In fact, all receptor tyrosine kinases activate RAS. Raf was described earlier as one effector protein that leads to the activation of the MAPK cascade, but there are several other effector proteins of RAS activation. Phosphatidylinositol 3-kinase (PI3K), a lipid kinase, is another effector protein downstream of RAS that can be introduced at this point (see Pause and Think on page 85).

Crystal studies have shown that RAS interacts directly with the catalytic structure of PI3K. Production of the second messenger, PIP3, recruits

4 . 1 E P I D E R M A L G R O W T H FAC TO R S I G N A L I N G : A N I M P O R TA N T PA R A D I G M 85

the serine/threonine kinase PDK-1 to the membrane. Akt, another serine/

PAUSE AND THINK

threonine kinase, is also recruited to the membrane where it is phosphorylated and activated by PDK-1. Activated Akt is translocated into the What is a lipid kinase? It is an

enzyme that phosphorylates

nucleus where it phosphorylates nuclear substrates, including transcrip-lipids. PI3K phosphorylates the

tion factors. Activated Akt is also involved in anti-apoptotic and survival 3′ OH group of PIP2 (phosphati-roles by phosphorylating distinct target proteins.

dylinositol-4,5-bisphosphate) to

produce the second messenger,

Self-test Draw a diagram of a growth factor signal transduction pathway including two PIP3 (phosphatidylinositol-3,4,5

effector proteins of RAS activation. Check your answer with Figure 4.6. Correct your work.

trisphosphate). Do not be dis-

couraged by these cumbersome

names: the difference between

the two is only a phosphate

The effect of cell signaling on cell behavior

group.

We have seen earlier in this chapter that growth factor signaling can lead to cell proliferation via signaling to the nucleus. In addition, cell signaling can have effects on cell behavior. This is clearly demonstrated by the intracellular tyrosine kinase SRC (the gene src is discussed in the next section).

EGF

EGF

EGFR

EGFR

PIP2

PIP3

PIP3

SOS

RAS

RAS

PI3K

PDK-1

AKT

P

P

GAPS

GDP

GTP

Active

Autophosphorylation

GRB2

SOS

Inactive

P

AKT

RAF

MEK

MAPK

MAPK

P

Transcription

factor

Figure 4.6 The EGF signal transduction pathway showing two effectors of RAS (shown in red).





86

4: G R O W T H FAC TO R S I G N A L I N G A N D O N C O G E N E S

In addition to having a role in cell proliferation, SRC plays an important role in the regulation of cell adhesion, invasion, and motility upon EGF

receptor activation. SRC is a phosphoprotein which contains SRC homology domains, including a SH2 and SH3 domain. It also contains a negative regulatory domain near the carboxy-terminus. When Tyr530 in this negative regulatory domain is phosphorylated, it binds to the internal SRC SH2 domain and results in an intramolecular association which

represses the kinase domain and keeps SRC in an inactive state (Figure 4.7). One way in which SRC can be activated is via receptor tyrosine kinases, such as the EGF receptor. Upon stimulation of the EGF receptor by growth factor, the autophosphorylated receptor can interact with the SH2 domain of SRC, disrupting its negative regulatory intramolecular conformation. The activated kinase phosphorylates a wide range of target proteins, including focal adhesion proteins (e.g. focal adhesion kinase, FAK), adaptor proteins, and transcription factors. The regulation of focal adhesion proteins within the dynamic subcellular structures called focal adhesions is particularly important for adhesion and motility. These structures associate with cytoskeletal fi bers that ultimately control cell shape and motility. Assembly of focal adhesions facilitates cell adherence while disassembly facilitates motility. Activation of SRC leads to disassembly of focal adhesions and thereby permits increased motility. SRC also regulates cell invasion by inhibiting E-cadherin (see Chapter 9).

Thus, the effects of growth factor cell signaling through tyrosine kinase receptors are indeed manifold, as is illustrated by the many downstream effects that occur upon SRC activation.

4.2 Oncogenes

Cancer arises from mutations in genes that are involved in growth, differentiation, or death. There are two major classifi cations of mutated genes Tyr

Domain structure

SH3

SH2

Kinase domain

530

of Src

Tyr

530

P

Inactive Src

SH3

SH2

Kinase domain

Figure 4.7 The protein domains of SRC and a negative regulatory intramolecular interaction.

4 . 2 O N C O G E N E S

87

that contribute to carcinogenesis: oncogenes and tumor suppressor genes.

A general description of an oncogene is a mutated gene whose protein product is produced in higher quantities or whose altered product has increased activity and therefore acts in a dominant manner. A mutation in only one allele is suffi cient for an effect. Tumor suppressor genes (see Chapter 6), however, are genes in which the mutation has caused a loss of function, and therefore most are recessive in nature because both alleles must be mutated. More than 100 oncogenes and at least 15 tumor suppressor genes have been identifi ed.

Studies of retroviruses

Studies of retroviruses have led to great insights into cancer biology and have become the foundation of our knowledge of oncogenes. Several

landmark experiments were performed based on the early observation

that viruses could cause cancer in animals and the results pointed to the discovery of oncogenes. In 1911, Peyton Rous prepared a cell-free fi ltrate from a chicken sarcoma and demonstrated that he could induce sarcomas in healthy chickens with this fi ltrate. The causative agent was identifi ed as the Rous Sarcoma Virus. Many decades later, oncogenic

transformation by this virus was found to be caused by an “extra” gene contained in its genome that was not required for viral replication. The fi rst so-called “oncogene” was identifi ed as v-src (pronounced “v sark”).

The oncogene product was characterized as a 60 kDa intracellular tyrosine kinase.

A LEADER IN THE FIELD . . . of oncogenes: Joan Brugge

Joan Brugge has been a personal infl uence in my own career. Although she was never one of my offi cial mentors, she created an extremely encouraging atmosphere at the State University of New York at Stony Brook while I was carrying out my PhD research. Her style in carrying out research was always natural, enthusiastic, and genuinely inquisitive. She is a model scientist. Joan’s own motivation for carrying out cancer research stemmed from the loss of a family member to cancer. Joan made great strides early in her career. Working with Ray Erikson at the University of Colorado during her post-doctoral tenure, she carried out pioneering work on the fi rst retroviral oncogene product, the SRC protein.

Joan received her BA in biology from Northwestern University and her PhD in virology from Baylor College of Medicine. In addition to the State University of New York at Stony Brook, she was on the faculty at the University of Pennsylvania and is currently Acting Chair of the Department of Cell Biology at Harvard Medical School. In between her academic appointments she was the Scientifi c Director of ARIAD Pharmaceuticals, Inc. in Cambridge, MA. Joan has recently been awarded a Research Professorship from the American Cancer Society, the Society’s most prestigious research award, for her signifi cant contributions to cancer research. She is currently investigating the initiation and progression of breast cancer using three-dimensional cellular models.

88

4: G R O W T H FAC TO R S I G N A L I N G A N D O N C O G E N E S

In 1976, a startling discovery was made. Bishop and Varmus found that there was a gene with a homologous sequence to v-src in uninfected chickens. Moreover, upon further investigation this gene could be found in organisms from fruitfl ies to humans. Following further examination, a fundamental principle of cancer biology was revealed: almost all known oncogenes are altered forms of normal genes or proto-oncogenes.

• Exception: some protein products of DNA tumor viruses behave like oncogenes but are not viral versions of cellular oncogenes. They act by blocking the activity of tumor suppressor proteins. See Chapters 6 and 10.

The name proto-oncogene is sometimes used in cancer biology to dis-

tinguish the normal cellular (c) gene (e.g. c-src) from the altered form transduced by retroviruses (v) (e.g. v src). The v-src sequence lacks the carboxy-terminal negative regulatory domain present in c-src and has point mutations throughout the gene.

A LEADER IN THE FIELD . . . of oncogenes: Harold Varmus

Harold Varmus, along with J. Michael Bishop, received the Nobel Prize in Physiology or Medicine in 1989 for studies carried out at the University of California, San Francisco, that laid down the foundation for the role of mutations in carcinogenesis. They discovered that some genes of cancer-causing viruses were mutated forms of normal cellular genes. As we see in this chapter, this was the birth of the concept of proto-oncogenes and of the molecular biology of cancer.

Harold Varmus is a native of Long Island, NY (like myself). He obtained a Master’s Degree in English from Harvard University and is a graduate of Columbia University’s College of Physicians and Surgeons.

Varmus was named by President Clinton to serve as the Director of the National Institutes of Health, a position he marked with many advancements during his six years’ service. He has acted as an advisor to the Federal Government and as a consultant for several pharmaceutical companies and academic institutions. He was the President and Chief Executive Offi cer of Memorial Sloan-Kettering Cancer Center in New York City. And now, after accepting President Obama’s nomination in 2010, he is the Director of the National Cancer Institute.

At this point a short review of the retroviral life cycle is necessary. The life cycle of retroviruses brands them as intracellular parasites in that they rely on their host cell for energy and to synthesize viral proteins. After injecting their infectious nucleic acid (RNA) into a host cell, the viral RNA is fi rst reverse transcribed into DNA. This provirus DNA is integrated randomly into the host chromosome, where it will be replicated, transcribed, and translated as host DNA. The translation of viral RNA then produces viral proteins for the synthesis of new viral particles. During evolution, the virus can acquire fragments of genes from the host at integration sites and

4 . 2 O N C O G E N E S

89

this process may result in the creation of oncogenes. The Rous Sarcoma Virus acquired a truncated form of c-src. Alternatively, and depending on the integration site, viral DNA may be translated as a fusion protein in conjunction with cellular DNA resulting in a novel fusion protein, or host genes may fall under the regulation of viral regulatory sequences. The resulting disruptions to host gene expression are other mechanisms of virus-induced oncogenesis. This knowledge aids our general understanding of the mechanisms of carcinogenesis, because although viruses are not the major cause of human cancers, the mechanism of oncogenic activation of proto-oncogenes is similar. For example, chromosomal translocations may have the same consequence as the integration of a virus into a host chromosome; a crucial gene may come under the infl uence of novel regulatory sequences and result in abnormal quantities of the gene product. The new gene confi guration may serve as an oncogene.

It is important to become familiar with examples of oncogenes to bol-ster the lesson learned from viral studies: almost all known oncogenes are altered forms of normal genes.

There are examples of oncogenes for every type of protein involved in a growth factor signal transduction pathway. Several examples are

described in the following sections.

Growth factors

The fi rst evidence for the role of proto-oncogenes came from analysis of the viral oncogene v-sis. Its protein product was cytoplasmic and was found to be a truncated version of a growth factor normally secreted by platelets, called platelet-derived growth factor (PDGF). Thus, the identity of the product of the proto-oncogene or cellular gene c-sis, is PDGF. It is a component of a wound response and its normal role is to stimulate epithelial cells around the wound edge to proliferate and repair the damage. The signifi cance of the oncogenic form may be its aberrant location (cytoplasmic rather than secreted) and the subsequent activation of the PDGF signal pathway at inappropriate times (e.g. other than in response to a wound), leading to unregulated growth.

Growth factor receptors

The oncogene v-erbB was originally identifi ed from (and named after) the avian erythroblastosis leukemia virus. It is a truncated form of the epidermal growth factor receptor whereby the extracellular domain is deleted.

Thus, the identity of the product of the proto-oncogene or cellular gene c-erbB, is EGFR. The mutated receptor triggers cell division in the absence of EGF. Point mutations that accomplish the same effect of interfering with growth factor binding and inducing constitutive (“always on”)

90

4: G R O W T H FAC TO R S I G N A L I N G A N D O N C O G E N E S

activation have been identifi ed in human cancers. Increasing the amount of normal c-erbB product by gene amplifi cation is another mechanism that contributes to carcinogenesis, particularly breast cancer. Gene amplifi cation involves multiple duplications of a DNA sequence owing to errors at DNA replication forks.

The proto-oncogene ret, another growth factor tyrosine kinase recep-PAUSE AND THINK

tor, heterodimerizes with cell-surface receptors GFR-α1–4 in order to What types of genes are usually

transduce the signal for glial-derived neurotrophic factor (GDNF). It involved in inherited predisposi-plays an important role in kidney development and neuronal differentia-tions to cancer? Although

tion. Papillary thyroid carcinoma cells often carry somatic chromosomal tumor suppressor genes are

re-arrangements involving the amino-terminal parts of numerous genes most often involved, here we

and the sequences of ret that code for the tyrosine kinase domain. The see an unusual example of an

fusion protein products display kinase activity that is independent of oncogene ( ret) playing a role in

GDNF signaling.

cancer predisposition.

Germline mutations are associated with three familial tumor syn-

dromes: multiple endocrine neoplasia 2A (MEN2A), MEN2B, and famil-

ial medullary thyroid carcinoma. The mutations that have been identifi ed illustrate different mechanisms for oncogenic activation. Almost all MEN2A patients have mutations in conserved extracellular cysteines.

Resulting intermolecular disulfi de bonds cause constitutive Ret dimerization and aberrant activation. In MEN2B patients, oncogenic activation is achieved by altering the substrate-binding pocket of the tyrosine kinase domain. A conserved Met is characteristic of the substrate-binding

domain of receptor tyrosine kinases whereby Thr is conserved for cytoplasmic tyrosine kinases. The characteristic mutation of MEN2B is a substitution mutation, whereby Thr replaces this conserved Met residue (Met918Thr). This results in altered substrate access leading to increased kinase activity and altered substrate specifi city that is characteristic of cytoplasmic tyrosine kinases instead of receptor tyrosine kinases. Thus, the signal transduction pathways are highly disrupted.

Oncogenic activation of receptor tyrosine kinases occurs through specifi c mutations that lead to constitutive tyrosine activation or dimerization.

Intracellular signal transducers

The oncogenic activation of ras is observed in about 30% of human tumors. The majority of mutations are located in codons 12, 13, and 61.

The consequence of each of these mutations is a loss of GTPase activity of the RAS protein, normally required to return active RAS–GTP to inactive RAS–GDP. The effect is constitutive activation of RAS protein, even in the absence of mitogens. Some specifi c mutations in the ras gene are characteristic for specifi c cancers. A point mutation within codon 12 that results in the substitution of valine (GTC) for glycine (GGC) is characteristic of

4 . 2 O N C O G E N E S

91

? HOW DO WE KNOW THAT?

Transformation assays and mutational analysis

construct shown in Figure 1 of Reddy et al. (1982)). The

research team then used comparative sequence analysis of

The early classical paper by Reddy et al. (1982) illustrates fun-the small fragment identifi ed by deletion analysis to identify

damental experimental methods that were used to identify

a single point mutation within the small fragment in human

oncogenes and their genetic alterations. The ability of the ras bladder carcinoma cells. The method of sequence analysis

oncogene (identifi ed in a 6.6 Bam H1 fragment of T24 DNA)

was according to the procedures of Maxam and Gilbert (see

to transform cells was demonstrated in a prototypical (origi-

Figure 4.8b).

nal) invitro celltransformationassay, Figure 4.8a(seeSection1.2).

In vivo experiments supported the role of the ras oncogenes This assay is based on the characteristic that cancer cells

in carcinogenesis. Cells transfected with a plasmid capable of

grow as foci against a monolayer of normal cells. To identify a

expressing high levels of c-ras showed the ability to form

smaller fragment of the gene that contained the genetic

tumors in mice (Chang et al. , 1982) and a ras knock-out mouse alteration, a series of deletion mutants were transfected into

exhibited decreased tumor formation during skin carcinogene-

NIH3T3 cells and assayed for formation of foci (transforming

sis (Ise et al. , 2000).

activity is indicated by a +/− sign next to each deletion

bladder carcinoma, while substitution of serine (AGC) is common in lung PAUSE AND THINK

cancer.

B-Raf is another transducer that may become oncogenic. Oncogenic acti-Classify each type of evidence

vation of B-Raf is common in melanomas. The common mutated form of

above according to the “show

B-Raf, B-Raf(V600E), found in melanoma patients causes constitutive it,” “block it,” “move it” criteria

discussed in Section 1.2.

kinase activity and insensitivity to feedback mechanisms. Thus, growth signaling initiated from the transducer and not from an external growth factor signal, occurs at inappropriate times and leads to abnormal cell growth.

Genes that code for cytoplasmic tyrosine kinases such as SRC, serine/

threonine kinases such as RAF and MAPK, and nuclear kinases such as ABL, can also undergo oncogenic activation. As discussed earlier, intramolecular associations normally regulate c-SRC kinase activity; the SRC

PAUSE AND THINK

SH2 domain binds a carboxy-terminal phosphorylated tyrosine residue (Tyr530) and results in a conformation that blocks the SRC kinase active How does the role of the SH2

site. Repression of SRC kinase activity can be relieved by dephospho-domain of SRC described above

rylation of Tyr530, or by the binding of the SH2 domain to specifi c acti-compare with that of the SH2

vated tyrosine kinase receptors (see Pause and Think). In colon cancer, domain of Grb2 and a receptor

the protein product of oncogenic src is characterized by a truncation at tyrosine kinase? In both cases,

Tyr530. This aberrant protein is unable to adopt the inactive conforma-the SH2 domain recognizes a

phosphotyrosine residue. The

tion described previously and therefore kinase activity is constitutive SH2 domain of SRC regulates

(“always on”).

intramolecular interactions but

Let us look at abl as another example. c-abl is a gene whose product is a the SH2 domain of Grb2 regu-nuclear tyrosine kinase that plays a role in DNA damage-induced apopto-lates intermolecular interactions

sis. It is normally activated by ionizing radiation and particular drugs via between itself and receptor

the serine/threonine kinase ATM. Oncogenic activation occurs through tyrosine kinases.

the chromosomal translocation t(9;22), whereby abl becomes juxtaposed

92

4: G R O W T H FAC TO R S I G N A L I N G A N D O N C O G E N E S

(a)

Cell transformation assay

(b)

Maxam-Gilbert sequencing

Tumor

Fragment to sequence

Label 5’ end with a radioactive marker

Tumor DNA

5’

Cut with a restriction enzyme

and separate two fragments by gel

5’ electrophoresis

Discard the smaller fragment

5’

G A G C G T

Calcium phosphate

+ Tumor DNA

Heat to denature

Transfection

Add DNA into four tubes

NIH 3T3

Human fibroblast

cell line

A

G

C

C+T

Add chemicals that cleave

Assay for foci

at a specific nucleotide

formation

corresponding to the label on

e.g. Chemical that

each tube

cleaves at G’s

G

Gel electrophoresis

Autoradiography

A G

C C+T

Read sequence from the bottom of

the gel: GAGCGT

Figure 4.8 (a) Cell transformation assay, (b) DNA sequencing by the Maxum–Gilbert method. Chemicals are used to cleave an end-labeled DNA segment at specifi c nucleotides and fragments are analyzed by gel electrophoresis and autoradiography. Note that there is not a specifi c enzyme that cuts only at Ts but instead cuts at Cs + Ts. Thus, if there is a band in both the C lane and the C + T lane, the nucleotide is a C; if there is a band only in the C + T lane, the nucleotide is a T.

to a breakpoint cluster region, bcr. Thus DNA sequences that are normally not next to each other are now fused and, upon transcription, give rise to a fusion protein with novel features (Figure 4.9). Translocated Bcr retains domains I and II (shown in white) while ABL retains the SH3 and SH2 domains, the kinase domain, the DNA-binding domain, and the

actin-binding domain (shown in red). BCR–ABL molecules associate with each other forming homo-oligomeric complexes, mediated by the coiled-coil motif in domain I of Bcr. Oligomerization permits autophosphorylation at Tyr177 within domain II, and this triggers activation of the ABL

tyrosine kinase. The fusion protein BCR–ABL is maintained in the cytoplasm. Consequently, a nuclear kinase is activated in the cytoplasm and

4 . 2 O N C O G E N E S

93

P

Tyr 177

Domain

Domain

Kinase

DNA-binding

Actin-binding

SH3

SH2

I

II

domain

domain

domain

Bcr (Chr22)

Abl (Chr9)

Bcr (Chr22)

Abl (Chr9)

Domain

Domain

Kinase

DNA-binding

Actin-binding

SH3

SH2

I

II

domain

domain

domain

Tyr 177

P

has access to a range of novel substrates, interfering in the normal signal Figure 4.9 The BCR–ABL fusion transduction pathways of the cell.

protein.

Transcription factors

It is not surprising that the transcription factor AP-1, which is an important regulator of cell growth, differentiation, and death, is also involved in transformation. Components of AP-1, Jun and Fos, are encoded by proto-oncogenes c-jun and c-fos and several mechanisms of oncogenic activation of these genes exist. Normally, c-fos mRNA is short-lived so that the response to a mitogen is transient. Truncation of the 3′ end of v-fos eliminates a motif involved in mRNA instability (ATTTATTT) and produces a mRNA with a longer half-life. The aberrant expression of v-fos mRNA results in an increase in v-fos gene product and an inappropriate increase in the transcription of AP-1-regulated genes. Oncogenic activation may also involve the deletion of a regulatory promoter sequence, the serum response element, such that transcription of the fos gene occurs even in the absence of serum mitogens.

Oncogenic activation of c-myc occurs from constitutive and overexpression of the c-Myc protein. Chromosomal translocation of myc (chromosome 8) to a location that falls within the regulation of the strong promoter of immunoglobulin genes (chromosome 14) increases the

amount of expression from the myc gene. This mechanism of oncogenic activation of c-myc is commonly observed in Burkitt’s lymphoma. The increase of Myc protein results in an inappropriate increase in the transcription of Myc-regulated genes.

Remember that steroid hormone receptors act as ligand-dependent

transcription factors. In addition to v-erbB discussed earlier, another oncogene, v-erbA, was originally identifi ed from (and named after) the avian erythroblastosis leukemia virus. The identity of the product of the

94

4: G R O W T H FAC TO R S I G N A L I N G A N D O N C O G E N E S

proto-oncogene or cellular gene c-erbA is the thyroid hormone (triiodo-PAUSE AND THINK

thyronine, T3) receptor. Oncogenic activation is achieved by mutations In the previous discussion regard-that prevent thyroid hormone binding and inhibit transcriptional activa-ing three specifi c transcription

tion. This type of mutation is referred to as a dominant negative mutation factors, you will notice that AP-1

because the product of this mutation codes for receptors that can bind to and Myc transcriptional activity

DNA and block access of wild-type receptors, including other steroid hor-increases in some cancers while

mone receptor family members that may form heterodimers with thyroid thyroid hormone receptor tran-receptors at their response elements. As the product of v-erbA can form scriptional activity decreases in

homodimers (note that the product of the proto-oncogene erbA homodi-some cancers. What can you pos-

tulate about the target genes of

merizes poorly), it is thought that the homodimers mediate the dominant these transcription factors? The

negative effect on the response elements. Most mutations of thyroid hor-target genes for AP-1 and Myc

mone receptors identifi ed in human cancers result in dominant negative are likely to code for proteins that

products, suggesting that they may be involved in human cancers, but this promote growth while the target

is an issue that needs further investigation (Gonzalez-Sancho et al. , 2003) genes of thyroid hormone recep-

(see Pause and Think).

tor are likely to inhibit growth.

Mechanisms of oncogenic activation

As can be seen from the previous sections, several mechanisms can be used to activate proto-oncogenes to become oncogenes (Figure 4.10). Point mutations and deletions in the coding region are a common mechanism and often change the structure and/or function of the proto-oncogene product.

Both mechanisms of oncogene activation were described for the EGFR

gene. Mutations in the gene promoter region can lead to over-expression of a proto-oncogene. Chromosomal translocations, as well as insertional Point mutations/deletions in coding sequences structural and functional changes

*

Point mutations and deletions in regulatory sequences over-expression

*

Chromosomal translocations fusion proteins with novel functions Insertional mutagenesis caused by viral integration aberrant expression V

Gene amplification: increase in gene dose and protein production Figure 4.10 Mechanisms that

activate proto-oncogenes to

become oncogenes.





4 . 3 K I N A S E S A S D R U G TA R G E T S 95

mutagenesis, cause the juxtaposition of sequences not normally next to each other, and often this confi guration can cause altered expression. The translocation involving c-myc and immunoglobulin regulatory sequences mentioned above is one example. Alternatively, fusion proteins can have novel characteristics. The Philadelphia chromosome t(9:22) relocates the nuclear kinase, c-Abl, to the cytoplasm where it encounters novel substrates. Gene amplifi cation is another mechanism for activation of erbB2

and is observed in breast cancer.

Therapeutic strategies

Knowledge of the molecular details of the EGFR signal transduction pathway and related pathways has led to the launch of many new cancer therapeutics targeting individual components. There has been great success for some and valuable lessons from others. The future is hopeful as we continue to unravel the molecular biology of signal transduction pathways and move forward in the design of additional new therapeutics. The strategies of some therapeutics aimed at molecular targets within these pathways are described in the next sections.

4.3 Kinases as drug targets

Many types of kinases, including transmembrane tyrosine kinases,

cytoplasmic kinases, and nuclear kinases, are implicated in cancer, as we have seen earlier. Therefore, they have become an important target for the design of new cancer therapeutics. In theory, one may predict that designing drugs with great specifi city to a subset of kinases would be diffi cult because the structure of the catalytic domains of different kinases is very similar when the kinases are in the active state. However, the synthesis of specifi c kinase inhibitors has clearly been demonstrated and examples are described in the following sections and illustrated in Figure 4.11.

Anti-EGFR drugs

The ErbB2 gene, a member of the EGFR family, is amplifi ed in 30% of breast cancer patients. Over-expression of this gene in cell culture experiments and in transgenic mice (see Box “Analysis of gene function using transgenic mice”) results in cell transformation and the induction of

96

4: G R O W T H FAC TO R S I G N A L I N G A N D O N C O G E N E S

Monoclonal antibodies:

Herceptin (Trastuzumab)

Erbitux (Cetuximab)

Vectibix (Panitumumab)

EGFR

Iressa

RAF

Nexavar

Zelboraf

Tarceva

Figure 4.11 Kinase inhibitors as

Tykerb

therapeutic strategies. Molecular

targets are indicated with a target

Gleevec

symbol () and therapeutic

agents are shaded in red. All

MEK

AZD6244

agents shown are approved

RDEA119

except those that target MEK.

Bcr

AbI

breast cancer, respectively. This suggests that ErbB2 has a causal role in breast cancer. Several small-molecule kinase inhibitor drugs directed against the tyrosine kinase activity of EGFR family members have been developed, including Iressa™ gefi

tinib, Tarceva™ (erlotinib), and

Tykerb™ (lapatinib). Iressa™ and Tarceva™ have been approved for the treatment of advanced non-small-cell lung cancer and Tykerb™ has been approved for the treatment of breast cancer (see Pao et al. , 2004 and Section 12.4 for further discussion).

Analysis of gene function using transgenic mice

One strategy for investigating the function of a gene is to put it in a place where it is not normally located or remove it from where it normally resides and observe any changes. Transgenic mice contain an additional or altered gene in all of their cells. Transgenic mice can be created by the direct injection of DNA into a fertilized egg. More commonly, foreign DNA is introduced into embryonic stem cells in culture prior to their transplantation into an early embryo (blastocyst). A series of breeding stages must follow to generate fully homozygous transgenic mice, as the founder animal is chimeric (not all cells of the organism contain the altered DNA) rather than transgenic. The cell culture step allows for selection and analysis of DNA integration to take place prior to the creation of a mouse. To create a knock-out mouse, a vector is designed so that it will insert into a specifi c gene location by homologous recombination (see Section 2.4) and disrupt the endogenous gene such that gene function is repressed. Complex transgenic experiments may use tissue-specifi c or inducible promoters to induce the expression of the foreign gene in a particular location or specifi c time.

4 . 3 K I N A S E S A S D R U G TA R G E T S 97

A different approach has also proved successful. Instead of targeting the tyrosine kinase domain of the ErbB2 receptor, the unique extracellular domain was targeted using monoclonal antibodies. Herceptin™ (trastuzumab) is a humanized (produced with human recombinant immuno-

globulin genes) monoclonal antibody that binds the extracellular domain of ErbB2 with high affi nity. Herceptin™ functions through a combination of mechanisms of action, including: enhanced receptor degradation, inhibition of angiogenesis and recruitment of immune cells, resulting in antibody-dependent cellular cytotoxicity. Herceptin™ was approved by the US Food and Drug Administration in 1998 for treatment of metastatic breast cancer whose tumors over-express ErbB2 and, thus, it is the fi rst genomics-based therapy administered selectively, based on the molecular profi le of the tumor. Erbitux™ (cetuximab) and Vectibix™ (panitumumab; ABX-EGF) are monoclonal antibodies that target EGFR and

have been approved to treat colorectal cancers. Patients with KRAS mutations in their tumors do not respond to these two drugs. Recalling the details of the EGF pathway helps to understand why tumors with KRAS

will not respond. It comes down to the sequence of carrying the oncogenic signal. If EGFR is the oncogenic signal then blocking it will be successful.

But if a molecule downstream of EGFR is the oncogenic signal, such as Ras, then blocking EGFR will not have an effect. The FDA now recommends screening patient tumor DNA for KRAS mutations before using

both Erbitux™ and Vectibix™. The infl uence of genetic information on a drug’s response, pharmacogenomics, helps doctors to choose best treatment for an individual (see Chapter 12). Genomic characterization of tumor DNA is elucidating subsets of molecularly distinct tumor types within a class of cancer (e.g. breast cancer) that will respond differently to targeted treatments. This is a signifi cant step towards individually tailored treatment, whereby treatment is matched to the molecular make-up of the patient’s tumor and promises to increase the success rate of a given drug.

Strategies against Raf

Although 20% of all tumors have activating mutations in ras and strategies directed at RAS have not yet been successful (e.g. farnesyltransferase inhibitors that compete with the carboxy-terminal CAAX motif of RAS), targeting downstream effectors have proved valuable as a cancer treatment. Several strategies to target the serine/threonine kinase Raf, one of the main effectors of RAS, have been developed.

The strategy commonly used to target other kinases has been applied to the serine/threonine kinase Raf. A multi-kinase inhibitor that targets the ATP-binding site of Raf, called Nexavar™ (sorafenib; previously called BAY43-9006), was approved for treatment of advanced renal cell carcinoma and hepatocarcinoma (USA 2005, Switzerland and Mexico 2006;

98

4: G R O W T H FAC TO R S I G N A L I N G A N D O N C O G E N E S

Wilhelm et al. , 2006). In order to investigate whether there was modulation of the defi ned molecular target, Raf, the phosphorylation of Raf targets was monitored. Data demonstrated a reduction in downstream

MAPK phosphorylation in the blood of patients receiving the well-

tolerated oral treatment. Note that it is important to monitor molecular endpoints (MAPK activity), in addition to clinical endpoints (anti-tumor activity). As a multi-kinase inhibitor, Nexavar™ also blocks several receptor tyrosine kinases (VEGFR1, -2, and -3, PDGFRb, c-Kit, and RET). The real contribution of Raf inhibition to clinical effectiveness compared with the other Nexavar™ targets will only be known by examining specifi c Raf inhibitors.

Another Raf inhibitor recently approved for the treatment of mela-

noma is Zelboraf™ (vemurafenib; PLX4032). Crystallography-guided

approaches using the kinase domain of B-Raf (V600E) allowed drug optimization. Zelboraf™ induced partial or complete tumor regression in 81% of patients who had melanoma with the B-Raf (V600E) mutation in an early clinical trial (Flaherty et al. , 2010). Although very promising, drug resistance develops for many of the patients. Resistance involves switching to other MEK kinases, rather than new mutations in the kinase domain and this suggests that combination treatments may be more effective for durable responses.

MEK Inhibitors

Inhibiting MEK is a strategy that would applicable to patients with mutations in either ras or raf genes. Mutations in MEK genes are rare; approximately 1% of tumors contain MEK mutations and no mutations have been identifi ed to date in MAPK (Fremin and Meloche, 2010). Several allosteric MEK inhibitors (inhibitors that do not compete with ATP) are in clinical trials (e.g. AZD6244 and RDEA119), but none have yet been approved.

Imatinib (Gleevec™; STI571)

Chronic myelogenous leukemia (CML) accounts for 15–20% of all leukemias. Bone marrow transplantation is the only hope for a cure but is not feasible for a variety of reasons (including donor matching) for the majority of patients. Interferon-α, accompanied by severe side-effects, was, until recently, the standard treatment. The knowledge of the molecular biology of the disease has led to successful specifi c molecular targeting and the development of a most successful drug. Most CML patients (95%) carry the Philadelphia chromosome, the product of the chromosomal translocation t(9;22)(q34;q11) generating the BCR–ABL fusion protein. As a result of this translocation, the tyrosine kinase activity of ABL is constitutive and

4 . 3 K I N A S E S A S D R U G TA R G E T S 99

is retained in the cytoplasm rather than the nucleus. As a result of aberrant kinase signaling, there is abnormal proliferation of white blood cells, the hallmark of leukemia. Transformation is dependent on the BCR–ABL

kinase activity and therefore it provides the perfect therapeutic target.

Imatinib (Gleevec™), a small-molecule tyrosine kinase inhibitor, has been successful in the treatment of CML, resulting in remission in 96% of early stage patients. It is a paradigm for targeted cancer therapy, having fl own through clinical trials and approval (2001) within three years (discussed further in Chapter 12). The compound was modeled and synthe-

sized after related lead compounds (compounds that show a desired activity, e.g. kinase inhibition) called phenylaminopyrimidines, were identifi ed from high-throughput screens of chemical libraries. The compound was originally optimized for inhibiting PDGF-R tyrosine kinase activity but was later found to inhibit ABL and c-kit as well. Gleevec™ binds to the ATP-binding pocket within the catalytic domain, but the fairly narrow specifi city of the compound seems to be a result of preferential binding of the drug to the inactive state of the kinase as evidenced by analysis of crystal structures (Schindler et al. , 2000). Gleevec™ recognizes the autoin-hibitory conformation of the activation loop of the protein that regulates the kinase activity. The structure of the inactive state is distinctive between different kinases. The drug has a half-life of approximately 15 h and con-veniently allows daily oral administration.

Pre-clinical data demonstrated inhibition of proliferation in cultured cells and in cells from CML patients with the Philadelphia chromosome, as well as tumor regression in mice. This evidence allowed progression to clinical trials. The threshold dose for signifi cant therapeutic effi cacy was found to be 300 mg in Phase I trials. Parameters of how well the drug works, effi cacy endpoints, were measured by the degree of cytogenetic (chromosomal) and hematologic (blood count) response. A complete

cytogenetic response was defi ned as 0% Philadelphia chromosome-

positive cells in metaphase (partial, 1–35%, minor, 36–65%, minimal, 66–95%, or no response >95%, were additional classifi cations used).

Hematologic response is simply graded by white blood cell counts. Importantly, molecular target inhibition was also analyzed. Quantifi cation of the levels of phospho-CRKL, a BCR–ABL substrate found in neutrophils, allowed for the assessment of the inhibition of kinase activity and aided in the determination of effective dosage. As mentioned earlier, it is important to monitor the modulation of the defi ned molecular target (BCR–ABL).

Note that the CML has three disease phases: chronic (lasting 3–5 years), accelerated (lasting from 3–9 months), and blast crisis (lasting 3–6

months). Owing to an increase of cell proliferation, the number of white blood cells increases as the disease progresses. The effectiveness of Gleevec™ decreases with advanced disease phase (53% response in accelerated phase and 30% response in blast crisis). Although only 9% of early

100

4: G R O W T H FAC TO R S I G N A L I N G A N D O N C O G E N E S

PAUSE AND THINK

stage patients relapsed, 78% of late-stage patients relapsed. The mechanism for the majority of these cases is owing to reactivation of the kinase What is the difference between

activity due to mutation or Bcr– Abl amplifi cation. Analysis of clinical the types of molecular targets

samples showed that six out of nine patients had a single amino acid sub-described in this section? They

stitution at a contact residue identifi ed in the crystal structure (Gorre include three different types of

et al. , 2001). These mechanisms suggest that the initial chromosomal kinases: a transmembrane recep-translocation is not only important for initiation but also for maintenance tor tyrosine kinase, a cytoplasmic

of the cancer phenotype and supports the concept of oncogene addiction: serine/threonine tyrosine kinase,

and a nuclear tyrosine kinase,

the dependence of a cancer cell on a specifi c oncogene for its maintenance.

respectively.

Imatinib has also been approved to target c-kit in gastrointestinal stromal tumors and additional studies are investigating its use against PDGF-R in glioblastomas (see Pause and Think).

Conclusion

Cancer is a disease characterized by uncontrolled growth. Therefore a clear understanding of growth regulation has helped to reveal the mechanisms of carcinogenesis. This was illustrated by the elucidation of the existence of oncogenes, which include altered versions of normal genes involved in growth. Oncogenes often play a role in growth factor signal transduction. The knowledge of the intricacies of growth factor signal transduction pathways have been, and will be, essential to the design of successful, low-toxicity cancer therapeutics designed against molecular targets.

■ CHAPTER HIGHLIGHTS—REFRESH YOUR MEMORY

•

Growth factors, growth factor receptors, intracellular sig-

factors in the nucleus. Another is affecting cell

nal transducers, and nuclear transcription factors play a

behavior.

role in growth factor signal transduction.

•

Retroviruses have been instrumental in the elucidation of

•

Many growth factor receptors are tyrosine kinases.

oncogenes.

Kinases phosphorylate specifi c amino acid residues in tar-

•

Most oncogenes are altered versions of normal genes.

get proteins.

•

Constitutive kinase activation is a common consequence

•

Phosphorylated proteins can be recognized by specifi c

of oncogenic mutations of tyrosine kinase receptors.

protein domains (e.g. SH2) and can thus serve as a

•

Aberrant subcellular localization is another consequence

recruitment platform.

of oncogenic activation.

•

RAS plays a pivotal role in the EGFR pathway; it links acti-

•

Many molecular components of growth factor signal

vation of tyrosine kinase receptors with downstream sign-

transduction pathways have been targets for new cancer

aling pathways.

therapeutics.

•

Raf, a serine/threonine kinase activated by RAS initiates a

•

Different domains of tyrosine kinase receptors have

cascade of phosphorylations by the MEK and MAP

been targeted for the development of new cancer

kinases.

therapies.

•

One ultimate result of signaling initiated

•

The testing of new therapeutics should include an assay

by growth factors is the regulation of transcription

for the modulation of the defi ned molecular target.

4 . 3 K I N A S E S A S D R U G TA R G E T S 101

■ ACTIVITY

1. Fibroblast growth factor receptor (FGFR3) can function as an oncogene. Somatic mutations have been identifi ed in approximately 50% of bladder cancers. Refer to Turner and Grose (2010) to identify the most common mechanism of the oncogenic activation and its consequences (what happens to the function of FGFR3?). Describe the components of the signal transduction pathway it activates and compare this to the pathway of EGFR. Suggest a therapeutic strategy for designing a new anticancer drug for this molecular target.

2. Discuss the importance of protein–protein interactions in growth factor signal transduction pathways.

■ FURTHER READING

Bennasroune, A., Gardin, A., Aunis, D., Cremel, G., and Hubert, P. (2004) Tyrosine kinase receptors as attractive targets of cancer therapy. Crit. Rev. Oncol. Hematol.

50: 23–38.

Blume-Jensen, P. and Hunter, T. (2001) Oncogenic kinase signaling. Nature 411: 355–365.

Downward, J. (2003) Targeting ras signalling pathways in cancer therapy. Nat. Rev.

Cancer 3: 11–22.

Druker, B.J. (2002) STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol.

Med. 8: S14–S18.

Grant, S. (2009) Therapeutic protein kinase inhibitors. Cell Mol. Life Sci. 66:1163–

1177.

Krause, D.S. and Van Etten, R.A. (2005) Tyrosine kinases as targets for cancer therapy . N. Engl. J. Med. 353: 172–187.

Maurer, G., Tarkowski, B., and Baccarini, M. (2011) Raf kinases in cancer-roles and therapeutic opportunities. Oncogene 30: 3477–3488.

Sawyers, C.L. (2002) Rational therapeutic intervention in cancer: kinases as drug targets. Curr. Opin. Genet. Dev. 12: 111–115.

Schlessinger, J. (2000) Cell signaling by receptor tyrosine kinases. Cell 103: 211–225.

Schlessinger, J. (2002) Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110: 669–672.

Yeatman, T.J. (2004) A renaissance for Src. Nat. Rev. Cancer 4: 470–480.

Zandi, R., Larsen, A.B., Andersen, P., Stockhausen, M.-T., and Poulsen, H.S. (2007) Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal. 19: 2013–2023.

Zhang, J., Yang, P.L., and Gray, N.S. (2009) Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9: 28–39.

■ WEB SITE

Tarceva. Download “How Tarceva works” http://www.tarceva.net/

102

4: G R O W T H FAC TO R S I G N A L I N G A N D O N C O G E N E S

■ SELECTED SPECIAL TOPICS

Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P.N., Cho, H., et al. (2010) Clinical effi cacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467: 596–599.

Chang, E.H., Furth, M.E., Scolnick, E.M., and Lowy, D.R. (1982) Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature 297: 479–483.

Flaherty, K.T., Puzanov, I., Kim, K.B., Ribas, A., McArthur, G.A., Sosman, J.A., et al.

(2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J.

Med. 363: 809–19.

Fremin, C. and Meloche, S. (2010). From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J. Hematol. Oncol. 3: 8–19.

Gonzalez-Sancho, J.M., Garcia, V., Bonilla, F., and Munoz, A. (2003) Thyroid hormone receptors/THR genes in human cancer. Cancer Lett. 192: 121–132.

Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Nagesh Rao, P., et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplifi cation. Science 293: 876–880.

Hingorani, S.R. and Tuveson, D.A. (2003) Ras redux: rethinking how and where Ras acts. Curr. Opin. Genet. Dev. 13: 6–13.

Ise, K., Nakamura, K., Nakao, K., Shimizu, S., Harada, H., Ichise, T., et al. (2000) Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis. Oncogene 19: 2951–2956.

Linggi, B. and Carpenter, G. (2006) ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol. 16: 649–656.

Pao, W., Miller, V.A., and Kris, M.G. (2004) ‘Targeting’ the epidermal growth factor receptor tyrosine kinase with gefi tinib (Iressa) in non-small cell lung cancer (NSCLC). Semin. Cancer Biol. 14: 33–40.

Reddy, E.P., Reynolds, R.K., Santos, E., and Barbacid, M. (1982) A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 300: 149–152.

Schindler, T., Bornmann, W., Pellicena, Miller, W.T., Clarkson, B., and Kuriyan, J.

(2000) Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289: 1938–1942.

Turner, N. and Grose, R. (2010) Fibroblast growth factor signaling: from development to cancer. Nat. Rev. Cancer 10: 116–129.

Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R.A., et al. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

Nat. Rev. Drug Discov. 5: 835–844.





Chapter 5

The cell cycle

Introduction

Cancer is characterized by abnormal cell proliferation. Cell proliferation involves the reproduction of a cell to form two daughter cells. Each daughter cell can reproduce to form two daughter cells, and so on; thus cell reproduction is cyclic. The sequence of stages through which a cell passes between one cell division and the next is called the cell cycle (Figure 5.1) and is made up of four stages: G ,

, and

, S, and G

1 S phase, G2

M phase. G1

2

make up the part of the cycle called interphase. The genetic material of a cell is replicated in S phase (DNA synthesis). M phase involves the partitioning of the cell to produce two daughter cells and includes mitosis and cytokinesis. G and G are ‘gaps’ preceding the S

1

2

and M phases during which time the cell prepares for the next phase.

2n

2n

kinesis

G1

4n

to

S

y C

M

G2

Centrosome

Mitosis

Telophase

Mitotic spindle

4n

Prophase

Metaphase

Anaphase

Figure 5.1 The cell cycle. The four phases, G1, S, G2, and M phase (including cytokinesis), are shown in the center of the diagram. Cells are illustrated around the phases of the cell cycle and their chromosome content in relation to the four phases of the cell cycle is depicted. Cells in different phases of the cell cycle have different DNA content: G1:2 n (two copies of every chromosome); S: begins with 2 n and becomes 4 n; G2: 4 n; M: begins with 4 n and produces 2 n daughter nuclei. Figure from The Cell Cycle: Principles of Control by David O. Morgan with the permission of Oxford University Press.





104

5 : T H E C E L L C Y C L E

In the last chapter we examined the molecular mechanisms involved in growth factor signal transduction pathways. We mentioned that the pathway culminates by regulating the expression of target genes, including the induction of genes whose products are essential in cell proliferation. In this chapter we will introduce the cyclins and cyclin-dependent kinases, main players in the cell cycle, some of which are encoded by genes regulated by growth factor signaling pathways. We will also examine the molecular mechanisms of the cell cycle and specifi c mutations that affect the cell cycle and play a role in carcinogenesis. Lastly we will discuss therapeutic strategies that target molecules of the cell cycle.

5.1 Cyclins and cyclin-dependent kinases (cdks)

The average length of the cell cycle is 16 h (15 h for interphase and 1 h for mitosis) as shown in Figure 5.2, but note that this can vary depending on the cell type. Cells in interphase can be distinguished microscopi-cally from cells in mitosis because chromosomes are not visible in

interphase and can only be observed during mitosis because of chromosome condensation.

Starting from the beginning of G1 (Figure 5.2, top), progression of the cell cycle is illustrated in a clockwise manner. Most cells in an adult are M checkpoint

16 hrs/0 hrs

G

G0

2 checkpoint

15 hrs

Mitogens

M

(mitosis)

Cyclin Ds +

cdk 4/6

G1 restriction

G2

point

Cyclin B/A +

G1

G1

cdk 1

checkpoint

Interphase

Cyclin E +

S phase

cdk2

Figure 5.2 The pattern of cyclin–

cdk activity during the cell cycle

(shown by red bars) and the cell

Cyclin A+

cycle checkpoints (G

cdk2

1, G2, and M).

5 . 1 C Y C L I N S A N D C Y C L I N - D E P E N D E N T K I N A S E S ( C D K S ) 105

not in the process of cell division. They are quiescent and enter an inactive period called G0, a phase outside of the cell cycle. Mitogens or growth factors can, however, induce cells in G0 to re-enter the cell cycle and pass a control point called the G1 restriction point (fi nd this point in Figure 5.2). Before the passage of the restriction point, cell division is dependent on mitogens; afterwards, cells are irreversibly committed to progress through the cycle without the need for growth factors. The passage of the cell through the different phases of the cell cycle is coordinated and regulated by a set of proteins called cyclins and their associated cyclin-dependent kinases (cdks). Cyclins were so named because of the

cyclical changes in their concentrations that occur over a series of cell divisions. The concentration of cyclin protein is dependent on the

transcription of its gene and by subsequent regulated protein degradation. The pairing of cyclins to the cdks is highly specifi c. Cyclins are regulatory subunits of their cdks. Upon binding of a cyclin to its cdk partner, cyclin induces a conformational change in the catalytic subunit of the cdk revealing its active site. Note that the concentration of cdks does not fl uctuate during the cell cycle.

Different cyclin–cdk complexes are present at specifi c points in the cell cycle and are important regulators of irreversible phase transitions (depicted by the red bars in Figure 5.2). In the last chapter we saw that the cyclin D gene is one of the fi nal targets of the EGF signaling pathway. This is an important molecular link between growth factors and how they

actually stimulate cell proliferation. Cyclin D is the fi rst cyclin to be synthesized and, together with cdks 4/6, drives progression through G1. As we will see later in this chapter, cyclin D plays a role in the regulation of expression of the cyclin E gene, whose product is important for the G1 to S

phase transition. Cyclin A–cdk2 is important for S phase progression.

Cyclins A, B–cdk1 directs G2 and the G2 to M phase transition.

Cell cycle checkpoints (see Figure 5.2), a series of biochemical signaling pathways that sense and induce a cellular response to DNA damage, are important for maintaining the integrity of the genome. The G1 checkpoint leads to the arrest of the cell cycle in response to DNA damage, ensuring that DNA damage is not replicated during S phase. The G2 checkpoint leads to the arrest of the cell cycle in response to damaged and/or unreplicated DNA to ensure proper completion of S phase. The M checkpoint

leads to the arrest of chromosomal segregation in response to misalignment on the mitotic spindle. The components of the checkpoints are proteins that act as DNA damage sensors, signal transducers, or effectors.

Disruption of checkpoint function leads to genomic and chromosomal

instability leading to mutations that can induce carcinogenesis.

The cyclin–cdk complexes exert their effect by phosphorylating target proteins. As we saw in Chapter 4, phosphorylation is an important

106

5 : T H E C E L L C Y C L E

mechanism for regulating the activity of proteins. The targets include a diverse set of proteins including transcriptional regulators, cytoskeletal proteins, nuclear pore and envelope proteins, and histones. Specifi c examples include condensins, nuclear lamins, GM130 of the Golgi apparatus, the famous transcriptional regulator, retinoblastoma protein (RB or pRB), and transcription factors E2F and Smad 3. Consequently, essential events of the cell cycle, including chromosomal condensation, nuclear breakdown, fragmentation of the Golgi apparatus, regulated gene expression, and mitotic spindle assembly, are facilitated. Note that dephosphorylation is an important mechanism for resetting the cell for another round of the cell cycle.

? HOW DO WE KNOW THAT?

Protein cross-linking and immunopurifi cation (see

fi lters and probed with a solution of a functionally active cdk of Sanchez and Dynlacht, 2005)

interest and labeled ATP. Proteins are produced from the cDNA

libraries, some of which interact with cdk. When cdk phospho-

There are several approaches that can help identify the sub-

rylates a target protein using the labeled ATP, a radioactive sig-

strates of cdks. One common method is to cross-link proteins,

nal is generated. The signal is visualized by autoradiography at

carry out immunopurifi cation of protein kinases, and use mass

the position of proteins phosphorylated during the assay.

spectroscopic analysis to identify associated proteins. The iden-

Candidate molecules must be validated by several criteria

tifi cation of RB as a cdk substrate was demonstrated by the

including: (i) the phosphorylation state must be the same

immunoprecipitation of RB using a cdk2 antibody.

in vitro and in vivo; (ii) phosphorylation must be shown to be Another method for identifying cdk substrates is to screen

cell cycle dependent; (iii) phosphorylation should have a func-

cDNA expression libraries using a solid-phase phosphorylation

tional consequence in the cell cycle.

assay. Bacterial expressed cDNA libraries are transferred to

LEADERS IN THE FIELD . . . of the cell cycle: Tim Hunt, Lee Hartwell, and Paul Nurse

The award of the Nobel Prize in Physiology or Medicine in 2001 to Tim Hunt, along with Lee Hartwell and Paul Nurse, indicates the great contributions that these men have made to science. The prize was received for studies on the regulation of the cell cycle during which the cyclins were discovered. Each of these three scientists worked independently on three different model systems: Hunt worked on sea urchins, Hartwell on budding yeast, and Nurse on fi ssion yeast. One early experiment seemed to serve as the foundation for future work on the cell cycle: the discovery that the cytoplasm of a hormone-treated frog oocyte was able to induce maturation (including the fi rst meiotic division) in a recipient untreated oocyte.

The substance in the cytoplasm was termed maturation-promoting factor (MPF). It was later identifi ed in mitotic cells and was then also called mitosis-promoting factor. Similarities between MPF and cyclins–cdks uncovered by these scientists led to the discovery that MPF

was in fact a cyclin–cdk complex. The mechanism by which the cell cycle is regulated, as elucidated by the work of Hunt, Hartwell, and Nurse, offered new insights into the molecular biology of cancer.

¼





5 . 2 M E C H A N I S M S O F C D K R E G U L AT I O N 107

¼Tim Hunt completed his PhD in Biochemistry in Cambridge and a post-doctoral fellow-ship at the Albert Einstein College of Medicine, New York. He is currently a Principal Scientist at Cancer Research, UK where he continues his research and teaching. I heard Tim give a talk at the Royal Society in London. He opened the lecture with a scan of a tumor from his mother-in-law to illustrate the devastating results of the deregulation of the cell cycle. He is a scientist who is skilled at communicating the mechanics of molecular science in relation to the human state of disease. Lee Hartwell earned his PhD at MIT, Massachusetts, and is the President and Director of the Fred Hutchinson Cancer Research Center where he applies his knowledge to the development of new cancer therapies. Paul Nurse obtained his PhD at the University of East Anglia, UK and is currently the President of The Royal Society and Chief Executive of the UK Centre for Medical Research and Innovation (UKCMRI).

5.2 Mechanisms of cdk regulation

In an adult more than 25 million cells undergo cell division per second.

The magnitude of this number suggests the need for precise regulation.

Cdks are serine/threonine kinases that, sequentially, regulate progression through the phases of the cell cycle via phosphorylation. Therefore, the regulation of cdk activity is crucial for precise cell reproduction.

There are four mechanisms of cdk regulation: association with cyclins, association with cdk inhibitors, addition of phosphate groups that activate cdk activity, and addition of phosphate groups that inhibit cdk activity (Figure 5.3). Because of the precise window of time for which regulators of the cell cycle are required, the ‘disappearance’ of a factor is as important as its appearance. That is, precise protein degradation also plays an important role in the control of the cell cycle (Reed, 2003). The mechanisms of cdk regulation are discussed in the following sections.

Association with cyclins

The binding of cyclins to their partner cdk causes a crucial conformational change in the cdk that allows binding of a protein substrate and correct positioning of ATP. The inactive cdk molecule has a conformation that blocks the binding of the protein substrate and correct alignment of ATP.

Some cyclins are also involved in increasing the affi nity of cdks to specifi c substrates. As mentioned earlier, the amounts of cyclin protein vary through the cell cycle. Protein levels are modifi ed by transcriptional regulation of the cyclin genes and by protein degradation. As we saw in the last chapter, the signaling pathway for the growth factor EGF results in the transcriptional activation of the cyclin D gene and allows progression through the restriction point. Degradation of cyclin proteins is carried out by the proteasome, a complex of proteases. The covalent addition of ubiquitin, a small polypeptide, to the lysine amino acids of the cyclin fl ags

108

5 : T H E C E L L C Y C L E

(a)

cdk

Cyclins

Active

Inhibitors

(b)

cdk

–p16

Inactive

–p21

wee 1

P

P

Kinase

Thr14 Tyr15

(c)

cdk

Cyclins

Inactive

Thr161

cdc 25

P + P

Phosphatase

Thr14 Tyr15

(d)

cdk

Cyclins

Active

Thr161

CAK

P

Figure 5.3 Mechanisms of cdk regulation: (a) association with cyclins activates cdks; (b) association with inhibitors inactivates cdks; (c) inhibitory phosphorylation at Thr14 and Tyr15 by wee1 kinase inactivates cdks; (d) the removal of inhibitory phosphates by cdc phosphatase and activating phosphorylation by cdk-activating kinases (CAK) activates cdk.

the protein for degradation by the proteasome. The enzyme that catalyzes the transfer of ubiquitin to the target protein is called a ubiquitin-protein ligase. Ubiquitin-mediated proteolysis of cyclins prevents constitutive activity of cdks. Note that ubiquitination is also important in stem cell maintenance and angiogenesis, and will be discussed in Chapters 8 and 9.

Association with inhibitors

Two families of inhibitors are involved in regulating cyclin–cdk activity: the p16ink4a (INK) family and the p21 (Cip/Kip) family. Members of the p16ink4a family include p16ink4a, p15ink4b, p18ink4c, and p19ink4d. The INK

proteins bind cdks 4/6 and interfere with the binding of cdks 4/6 to cyclin D. The p21 family members include p21cip1, p27kip1, and p57kip2. These inhibitors interact with both cyclins and their associated cdks (mainly with cdk2 and cyclin E) and block the ATP-binding site, thus disabling kinase activity. Upon mitogenic stimulation and subsequent cyclin D synthesis, cyclin D-dependent kinases sequester inhibitors of the Cip/Kip





5 . 3 P R O G R E S S I O N T H R O U G H T H E G 1 CHECKPOINT 109

family, facilitating cyclin E–cdk2 activation. Again, ubiquitin-mediated degradation of inhibitors ensures that the inhibitors are present during a defi ned window of time during the cell cycle.

Regulation by phosphorylation

Regulation of cdk activity by phosphorylation involves both activation and inhibition. Two phosphorylation sites on the amino-terminal end are inhibitory when phosphorylated. The tyrosine kinase, wee1, phosphorylates Thr14 and Tyr15. These amino acids are located deep within the ATP-binding site of the cdk and phosphorylation of these sites physically interferes with ATP binding. Two steps are required for cdks to become active: dephosphorylation of the inhibitory phosphate groups by cdc25

phosphatases and phosphorylation of a central threonine residue, Thr161, by cdk-activating kinase (CAK). Note that complete activation of cdks requires phosphorylation at this site and that association with cyclins alone does not lead to full activation. In addition, this phosphorylation event is not temporally regulated with respect to the phases of the cell cycle as CAK activity is constant throughout the cycle.

5.3 Progression through the G1 checkpoint

A key substrate of the cyclin D–cdk 4/6 complex is the RB protein (discussed further in the next chapter). RB serves as a molecular link for the G1–S phase transition. RB does not bind to specifi c DNA sequences but instead regulates the activity of the E2F transcription factor family, which is crucial for the expression of genes needed for S phase. It does this by physically interfering with the transactivation domain of E2Fs. Note that, to date, there are eight E2Fs and two associated subunits (called DP). The activity of RB is regulated by sequential phosphorylation events by cyclin–

cdks. Let us now examine the details of the RB protein.

Structure of the RB protein

The nuclear RB protein, along with two other related proteins, p107 and p130, is a member of the ‘pocket proteins’ and contains conserved structural and functional domains that bind to various cell proteins. The pocket comprises the A domain and the B domain joined by a linker

region. The binding of the two main cellular effector proteins, histone deacetylase (HDAC) and the E2F transcription factor, to the pocket region (Figure 5.4) is important for its function. HDACs contain the LXCXE

motif, an amino acid sequence that is required to bind to the B domain of

110

5 : T H E C E L L C Y C L E

(a)

Rb

HDAC

A E2F DP

B

E2F target genes

(b)

HDAC

Rb

P

B

Cyclin D

Figure 5.4 Structure and function

Growth factor

of the RB protein. (a)

A E2F DP

B

Cdk4

Hypophosphorylated RB

Cyclin E gene

sequesters E2F/DP and HDAC.

Transcription is repressed. (b)

HDAC

Partial phosphorylation of RB by

Rb

P

B

Cyclin D

cyclin D–cdk4 causes a

Growth factor

conformational change, and

A E2F DP

B

Cdk4

release of HDAC but not E2F/DP.

E2F target genes

Repression is relieved for some

genes such as cyclin E (top) but

(c)

Cyclin E

not for E2F target genes (bottom).

A

Rb

P

B

Cdk2

(c) Additional phosphorylation by

P

cyclin E–cdk2 causes an

additional conformational

E2F DP

change, release of E2F/DP, and

transcription of E2F target genes.

E2F target genes

the pocket of the RB protein. E2F and its associated subunit DP can bind to the pocket of RB simultaneously with HDAC because E2F and DP

recognize a different conserved sequence at the interface of the A and B

domains of the pocket. The next question to examine is how binding of HDAC and E2F contributes to the function of RB.

Molecular mechanisms of the effects of RB

The major point of control for RB protein is the transition from the G1

phase of the cell cycle to S phase (see Figure 5.2). It executes this control by its interactions with the transcription factor E2F and HDACs. (Recall that HDACs regulate gene expression via an epigenetic mechanism; see Chapter 3.) The interactions between RB and E2F and HDACs are regulated by serine/threonine phosphorylation. In the absence of a growth signal, RB is in a hypophosphorylated state (i.e. it does not have many phosphates attached) and binds to both E2F and HDAC (Figure 5.4a). By binding to E2F, RB sequesters it and blocks its transactivation domain, preventing E2F from interacting with the general transcription factors (e.g. TATA-binding protein). RB also inhibits the expression of E2F target genes by recruiting HDACs, enzymes that deacetylate histones and

increase chromatin compaction. Thus, the trimeric complex of RB with HDAC and E2F regulate transcription and, consequently, cell cycle





5 . 4 T H E G 2 CHECKPOINT 111

progression; genes such as cyclin E, cyclin A, and cdk 2, whose products are required for progression through the cell cycle, are not expressed.

It is the cyclin D and E families and their cdks that phosphorylate RB in a progressive manner, in response to a growth signal. Figure 5.4 shows how phosphorylation leads to conformational changes in the RB protein and causes the sequential release of HDAC and E2F. HDAC is no longer localized to repress transcription and the transcription factor E2F is free to activate genes necessary for proliferation. Phosphorylation of RB is carried out in two steps. First, cyclin D–cdk4 phosphorylates carboxy-terminal residues of RB upon growth factor stimulation. The increase in negative charge causes intramolecular interactions with lysine residues (positively-charged amino acids) near the LXCXE domain. The resulting conforma-

tional change releases HDAC, a LXCXE-bound protein, but not E2F

(Figure 5.4b). RB-mediated transcriptional repression of some genes, and not others, is relieved in the absence of HDAC. The cyclin E gene (Figure 5.4b, top), but not other E2F target genes (Figure 5.4b, bottom), is expressed upon the release of HDAC from RB. The cyclin E–cdk2 complex then phosphorylates additional amino acid residues of RB, including Ser567 close to the linker region. This results in a conformational change of the RB pocket domain causing the release of E2F and subsequent expression of its target genes, such as cyclin A, thymidylate synthase, and dihydrofolate reductase, that are important for S phase (Figure 5.4c).

In conclusion, the sequential action of these two cyclin–cdk complexes is important. Phosphorylation of RB by cyclin D–cdk4 is a prerequisite for cyclin E–cdk2 phosphorylation in that it induces the expression of the cyclin E gene and uncovers cyclin E–cdk2 phosphorylation sites. Subsequent phosphorylation of RB by cyclin E–cdk causes the release of E2F. It is speculated that additional cyclin–cdk complexes may also be involved.

Note that there are many phosphorylation sites within RB which are

involved in its regulation but Figure 5.4 is a simplifi ed version used to illustrate the concept of sequential phosphorylation. For example,

recently phosphorylation of the carboxy-terminal domain has been demonstrated to be involved in the release of E2F (Rubin et al. , 2005).

Self test Close this book and try to redraw Figure 5.4. Check your answer. Correct your work. Close the book once more and try again.

5.4 The G2 checkpoint

The G2 checkpoint blocks entry into M phase in cells that have incurred DNA damage in previous phases or have not correctly completed S phase.

DNA damage activates either of two kinases, ATM or ATR. These kinases





112

5 : T H E C E L L C Y C L E

DNA damage

ATM

ATR

Figure 5.5 Mechanism of the G2

checkpoint. DNA damage

activates ATM or ATR. The ATM

P

Chk 1/2

P

and ATR kinases phosphorylate

and activate Chk1/2 kinases. The

Chk1/2 kinases inhibit cdc25.

Cdc25

P

Cdc25 is then unable to remove

cdk

cdk

phosphatase

inhibitory phosphate groups and

activate cdks.

Active

then phosphorylate and activate checkpoint kinases Chk1 and Chk2. One target of these checkpoint kinases are the Cdc25 tyrosine phosphatases PAUSE AND THINK

(mentioned earlier) that regulate cdk activity by removing inhibitory Try to draw a diagram that illus-phosphates. Specifi c Cdc25s (type B and C) are important in the G2–M

trates this pathway. Compare

phase transition. Activation of the G2 checkpoint results in the inhibition your diagram with Figure 5.5.

of Cdc25s by Chk1/2.

There is also a decatenation G2 checkpoint that is involved in detangling intertwined daughter chromatids after DNA synthesis. This process ena-PAUSE AND THINK

bles chromatid separation during anaphase of mitosis. Topoisomerase II, One of the types of classical

an enzyme that can release torsional stress by making double-strand DNA chemotherapies discussed in

breaks to allow unwinding, is key in the decatenation G2 checkpoint.

Chapter 2 targets topoisomer-

ase II. Can you remember the

name of this drug? The answer

is doxorubicin, a fungal anthra-

5.5 The mitotic checkpoint

cycline antibiotic.

The mitotic checkpoint (also known as the spindle assembly checkpoint) is a signaling cascade that ensures correct chromosomal segregation during mitosis and the production of two genetically identical nuclei.

A little lesson about the stages of mitosis . . .

There are four stages of mitosis: prophase, metaphase, anaphase, and telophase (see Figure 5.6 and Plate 3).

Prophase is marked by the appearance of the chromosomes as a result of condensation, nuclear membrane breakdown, separation of duplicated centrosomes, and assembly of mitotic checkpoint proteins at the centromeres.

Metaphase is characterized by the aligning of the chromosomes on the metaphase plate and the assembly of microtubules to form the mitotic spindle. Microtubule capture of ¼



5 . 5 T H E M I TOT I C C H E C K P O I N T 113

¼both centromere regions of a chromatid pair results in checkpoint silencing. When the last pair is attached to the spindle metaphase is completed and anaphase begins.

Anaphase is marked by the spindle pulling apart and separating chromatid pairs.

Telophase includes the accumulation of chromosomes at their respective poles, re-forming of the nuclear membrane, chromosome decondensation, and cytokinesis (separation into two separate cells).

Spindle microtubules attach to the centromere regions of chromosomes

during metaphase such that sister chromatids can be pulled to opposite poles during anaphase. Unattached chromatid pairs recruit several checkpoint proteins that produce inhibitors of the anaphase-promoting complex. This complex functions as a ubiquitin-protein ligase and targets specifi c proteins for degradation in order for anaphase to begin. After each chromatid pair is attached to the spindle, the inhibition of the anaphase-promoting complex stops. One crucial target protein of the anaphase-promoting complex is securin; upon its degradation the protease separase is activated. Separase cleaves a protein link between sister chromatids and this allows them to separate during anaphase. Cyclins are also targets of the anaphase-promoting complex. Thus, the mitotic checkpoint plays an important role, preventing mis-segregation of single chromosomes.

Figure 5.6 Cells in the four stages

of mitosis: (a) prophase, (b)

metaphase, (c) anaphase, (d)

telophase (all magnifi ed about

2700 times). Courtesy of www.

micro.utexas.edu. See Plate 3.





114

5 : T H E C E L L C Y C L E

Aurora C

Phase of

Interphase

Mitosis

cell cycle

Early

Late

Aurora A

Aurora B

Subcellular

location

Figure 5.7 Subcellular location

Function

Centrosome

Spindle

Bipolar

Spindle

Coordination

of Aurora kinase A, B, and C

maintenance

assembly

chromosome

checkpoint of chromosome

(illustrated in red) in relation to

attachment

segregation with

the cell cycle. Implicated functions

cytokinesis

are noted.

Aurora kinases

The Aurora kinases (A, B, and C) regulate important aspects of mitosis, including chromosome segregation and the spindle checkpoint. (Note that Aurora kinases A, B, and C are also known as STK15, STK12, and STK13, respectively.) They are serine/threonine kinases that phosphorylate target proteins, many of which play a role in chromosome structure and spindle assembly. Histone H3 is one such target. The activities of the Aurora kinases are coordinated to specifi c cellular locations and events of the cell cycle (Figure 5.7). Aurora kinase A localizes to centrosomes during interphase. It is upregulated at the beginning of mitosis and relocates to the spindle poles and spindle microtubules, suggesting a role in centrosome maturation and assembly of the spindle apparatus. Aurora kinase B activity is highest later in mitosis and localizes fi rst with centromeres, then with the middle of the spindle, and later between the dividing cells, suggesting a role in bipolar spindle attachment to chromosomal centromeres, and the spindle checkpoint and monitoring of chromosomal segregation and

cytokinesis. Aurora kinase C is active during late mitosis and localizes to spindle poles. The precise temporal regulation of the Aurora kinases is regulated by phosphorylation, protein inhibitors, and targeted degradation.

5.6 The cell cycle and cancer

Genes encoding cell cycle regulators are frequently mutated in human tumors leading to aberrant regulation of the cell cycle, unscheduled proliferation, and carcinogenesis. Recall from Chapter 1 that growth signal

5 . 6 T H E C E L L C Y C L E A N D C A N C E R 115

autonomy is one of the six hallmarks of cancer. Mutations in genes of the molecular components of the growth factor signaling pathway (Chapter 4) and in genes that code for regulation of the cell cycle can lead to growth signal autonomy.

Mutations in CDK genes found in cancer cells have been well characterized. For example, a miscoding mutation (Arg24Cys) in CDK4 blocks

binding to INK4 inhibitors in a subset of melanoma patients. Expression of this mutation in mice leads to the induction of several types of tumors.

Chromosomal translocations cause over-expression of CDK6 in some leukemias. In addition, recent data suggest that the CDK profi les described in the classical model of the cell cycle (Figure 5.2) may be modifi ed in specifi c cell types and tumor cells. For example, CDK4 is dispensable for mammary gland development but is required for the development of tumors of the mammary gland. Thus, CDK4 inhibition may a drug strategy for

breast cancer.

Alterations in cell cycle regulation in cancer include over-expression of cyclins (e.g. cyclin D and E) by gene amplifi cation. DNA amplifi cation of the cyclin D gene occurs in one in six breast cancers (about 15%). One study reported 20% of squamous cell carcinomas of the skin contain

additional cyclin D gene copies.

? HOW DO WE KNOW THAT?

Fluorescent in situ hybridization (FISH) (see Utikal

probes may be viewed immediately under a fl uorescence

et al., 2005)

microscope. Alternatively, a fl uorescently labeled molecule

that binds biotin (e.g. avidin and/or antibodies) may be used to

FISH is used to detect gene amplifi cation. Serial sections of tis-

‘visualize’ the DNA of interest. Fluorescence can be used to

sue or cells in culture are placed on a microscope slide and

quantify gene copy number. Controls may include unaffected

incubated at a high temperature in a solution that causes the

healthy tissue and probes to additional unrelated genes. An

DNA strands to separate. A single-stranded DNA probe that

example of cells analyzed by FISH is shown in Plate 4. When

consists of a section of the sequence that is being searched for

looking at this image one can see that there is a higher number

is either directly fl uorescently labeled or labeled with a small

of cyclin D gene copies (red) in relation to the number of cen-

molecule (usually biotin) and allowed to hybridize to the chro-

tromeric regions of chromosome 11 (green) in many of the

mosomal DNA within the tissue. Molecules that have not

nuclei of the carcinoma.

hybridized are washed away. Directly labeled fl uorescent

Cyclin D mRNA and protein levels are over-expressed in 50% of

breast cancers. Experimental evidence, including the induction of hyper-plasia and adenocarcinoma of the breast in transgenic mice, suggests that the gene for cyclin D is a proto-oncogene. Both EGFR and estrogen exert their mitogenic effect by transcriptional activation of cyclin D. The cyclin D gene does not contain an estrogen response element in its promoter region and thus the estrogen receptor (ER) may act as a transcriptional co-activator (Chapter 3). However, the mechanism by which cyclin D

116

5 : T H E C E L L C Y C L E

exerts its oncogenic effects is not clear and may even involve a cdk-independent mechanism (Roy and Thompson, 2006). Cyclin D enhances

estrogen receptor-mediated transcription by binding to the hormone-

binding domain of ER and increasing protein interactions with ER’s coactivators.

Deletion of the gene coding for the inhibitor p16ink4a (frequent in mesothelioma, a cancer linked to asbestos exposure and pancreatic carcinomas) is also common. Experimental fi ndings from p16ink4a knock-out mice demonstrated that loss of p16ink4a results in increased incidence of spontaneous and carcinogen-induced cancers (Sharpless et al. , 2001).

Mutations in RB will be discussed in Chapter 6.

Defects in the decatenation G2 checkpoint are associated with chromosome breakage and may lead to genetic instability. This has been supported by evidence from cancer cell lines (see references within Kaufmann (2006), such as the work of Doherty et al. (2003) and Nakagawa et al. (2004)).

It is a current debate about whether aneuploidy, the condition of having an abnormal chromosome number and content, facilitates or drives tumorigenesis. Whatever the answer, aneuploidy is the most common characteristic of human solid tumors. Aneuploidy may be caused by defects in

centrosomes, the organizers of the mitotic spindle, or in cytokinesis. Aberrations of the mitotic checkpoint may also lead to aneuploidy. The mitotic checkpoint is not all or none but rather can be weakened by depleted individual components. This is because many proteins are involved, so a deletion of one component may allow the mitotic checkpoint to function, albeit at a reduced effi ciency. Large numbers of mis-segregated chromosomes leads to cell death, but a weakened checkpoint may lead to some abnormal number of chromosomes that is not suffi cient to induce cell death.

Evidence suggests that mutations in genes that code for components of the mitotic spindle are not common in human tumor cells. However, a decreased quantity of mitotic checkpoint proteins has been observed in aneuploid tumor cells with an aberrant mitotic checkpoint. Tumor suppressors or oncoproteins may transcriptionally regulate these proteins, causing a decrease in protein levels. A rare recessive disorder called mosaic variegated aneuploidy, caused by mutations in a gene encoding one of the checkpoint proteins, is characterized by aneuploidy and an increased risk of childhood cancers. The evidence described supports a link between a weakened mitotic checkpoint and the process of carcinogenesis.

The Aurora kinases are frequently amplifi ed in several types of tumors.

The gene encoding for Aurora A has been demonstrated to be a cancer-susceptibility gene (Ewart-Toland et al. , 2003). Researchers found that there is a genetic variant involving an amino acid substitution that modifi es cancer risk, perhaps by causing aneuploidy. They suggest that the variant form modifi es the interactions of Aurora A with associated regulatory proteins in humans. Additional data from other laboratories show that





5 . 7 C Y C L I N - D E P E N D E N T K I N A S E I N H I B I TO R S 117

Flavopiridol

UCN-01

CYC202

BMS-387032

PD0332991

AT-7519

Figure 5.8 Cyclin-dependent

cdk

Cyclin

kinase inhibitors. Inhibitors are

shown in red.

over-expression of this gene leads to centrosome amplifi cation, chromosomal instability, and transformation. Over-expression of this gene has been reported in 94% of invasive ductal breast adenocarcinomas, characterized in early stages by genetic instability.

Therapeutic strategies

Therapeutic strategies that target components of the cell cycle are in development, and several are in clinical trials. Because kinases play a central role in the cell cycle and have been implicated in carcinogenesis, identifi cation of kinase inhibitors is an important drug strategy. Proteins involved in the mitotic spindle are other important drugs targets. Several strategies are discussed in the following sections.

5.7 Cyclin-dependent kinase inhibitors

As we have seen earlier (Section 5.1), phosphorylation by cdks is a key step in the regulation of the cell cycle. These serine/threonine kinases are over-expressed and/or amplifi ed in some cancers, making them possible molecular targets for cancer therapies. A semi-synthetic fl avonoid called fl avopiridol acts as a competitive inhibitor of all cdks tested, by targeting their ATP-binding site (Senderowicz, 2003). Interestingly, it is related to a compound isolated from a plant found in India that is known to have medicinal properties. Flavopiridol induces cell cycle arrest at G1/S and G2/M phases. It also affects cdk family members that have a role in transcriptional control and inhibits gene expression of cyclin D1 and D3.

Flavopiridol was the fi rst cdk inhibitor to be tested in clinical trials.

Owing to its poor oral bioavailability, it is administered intravenously.

Anti-tumor activity was demonstrated in some patients with lymphoma but, in general, fl avopiridol failed to demonstrate signifi cant clinical





118

5 : T H E C E L L C Y C L E

activity as a single agent for many solid tumors in Phase II studies. However, investigations into its potential in combination with existing chemotherapeutic agents is ongoing. Preclincal evidence suggests that CDK

inhibitors are synergistic with cytotoxic drugs (e.g. cisplatin, 5-fl uorouracil), possibly because cells that are arrested or synchronized with respect to the cell cycle are more sensitive to CDK inhibitors (Musgrove et al. , 2011). The number of specifi c CDK inhibitors in clinical trials has increased in recent years. UCN-01, CYC202 (R-roscovitine; Cyclacel

Ltd), PD0332991 (Pfi zer; a selective inhibitor of cdks 4/6), AT-7519

(Astex), and BMS-387032 (Sunesis) are a few examples of cdk inhibitors currently in clinical trials (Figure 5.8). In light of the increasing complex roles of the cdk family (such as in transcriptional regulation and neuronal function) and cancer-type specifi c requirements, potential side-effects and trial design will need careful evaluation for future drug development.

5.8 Other cell cycle kinase targets

Cell cycle checkpoint kinase inhibitors (e.g. against Chk1 and Chk2) are also being identifi ed and used as an anticancer strategy. These agents prevent cell cycle arrests and may potentiate the effects of classical chemotherapeutics that cause DNA damage and subsequent apoptosis.

Inhibitors of the aurora kinases (many of which are ATP-competitive inhibitors) are in early phase clinical trials. Their selectivity ranges from pan-aurora inhibitors (CYC-116) to dual aurora inhibitors (aurora B and aurora C: AZD1152) to selective aurora inhibitors (aurora A specifi c: MLN8237). Pre-clinical studies have shown growth arrest and tumor

regression in human tumor models/xenografts in mice for a range of

tumors. We await the results of this fi rst wave of clinical trials for these aurora inhibitors.

5.9 Inhibitors of the mitotic spindle

As discussed under therapeutic strategies in Chapter 2 (see “Organic drugs”), some conventional chemotherapies interfere with microtubule formation and spindle formation. Paclitaxel/taxol stabilize micro tubules while the vinca alkaloids (vinblastine, vincristine) inhibit microtubule assembly. These drugs result in chromatid pairs that are not attached to spindle fi bers and thus activate the mitotic checkpoint. It is thought that the mechanism of action of these drugs is cytostatic, but induction of

5 . 9 I N H I B I TO R S O F T H E M I TOT I C S P I N D L E 119

apoptosis may also be a consequence. A molecule called KSP, an ATP-

dependent microtubule-motor protein, is required for spindle pole separation and is a new molecular target for the development of cancer therapies.

A small-molecule inhibitor of KSP called ispinesib (Cytokinetics) prevents mitotic spindle pole separation and also leads to chronic mitotic checkpoint activation and is being tested in multiple Phase I and II trials. Thus far, it shows a favorable safety profi le and a 9% response rate in patients with advanced or metastatic breast cancer.

■ CHAPTER HIGHLIGHTS—REFRESH YOUR MEMORY

•

The cell cycle is made up of four phases: G , S, G , and M.

1

2

•

Hypophosphorylated RB inactivates E2F and recruits

•

There are three cell cycle checkpoints: the G , G , and M

HDACs.

1

2

checkpoints.

•

Phosphorylated RB releases E2F and HDACs, which facili-

•

The progression of a cell through the different phases of

tates transcription and cell cycle progression into S

the cell cycle is highly regulated by cyclins and cyclin-

phase.

dependent kinases (cdks).

•

The G checkpoint is induced by DNA damage and aber-

2

•

Cdks are regulated by association with cyclins, inhibitors,

rant DNA synthesis and blocks entry into M phase.

and by activating and inhibitory phosphorylation.

•

The mitotic checkpoint prevents mis-segregation of chro-

•

Proteolysis is important for regulating the activity of key

mosomes during anaphase.

regulators of the cell cycle.

•

Aurora kinases are important for centrosome and mitotic

•

The retinoblastoma (RB) protein is an important target of

spindle function.

cyclin D–cdks 4/6 and a key regulator of the G to S phase

1

•

Aberrant regulation of the cell cycle can lead to cancer.

transition.

•

Cyclin D amplifi cation often occurs in breast cancer and

•

RB exerts its effects by protein–protein interactions with

squamous cell carcinoma.

the E2F transcription factor and HDACs.

•

Several cdk inhibitors have entered clinical trials.

•

The activity of RB is regulated by phosphorylation via dif-

•

Several conventional chemotherapies exert their effects

ferent cyclins–cdks.

by activating the mitotic checkpoint.

■ ACTIVITY

1. Critically discuss your views on whether you would carry out research on cdk inhibitors, and if so what strategy would you use. Support your view with pre-clinical and clinical evidence.

2. It has been stated in this chapter that ubiquitin-mediated proteolysis is crucial for regulation of the cell cycle. Find evidence that supports the statement that unregulated proteolysis in the cell cycle can lead to cancer. Begin with the paper by Reed (2003).

■ FURTHER READING

Burkhart, D.L. and Sage, J. (2008) Cellular mechanisms of tumor suppression by the retinoblastoma gene. Nature Rev. Cancer 8: 671–682.

120

5 : T H E C E L L C Y C L E

Chinnam, M. and Goodrich, D.W. (2011) RB1, development, and cancer. Curr. Topics Devel. Biol. 94: 129–169.

Collins, I. and Garrett, M.D. (2005) Targeting the cell division cycle in cancer: CDK

and cell cycle checkpoint kinase inhibitors. Curr. Opin. Pharmacol. 5: 366–373.

DiCiommo, D., Gallie, B.L., and Bremner, R. (2000) Retinoblastoma: the disease, gene and protein provide critical leads to understand cancer. Semin. Cancer Biol. 10: 255–269.

Kaufmann, W.K. (2006) Dangerous entanglements. Trends Mol. Med. 12: 235–237.

Kops, G.J.P.L., Weaver, B.A.A., and Cleveland, D.W. (2005) On the road to cancer: aneuploidy and the mitotic checkpoint. Nature Rev. Cancer 5: 773–785.

Lapenna, S. and Giordano, A. (2009) Cell cycle kinases as therapeutic targets for cancer. Nature Rev. Drug Discov. 8: 547–566.

Malumbres, M. and Barbacid, M. (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nature Rev. Cancer 9: 153–166.

Massagué, J. (2004) G1 cell-cycle control and cancer. Nature 432: 298–306.

Meraldi, P., Honda, R., and Nigg, E.A. (2004) Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr. Opin. Genet. Dev. 14: 29–36.

Shah, M.A. and Schwartz, G.K. (2006) Cyclin dependent kinases as targets for cancer therapy. Update Cancer Ther. 1: 311–332.

Sherr, C.J. and Roberts, J.M. (2004) Living with or without cyclins and cyclin-dependent kinases. Genes Devel. 18: 2699–2711.

Swanton, C. (2004) Cell-cycle targeted therapies. Lancet Oncol. 5: 27–36.

Weaver, B.A.A. and Cleveland, D.W. (2005) Decoding the links between mitosis, cancer and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 8: 7–12.

Zhu, L. (2005) Tumour suppressor retinoblastoma protein Rb: a transcriptional regulator. Eur. J. Cancer 41: 2415–2427.

■ SELECTED SPECIAL TOPICS

Emanuel, S., Rugg, C.A., Gruninger, R.H., Lin, R., Fuentes-Pesquera, A., Connolly, P.J., et al. (2005) The in vitro and in vivo effects of JNJ-7706621: A dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res. 65: 9038–9046.

Ewart-Toland, A., Briassouli, P., de Koning, J.P., Mao, J.-H., Yuan, J., Chan, F., et al.

(2003) Identifi cation of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nature Genet. 34: 403–412.

Musgrove, E.A., Caldon, C.E., Barraclough, J., Stone, A., and Sutherland, R.L. (2011) Cyclin D as a therapeutic target in cancer. Nature Rev. Cancer 11: 558–572.

Reed, S.I. (2003) Ratchets and clocks: the cell cycle, ubiquitylation and protein turnover. Nature Rev. Mol. Cell Biol. 4: 855–864.

Roy, P.G. and Thompson, A.M. (2006) Cyclin D1 and breast cancer. Breast 15: 718–727.

5 . 9 I N H I B I TO R S O F T H E M I TOT I C S P I N D L E 121

Rubin, S.M., Gall, A.-L., Zheng, N., and Pavletich, N.P. (2005) Structure of the Rb C-terminal domain bound to E2F-DP1: A mechanism for phosphorylation-induced E2F release. Cell 123: 1093–1106.

Sanchez, I. and Dynlacht, B.D. (2005) New insights into cyclins, CDKs, and cell cycle control. Semin. Cell Dev. Biol. 16: 311–321.

Senderowicz, A.M. (2003) Small-molecule cyclin-dependent kinase modulators.

Oncogene 22: 6609–6620.

Sharpless, N.E., Bardeesy, N., Lee, K.H., Carrasco, D., Castrillon, D.H., Aguirre, A.J., et al. (2001) Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413: 86–91.

Utikal, J., Udart, M., Leiter, U., Kaskel, P., Peter, R.U., and Krahn, G. (2005) Numerical abnormalities of the Cyclin D1 gene locus on chromosome 11q13 in non-melanoma skin cancer. Cancer Lett. 219: 197–204.

This page intentionally left blank





Chapter 6

Growth inhibition and tumor

suppressor genes

Introduction

The human body has mechanisms exerted by tumor suppressor genes that normally

“police” the processes that regulate cell numbers and ensure that new cells receive DNA that has been precisely replicated. Recall from Chapter 1 that the balance between cell proliferation, differentiation, and apoptosis maintains appropriate cell numbers. Many tumor suppressor gene products act as stop signs to uncontrolled growth and therefore may inhibit the cell cycle, promote differentiation, or trigger apoptosis. If both copies of a tumor suppressor gene become inactivated by mutation or epigenetic changes, the inhib-PAUSE AND THINK

itory signal is lost, and the result may be unregulated cell growth, a hallmark of cancer.

Other tumor suppressor gene products are involved in DNA repair. If inactivated, DNA Theoretically, mutation in only

one allele allows the other allele

repair may be defective and failure to repair DNA may give rise to mutations that lead to to make the tumor suppressor

cancer. Two alleles of every gene are present in the human genome (except those on sex protein and tumor suppression

chromosomes) and, in most cases, loss of tumor suppressor gene function requires inacti-may still occur.

vation of both copies. This often happens by mutation in one copy and loss of the remaining wild-type allele (loss of heterozygosity, LOH).

6.1 Defi nitions of tumor suppressor genes

Hereditary syndromes that predispose individuals to cancer can be

explained by the inheritance of a germline mutation (passed on from egg/

sperm DNA and thus present in all cells of an individual) in one tumor suppressor allele and the acquisition of a somatic mutation or other inactivating alteration in the second allele later in life. This was fi rst proposed by Knudson and is known as Knudson’s two-hit hypothesis. It states a strict defi nition of a tumor suppressor gene: a gene in which a germline mutation predisposes an individual to cancer. Examples of tumor suppressor genes that fi t this defi nition are shown in Table 6.1.

124

6 : G R O W T H I N H I B I T I O N A N D T U M O R S U P P R E S S O R G E N E S

Table 6.1 Tumor suppressor genes. From Macleod, K. (2000) Tumor suppressor genes. Curr. Opin. Genet. Dev. 10: 81–93, Copyright (2000). Reprinted with permission from Elsevier

Tumor suppressor

Human

Gene function

Human tumors

Associated cancer

Tumor phenotype of

gene

chromosomal

associated with

syndrome

knock-out mouse

location

sporadic mutation

mutants (hetero/

homozygote)

RB1

13q14

Transcriptional

Retinoblastoma,

Familial

MTC, pituitary

regulator of cell cycle

osteosarcoma

retinoblastoma

adenocarcinoma,

pheochromocytomas

Wt1

11p13

Transcriptional

Nephroblastoma

Wilms tumor

None

regulator

p53

17q11

Transcriptional

Sarcomas, breast/brain Li–Fraumeni

Lymphomas, sarcomas

regulator/growth

tumors

arrest/apoptosis

NF1

17q11

Ras-GAP activity

Neurofi bromas,

Von Recklinghausen

Pheochromocytomas,

sarcomas, gliomas

neurofi bromatosis

myeloid leukemia,

neurofi bromas in DKO

chimeras

NF2

22q12

ERM protein/

Schwannomas,

Neurofi bromatosis

Sarcomas: metastases

cytoskeletal regulator

meningiomas

type 2

on p53 background

VHL

3p25

Regulates proteolysis

Hemangiomas, renal,

Von–Hippel Lindau

None

pheochromocytoma

APC

5q21

Binds/regulates

Colon cancer

Familial adenomatous

Intestinal polyps in

β-catenin activity

polyposis

ApcMin

INK4a

9p21

p16Ink4a cdki for cyclin

Melanoma, pancreatic

Familial melanoma

Lymphomas, sarcomas

D–cdk (4/6); p19ARF

binds mdm2, stabilizes

p53

PTC

9q22.3

Receptor for sonic

Basal cell carcinoma,

Gorlin syndrome

Medulloblastomas

hedgehog

medulloblastoma

BRCA1

17q21

Transcriptional

Breast/ovarian tumors

Familial breast cancer

None

regulator/DNA repair

BRCA2

13q12

Transcriptional

Breast/ovarian tumors

Familial breast cancer

None

regulator/DNA repair

DPC4

18q21.1

Transduces TGF-β

Pancreatic, colon,

Juvenile polyposis

Cooperates with

signals

hamartomas

ApcΔ716 in colorectal

carcinoma

FHIT

3p14.2

Nucleoside hydrolase

Lung, stomach,

Familial clear cell renal

Not reported

kidney, cervical

carcinoma

carcinoma

PTEN

10q23

Dual-specifi city

Glioblastoma,

Cowden syndrome,

Lymphoma, thyroid,

phosphatase

prostate, breast

BZS, Ldd

endometrium,

prostate

TSC2

16

Cell cycle regulator

Renal, brain tumors

Tuberous sclerosis

Not reported

NKX3.1

8p21

Homeobox protein

Prostate

Familial prostate

Not reported

carcinoma

6 . 1 D E F I N I T I O N S O F T U M O R S U P P R E S S O R G E N E S 125

LKB1

19p13

Serine/threonine

Hamartomas,

Peutz–Jeghers

Not reported

kinase

colorectal, breast

E-Cadherin

16q22.1

Cell adhesion

Breast, colon, skin,

Familial gastric cancer

Dominant negative,

regulator

lung carcinoma

promotes invasion/

metastasis

MSH2

2p22

mut S homolog,

Colorectal cancer

HNPCC

Lymphoma, colon/skin

mismatch repair

carcinoma

MLH1

3p21

mut L homolog,

Colorectal cancer

HNPCC

Lymphoma, intestinal

mismatch repair

adenoma/carcinoma

PMS1

2q31

Mismatch repair

Colorectal cancer

HNPCC

None

PMS2

7p22

Mismatch repair

Colorectal cancer

HNPCC

Lymphoma, sarcoma

MSH6

2p16

Mismatch repair

Colorectal cancer

HNPCC

Lymphoma, intestinal

adenomas/carcinomas

This table does not include the susceptibility genes associated with ataxia telangiectasia ( ATM/ATR), xeroderma pigmentosum (nucleotide excision repair genes), Bloom’s syndrome ( BLM), Werner’s syndrome ( WRN), or Fanconi’s anemia ( FAA, FAC, FAD), although mutation of these genes is associated with cancer predisposition. Nor does it include putative tumor suppressor genes which are subverted by chromosomal translocation, for example PML. Genes such as MADR2, TGF-β receptor 2, IRF-1, p73, p33ING1, PPARγ, BUB1, and BUBR1 have been shown to be mutated in certain human tumors but are not included here because germline mutation of these genes is not yet associated with any hereditary human cancer syndrome.

BZS, Bannayan–Zonana syndrome; HNPCC, hereditary non-polyposis colorectal cancer; Ldd, Lhermitte–Duclos syndrome.

Although this hypothesis describes the mechanism by which mutation

of most tumor suppressor genes has an effect, exceptions and additional complexities exist and will be mentioned later.

Let’s look at the breast cancer susceptibility genes BRCA1 and BRCA2 examples. Some families are prone to increased risk of developing breast and ovarian cancers. The hereditary breast and ovarian cancer susceptibility genes BRCA1 and BRCA2 are well known tumor suppressor genes that play a role in this hereditary syndrome, which make up about 5–10% of all breast cancer cases. The mechanism of

these tumor suppressors follows Knudson’s hypothesis in that one germline mutation predisposes individuals to breast and ovarian cancer.

The mutated genes most often produce a truncated protein and there-

fore cause loss of function. Breast and ovarian tumors that develop in these individuals exhibit a loss of heterozygosity. In some cases of sporadic (non-hereditary) breast cancer, BRCA1 protein levels are reduced, not because of mutation but rather as a result of epigenetic mechanisms.

Both BRCA proteins are involved in homologous recombination and

double-strand break repair (see Figure 2.9) and therefore help maintain the integrity of the genome. They also have a role in the regulation of transcription and chromatin structure. Note, however, that there is no clear homology between BRCA1 and BRCA2. One proposal of how

126

6 : G R O W T H I N H I B I T I O N A N D T U M O R S U P P R E S S O R G E N E S

mutations in the BRCA genes cause cancer suggests that defective recombination destabilizes the genome and leads to chromosomal rearrangements and mutation. Another proposal regarding a role for BRCA proteins in estrogen signaling is discussed in Chapter 11.

Historically, tumor suppressor genes were called “anti-oncogenes” as some of them seemed to “undo” pathways of oncogene activation.

Although the term is no longer used, it can be a helpful tool for illustrat-PAUSE AND THINK

ing the function of some tumor suppressor genes.

The role of aberrant phosphorylation by kinases during carcinogene-

As kinases are enzymes that

sis was emphasized in Chapter 4. It is therefore predictable that some phosphorylate, what types of

genes that encode phosphatases which antagonize kinase activity, could enzymes “undo” kinases? Phosphatases are enzymes that

act as “anti-oncogenes.” Inactivation of these phosphatase genes by remove phosphate groups.

mutation removes the inhibitory signal and the kinase activity becomes unregulated.

One gene encoding a phosphatase that is frequently mutated in many

cancers is PTEN (phosphatase and tensin homolog on chromosome PAUSE AND THINK

10). PTEN codes for a phosphatase with dual specifi city: it can act as Recall that stimulation of cell

both a protein and lipid phosphatase. Its role as a lipid phosphatase in membrane receptors recruits PI3

oncogenesis is best known. PTEN dephosphorylates the membrane

kinase to the membrane where

lipid PIP3 (phosphatidyl-inositol-3 phosphate) to form PIP2. This

it phosphorylates PIP2 to gener-

antagonizes (shown by the reversed red arrow) the PI3 kinase pathway ate PIP3, a potent second mes-

(Figure 6.1).

senger that activates a cascade

Loss of the inhibitory dephosphorylation activity of PTEN in the

of proteins important for cell

PTEN mutant phenotype results in a constitutively active PI3 kinase division and inhibition of apoptosis. This signal must be tightly

pathway, involving activation of protein kinases Akt and mTOR (mam-

regulated to prevent uncon-

malian target of rapamycin). The net result is the inhibition of apoptosis trolled growth.

and induction of cell proliferation. This favors oncogenesis. Note that this gene also fi ts the tumor suppressor defi nition given earlier as a germline mutation of PTEN causes Cowden syndrome which predisposes patients to cancer.

Another protein-tyrosine phosphatase, PTPN1, encoded by the PTPN1

gene, regulates tyrosine kinase receptor signaling by dephosphorylating EGFR and PDGFR. Accelerated development of lymphomas has been

reported upon analysis of PTPN1 knock-out mice. Several other protein-tyrosine phosphatases also act as tumor suppressor genes.

Note that not all kinases are oncogenic and not all phosphatases are tumor suppressors. Ataxia telangiectasia mutated (ATM) kinase functions in DNA repair as mentioned in Chapter 2, and plays a role in tumor suppression. Many other examples exist. The role of different protein-tyrosine phosphatases as either oncogenes or tumor suppressor genes is reviewed in Ostman et al. (2006).

An examination of two “star players” in the world of tumor suppressor genes, the retinoblastoma ( Rb) gene (also discussed in Chapter 5) and the





6 . 2 T H E R E T I N O B L A S TO M A G E N E 127

EGF

EGFR

PTEN

PIP2

PIP3

PI3K

AKT

mTOR

Proliferation

Figure 6.1 PTEN antagonizes the

Apoptosis

PI3 kinase pathway.

? HOW DO WE KNOW THAT?

Enyzme kinetics and cell growth assays (see data

bacteria. After purifi cation, enzyme kinetics was studied. The

reported in Wang et al., 2004)

rate of substrate hydrolysis was plotted against substrate con-

centration and the Michaelis–Menton equation was used to

Mutations in several protein-tyrosine phosphatase genes were

determine K and K . Growth of cells in culture was suppressed identifi ed in human colorectal tumors. This was done by amplify-m

cat

by transfection of the wild-type protein but not upon transfec-

ing the exons of 87 different protein-tyrosine phosphatase genes

tion of the mutant proteins. Growth was examined by staining

from tumor genomic DNA and sequencing these exons. DNA

cells with crystal violet two weeks post-transfection and colonies

from normal tissue of matching patients was used as a control to

were counted. This genetic, biochemical, and cellular evidence

identify somatic (tumor-specifi c) mutations. Biochemical analysis

demonstrates that these protein-tyrosine phosphatase genes are

demonstrated that these mutations gave rise to proteins that

mutated in tumors and produce loss-of-function proteins, sug-

had reduced phosphatase activity. This was done by expressing

gesting that they act as tumor suppressors.

mutant protein-tyrosine phosphatase catalytic domains in

p53 gene, is central to this chapter. The roles of both gene products during carcinogenesis are described in the following sections.

6.2 The retinoblastoma gene

Retinoblastoma is a rare childhood cancer with a worldwide incidence of 1 in 20,000. There are two forms of the disease, a familial (inherited)

128

6 : G R O W T H I N H I B I T I O N A N D T U M O R S U P P R E S S O R G E N E S

form and a sporadic form (Figure 6.2). About 40% of all retinoblastoma cases are familial and about 60% are sporadic. In the familial form of the disease, one germline mutation in the Rb gene is passed to the child and is present in all cells. A second mutation is acquired in a particular retinoblast that consequently gives rise to a tumor in the retina. One inherited mutated gene results in a suffi ciently high probability that a second mutation may occur. The second mutation most often results

from somatic mitotic recombination during which the normal gene copy is replaced with a mutant copy. In sporadic retinoblastoma, both mutations occur somatically in the same retinoblast. As there are approximately 108 retinoblasts in the retina there is a low chance that sporadic retinoblastoma will occur more than once in an individual; hence, sporadic cases usually only affect one eye while familial cases are often bilateral. The disease demonstrates Knudson’s two-hit hypothesis: two separate mutations—one in each of the two retinoblastoma alleles—are needed to inactivate the two copies of the Rb allele and prevent expression of the RB protein. A mutation in one Rb allele is insuffi cient to knock out functional RB and so cancer-causing mutations are recessive.

An understanding of the molecular mechanisms of the gene product

underlying this disease elucidates important principles about tumor suppressor proteins.

The retinoblastoma protein (RB, sometimes called pRB) is the product of the retinoblastoma tumor suppressor gene ( Rb). As we discussed in Chapter 5, its main role is to regulate the cell cycle by inhibiting the G1 to S phase transition. Cell proliferation is dependent on the transcription of a set of target genes to produce proteins that are needed for cell division At birth

After birth

Familial

Retinoblastoma

form

Germline

Germline

Somatic

mutation

mutation

mutation

Sporadic

Retinoblastoma

form

Figure 6.2 The familial and

sporadic forms of retinoblastoma:

Somatic

Somatic

Somatic

germline versus somatic

mutation

mutation mutation

mutations.





6 . 4 T H E P 5 3 PAT H WAY 129

(e.g. thymidylate synthase; dihydrofolate reductase). RB is an indirect regu-PAUSE AND THINK

lator of transcription for specifi c gene expression that affects cell proliferation and differentiation. Protein–protein interactions facilitate the As a tumor suppressor protein,

function of RB as a transcriptional regulator; RB binds to and modulates do you suppose RB inhibits or

activates the transcription fac-

the activity of a critical transcription factor (E2F) and chromatin remodel-tors needed for cell prolifera-

ing enzymes (see Figure 5.4).

tion? It inhibits the transcriptional

activity of factors needed for cell

cycle progression. Therefore, tar-

get genes important for cell

6.3 Mutations in the RB pathway and cancer

growth are not expressed. How-

ever, loss of the tumor suppres-

Retinoblastoma is initiated by the loss of both Rb alleles. The types of sor protein RB results in the loss

mutations identifi ed are mostly deletions, frameshift, or nonsense muta-of inhibition and, consequently,

tions that result in the abrogation of RB function as would be predicted uncontrolled cell cycle progres-from Knudson’s two-hit hypothesis. In addition, missense mutations that sion and division. Think about

lie within the pocket domain have been reported. It is of interest that the role of RB in differentiation.

Do you suppose it inhibits or acti-

mutations of Ser567 (described earlier) have been found in human tumors vates transcription factors that

because, normally, phosphorylation of this amino acid causes the release are responsible for turning on

of E2F. Mutation of Ser567 may disrupt the regulation usually observed cell-type specifi c genes? As a

at this site. As the RB pathway is central in cell cycle regulation, tumor tumor suppressor it stimulates

initiation may be induced via any mutation that blocks RB function and the activity of transcription fac-causes E2F to be available to activate transcription regardless of the pres-tors, such as Myo D, that activate

ence or absence of a growth signal. Although the Rb gene is expressed in genes involved in differentiation.

all adult tissues, only retinoblastoma and a very few other types of cancer Loss of RB leads to an increase in

are initiated by loss of RB. Yet this pathway is still inactivated in most cell number and to the failure of

human tumors and is targeted by human tumor viruses (see Section 6.6).

differentiation.

These observations suggest that we have more to learn about the different roles of RB and the requirements of different cell types. For example, early studies suggest that RB may have a role in differentiation, as well as cell cycle progression in the developing retina.

6.4 The p53 pathway

The p53 gene was the fi rst tumor suppressor gene to be identifi ed and, since

its discovery, scientists have found that the p53 pathway is altered in most human cancers. Two p53 homologs, p73 and p63, have also been identifi ed but mutations in cancer cells are rare. Its protein product, p53, is at

the heart of the cell’s tumor suppressive mechanism and thus has been nicknamed the “guardian of the genome.” In the absence of cellular stress, low levels of p53 induce antioxidant activity which decreases the levels of reactive oxygen species (ROS) and subsequent DNA damage (Sablina et al. , 2005). As mentioned in Chapter 2, normal cell metabolism produces ROS

130

6 : G R O W T H I N H I B I T I O N A N D T U M O R S U P P R E S S O R G E N E S

that can react with DNA. It has been estimated that endogenous ROS

modify approximately 20,000 bases of DNA per day in a single cell

(Sablina et al. 2005). p53 protects against ROS by upregulating genes whose products have antioxidant functions, such as glutathione peroxidase 1 and sestrins—proteins involved in hydrogen peroxide metabolism. This antioxidant activity guards against mutation and may help prevent cancer.

Many types of “danger signals,” such as cell stress and DNA damage, can activate p53 and trigger several crucial cellular responses that suppress tumor formation (Figure 6.3). Upstream stress activators include radiation-, drug-, or carcinogen-induced DNA damage, oncogenic activation, hypoxia, and low ribonucleotide pools. These conditions may nurture tumor initiation. In response to these stress signals p53 can elicit downstream cellular effects, including transient or permanent cell cycle arrest, DNA repair, apoptosis, and inhibition of angiogenesis (see section 9.7). The ability to cause the cell cycle to pause allows for the repair of mild DNA damage and prevents the propagation of mutations within the genome.

More severe DNA damage induces irreversible cell cycle arrest called senescence. Apoptosis is another means of preventing propagation of mutations; cell suicide benefi ts the organism as a whole if DNA damage cannot be repaired. Mutated cells are better dead. Apoptosis is the critical biological function mediating the tumor suppressor function of p53. Under certain stress conditions p53 may play a pro-oxidant role that may contribute to the cellular effect of apoptosis. It should be mentioned that p53 may also play a role in regulating metabolism (discussed in Chapter 11).

Aberrant growth signals

Cell stress

DNA damage

Oncogene activation

- Hypoxia

- Nucleotide

depletion

Upstream

activators of p53

p53

Downstream

cell effects of p53

Cell cycle

DNA repair

Apoptosis

Inhibition of angiogenesis

arrest or

Figure 6.3 Upstream activators

senescence

and downstream effects of p53.

6 . 4 T H E P 5 3 PAT H WAY 131

Self test Close this book and try to redraw Figure 6.3. Check your answer. Correct your work. Close the book once more and try again.

The overall regulation of the p53 pathway possesses an extraordinary complexity that compels us to try to unravel each layer. Let us begin by examining the structure of the p53 protein and its interactions with its inhibitors, and then move on to dissecting how its activity is switched on and how it exerts its effects.

Structure of the p53 protein

The p53 gene, located on chromosome 17p13, contains 11 exons that encode a 53 kDa phosphoprotein. The p53 protein is a transcription

factor containing four distinct domains: the amino-terminal transactivation domain, the DNA-binding domain containing a Zn2+ ion, an

oligomerization domain, and a carboxy-terminal regulatory domain

(Figure 6.4). The p53 protein binds as a tetramer to a DNA response element containing two inverted repeats of the sequence 5′-PuPuPu

C(A/T)-3′ (Pu symbolizes either purine base A or G) in order to regulate transcription of its target genes. Oligonucleotide array experiments have demonstrated that p53 binds to approximately 300 different gene promoter regions, thus suggesting that p53, has a powerful regulatory role. The p53 target genes code for proteins and microRNAs. Phosphorylation patterns of p53, as well as interactions with binding partners, are correlated with distinct transcriptional programs. Several specifi c p53 target genes and the mechanism of how they exert their effect will be discussed later in the chapter.

Transactivation

DNA

domain and

N –

Oligomerization

Regulatory

binding

– C

MDM2 binding

domain

domain

domain

site

Amino

acids 1

42 102

292 324

355

393

175

248 273

245 249 282

Figure 6.4 Domains of the p53

Mutational

protein and location of mutational

hotspots

hotspots (marked in red).

132

6 : G R O W T H I N H I B I T I O N A N D T U M O R S U P P R E S S O R G E N E S

Regulation of p53 protein by MDM2

Normally, the level of p53 protein in a cell is low. The activity of p53 in a cell is regulated at the level of protein degradation, not at the level of expression of the p53 gene. The MDM2 protein, a ubiquitin ligase, is its main regulator. Ubiquitin ligases are enzymes that attach a small peptide called ubiquitin to proteins, fl agging it for proteolysis (enzymatic protein degradation involving cleavage of peptide bonds) in proteosomes.

MDM2 modifi es the carboxy-terminal domain of p53 and thus targets it for degradation by proteosomes in the cytoplasm. In addition, MDM2

modifi es the activity of p53 as it binds to and inhibits the p53 transactivation domain at the amino-terminal and transports the protein into the cytoplasm, away from nuclear DNA. Thus, the activity of p53 as a transcription factor is out of reach. The binding of MDM2 to p53 is part of an autoregulatory feedback loop (Figure 6.5, shown by red arrows) as the MDM2 gene is a transcriptional target of p53. Therefore, p53 stimulates the production of its negative regulator MDM2 that causes the degradation of p53. Small amounts of p53 will reduce the amount of MDM2

protein and this will result in an increase of p53 activity, thus completing the loop.

Upstream: molecular pathways of p53 activation

The mechanism by which p53 becomes activated depends on the nature of the stress signal. Stress is “sensed” by cellular proteins, many of which are kinases that convey the danger signals to p53 via phosphorylation.

Nucleus

p53

mdm2

p53

p53

MDM2

Active

Ubiquitin

Low MDM2

Low p53

p53

p53 inactivation:

Degradation

Nuclear

Inhibition of p53

Figure 6.5 Regulation of p53 by

export

transcriptional activity

MDM2. See text for details.

6 . 4 T H E P 5 3 PAT H WAY 133

Upstream factors

DNA

Oncogene

Cell stress

damage

activation

ATM

p14arf

ATR

Casein

ChK2

MDM2

kinase II

Figure 6.6 Upstream activators

of p53. The fi rst and the last

P

P

pathways involve kinases and

P53

result in the phosphorylation of

p53 (shown as P). All pathways

Active

disrupt the interaction of p53

with MDM2.

Disruption of the p53–MDM2 interaction is fundamental to the activation of p53 by its upstream factors.

The upstream activators of p53 utilize three main independent molecular pathways to signal cellular distress (Figure 6.6). DNA damage

caused by ionizing radiation is signaled by two protein kinases. The fi rst kinase, ATM, stimulated by DNA double-strand breaks, phosphorylates and activates a second kinase Chk2. Both ATM and Chk2 kinases phosphorylate amino-terminal sites of p53 and this phosphorylation interferes with binding of MDM2. A second molecular pathway that signals cellular distress to p53 is executed by two different kinases, ATR and casein kinase II. These also phosphorylate p53 and disrupt its interaction with MDM2. Lastly, activated oncogenes, such as Ras, induce the activity of the protein p14arf, another modulator of the p53–MDM2 complex.

P14arf is one of two translational products of the INK4a/ CDKN2A gene (p16, a cyclin kinase inhibitor, is the other product). P14arf does not bind to the interface of p53–MDM2, but functions by sequestering MDM2 to the nucleolus of the cell. All three pathways prevent degradation of p53

by MDM2.

Downstream: molecular mechanisms of p53 cellular effects

The main mechanism by which p53 exerts its tumor suppressing effects is by inducing the expression of specifi c target genes. Let us examine how the resulting network of proteins triggers these responses (Figure 6.7).

134

6 : G R O W T H I N H I B I T I O N A N D T U M O R S U P P R E S S O R G E N E S

Inhibition of the cell cycle

PAUSE AND THINK

One of the central functions of p53 is to cause either transient cell cycle Why would an inhibitor of cyc-arrest or senescence in response to DNA damage so that there is either an lin–cdk complexes cause a pause

opportunity to repair the damage prior to the next round of replication or in the G –S transition? Recall the

1

a complete restraint of cell division, respectively; thus, damaged DNA will role of cyclin–cdk complexes in

be prevented from being replicated and passed on to daughter cells and the cell cycle; importantly they

maintenance of the genome will be facilitated. The molecular mechanism act as kinases. As kinases they

responsible for this cellular response involves the transcriptional induc-phosphorylate. What do they

phosphorylate? RB. Failure of the

tion of the p21 gene. Its product, the p21 protein, inhibits several cyclin–

cdk complex to phosphorylate

cdk complexes and causes a pause in the G1 to S (and G2 to M) transition RB prevents the release of the

of the cell cycle (see Pause and Think).

transcription factor E2F and

In addition, p21 also binds PCNA (proliferating cell nuclear antigen), a blocks the transition into S

protein that has a role in DNA synthesis and DNA repair. The interaction phase.

with p21 is such that it inhibits PCNA’s role in DNA replication but not in DNA repair. Therefore, p21 is an important part of the molecular mechanism that facilitates the ability of p53 to bring about a pause in the cell cycle and at the same time allow DNA repair. A microRNA regulated by p53 and miR-34a can also induce cell cycle arrest and senescence (not shown in Figure 6.7).

p53

p53

p53

p 21

p53

Thrombospondin

p21

Noxa

Puma

P 53 AIP 1

Bax

FASR

IGF-BR 3

p21

Cyclin

p21

CdK

p53

Bcl-2

PCNA

p53

XPC

Figure 6.7 Downstream effects of

Cell cycle

Inhibition

p53. p53 exerts many of its effects

arrest or

DNA

Apoptosis

of

by regulating target genes as

senescence

repair

angiogenesis

shown.

6 . 4 T H E P 5 3 PAT H WAY 135

Apoptosis

The expression of several mediators of apoptosis is transcriptionally regulated directly by p53 (Table 6.2). The targets include genes that code for proteins involved in two apoptotic pathways that respond to external and internal signals, respectively. (Apoptosis will be described in Chapter 7.) In general, genes encoding proteins that promote apoptosis, pro-apoptotic proteins, are induced while genes encoding proteins that antagonize apoptosis, anti-apoptotic proteins, are repressed. The mitochondrial proapoptotic proteins NOXA, PUMA, and p53AIP1, that cause the release of cytochrome c and activate the apoptosome, are induced. Also, p53 tips the balance regulated by the Bcl-2 protein family towards apoptosis by inducing gene expression of the pro-apoptotic protein Bax and repressing the expression of anti-apoptotic protein Bcl-2. Fas receptor (FASR) is a transmembrane receptor that receives extracellular stimuli to stimulate apoptosis. Expression of the Fas receptor gene is induced by p53. Apoptosis is also triggered when survival signaling is blocked by p53’s induction of IGF-BP3 (insulin-like growth factor-binding protein 3). IGF-BP3 blocks the signaling of IGF-1 to its receptor. Activation of these different pathways in concert is required for a full apoptotic response. Transcription-independent mechanisms for the induction of apoptosis by p53 also exist and will be discussed in Chapter 7.

DNA repair and angiogenesis

Both DNA repair and angiogenesis are covered in depth elsewhere in

this volume (Chapters 2 and 9, respectively). In general, a role for the transcriptional regulation of important genes in these processes by p53

Table 6.2 p53-inducible apoptotic target genes

Gene

Location of gene product

Bax

Intrinsic pathway

NOXA

Intrinsic pathway

PUMA

Intrinsic pathway

P53AIP1

Intrinsic pathway

FAS

Extrinsic pathway

IGF-BP3

Extrinsic pathway

DR5

Extrinsic pathway

PIDD

Extrinsic pathway

PERP

Endoplasmic reticulum

136

6 : G R O W T H I N H I B I T I O N A N D T U M O R S U P P R E S S O R G E N E S

has been established. For example, the gene XPC that is involved in nucleotide excision repair is regulated by p53 through a p53 response element in its promoter. Thrombospondin, an inhibitor of angiogenesis, is also transcriptionally regulated by p53. This further supports the role of p53 as a transcriptional regulator in different biological responses.

Decision making

As the guardian of the genome, p53 prevents damaged DNA from being

passed on to daughter cells either by inhibiting the cell cycle or by inducing apoptosis. Cell cycle inhibition and apoptosis are two independent effects of p53. The molecular factors that determine the biological outcome of whether inhibition of the cell cycle or apoptosis takes place are just being elucidated. One model that has been put forth is that different combinations of transcription factors that act as dimers infl uence the biological response. Oncogene activation (e.g. Myc) is an upstream inducer of p53 that triggers apoptosis. The mechanism of this stress signal acts via the cyclin–cdk inhibitor p21, the main effector of cell cycle inhibition but also an inhibitor of cell death. The regulation of the p21 gene is a pivotal point in the p53 decision-making process. Both p53 and a transcription factor called Miz-1 are required for p21 gene expression. Now enter the oncogene, Myc, which competes with p53 for binding with Miz-1. Myc

interacts with Miz-1 and inhibits the transcription of p21. Through this mechanism of preventing expression of p21, Myc not only overrides the p53-regulated block to cell cycle progression but also blocks the

p21-mediated inhibition of apoptosis (Figure 6.8). p53 is not altered and is free to induce the expression of pro-apoptotic targets. Additional events are also required for full activation of apoptosis, as p53 phosphorylation and apoptotic co-factors are required for the induction of some apoptotic genes. Revealing the mechanisms behind other modes of upstream stress inducers of p53, such as oxidative stress, requires further studies.

The apoptosis-stimulating proteins of p53 (ASPP) family also plays a role in p53 decision making (Slee and Lu, 2003). These proteins bind to the p53 DNA-binding domain and have been shown specifi cally to

enhance the ability of p53 to activate genes involved in apoptosis and not cell cycle arrest. The selection of apoptotic genes versus growth arrest genes could potentially be accomplished by specifi c promoter sequences that serve to distinguish the functionally distinct classes of genes. The regulation of ASPP itself requires further study. Mutations in the ASPP binding site of the p53 gene and epigenetic silencing of the ASPP gene have been identifi ed in tumor cells. These tumor cells may have been initiated because they escaped from the apoptotic program normally augmented

by ASPP. Other co-activators may also enhance the selectivity of p53 to activate apoptotic genes.





6 . 5 M U TAT I O N S I N T H E P 5 3 PAT H WAY A N D C A N C E R 137

Cell cycle inhibition

Apoptosis

p53

MIZ-1

Figure 6.8 Molecular factors in

p 21

deciding the effects of p53: cell

cycle inhibition or apoptosis? The

?

regulation of a gene that codes for

a cyclin–cdk inhibitor, the p21

gene, plays a pivotal role. Top:

Decisions!

p53

Decisions!

without competition from Myc,

p53 and MIZ-1 bind to the

promoter of p21, induce

?

transcription resulting in cell cycle

inhibition. Bottom: upon

oncogenic activation, Myc

p53

+

ASPP

Apoptosis

competes with the binding of p53.

Myc and MIZ-1 bind to the p21

Cell cycle inhibition

promoter, inhibit transcription,

and block cell cycle inhibition.

Myc

MIZ-1

ASPP binds to p53 and facilitates

activation of apoptotic genes to

p 21

induce apoptosis.

6.5 Mutations in the p53 pathway and cancer

Owing to the central role of p53 as a tumor suppressor and guardian of the genome, cell transformation is less likely to occur in cells that maintain a functional p53 pathway. p53 mutant cells are characterized by genomic instability, as mutations are more likely to be maintained in dividing cells, providing an environment that is permissive for tumor initiation. The high frequency of p53 pathway mutations found in tumor cells is most likely to be the result of selective pressure favoring mutant cells that escape tumor suppression. Over 75% of all p53 mutations are missense mutations and result in single amino acid substitutions. Thus, p53 differs from many “classical” tumor suppressor genes in that “classical” tumor suppressor are usually characterized by nonsense or frameshift mutations that lead to inactivated truncated proteins. Many mutant p53

molecules are more stable than wild-type p53 protein and can accumulate in cells and show “gain of function.” That is, some mutant p53 proteins show oncogenic capabilities and this effect may be driven by altered target gene profi les or inappropriate protein–protein interactions. More than 90% of the missense mutations are located in the DNA-binding domain (amino acids 102–292) and more than 30% of these affect only six codons and are therefore referred to as “hotspots” (see Figure 6.4).

In addition to mutation of the p53 gene, there are other ways to interfere with the p53 pathway. Defects in pathways that lead to the activation

138

6 : G R O W T H I N H I B I T I O N A N D T U M O R S U P P R E S S O R G E N E S

of p53 in response to stress, such as mutations in the chk2 gene, have been identifi ed in cancer cells that do not contain mutations in the p53 gene. In these cases, the stress signal would not be transmitted to p53 via phosphorylation as in normal cells (see Figure 6.6). Also, over-expression of the MDM2 protein has been demonstrated to alter the regulation of p53,

leading to a “p53-inactivated” phenotype. Inactivation of downstream effectors, such as Bax and FASR, perturbs the apoptotic response. Some of these other p53 pathway disruptions may not lead to effects as severe as p53 mutation, as the p53 protein is a central node for receiving and eliciting many stress signals and biological responses, respectively, but may mimic a partial aspect of p53 inactivation and be permissive for tumor formation.

Li–Fraumeni syndrome

Li–Fraumeni syndrome is predominantly characterized by a germline

mutation of the p53 gene and leads to a predisposition to a wide range of cancers. It is an autosomal dominant disease, so an affected individual has a 50% chance of passing the mutation to each offspring. Patients have a 25-fold increased risk of developing cancer before they are 50 years old compared with the general population. The young age at which individuals develop cancer and the frequent occurrence of multiple primary tumors in individuals are characteristic features of the syndrome. The types of cancer seen within families that carry the mutation include sarcomas, breast cancer, leukemia, and brain tumors. Cancer develops at an earlier age over several generations. It is noteworthy that tumors in Li–Fraumeni syndrome patients do not always exhibit loss of the wild-type p53 allele, suggesting that haploinsuffi ciency of p53 is suffi cient for tumor formation.

More complex than Knudson’s two-hit hypothesis

The mechanism of tumor suppressor genes may be more complex than

Knudson’s two-hit hypothesis suggests. This is particularly clear for p53.

As stated earlier, loss of heterozygosity is not commonly observed in tumors from Li–Fraumeni syndrome patients, suggesting that reduced

amounts (haploinsuffi ciency) of p53 can cause transformation. In addition, specifi c mutations may result in varied amounts of tumor suppressor gene expression and therefore tumor suppressor “dose” may play a role in the cancer outcome. Recent experiments which generated p53 hypomorphs (animals that exhibit reduced levels of p53 expression) using RNA interference (see Section 1.6) support this mechanism (Hemann

et al. , 2003).

Unlike most other tumor suppressor genes, some p53 mutations do not lead to loss of function. Some missense mutations form an altered protein





6 . 6 I N T E R AC T I O N O F D N A V I R A L P R OT E I N P R O D U C T S W I T H R B A N D P 5 3 139

that interacts with the product of a normal p53 allele via dimerization to inactivate its function. This type of effect is referred to as dominant negative, whereby the mutated gene product dominates to inactivate the wild-type gene product. In this situation, the autoregulatory loop is affected because p53 fails to induce its inhibitor, MDM2, and, as a result, p53

mutant protein accumulates. Other mutations can lead to a newly

acquired “gain-of-function” phenotype that can accumulate in, and transform, cells. In this instance, mutant p53 (not wild-type p53) can be considered an oncogene having an active role in carcinogenesis.

The continuum model of tumor suppression

A new model called the continuum model for tumor suppression that integrates the two-hit hypothesis with a broader concept that also explains exceptions to this rule has been proposed (Berger et al. , 2011). It states that subtle dosage effects of tumor suppressors, either as a result of expression levels or protein activity, can play an important role in carcinogenesis. As described earlier for p53, a single dominant negative mutation over the wild-type protein is a possible mechanism of tumor suppression that does not fi t Knudson’s two-hit hypothesis. Tumor suppressor dosage plays a role for other tumor suppressors. It has been reported that Pten haploinsuffi ciency is actually more tumorigenic in some contexts compared with complete loss, because complete loss triggers p53 induced senescence.

Mutations of the tumor suppressor Pax5 gene most often affect one allele and seem to function as hypomorphs. This concept of dosage is not new for oncogenes: gene amplifi cation of mutated EGFR is one example of altered oncogene dosage in cancer. Also, it is easy to envisage that single nucleotide polymorphisms may affect regulation by microRNAs and lead to altered protein levels. Further research about microRNAs and aberrant regulation in cancer may help to further elucidate our understanding of gene dosage of tumor suppressors in cancer.

6.6 Interaction of DNA viral protein products with RB

and p53

Viruses are cellular parasites that hijack host cell proteins to maintain their life cycle. Coercing the host cell into S phase is essential for viral propagation. Several DNA viruses have been shown to be carcinogenic to humans.

Most notable are papovaviruses, adenoviruses, herpes viruses, and hepatitis B. Interestingly, several of the DNA viruses share a common oncogenic mechanism that involves the interaction of viral proteins with the two important regulators of tumor suppression, RB and p53 (Figure 6.9). The viral proteins adenovirus E1A, papilloma virus E7, and SV40 Large T

140

6 : G R O W T H I N H I B I T I O N A N D T U M O R S U P P R E S S O R G E N E S

(a)

E2F

Cell cycle

pRB

(b)

E2F

Adenovirus EIA

Papilloma virus E7

pRB

Cell cycle

SV40 LgT

progression

(c)

p53

apoptosis

Figure 6.9 Viral protein products

interact with RB (pRB) and p53

(d)

Adenovirus EIB

(parts b and d, respectively) and

Papilloma virus E6

p53

Apoptosis

inhibit their normal function

SV40 LgT

(shown in a and c).

antigen inactivate RB (Figure 6.9b), adenovirus E1B, and papilloma virus E6 and SV40 Large T antigen, inactivate p53 (Figure 6.9c).

The ability of both E6 and E7 to degrade p53 and RB, respectively,

using the ubiquitin-proteasome system, correlates with their oncogenic potential. The biochemical events involved in p53 degradation by E6 are as follows: E6 binds to a ubiquitin-protein ligase (E6-AP) and forms a dimer that subsequently binds to p53. p53 is then ubiquitinated and tagged for recognition by the proteosome for degradation. A similar mechanism is likely for E7-targeted degradation of RB and E1B-targeted degradation of p53.

A LEADER IN THE FIELD . . . of apoptosis: David Lane

David Lane’s contributions to cancer research were acknowledged when he received a knighthood from Queen Elizabeth II in January 2000. He discovered the p53 protein–SV40

T antigen complex that helped characterize the mechanisms of viral transformation and tumor suppressor gene function. Sir David was the second most highly cited medical scientist in the UK in the 1990s. He was instrumental in publicizing the importance of p53 as the

“guardian of the genome.”

David carried out his undergraduate and post-graduate degrees at University College London where he studied autoimmunity. He carried out two post-doctoral tenures, at the Imperial Cancer Research Fund (ICRF) in London and the other at the Cold Spring Harbor Laboratory in New York. David returned to the UK to carry out research, fi rst at Imperial College, London, and later at the ICRF laboratories. He is currently a Professor and Director of the Cancer Research UK Transformation Research Group at the University of Dundee. David is also the Founder and Chief Scientifi c Offi cer of a biotechnology company called Cyclacel, which is developing new cancer therapeutics based on the biology of the tumor suppressor protein p53.





6 . 7 TA R G E T I N G O F T H E P 5 3 PAT H WAY 141

Human papilloma virus (HPV) causes cervical cancer

The p53 gene is rarely mutated in cervical cancers, suggesting that the causative agent, HPV, may be functionally equivalent to p53 mutation. A polymorphism in the p53 gene at amino acid 72 in humans leads to differences in the risk of cervical cancer following exposure to HPV. Patients with two alleles coding for Arg at this position have a seven times higher risk of cervical cancer than those with alleles coding for Pro at this site.

The Arg-containing p53 protein is more susceptible to degradation by HPV E6 (probably because of altered protein conformation). As a result of these cells having decreased p53 activity, they are likely to have an increased mutation rate and an increased potential to form tumors.

Therapeutic strategies

6.7 Targeting of the p53 pathway

The role of p53 as a “star player” in suppressing tumorigenesis and the high occurrence of mutations in the p53 gene found in tumors draws attention to the p53 pathway as a promising cancer therapeutic target. As a result, many different strategies that target the p53 pathway have been developed (see Chen et al. , 2010). Several are described in the following sections. The variety of p53 pathway aberrations, including both p53

gene mutations and defective regulation, suggests that the future success of these therapies will be dependent on knowing the p53 genotype of tumors in patients prior to treatment. We need to know if there are mutations in the p53 gene itself or in its regulators and, if so, the type of mutations present. You have to know what is wrong before you can fi x it.

Therapeutics may strive to correct a p53 mutation or potentiate normal p53 protein function in cases where other alterations in the p53 pathway affect its function. Several different strategies are now described and illustrated in Figure 6.10 (therapeutics are shaded red).

Strategies that aim to correct a p53 mutation

Gene therapy is one of the most obvious approaches to correct for a p53 mutation. In fact, many different vectors have been examined in pre-clinical and clinical settings (see Bouchet et al. , 2006). Retroviruses have been used in several pre-clinical studies and have shown anti-tumor activity. However, only one Phase I clinical trial using retrovirus-mediated p53

142

6 : G R O W T H I N H I B I T I O N A N D T U M O R S U P P R E S S O R G E N E S

p53

p53M

(a)

Advexin

Gene therapy

p53M

(b)

Onyx015 virus

Apoptosis

Replication competent

Aberrant

p53

Restores p53

(c)

CDB3

conformation

or

PRIMA-1

(d)

Nutlins

Target p53 inhibitor MDM2

Activates p53

p53

Figure 6.10 Therapeutic strategies

MDM2

that target the p53 pathway. Cell

targets are indicated with a ()

symbol; therapeutic agents (red);

p53

(e)

Pifithrin-

p53M, mutant p53; nutlins

α

Limits side-effects

in normal cells

compete (///) with p53.

gene therapy has been published to date (discussed in Bouchet et al. , 2006) and expression of p53 could not be detected, although some clinical responses in lung cancer patients were observed. Unlike retroviruses that integrate into the genome and therefore carry a risk of causing insertional mutagenesis, adenoviruses, which are DNA viruses, do not cause damage to the genome. Frequently used adenoviral vectors can carry large

amounts of DNA and can infect a range of cell types via coxsackievirus and adenovirus receptors (CAR) with high effi ciencies. Adenoviruses that have been modifi ed to be replication defective have been popular vectors.

Advexin™ (Introgen Therapeutics; Genedicine™, Shenzhen SiBono

GeneTech Co. Ltd ) is a replication-defective adenoviral vector that contains the human p53 gene, driven by a viral promoter (the cytomegalo-virus promoter; CMV), within the region of an E1 deletion (Figure 6.10a).

Many clinical trials have demonstrated safety and low toxicity. It has been reported recently that Advexin™ was used as an adenoviral-mediated

p53 gene therapy to treat one individual with Li–Fraumeni syndrome.

Genedicine™ obtained a drug license in China and is the world’s fi rst commercial gene therapy for cancer.

Replication-competent adenoviruses provide another strategy as the

basis of new cancer therapeutics. As mentioned previously, wild-type adenovirus can replicate in cells by inactivating p53 and RB (Figure 6.11a). The Onyx 015 virus, a replication-selective adenovirus, was designed to selectively kill cancer cells that contain p53 mutations (Figure 6.11b). It takes advantage of the fact that interference with the RB

6 . 7 TA R G E T I N G O F T H E P 5 3 PAT H WAY 143

(a)

(b)

(c)

Adenovirus

Onxy 015

Onxy 015

(WtAdE1B)

adenovirus

adenovirus

(lacks AdE1B)

(lacks AdE1B)

+

+

+

p53

p53M

p53

Cancer cell with

Normal cell

p53 mutation

(–) p53

AdE1B

p53

(–) AdE1B

p53

Viral replication

Viral replication

Viral replication

Cell cycle arrest

Figure 6.11 The Onyx 015

adenovirus can selectively kill

Cell death

Cell death

cancer cells with p53 mutations.

and p53 pathways is exploited both by viruses and cancer cells (Ries and Korn, 2002). The Onyx 015 virus contains a deletion of the E1B gene and thus it can only replicate within, and subsequently kill, cells that have an inactive p53 pathway (Figure 6.11b). The E1A product of the Onyx 015 virus binds to and inactivates RB and, as a result, induces the G1–S phase transition of the cell cycle allowing for viral replication and cell destruction. The Onyx 015 adenovirus (lacking E1B) triggers a p53

response (growth arrest) in normal cells resulting in the interference of viral replication (Figure 6.11c). Such selective replication produces a treatment with minimal side-effects. Phase I and II clinical trials have given encouraging results. Intratumoral injection proved safe and specifi c anti-tumor effects were demonstrated. Although further development of Onyx-015 has been halted, H101, an oncolytic adenovirus

similar to Onyx-015 was approved by the Chinese State Food and Drug Administration in 2005 for use in combination with chemotherapy for the treatment of nasopharyngeal cancers.

Small molecules that can restore wild-type function to products of p53

gene mutations have been investigated (Bykov et al. , 2003). Many missense mutations of p53 result in aberrant protein conformation and subsequently interfere with the DNA-binding function of the p53 protein. As a result, the p53 inhibitor, MDM2, and target genes essential for apoptosis are not induced. Note that tumors that carry such mutations are more likely to be resistant to conventional chemo- and radiotherapies as these

144

6 : G R O W T H I N H I B I T I O N A N D T U M O R S U P P R E S S O R G E N E S

drugs work via the induction of apoptosis. Reactivation of p53 mutants aims to eliminate tumor cells via the induction of apoptosis. A short (nine residues) synthetic peptide, CDB3, has been shown to stabilize the structure of several p53 mutants and to restore their transcriptional function (Figure 6.10c.). CDB3 is thought to act as a chaperone protein that aids in the refolding of the mutant p53 protein. Similarly, PRIMA-1 (Figure 6.10c), identifi ed from a chemical library, demonstrates restoration of the PAUSE AND THINK

wild-type p53 conformation and DNA binding in a number of mutant

p53 proteins, including those with mutations in the hotspots (see Figure What type of information is

required to begin to design

6.4). Its specifi city for cells expressing mutant p53 is notable. PRIMA-1

inhibitors of the p53–MDM2

showed low toxicity and mutant p53-dependent anti-tumor effects in

interaction?

human tumor xenografts in animal models and has now entered Phase 1

clinical trials.

Strategies that aim to activate endogenous p53

In many tumors wild-type p53 is expressed but the regulation of the p53

protein is defective and results in an altered p53 pathway. As mentioned earlier, over-expression of the p53 inhibitor, MDM2, leads to defective regulation and p53 inactivation. Note that cancers caused by viruses do not usually harbor a p53 mutation; instead viral proteins act to inactivate p53 function. An approach on the horizon to activate wild-type p53 protein is the development of inhibitors of the p53–MDM2 interaction (see Pause and Think).

Detailed structural information about the p53–MDM2 complex has

been obtained by nuclear magnetic resonance and X-ray crystallography and has revealed that MDM2 has a well-defi ned binding site for p53. The opposite is not true. Thus, inhibitors are best designed to mimic amino acids of p53. In addition, the binding interface was found to be relatively small, which suggested that it was possible to design small inhibitors that could be taken orally. Following a strategy of high-throughput screening of synthetic chemicals and computer modeling, drugs called nutlins (Figure 6.10d) were identifi ed and have shown promising results in pre-clinical tests (Vassilev et al. , 2004). These results include triggering p53

activation and its biological responses in cancer cells containing wild-type p53. In addition, inhibition of tumor growth by 90% was demonstrated in animal models. Nutlins support the idea that protein–protein interactions are good targets for cancer therapeutics and are currently in early-phase clinical trials.

Strategies that aim to suppress endogenous p53

It is clear that p53 is important for the disposal of tumor cells. The success of chemo- and radiotherapy is often limited by side-effects in normal

6 . 7 TA R G E T I N G O F T H E P 5 3 PAT H WAY 145

tissues. Many of the side-effects of chemo- and radiotherapy are, in part, mediated by p53. There is normally high expression of p53 in the tissues that are sensitive to these conventional therapies, such as the hematopoietic organs and intestinal epithelia, and the DNA damage caused by these agents induces p53 to elicit apoptosis, the mechanism behind the side-effects. Therefore, temporary and reversible suppression of p53 in normal tissue may help alleviate the side-effects of conventional therapies only in patients with tumors that have lost p53 function. A chemical PAUSE AND THINK

screen has identifi ed pifi thrin-α (p fifty three inhibitor) as a potential agent When and where would sup-to test this approach (Figure 6.10e). Pifi thrin inhibits p53 gene transcrip-pression of p53 be clinically

tion. Prevention of hair loss and an increase in tolerated dose in irradiated benefi cial?

mice show promise in pre-clinical tests.

■ CHAPTER HIGHLIGHTS—REFRESH YOUR MEMORY

•

Tumor suppressor genes act as stop signals for uncon-

•

MDM2 is a main regulator of p53 protein activity.

trolled growth or may play a role in DNA repair.

•

The protein product of the p21 gene, a cdk inhibitor, is

•

Knudsons’s two-hit hypothesis states that a germline

key for eliciting the p53 response of cell cycle inhibition.

mutation in one tumor suppressor allele predisposes an

•

Several gene products, including Bax and IGF-BP3, are

individual to cancer. Acquiring a second mutation in the

important for eliciting the apoptotic response of p53.

second allele later in life triggers carcinogenesis.

•

The biological response exerted by p53, either inhibition

•

Germline mutations in BRCA1 and BRCA2 predispose

of the cell cycle or apoptosis, is mediated by the regula-

individuals to breast and ovarian cancer.

tion of p21 and by the ASPP family.

•

PTEN is a tumor suppressor gene that codes for a phos-

•

Li–Fraumeni syndrome is a disease that is characterized by

phatase regulating the activity of a potential oncogenic

an inherited mutation of the p53 gene. Patients have a

kinase.

predisposition to a variety of cancers.

•

The Rb tumor suppressor gene in retinoblastoma follows

•

The continuum model for tumor suppression has recently

Knudson’s two-hit hypothesis: mutations in both alleles

been proposed and it states that subtle dosage effects of

are necessary for tumor initiation.

tumor suppressors, either because of expression levels or

•

The tumor suppressor p53 has been nicknamed the

protein activity, can play an important role in carcino-

“guardian of the genome” because of its central role in

genesis.

maintaining the integrity of the cell’s DNA.

•

Viral proteins from adenovirus, papilloma virus, and SV40

•

The p53 protein is a transcription factor that regulates

virus inactivate p53 and RB as a common oncogenic

genes involved in an antioxidant response, inhibition

mechanism; several utilize the ubiquitin-proteosome

of the cell cycle, DNA repair, apoptosis, and angio-

system.

genesis.

•

Both the RB pathway and the p53 pathway provide

•

More than 90% of p53 missense mutations are located in

molecular targets for the design of new cancer

the DNA-binding domain.

therapeutics.

■ ACTIVITY

1. Choose a genetic syndrome that leads to a predisposition to cancer (excluding familial breast cancer and Li–Fraumeni syndrome). Describe in detail the molecular mechanisms involved.

146

6 : G R O W T H I N H I B I T I O N A N D T U M O R S U P P R E S S O R G E N E S

2. Find evidence of specifi c tumor suppressor genes that exemplify the spectrum of the continuum model for tumor suppression (see Berger et al. , 2011).

■ FURTHER READING

Brown, C.J. Lain, S., Verma, C.S., Fersht, A.R., and Lane, D.P. (2009) Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 9: 862–873.

Goh, A.M., Coffi ll, C.R., and Lane, D.P. (2011) The role of mutant p53 in human cancer. J. Pathol. 223: 116–126.

Goldstein, I., Marcel, V., Olivier, M., Oren, M., Rotter, V., and Hainaut, P. (2011) Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther. 18: 2–11.

Levitt, N.C. and Hickson, I.D. (2002) Caretaker tumour suppressor genes that defend genome integrity. Trends Mol. Med. 8: 179–186.

Macleod, K. (2000) Tumor suppressor genes. Curr. Opin. Genet. Dev. 10: 81–93.

Scully, R. and Pudget, N. (2002) BRCA1 and BRCA2 in hereditary breast cancer.

Biochimie 84: 95–102.

Sherr, C.J. (2004) Principles of tumor suppression. Cell 116: 235–246.

Sulis, M.L. and Parsons, R. (2003) PTEN: from pathology to biology. Trends Cell Biol. 13: 478–483.

Volgelstein, B., Lane, D., and Levine, A. (2000) Surfi ng the p53 network. Nature 408: 307–310.

Vousden, K.H. and Prives, C. (2009) Blinded by the light: The growing complexity of p53. Cell 137: 413–431.

■ WEB SITE

International Agency for Research on Cancer. Database of p53 mutations http://

www-p53.iarc.fr/index.html

■ SELECTED SPECIAL TOPICS

Berger, A.H. Knudson, A.G., and Pandolfi , P.P. (2011) A continuum model for tumor suppression. Nature 476: 163–169.

Bouchet, B.P., de Fromentel, C.C., Puisieux, A., and Galmarini, C.M. (2006) P53 as a target for anti-cancer drug development. Crit. Rev. Oncol. Hematol. 58: 190–207.

Bykov, V.J.N., Selivanova, G., and Wiman, K.G. (2003) Small molecules that reactivate mutant p53. Eur. J. Cancer 39: 1828–1834.

Chen, F., Wang, W., and El-Deiry, W.S. (2010) Current strategies to target p53 in cancer. Biochem. Pharmacol. 80: 724–730.

Hemann, M.T., Fridman, J.S., Zilfou, J.T., Hernando, E., Paddison, P.J., Cordon-Cardo, et al. (2003) An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes. Nat. Genet. 33: 396–400.

6 . 7 TA R G E T I N G O F T H E P 5 3 PAT H WAY 147

Ostman, A., Hellberg, C., and Bohmer, F.D. (2006) Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer 6: 307–320.

Ries, S. and Korn, W.M. (2002) ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br. J. Cancer 86: 5–11.

Sablina, A.A., Budanov, A.V., Ilyinskaya, G.V., Agapova, L.S., Kravchenko, J.E., and Chumakov, P.M. (2005) The antioxidant function of the p53 tumor suppressor. Nat.

Med. 11: 1306–1313.

Slee, E.A. and Lu, X. (2003) The ASPP family: deciding between life and death after DNA damage. Toxicol. Lett. 139: 81–87.

Vassilev, L.T., Vu, B.T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., et al.

(2004) activation of the p53 pathway by small-molecule antagonists of MDM2.

Science 303: 844–848.

Vassilev, L.T. (2006) MDM2 inhibitors for cancer therapy. Trends Mol. Med. 13: 23–31.

Wang, Z., Shen, D., Parsons, D., Bardelli, A., Sager, J., Szabo, S., et al. (2004) Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 304: 1164–1166.

This page intentionally left blank





Chapter 7

Apoptosis

Introduction

Apoptosis is a highly regulated process of cell death that not only plays a role in developmental morphogenesis but also controls cell numbers and gets rid of damaged cells. It therefore plays an important role in tumor suppression. As described in Chapter 1, the balance between cell growth, differentiation, and apoptosis affects the net number of cells in the body and aberrant regulation of these processes can give rise to tumors. Apoptosis is a crucial tumor suppression mechanism within the body because it gets rid of cells that have extensive DNA damage and the potential to lead to cancer. The peeling of your skin after a sunburn is, in fact, a result of apoptosis of cells that have had extensive DNA damage after UV exposure. This process is an important defense against skin cancer. Elimination of cells that have damaged DNA helps protect the entire organism from cancer. Defects in apoptosis also infl uence the effectiveness of those conventional therapies that mainly exert their effect by inducing apoptosis. In this chapter we will describe the molecular mechanisms of apoptosis and examine specifi c mutations that affect the apoptotic pathway and play a role in carcinogenesis. We will also investigate how mutations in the apoptotic pathway can lead to resistance to chemotherapeutic drugs. Lastly, strategies for the design of new cancer therapeutics that target apoptosis will be presented. Let us begin with a description of apoptosis.

Apoptosis is a type of “cell suicide” that is intrinsic to the cell. It is an active process requiring the expression of a genetic program that every cell is capable of executing. The apoptotic process is organized, neat, and tidy, leaving behind little evidence of the pre-existing cell. The cell undergoing apoptosis is swept clean during phagocytosis by macrophages and neighboring cells that recognize molecular fl ags (e.g. phosphatidylserine) exhibited by the apoptosing cell. Apoptosis is characterized by cell shrinkage, membrane blebbing and budding, and chromatin condensation and precise fragmentation, all which contribute to the neat disposal of the cell. This sharply contrasts with the “sloppy” process of necrosis, whereby cells swell, cell membranes become leaky, and cells spill out their contents into the surrounding tissue and cause infl ammation. Morphological differences between cells undergoing necrosis and apoptosis can be seen in Figure 7.1.

Similar to the central role that kinases have in growth factor signaling pathways, particular proteases, called caspases, play a central role in apoptosis. Proteolysis, catalyzed by caspases, helps to break down cellular components for the neat disposal that





150

7 : A P O P TO S I S

(a)

(b)

Figure 7.1 (a) Transmission

electron microscopy (TEM) of a

necrotic cell: the disruption of the

plasma membrane and organelles

is observable. A relative

preservation of nuclear

morphology appears (original

magnifi cation ×10,000). (b) TEM

of an apoptotic (A) and a normal

(N) cell. The characteristic

chromatin rearrangement appears

in A, strongly different from its

normal organization (N). The

good preservation of membrane

and organelles is also evident

(c)

(d)

(original magnifi cation ×8000). (c)

Scanning electron microscopy

(SEM) of a necrotic cell.

Numerous lesions appear on the

cell surface (original magnifi cation

×5000). (d) SEM of an apoptotic

cell. Surface blebbing is evident

(original magnifi cation ×5000).

From Watson, J. (1997) The

Purdue Cytometry CD-ROM, Vol.

4, guest ed. J. Paul Robinson.

Purdue University Cytometry

Laboratories, West Lafayette, IN

(ISBN 1-890473-03-0).

is characteristic of apoptosis. For example, the shrinkage of the nucleus is aided by caspases that degrade the protein network of lamins that underlie the structure of the nuclear envelope.

7.1 Molecular mechanisms of apoptosis

Cells may be induced to undergo apoptosis by extracellular signals, so-called “death factors,” or by internal physical/chemical insults such as DNA damage or oxidative stress. Subsequently, two non-exclusive molecular pathways, the extrinsic and the intrinsic, respectively, may be acti-

vated. Caspases are specifi c proteases that act like molecular scissors to cleave intracellular proteins at aspartate residues (one of the 20 amino acids). Caspases are central to both apoptotic pathways. The term

7 . 1 M O L E C U L A R M E C H A N I S M S O F A P O P TO S I S 151

Caspase X

ASP

Pro caspase Y

Caspase Y

ASP

Pro caspase Z

Caspase Z

Figure 7.2 A simple caspase

cascade.

“caspases” derives from three of the characteristics of the enzymes: they are cysteine-rich aspartate proteases. More than 13 mammalian caspases have been identifi ed. They are synthesized as inactive enzymes called procaspases that need to be cleaved at aspartate residues in order to be activated. Although for the most part procaspases are considered inactive, procaspases possess some activity—about 2% of the proteolytic activity of fully activated caspases. This may seem insignifi cant at the moment but, as we will see later, it is an important feature for some pathways of caspase activation. Moreover, as caspases cleave at aspartate residues and procaspases are themselves activated by cleavage at aspartate residues, caspases participate in a cascade of activation whereby one caspase can activate another caspase in a chain reaction (Figure 7.2). This mechanism, whereby caspases activate procaspases, leads to amplifi cation of an apoptotic signal: only a few initially activated caspase molecules can produce the rapid and complete conversion of a pool of procaspases. Let us now examine both the extrinsic and intrinsic apoptotic pathways.

The extrinsic pathway: mediated by membrane death receptors

The extrinsic pathway for triggering cell death (Figure 7.3) shares some common features with pathways involved in triggering cell growth (see Chapter 4). A death factor such as Fas ligand (shown as a black diamond) or tumor necrosis factor (TNF) (shown as a black circle) is received by a transmembrane death receptor such as Fas receptor or TNF receptor,

respectively. TNF is a soluble factor while Fas ligand is bound to the plasma membrane of neighboring cells. When ligands bind to the death receptors, the receptors undergo a conformational change and oligomerize (several come together) in order to transduce the signal into the cell.

The conformational change exposes so-called death domains (red squares) that are located on the receptors’ cytoplasmic tail and enable intracellular adaptor proteins such as FADD (Fas-associated death domain protein) and TRADD (TNF receptor-associated death domain protein) to bind via their death domains (see Pause and Think).

152

7 : A P O P TO S I S

FAS

TNF receptor

FAS

Figure 7.3 The extrinsic pathway

TNF

receptor

of apoptosis. Death signals, TNF

erization

and FAS, activate their death

ligom

receptors TNF receptor and FAS

O

receptor respectively. Binding

causes a change in shape and

oligomerization of the receptors.

TRADD

TRADD

FADD

Adaptor proteins recognize the

c-flip

activated receptors and lead to the

aggregation of procaspase 8.

Procaspase 8

Procaspase 8

Procaspase 8

Procaspase aggregation leads to

caspase 8 activation (shown in

Caspase 8

red). This initiator caspase

initiates a caspase cascade,

Caspase cascade

proteolysis, and apoptosis. The

protein c-fl ip (shaded gray) can

Protein targets

inhibit the interactions of

DNase

Lamins

Actin

procaspase 8 adaptors.

The function of adaptor proteins is to transduce the death signal from the receptor to caspases. The adaptors recruit several molecules of procaspase-8 via death effector domains (DEDs; red triangles). Molecules of procaspase-8, now in close proximity to each other, become activated by self-cleavage as procaspases have low enzymatic activity.

Caspase-8 is known as an initiator caspase as it is the fi rst link between the receptor and the apoptotic proteases and it is key to the extrinsic pathway. Together the death ligands, receptors, adaptors, and initiator caspase are called the death inducing signaling complex (DISC).

Caspase-8 initiates a cascade of caspase activation: one activated caspase cleaves and activates other caspases, called executioner caspases (caspase-3, -6, and -7). The cascade ultimately causes the cleavage of specifi c protein targets and results in apoptosis.

This process can be inhibited by c-Flip (shown in gray in Figure 7.3), an PAUSE AND THINK

inhibitor of apoptosis. c-Flip can bind to adaptor FADD via a DED and What do you think is the func-inhibit caspase-8 recruitment and activation.

tion of a death domain? A death

The breakdown of the cell results from the proteolysis of the target pro-domain is part of a protein,

teins. Target proteins include nuclear lamins allowing for nuclear shrink-approximately 70 amino acids,

age, cytoskeletal proteins such as actin and intermediate fi laments for that allows for specifi c protein–

rearranging cell structure, specifi c kinases for cell signaling, and other protein interactions to occur

enzymes such as caspase-activated DNase for the cleavage of chromatin.

and is analogous to the SH2

The caspase-activated DNase cuts DNA between nucleosomes and gener-

domain characteristic of growth

factor signal transduction path-

ates a DNA ladder (corresponding to multiples of 180 bp—the distance ways.

between nucleosomes; Figure 7.4a), that can be detected experimentally and used by scientists as a molecular marker of apoptosis. The TUNEL





7 . 1 M O L E C U L A R M E C H A N I S M S O F A P O P TO S I S 153

(a)

Mouse B

(b)

Figure 7.4 Methods for the

lymphoma cells

detection of apoptotic cells. (a) A

typical DNA ladder characteristic

ol

of cells undergoing apoptosis.

Detection by agarose gel

Contr

Heat-

shocked

electrophoresis and visualized by

ethidium bromide staining under

UV light. Reprinted from Otsuki,

Y, Li, Z., and Shibata, M.A.

(2003) Apoptotic detection

methods—from morphology to

gene. Progress in Histochemistry

and Cytochemistry, 38: 275–339,

Figure13a. Copyright (2003),

with permission from Elsevier. (b)

TUNEL staining. The induction of

apoptosis in a human

neuroblastoma cell line was

analyzed by TUNEL staining

(described in “Analysis of

apoptosis by the TUNEL

technique” box). Control (top)

and induced (bottom) cells.

Apoptotic cells (red in Plate 5) are

detected using an alkaline

technique, described in the box below is another procedure used by scien-phosphatase-conjugated anti-

tists to detect apoptosis. Caspases also cleave the tumor suppressor fl uorescein antibody. Reprinted protein, RB (discussed in Chapters 5 and 6), and this cleavage results in from Lui, X.-H., Yu, E.Z., Li, Y.-Y., Rollwagen, F.M., and

the degradation of RB protein. This event is required for apoptosis Kagan, E. (2006) RNA induced by TNF and points to a role for RB in the inhibition of apoptosis.

interference targeting Akt

promotes apoptosis in hypoxia-

exposed human neuroblastoma

Self test Close this book and try to redraw Figure 7.3. Check your answer. Correct your cells. Brain Research 1070: work. Close the book once more and try again.

24–30, Figure 1. Copyright

(2006), with permission from

Elsevier. See Plate 5.

Analysis of apoptosis by the TUNEL technique

Apoptotic cells can be detected by a technique called terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL). As mentioned earlier, specifi c fragmentation of DNA at internucleosomal sites is characteristic of apoptosis. The apoptotic endonucleases generate free 3′ OH groups at the ends of the DNA fragments that can be end-labeled using tagged nucleotides. The enzyme terminal deoxynucleotidyl transferase (TdT) catalyzes the addition of labeled deoxynucleotides to the 3′ OH ends of the many DNA fragments within an apoptotic nucleus. The tags most commonly used are biotin or fl uorescein. Biotin tags can be detected using diaminobenzidine and a streptavidin–horseradish peroxidase conjugate to generate a color reaction at the site of the DNA ends. Fluores-cein can be detected with a fl uorescent microscope or by fl ow cytometry. Alternatively, an alkaline phosphatase-conjugated anti-fl uorescein antibody can be used to generate a color reaction. Cells stained by the TUNEL assay using an alkaline phosphatase-conjugated anti-fl uorescein antibody are shown in Figure 7.4(b) (see also Plate 5).

154

7 : A P O P TO S I S

The intrinsic pathway: mediated by the mitochondria

The intrinsic pathway of apoptosis (Figure 7.5) does not depend on external stimuli (e.g. death factors). Stimuli from inside the cell, such as DNA damage and oxidative stress, induce the intrinsic pathway of apoptosis

through the Bcl-2 family of proteins that act at the outer mitochondrial membrane. The Bcl-2 family consists of approximately 25 members, all of which contain at least one Bcl-2 homology (BH) domain that mediates protein–protein interactions. Most family members share three or four BH domains. There are two groups within the Bcl-2 family that have

opposing functions: one group of Bcl-2 proteins inhibits apoptosis and another group promotes apoptosis (Table 7.1). Within the group of proapoptotic molecules is a subset referred to as the BH3-only proteins because they only share one BH domain, BH3. The BH3-only proteins

function by either inducing the activity of the pro-apoptotic molecules (BH3-only activators) or by binding and inhibiting the anti-apoptotic DNA damage/cell stress

DNA

Bax

Bid

Mitochondria

Cytochrome C

+

+

Apaf-1

( Bcl-2)

Procaspase 9

Figure 7.5 The intrinsic pathway

Bax

Smac/Diablo

Cytosol

of apoptosis, based on current

knowledge. Cell stress triggers the

BH3 only protein, Bid, to

transiently bind to and activate

Bax. Bax undergoes a

conformational change, inserts

Apaf-1

Procaspase 9

Apoptosome

into the outer mitochondrial

membrane and oligomerizes (6–8

molecules). Important regulators

Cyto C

are released from the

intermembrane space (shown in

red). Cytochrome c and

procaspase 9 join Apaf-1 to form

Caspase 9

the apoptosome. Caspase

aggregation leads to the activation

of procaspase 9 and fi nally a

Caspase cascade

caspase cascade. Smac/DIABLO

IAPs

(red triangle), also released from

the mitochondria, inhibits IAPs

NFκB

that normally act to block

Protein targets

caspases.

IAP

7 . 1 M O L E C U L A R M E C H A N I S M S O F A P O P TO S I S 155

Table 7.1 Members of the Bcl-2 family

Anti-apoptotic members

Pro-apoptotic members

Pro-apoptotic members—

BH3-only members

Bcl-2

Bax

Bad

Bcl-x

Bok/Mtd

Bik/Nbk/Blk

L

Bcl-w

Bcl-x

Bid

s

A1

Bak

Hrk/DP5

Mcl-1

Bcl-G

Bim/Bod

L

Boo

Bmf

Noxa

Puma/Bbc3, BNIP3, BNIP3L

Bcl-2 proteins (BH3-only enablers). The Bcl-2 family of proteins is thought to act either by forming channels to promote apoptosis or blocking the BH3 domains of pro-apoptotic proteins to inhibit apoptosis. It is the balance of these two activities that regulates the release of important molecular apoptotic mediators from the mitochondria. The members of this family can associate by protein–protein interactions and it appears that it is the ratio of activity that determines function and hence the outcome. For example, if the activity of the pro-apoptotic factors is high owing to low inhibition from anti-apoptotic factors, apoptosis is triggered. The activity of the proteins of the Bcl-2 family can also be regulated by phosphorylation.

The intermembrane space between the two mitochondrial membranes

acts as a supply cabinet for apoptotic mediators. The pro-apoptotic Bcl-2

members regulate the release of the apoptotic mediators from this mitochondrial compartment in a process sometimes referred to as mitochondrial outer membrane permeabilization (MOMP). Upon activation by an apoptotic signal, BH3 only proteins, Bid and Bim, bind to and activate Bax. This interaction is transient and induces a conformational change in Bax as it translocates from the cytoplasm to the mitochondria, and inserts into the outer mitochondrial membrane. Oligomerization of six to eight molecules occurs after insertion (six are shown in Figure 7.5). This new conformation within the mitochondrial membrane increases the permeability of the outer mitochondrial membrane by forming membrane channels and allows the release of apoptotic mediators. The BH3 domain of Bax is required for its killing activity and interactions with anti-apoptotic proteins.

156

7 : A P O P TO S I S

A new model has been presented that suggests oligomers of Bax and

Bak form polymers within the membrane that lead to generalized mem-

brane disruption (MOMP), and the anti-apoptotic molecules, such as

Bcl-2 and Bcl-xL, block their action by acting as chain terminators (Reed, 2006).

As shown in Figure 7.5, cytochrome c, which also functions in the electron transport chain of aerobic respiration, and procaspase-9 (both shaded in red) are released into the cytoplasm and assemble into a complex called an apoptosome, along with dATP bound to Apaf-1. The binding of cytochrome c to cytosolic Apaf-1 triggers the formation of a wheel-like heptameric complex that facilitates the recruitment of procaspase-9 via protein domains, called CARD domains, present on

both Apaf-1 and procaspase-9. Recent structural studies suggest that the CARD domains, and therefore procaspase-9 molecules, reside in a central ring. Further, cytochrome c binds to Apaf-1 within clefts formed by a pair of β propellers at the end of the spoke-like helical domain of Apaf-1 with a 1:1 stoichiometry (see Figure 7.5).

Apaf-1 is a protein co-factor that is required for activation of

procaspase-9. Caspase-9 is an initiator caspase activated by procaspase aggregation that begins another caspase cascade activating downstream caspases-3, -6, and -7. Thus, caspase-9 is key to the intrinsic pathway.

? HOW DO WE KNOW THAT?

Electron microscopy (see Yu et al., 2005)

inverted; procaspase-9 was illustrated on the outside of the

wheel-like heptameric structure and cytochrome c was drawn

Yu et al. (2005) used electron cryomicroscopy and single-parti-at the center. This was a model put forth based on stoichiome-

cle methods to elucidate the structure of the human apopto-

try. Structural data were not available at the time. The update

some at 12.8 Å resolution. Based on the scientifi c evidence

presented in Figure 7.5 illustrates the progress made in under-

available at the time, the fi rst edition of this book included a

standing of the apoptosome.

diagram in which the structure of the apoptosome was shown

Other factors, such as inhibitors of apoptosis proteins (IAPs; eight mammalian IAPs have been identifi ed) and Smac (second mitochondria-derived activator)/DIABLO (both shown in gray, Figure 7.5) play a role in

modulating the process. The X-chromosome linked member, XIAP, is one member of the IAP family that directly binds to and inhibits the activity of caspase-3 and caspase-7, after they have been processed, by binding to their active site. XIAP also inhibits caspase-9, but does so by binding to monomeric caspase-9 and locking the active site in an aberrant conformation. A transcription factor called NFκB, a major player in infl ammation (see Chapter 10), is a potent inhibitor of apoptosis. It induces the transcription of IAPs.

7 . 1 M O L E C U L A R M E C H A N I S M S O F A P O P TO S I S 157

Smac/DIABLO, another regulator released from the mitochondria,

eliminates inhibition by IAPs. Smac/DIABLO competes with activated

caspase-9 for binding to XIAP. Both caspase-9 and Smac contain a similar tetrapeptide domain that binds to XIAP. Thus, opposing effects on caspase activity are regulated by conserved IAP-binding motifs in caspase-9

and Smac.

Self test Study Table 7.1. It is crucial to remember that Bcl-2 blocks apoptosis and this fact will help you to remember the role of the other Bcl-2 family members. Close this book and try to redraw Figure 7.5. Check your answer. Correct your work. Close the book once more and try again.

Cross-talk between extrinsic and intrinsic pathways

Note that there is cross-talk between the extrinsic and intrinsic pathways and the two converge at the activation of downstream caspases. For

example, caspase-8, a key regulator of the extrinsic pathway, can proteolytically cleave and activate Bid, a pro-apoptotic Bcl-2 family member (Figure 7.6). Bid can then stimulate the intrinsic pathway of apoptosis by directly activating Bax and Bak, facilitating the release of cytochrome c from the mitochondria, and inducing the subsequent activation of downstream caspases. In addition, Bid links the intrinsic pathway with the regulation of cell cycle progression in response to DNA damage. Recall from A LEADER IN THE FIELD . . . of apoptosis: In memory of Stanley

Korsmeyer

Stan Korsmeyer did pioneering work on the regulation of apoptosis, including the identifi -

cation of Bax, one of the fi rst pro-apoptotic members of the Bcl-2 family reported, and structural analysis of the Bcl-2 homology domains and how they allow for family member heterodimerization. He and his research group have helped to elucidate the molecular mechanisms of the Bcl-2 family and their role in cancer. The basic research carried out by Korsmeyer and his research group has created a foundation for the development of future cancer therapeutics.

Dr Korsmeyer was a Professor at Harvard Medical School and Director of the Program in Molecular Oncology at the Dana-Farber Cancer Institute. He received his BS degree in biology and a MD degree from the University of Illinois. He carried out a residency in medicine at the University of California, San Francisco and a post-doctoral tenure under Thomas Wald-mann and Philip Leder at the National Cancer Institute.

He was a member of the National Academy of Sciences and the Institute of Medicine.

Several awards for distinguished achievement in cancer research are among his honors.

Importantly, he was an excellent mentor of young scientists who are continuing his work today.

158

7 : A P O P TO S I S

Extrinsic pathway

Intrinsic pathway

Caspase 8

DNA damage

Bid

ATM

Bid

Bax

Bak

Bid

P

Figure 7.6 Bid links the intrinsic

MOMP

and extrinsic pathways of

Cell cycle arrest

apoptosis.

Apoptosis

Chapter 2 that ATM kinase is activated upon DNA damage. Recent data demonstrate that phosphorylation of Bid by ATM kinase is required for cell cycle arrest in response to DNA damage (Figure 7.6; Kamer et al. , 2005; Zinkel et al. , 2005).

p53 and apoptosis

As we saw in Chapter 6, the tumor suppressor protein p53 accomplishes its role as the guardian of the genome, in part, by inducing apoptosis in response to DNA damage and cellular stress. It does this by both transcription-dependent and transcription-independent means. As a transcription factor, p53 induces the expression of genes that code for death receptors and pro-apoptotic members of the Bcl-2 family (see Table 6.2).

Examples include Fas receptor, Bax, and Bak. These genes contain a consensus p53-binding site in their promoter regions. p53 can also repress the expression of anti-apoptotic factors, such as Bcl-2 and Bcl-x and IAPs.

Recent evidence demonstrates that a member of the Bcl-2 family called PUMA (p53 upregulated modulator of apoptosis), a target of p53, is essential for apoptosis induced by p53. Apoptosis induced by DNA-damaging drugs, irradiation, oncogenic activation, and cell stress was blocked in PUMA gene knock-out mice. p53 can exert transcription-independent regulation of apoptosis. This has been demonstrated by the induction of apoptosis with p53 mutants incapable of regulating transcription; these p53 mutants included one that lacked the DNA-binding domain, disabling interaction with p53 target genes, one without a nuclear localization signal preventing p53 from reaching the target genes in the nucleus, and one mutated in the p53 transactivation domain preventing the transcriptional activation function. It was also demonstrated that UV-induced apoptosis could be triggered by wild-type p53 strictly from the cytoplasm in

7 . 1 M O L E C U L A R M E C H A N I S M S O F A P O P TO S I S 159

cells that were treated with wheatgerm agglutinin, a nuclear import inhibitor. The mechanism of p53 transcription-independent apoptosis involves p53 activation of Bax in the cytoplasm and subsequent release of cytochrome c and caspase activation (Chipuk et al. , 2004). Evidence also supports the role of p53 in releasing pro-apoptotic proteins (e.g. Bid) from sequestration by anti-apoptotic proteins (e.g. Bcl-xL), altering the net functional balance of the Bcl-2 family of proteins. The protein PUMA has provided a link between the transcriptional and cytoplasmic functions of p53 (Chipuk et al. , 2005). Data suggest that p53 activates transcription of PUMA; PUMA protein then acts as an enabler to release p53 from Bcl-xL

in the cytoplasm so that p53 can directly activate Bax (Figure 7.7). In summary, p53 functions in both the nucleus and the cytoplasm by transcription-dependent and transcription-independent means and these

functions are linked by PUMA.

? HOW DO WE KNOW THAT?

Immunoprecipitation (see Chipuk et al., 2005)

Another experiment was designed to investigate the kinetics

of the formation of the p53–Bcl-x complex after treatment

Ultraviolet treatment of cells results in DNA damage and induc-

L

with UV. Bcl-x was immunoprecipitated at specifi c time points

tion of apoptosis. One question investigated by Chipuk et al.

L

after UV treatment and analyzed. The data show that the

(2005) was whether there are any regulators of the Bcl-x –p53

L

amount of p53 complexed with Bcl-x decreased over time

complex. They analyzed the extracts of cells that were treated

L

after UV treatment and this correlated with the induction of

with UV by a technique called immunoprecipitation. Here, an

apoptosis (see fi gure S2C in Chipuk et al. , 2005). What do the antibody against Bcl-x was used to isolate proteins complexed

L

asterisks above the fi fth band in the row labeled p53 repre-

to Bcl-x and these proteins were analyzed by SDS-polyacryla-

L

sent? Read the methods and see how they determined the time

mide gel electrophoresis and visualized by silver staining and

of induction of apoptosis.

also by western blot. Both p53 and PUMA were identifi ed (look

carefully at the data in fi gures 1 and S1A in Chipuk et al. , 2005).

p53

Puma

Nucleus

Cytoplasm

p53

Puma

Bcl-x

Figure 7.7 Transcription-

Bax

dependent and transcription-

independent functions of p53

Apoptosis

linked to PUMA.





160

7 : A P O P TO S I S

7.2 Apoptosis and cancer

Evasion of apoptosis is one of the hallmarks of cancer (Figure 1.1). Tumor cells produce many signals, such as those in response to DNA damage and oncogene activation, that normally induce apoptosis. Through tumor

suppression pathways, most cells that acquire carcinogenic characteristics are eliminated by apoptosis. However, tumor cells that acquire mutations that allow them to escape from the apoptotic response survive and proliferate. The avoidance of apoptosis permits further accumulation of mutations. This draws our attention to a difference that develops between tumor cells and normal cells (Figure 7.8): as tumor cells receive many apoptosis-inducing signals (such as oxidative stress and oncogene activation) compared with normal cells, tumor cells are “closer” to triggering an apoptotic response compared with normal cells. However, the apoptotic

pathway is often defective in tumor cells. This has stimulated the concept that repair of the apoptotic pathway in tumor cells by targeting p53 may be a valuable strategy for new cancer therapeutics (see Chapter 6).

Evidence suggests that there is a fundamental difference in the state of caspase activation between cancer cells and normal cells because of the stresses characteristic of cancer cells mentioned earlier: cancer cells contain activated caspases that are inhibited by upregulated IAPs but normal cells contain inactive procaspases that require proteolytic cleavage (Figure 7.8). Therefore, cancer cells are “closer” to triggering an apoptotic response compared with a normal cell. In support of this, processed caspase-3 has been identifi ed in tumor cells. Tumor cells share this characteristic with the normal Drosophilia apoptotic process, whereby activated caspases are inhibited by IAPs in normal cells and induction of apoptosis requires release from IAP inhibition. In summary: apoptotic Normal cell

Cancer cell

Oxidative stress

ASP

Oncogene activation

Pro caspaseX

Caspase

IAP

+

+

TRAIL

TRAIL

Figure 7.8 Differences in caspase

activation and response to TRAIL

in normal cells versus cancer cells.

Apoptosis

7 . 2 A P O P TO S I S A N D C A N C E R 161

signals stimulate procaspase processing in normal cells, while apoptotic signals stimulate the cessation of IAP inhibition of processed caspases in cancer cells.

TRAIL receptors

A subfamily of TNF receptors, called TRAIL receptors (TRAILR1 and

TRAILR2; also know as death receptor 4 and 5—DR4, DR5), has been

found to elicit a differential sensitivity to apoptosis between normal cells and cancer cells. Its ligand, TRAIL (TNF-related apoptosis-inducing

ligand), induces apoptosis in many cancer cells (regardless of the p53

gene profi le) but not in most normal cells (Figure 7.8). This subfamily signals apoptosis in a similar manner to TNF receptors recruiting adaptors (e.g. FADD) and an initiator caspase, caspase-8, to the membrane (see Figure 7.3). As TRAIL and its receptors are expressed in most organs, it is hypothesized that the addition or loss of regulatory molecules determines whether apoptosis will be induced in particular cell types.

The differences identifi ed between normal and tumor cells create an opportunity for designing drugs that target the apoptotic pathways and suggest that attempts to restore apoptotic activity will not affect normal cells. Such drugs are likely to have few side-effects. Before discussing apoptotic therapies, we will fi rst examine a sample of mutations in the apoptosis pathways that have been identifi ed in cancers.

Mutations that affect the extrinsic pathway

Mutations in death receptor genes, such as those encoding the Fas receptor and TRAIL receptor, occur in some cancers. Fas ligand and receptor are induced by UV light. Signaling through Fas receptors induces the development of sunburn in response to UV and is an important defense against skin cancers (Guzman et al. , 2003). Somatic mutations in Fas receptors have been reported in melanomas and squamous cell carcinomas.

Suppression of caspase gene expression in the development of particular cancers, such as small-cell lung carcinoma and neuroblastomas, has also been demonstrated. Remember that caspase-8 is the fi rst caspase activated by the death receptors (Figure 7.3) and it maintains a top position in the initiation of the caspase cascade. Loss of caspase-8 expression observed in cancers is a result of both epigenetic and mutational alterations; hypermethylation of the caspase-8 promoter, deletions, and missense mutations have been identifi ed. Caspase-8 defi ciency is particularly characteristic of neuroblastomas and small-cell lung cancer. Methylation of the caspase gene promoter was found to be the mechanism of loss of expression in a majority of cell lines examined. Also, a deletion of Leu62 was identifi ed in human vulval squamous carcinoma cells and this mutation blocks the

162

7 : A P O P TO S I S

interaction of caspase-8 with the adaptor FADD, thus abolishing its link with the death signal and receptor.

Mutations that affect regulators of the intrinsic pathway

Alterations of the intrinsic pathway of apoptosis are much more common than alterations in the extrinsic pathway during carcinogenesis. Mutations that bypass the transduction of apoptotic signals that are triggered by DNA damage, a dominant characteristic of cancer cells, are favored by natural selection. A major contribution to intrinsic pathway alterations occurs through mutations that affect the p53 pathway. Mutations in the p53 gene itself are the most frequently found mutations in cancer cells, and current estimations may be underestimated as many earlier studies restricted their analysis to exons 5–9 only, rather than the full length of the gene. The p53 mutations provide the cancer cells with a survival advantage by disrupting apoptosis. Abnormal methylation and loss of heterozygosity for p73, a p53 family member capable of inducing apoptosis, is frequent in lymphomas. Also, the p73 gene undergoes alternative splicing to generate several RNAs, including amino-terminally deleted variants which can act as inhibitors of p53. These variants are overexpressed in many cancers. In addition, mutations in genes involved in the upstream regulation of p53 (e.g. ATM and Chk2; see Chapter 6, Figure 6.6) and also in the downstream targets of p53 have also been identifi ed in human tumors. Mutations in molecular components that affect MDM2,

the major regulator of p53 activity, are common in tumors that maintain wild-type p53 alleles.

Bcl-2, the fi rst member of the Bcl-2 family of proteins to be discovered, was initially identifi ed from a chromosomal translocation, t(14;18) in B-cell lymphomas, hence the name bcl. In t(14;18), the Bcl-2 gene is translocated to a position juxtaposed to the immunoglobulin heavy chain enhancer. As a consequence of its relocation next to a strong promoter, oncogenic activation of the Bcl-2 gene occurs. Over-expression of the anti-apoptotic protein Bcl-2 leads to insuffi cient apoptotic turnover and accumulation of B-cells.

This translocation is not only found in most cases of follicular B-cell lymphomas but also in other types of cancer such as gastric, lung, and prostate.

Aberrant expression of most of the genes in the Bcl-2 family is linked to carcinogenesis. All anti-apoptotic members of the Bcl-2 family may function as oncogenes, and pro-apoptotic members act as tumor suppressor genes. Mutations in genes that code for pro-apoptotic proteins, such as deletions in the bak and bid genes, are characteristic of some tumors. Bax is mutated in over 50% of a specifi c class of colon tumors. Remember that p53 regulates many genes of the Bcl-2 family. Thus, many mutations in p53

that are common in tumors also affect the transcriptional regulation of its target genes, including those of the Bcl-2 family.

7 . 2 A P O P TO S I S A N D C A N C E R 163

Molecules involved in events downstream of the release of mitochon-

drial apoptotic factors also play a role in tumorigenesis. The gene encoding Apaf-1, the co-activator of caspase-9 upon its release from the mitochondria, is mutated and transcriptionally repressed in metastatic melanoma. Note that epigenetic inactivation, in addition to mutation, plays a role in the inactivation of the apoptotic pathway.

The induction of inhibitors of apoptosis also plays a role in carcinogenesis. XIAP is induced in many types of cancer, including leukemias, lung cancer, and prostate cancer. As XIAP acts to suppress caspase-9, -3, and

-7, it affects downstream caspases that are common to both the extrinsic and intrinsic pathways.

Alternative death pathways

The observation that many apoptotic stimuli do not require caspases has led to studies of alternative death pathways. In addition to necrosis, autophagy, and mitotic catastrophe are other non-apoptotic mechanisms of cell death. Autophagy (meaning “eating oneself”) acts as a recycling system for the cell whereby proteins and components of damaged organelles that require degradation are targeted to the lysosomes. Cells can recycle the resulting products of degradation. This process is important under starvation conditions and for ridding the cell of defective organelles. Targeted proteins and organelles are surrounded by a double membraned structure called an autophagosome. The contents of the

autophagosome are degraded upon fusion of these vesicles with lys-

osomes. Excessive autophagy triggers non-apoptotic cell death. Mitotic catastrophe, another type of cell death, is caused by aberrant mitosis.

Defects in genes (e.g. BECN1) required for these processes can contribute to tumorigenesis (see Activity).

The details of the molecular events involved in caspase-independent cell death are not known fully. However, it is known that they also utilize proteases and facilitate permeabilization of the mitochondrial outer membrane. Alternative proteases such as calpains, cathepsins, and serine proteases cleave target proteins to bring about morphological

changes characteristic of programmed cell death. Calpains, like caspases, are found as inactive zymogens in the cytoplasm. Cathepsins

become activated in lysosomes before being translocated into the cytoplasm and/or nucleus. Apoptosis-inducing factor (AIF) is one molecular player released from the mitochondrial intermembrane space that induces caspase-independent DNA degradation.

The abnormal expression of molecules involved in alternative death

pathways is observed in tumor cells. For example, mutations in genes that encode the tumor suppressor proteins, Bin1 and promyelocytic leukemia (PML) protein, which induce alternative death pathways are found in





164

7 : A P O P TO S I S

human cancers. Bin activates a caspase-independent pathway that is

blocked by a serine protease inhibitor. As more is learned about the molecular players of alternative death pathways, new potential drug targets will be uncovered. In fact, several drugs in clinical trials (e.g. EB1089/seocalci-tol, a vitamin D analog) induce calpain-dependent and caspase-independent cell death.

7.3 Apoptosis and chemotherapy

Disruption of the apoptotic pathway has important effects on the clinical outcome of chemotherapy. In order for chemotherapy to be successful, cells must be capable of undergoing apoptosis. Chemotherapeutic agents act primarily by inducing DNA damage. This damage consequently

triggers the intrinsic apoptotic pathway. Some types of chemotherapy induce particular cells of the immune system to produce TNF, thus triggering the extrinsic pathway. Drugs with varying structures indirectly elicit the same morphological changes typical of apoptosis. However, remember that one of the hallmarks of cancer cells is that they evade apoptosis. Many tumors have defective apoptotic pathways and are inherently resistant to chemotherapies, regardless of whether or not they have been previously exposed to the drugs. This type of resistance contrasts the classical acquired mechanisms that are associated with drug accumulation and drug stability, such as the use of the P-glycoprotein pump (Chapter 2). As resistance to chemotherapy is a major clinical problem, elucidating the role of apoptosis in drug responses is important for future therapeutic strategies.

Drug resistance can arise through mutations in genes that code for

molecular regulators of apoptosis. These mutations serve to uncouple drug-induced damage from the activation of apoptosis. As mentioned earlier, mutations in the p53 pathway are common in cancer cells and greatly contribute to the inherent drug resistance observed for many cancers. Cells engineered to have a p53 knock-out are resistant to drug-induced apoptosis. Yet, even some “gain-of-function” p53 mutations may confer resistance to specifi c chemotherapies. One p53 mutant induces the expression of the dUTPase gene and results in resistance to 5-fl uorouracil. Therefore, on one hand, both “loss-of-function” and some “gain-of-function” mutations can give rise to resistance. On the other hand one mutant p53 sensitizes some cells to taxanes.

The upregulation of the anti-apoptotic members of the Bcl-2 family and the downregulation of the pro-apoptotic members of the Bcl-2 family in tumors are associated with an increased resistance to chemotherapies. For example, loss of Bax, a pro-apoptotic protein, increases drug resistance in





7 . 4 A P O P TOT I C D R U G S 165

human colorectal cancer cells to the antimetabolite 5-fl uorouracil and nonsteroidal anti-infl ammatory drugs (NSAIDs) used as chemopreventative agents (Zhang et al. , 2000). Over-expression of Bcl-2 in metastatic tumors may contribute to the fact that they are notoriously chemoresistant.

Overall, these observations point to an important clinical implication: the genotype of a tumor, especially with respect to the p53 and Bcl-2 gene families, is an important factor that infl uences the effectiveness of therapy.

There is another important implication of treating cells that have non-functional apoptotic pathways with chemotherapy. The lack of an apoptotic effect in response to extensive DNA damage caused by these

genotoxic drugs provides an opportunity for the accumulation of mutations. Consequently, the risk of carcinogenesis increases. Indeed, therapy-related leukemia, whereby a new cancer arises after the administration of chemotherapy, is a clinical problem. Therapy-related leukemias have relatively short latency times. Specifi c cytogenetic aberrations are associated with different chemotherapeutic agents; chromosomal deletions of chromosome 5 and/or chromosome 7 are characteristic of alkylating drugs.

(For a recent case study see Griesinger et al. , 2004.)

Therapeutic strategies

7.4 Apoptotic drugs

The ability to trigger apoptosis in tumor cells is an important strategic design for cancer therapeutics. This is supported by the fact that many successful conventional chemotherapies work by triggering apoptosis, albeit indirectly. Using the knowledge of the molecular players in the apoptotic pathways enables us to design direct apoptotic inducers. Alternatively, endogenous inhibitors can be blocked. This approach crucially by-passes the need for a drug to be mutagenic and avoids therapy-related leukemias. In addition, the induction of apoptotic factors in normal cells PAUSE AND THINK

should have little effect on these cells as they are not poised to trigger apo-What molecules would you tar-

ptosis to the same degree as tumor cells (see Pause and Think).

get if asked to design an apop-

Next is a description of strategies targeted against caspases, the Bcl-2

totic drug?

family, and TRAIL.

Direct and indirect activation of caspases

Selective activation of caspases is the most obvious apoptotic target.

However, because they comprise a large family of over 13 members and

166

7 : A P O P TO S I S

are in every cell type, selectivity has been a problem thus far. Yet, screening for small-molecule caspase activators is in progress (e.g. Merck Frosst,

http://www.merckfrosst.ca/). Procaspase-3, the pro-enzyme of a key effector

caspase, is inhibited by an intramolecular interaction facilitated by three aspartate residues, called the “safety-catch.” Screens are being pursued for small molecules that are able to interfere with this intra molecular inhibitory conformation of procaspase-3. Time is needed to see whether caspases are successful cancer therapeutic targets.

However, the activation of caspases by indirect methods is promising.

As endogenous caspase inhibitor XIAP is over-expressed in many cancers it is a good molecular target for new cancer therapeutics. A synthetic chemical screen aimed at inhibiting XIAP activity identifi ed a class of polyphenylureas that directly relieves the inhibition of caspase-3 and caspase-7 but not caspase-9 (Schimmer et al. , 2004). This is feasible because one domain of XIAP directly blocks the active site of caspase-3 and caspase-7 while another distinct domain inhibits caspase-9. The small-

molecule inhibitors bind to the XIAP domain known to block the active site of caspase-3 and caspase-7, the downstream caspases. Furthermore, these compounds induced apoptosis in a range of tumor cell lines and showed anti-tumor activity in animal tumor models. Little toxicity was observed for normal cells. This was the fi rst demonstration that relief of caspase inhibition can induce tumor cell apoptosis. Interestingly, other XIAP inhibitors (e.g. Smac peptides) were less successful because of their selective relief of caspase-9 inhibition only, thereby leaving the downstream caspases 3 and 7 available for inhibition.

Regulation of the Bcl-2 family of proteins

The Bcl-2 family is another target for the design of apoptotic drugs (Kang and Reynolds, 2011). Three main strategies have been used and these are illustrated in Figure 7.9: (a) antisense RNA, (b) small molecules to inhibit protein function and protein–protein interactions of anti-apoptotic molecules, and (c) drugs that induce the activity of pro-apoptotic molecules. As Bcl-2 is over-expressed in a broad range of tumors, inhibition of its expression by antisense is one strategy that has been employed to create a new cancer drug. G-3139 (oblimersen sodium, Genasense™) is an 18-mer

modifi ed antisense oligonucleotide that is complementary to the fi rst six codons downstream of the translational start site on the Bcl-2 mRNA.

Upon hybridization, translation is inhibited and the mRNA is degraded.

This alters the balance of pro- and anti-apoptotic factors in favor of apoptosis. Currently, G-3139 is being tested in combination with chemotherapeutic drugs. Although in early clinical trials it failed to meet the primary survival endpoint in a phase III and was denied approval by the US Food and Drug Administration (Frantz, 2004), new long-term, follow-up data

7 . 4 A P O P TOT I C D R U G S 167

(a)

Bcl-2

mRNA

–mRNA

degraded

G-3139

–Translation

blocked

(b)

ABT-737

Inhibits anti-apoptotic

Bcl-2

activity

HDAC

(c)

Cytochrome C

Bid

Bax

Procaspase 9

Figure 7.9 Drug strategies that

SAHA

target the Bcl-2 family of

Bid

proteins. Therapeutic agents are

Mitochondria

Apoptosis

shown in red.

has led to an amended new drug application for G-3139 and it is currently under review by the US Food and Drug Administration.

Structural studies of Bcl-2 have revealed that a hydrophobic groove forms the binding site for the BH3 region of pro-apoptotic Bcl-2 family members. Small-molecule inhibitors that bind to Bcl-2/Bcl-xL and interfere with protein–protein interactions with pro-apoptotic molecules in order to induce apoptosis have been identifi ed (e.g. ABT-737, Abbott Laboratories). These small molecules inhibitors are also called BH3

mimetics as they mimic the action of BH3 proteins. ABT-737 and an oral version, ABT-263, targets Bcl-2, Bcl-XL and Bcl-w. The drug was developed by structure-based design using nuclear magnetic resonance-based screening and binds to the anti-apoptotic proteins with high affi nity.Two other small molecules, AT-101 (Ascenta) and GX15-070 (Gemin X) also bind anti-apoptotic Bcl-2 molecules. All three small molecules discussed here are in Phase I or II clinical trials.

Suberoylanilide hydroxamic acid (SAHA) works by an opposing

mechanism; instead of inhibiting an anti-apoptotic factor, it promotes the activity of a pro-apoptotic factor. SAHA is a HDAC inhibitor and therefore acts to induce the expression of epigenetically suppressed genes.

SAHA induces the expression of the pro-apoptotic proteins, such as Bid, which activates BAX. Bax translocates into the mitochondria and results in the release of apoptotic factors such as cytochrome c. SAHA (vorinostat) has received approval for treatment of non-Hodgkin’s lymphoma.

Targeting TRAIL and its receptor

The differential activity of TRAIL and its receptor in normal cells versus cancer cells suggests that they are good molecular targets for apoptotic

168

7 : A P O P TO S I S

therapies. Approximately 80% of cancer cell lines are sensitive to TRAIL

ligand and can be induced to undergo apoptosis. In addition, apoptosis induced via a death receptor is thought to be independent of p53 and so the many cancers with inactivated p53 mutations may still be vulnerable to such an approach (see Pause and Think).

The administration of recombinant human TRAIL ligand has exhibited

PAUSE AND THINK

promising anti-tumor activity in animal models and Phase I trials have What strategy would you use to

been initiated for the treatment of solid tumors (de Bruyn et al. , 2011).

induce apoptosis through acti-

Caution is being exercised because of the hepatic toxicity known to result vation of the TRAIL receptor?

from related Fas and TNF-α ligand administration and also because of one study that reported a TRAIL-induced apoptotic response in human hepatocytes in culture, even though toxicity was not observed in mice and non-human primates. The variability of the effects among different species reminds us that animal studies have limitations for predicting the toxicity of cancer therapies in humans. Also, the critical eye will notice upon reading of the literature that different structural forms of recombinant TRAIL were used in different studies because of variation in the preparation of the recombinant protein and thus may be a source of the different toxicities. TRAIL without extraneous amino acid residues showed no

toxicity in non-human primates (see references within Fesik, 2005). Further along is the testing of a TRAIL receptor agonistic monoclonal antibody that recognizes the receptor’s extracellular domain. Patients have been enrolled in Phase I and Phase II trials to evaluate drug pharmacology and toxicity (see references within Bremer et al. , 2006).

■ CHAPTER HIGHLIGHTS—REFRESH YOUR MEMORY

•

Apoptosis is an important tumor suppression mechanism.

•

Caspase activity is regulated differently in normal cells

•

Caspases, aspartate proteases, are the main molecular

and tumor cells: normal cells require procaspase process-

players during apoptosis.

ing while tumor cells require release of processed cas-

•

Apoptosis can be triggered by extracellular death signals

pases from IAPs.

or internal stimuli that act via an extrinsic and intrinsic

•

Alterations in the p53 and Bcl-2 related pathways play a

pathway, respectively.

major role during carcinogenesis.

•

TNF/TNFR and FAS/FASR signaling are paradigms of the

•

Chemotherapies act indirectly via DNA damage to induce

extrinsic pathway.

apoptosis.

•

The mitochondria store apoptotic molecules involved in

•

Tumors with defective apoptotic pathways are resistant to

the intrinsic pathway.

chemotherapies.

•

The Bcl-2 family regulates the permeability of the outer

•

Mutations in apoptotic proteins enable cancer cells to

mitochondrial membrane.

both survive and become drug resistant.

•

p53 induces apoptosis by both transcription-dependent

•

Treatment with chemotherapies can cause therapy-

and transcription-independent means.

related leukemia.

•

Evasion of apoptosis is a hallmark of cancer cells.

•

Apoptotic drugs aim to trigger apoptosis directly and do

•

A tumor cell is “closer” to eliciting an apoptotic response

not require genotoxic activity.

than a normal cell if the apoptotic pathway were to be

functional.

7 . 4 A P O P TOT I C D R U G S 169

■ ACTIVITY

1. Think about a therapeutic strategy that targets Smac/DIABLO and write a proposal for the development of such a drug (hint: begin with Martinez-Ruiz et al. (2008) Role of Smac/

DIABLO in cancer progression. J. Exp. Clinic. Cancer Res. 27: 48).

2. Beclin-1 is involved in the induction of autophagy in response to starvation. Studies of the gene encoding Beclin, BECN1, have demonstrated that impaired autophagy is linked to tumorigenesis. Critically discuss the experimental evidence that supports this link beginning with the following leads: White et al. (2011) Am. J. Cancer Res. ; Qu et al. (2003) J. Clin. Invest. 112: 1809; Yue et al. (2003). Proc. Natl. Acad. Sci. USA 100: 15077.

■ FURTHER READING

Adrian, C., Brumatti, G., and Martin, S.J. (2006) Apoptosomes: protease activation platforms to die from. Trends Biochem. Sci. 31: 243–247.

Constantinou, C., Papas, K.A., and Constantinou, A.I. (2009) Caspase-independent pathways of programmed cell death: the unraveling of new targets of cancer therapy? Curr. Cancer Drug Targets 9: 717–728.

Danial, N.N. and Korsmeyer, S.J. (2004) Cell death: critical control points. Cell 116: 205–219.

Er, E., Oliver, L., Cartron, P.-F., Juin, P., Manon, S., and Vallette, F.M. (2006) Mitochondria as the target of the pro-apoptotic protein Bax. Biochim. Biophys. Acta–

Bioenerget. 1757: 1301–1311.

Fesik, S.W. (2005) Promoting apoptosis as a strategy for cancer drug discovery. Nat.

Rev. Cancer 5: 876–885.

Fulda, S. and Debatin, K.M. (2006) Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25: 4798–4811.

Hu, W. and Kavanagh, J.J. (2003) Anticancer therapy targeting the apoptotic pathway.

Lancet Oncol. 4: 721–729.

Indran, I.R., Tufo, G., Pervaiz, S., and Brenner, C. (2011) Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochim. Biophys. Acta 1807: 735–745.

Johnstone, R.W., Ruefl i, A.A., and Lowe, S.W. (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153–164.

Kirkin, V., Joos, S., and Zornig, M. (2004) The role of Bcl-2 family members in tumorigenesis. Biochim. Biophys. Acta 164: 229–249.

Los, M., Burek, J.C., Stroh, C., Benedyk, K., Hug, H., and Mackiewicz, A. (2003) Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design. Drug Discov. Today 8: 67–77.

Okada, H. and Mak, T.W. (2004) Pathways of apoptotic and non-apoptotic death in tumor cells. Nat. Rev. Cancer 4: 592–603.

Ow, Y.P., Green, D.R., Hao, Z., and Mak, T.W. (2008) Cytochrome c: functions beyond respiration. Nat. Rev. Mol. Cell. Biol. 9: 532–542.

Shiozaki, E.N. and Shi, Y. (2004) Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. Trends Biochem. Sci. 39: 486–494.

170

7 : A P O P TO S I S

Vousden, K.H. and Lu, X. (2002) Live or let die: the cell’s response to p53. Nat. Rev.

Cancer 2: 594–604.

Walensky, L.D. and Gavathiotis, E. (2011) Bax unleashed: the biochemical transformation of an inactive cytosolic monomer into a toxic mitochondrial pore. Trends Biochem. Sci. 36: 642–52.

Wong, R.S.Y. (2011) Apoptosis in cancer: from pathogenesis to treatment. J. Exper.

Clin. Cancer Res. 30: 87.

Zhivotovsky, B. and Orrenius, S. (2003) Defects in the apoptotic machinery of cancer cells: role in drug resistance. Semin. Cancer. Biol. 13: 125–134.

■ WEB SITE

Screens for caspase activators: Merck Frosst http://www.merckfrosst.ca

■ SELECTED SPECIAL TOPICS

Bremer, E., van Dam, G., Kroesen, B.J., de Leij, L., and Helfrich, W. (2006) Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends Mol. Med. 12: 382–393.

Chipuk, J.E., Kuwana, T., Bouchier-Hayes, L., Droin, N.M., Newmeyer, D.D., Schuler, M., et al. (2004) Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303: 1010–1014.

Chipuk, J.E., Bouchier-Hayes, L., Kuwana, T., Newmeyer, D.D., and Green, D.R.

(2005) PUMA couples the nuclear and cytoplasmic proapoptotic function of p53.

Science 309: 1732–1735 (supporting online material: http://www.sciencemag.org/cgi/

content/full/309/5741/1732/DC1).

De Bruyn, M., Bremer, E., and Helfrich, W. (2011) Antibody-based fusion proteins to target death receptors in cancer. Cancer Lett. available online 6 January 2011.

Frantz, S. (2004) Lessons learnt from Genasense’s failure. Nat. Rev. Drug Discov. 3: 542–543.

Griesinger, F., Metz, M., Trumper, L., Schulz, T., and Haase, D. (2004) Secondary leukemia after cure for locally advanced NSCLC: alkylating type second leukemia after induction therapy with docetaxel and carboplatin for NSCLC IIIB. Lung Cancer 44: 261–265.

Guzman, E., Langowski, J.L., and Owen-Schaub, L. (2003) Mad dogs, English-man and apoptosis: the role of cell death in UV-induced skin cancer. Apoptosis 8: 315–325.

Kamer, I., Sarig, R., Zaltsman, Y., Niv, H., Oberkovitz, G., Regev, L., et al. (2005) Proapoptotic BID is an ATM effector in the DNA-damage response. Cell 122: 593–603.

Kang, M.H. and Reynolds, C.P. (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res. 15: 1126–1132.

7 . 4 A P O P TOT I C D R U G S 171

Reed, J.C. (2006) Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ. 13: 1378–

1386.

Schimmer, A.D., Welsh, K., Pinilla, C., Wang, Z., Krajewska, M., Bonneau, M.- J., et al. (2004) Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad anti-tumor activity. Cancer Cell 5: 25–35.

Yu, X., Achehan, D., Menetret, J.-F., Booth, C.R., Ludtke, S.J., Riedl, S., et al. (2005) A structure of the human apoptosome at 12.8 Å resolution provides insights into this cell death platform. Structure 13: 1725–1735.

Zhang, L., Yu, J., Park, B.H., Kinzler, K.W., and Vogelstein, B. (2000) Role of BAX in the apoptotic response to anticancer agents. Science 290: 989–992.

Zhivotovsky, B. and Orrenius, S. (2003) Defects in the apoptotic machinery of cancer cells: role in drug resistance. Semin. Cancer Biol. 13: 125–134.

Zinkel, S.S., Hurov, K.E., Ong, C., Abtahi, F.M., Gross, A., and Korsmeyer, S.J. (2005) A role for proapoptotic BID in the DNA-damage response. Cell 122: 579–591.

This page intentionally left blank





Chapter 8

Stem cells and differentiation

Introduction

As described in Chapter 1, the balance between cell growth, differentiation, and apoptosis affects the net number of cells in the body and aberrant regulation of these processes can give rise to tumors. In this chapter we will describe the characteristics of cells at different degrees of differentiation and discuss the relationship of these characteristics to those of cancer cells. We will also investigate the molecular mechanisms that underlie the regulation of differentiation and examine specifi c mutations in differentiation pathways that can lead to cancer. Lastly, new cancer therapeutics designed to target different aspects of differentiation pathways are presented. Let us begin with an overview of the process of differentiation during development and in the adult.

We seldom refl ect upon our own ontogeny, or individual development. The processes involved in the development of a complete person from a formless fertilized egg are almost magical. Hundreds of specialized cell types must form from the fertilized egg and its unspecialized progeny cells called embryonic stem cells that reside in the inner cell mass. The process whereby cells become specialized to perform a particular function is called differentiation and relies on the regulation of a particular subset of genes that defi ne a certain cell type. All cells in the body (except red blood cells and germ cells) contain a full complement of genes of the human genome but it is the expression of a subset of genes that makes one cell type different from another: for example, a brain cell expresses different genes from a liver cell. Lineage-specifi c transcription factors responsible for turning on cell type-specifi c genes, as well as epigenetic mechanisms, are important in this process. During our development, different cell types are organized into varying tissues by pattern formation; although the same cell types are present in an arm and a leg, the morphology, or form of the structures, differs. Regulated gene expression is also important for patterning during development.

In addition to embryonic stem cells, there are also stem cells in the adult that are involved in the regeneration of tissues during the lifetime of the individual. In fact, stem cells are believed to be present in all tissues. Some stem cells are continually active to replace cells as they mature and die off. For example, adult hematopoietic stem cells, stem cells that give rise to the blood, self-renew and differentiate to sustain the different types of blood cells over the lifetime of the individual. Other stem cells remain dormant until a physiological signal is received. Hair follicle stem cells respond to a wound. Breast stem cells strongly respond to pregnancy hormones and, to a lesser extent, to hormones





174 8: STEM CELLS AND DIFFERENTIATION

within the female monthly cycle. It has recently been demonstrated that hematopoietic PAUSE AND THINK

stem cells show differentiation plasticity—that is they can give rise to non-hematopoietic To remember the meaning of

cells (see Pause and Think).

plasticity remember that plastic

But perhaps this should not be too surprising. Recent cloning experiments have demon-is a material that is fl exible.

strated that a nucleus from a differentiated cell can be reprogrammed to direct the development of another individual. The cloning of Dolly the sheep from a mammary cell nucleus is a notable demonstration that the pattern of gene expression of a differentiated cell is not permanently fi xed.

The process of differentiation is fueled by a source of stem cells in both the embryo and the adult. Stem cells self-renew while at the same time giving rise to cells that are more committed to differentiate along a particular cell lineage. Withdrawal from the cell cycle is characteristic of differentiated cells. A block in differentiation results in a higher net number of cells and therefore is a mechanism for tumor formation in some cancers, such as leukemia. Also, even though all the cells from a particular tumor are of clonal origin (see Section 1.2), the tumor contains a mix of cells that have different genetic and physical characteristics. Restated in genetics terminology, a tumor is a mass of genotypically and phenotypically heterogeneous cells despite all the cells being of clonal origin. This heterogeneity may refl ect aberrant differentiation and development in addition to accumulation of different mutations. Indeed, the differentiation status of a tumor may be indicative of a patient’s prognosis. The most malignant tumors often show the smallest number of differentiation markers. Although tumors may exhibit features of differentiation (e.g. teeth in teratomas), the normal pattern formation of cells that underlies the morphology of a normal organ is abandoned. We will examine two features of differentiation pathways that have implications for carcinogenesis: fi rst, the characteristics of stem cells, which are the precursors of differentiated cells, and secondly, the role of lineage-specifi c transcription factors and epigenetics that act as master switches for sets of genes during the differentiation process.

8.1 Stem cells and cancer

Two defi ning features of stem cells are their ability to self-renew and their ability to give rise to committed progenitors of differentiated cell types of one or more cell lineages. Upon cell division, one daughter cell maintains the characteristics of a stem cell, including the ability to self-renew, and the other daughter cell shows characteristics of commitment towards differentiation (Figure 8.1). The feature of self-renewal is shared with tumor cells. This common feature has led to two proposals for the relevance of stem cell biology to carcinogenesis. The fi rst proposal is that self-renewal provides increased opportunities for carcinogenic changes to occur. The second proposal suggests that altered regulation of self-renewal directly underlies carcinogenesis. We will explore each of these next, where we will fi nd that the concepts from both proposals will intertwine. Note that

8 . 1 S T E M C E L L S A N D C A N C E R 175

Stem cell

Figure 8.1 Features of stem cells.

Stem cell

Stem cells have the ability to self-

renew and can also give rise to

daughter cells that show a

commitment towards

Differentiated cell

differentiation.

research into this topic is relatively in its infancy and these proposals require further investigation.

Self-renewal provides an extended window of time for mutation

Stem cells are long-lived targets for chance mutations compared with many differentiated cells that die within days or months. The accumulation of mutations necessary for carcinogenesis is more likely to occur in stem cells that self-renew over the lifetime of an individual rather than in mature cells that exit the cell cycle and/or undergo apoptosis after a brief period. This concept supports the proposal that tumors are likely to arise from stem cells. Because restricted progenitor cells self-renew for shorter periods of time they are less likely than stem cells to become oncogenic.

Let us look at the process of skin carcinogenesis. Skin is a tissue with a clearly defi ned hierarchical organization of differentiation. The differentiation pathway begins in the basal layers and leads to the formation of the dead, cornifi ed outer layer of the skin. Epithelial cells of the skin have a turnover rate of 60 days in humans. However, malignant transformation involving the accumulation of specifi c mutations takes 18 months or more, so the 60-day lifespan of a differentiating cell is not long enough to allow a suffi cient number of mutations to accumulate. Self-renewal is a quality of stem cells that allows for the accumulation of transforming mutations as an individual mutation may be passed on to daughter cells which are themselves susceptible to additional mutations and can pass on accumulated mutations to future progeny cells. This rationale suggests that the accumulation of mutations required for the initiation of skin cancer is likely to occur in the normal stem cell or early progenitor cell compartment.

176 8: STEM CELLS AND DIFFERENTIATION

Deregulation of self-renewal

Stem cells must maintain a balance between self-renewal and differentiation. One proposal for the relevance of stem cell biology to carcinogenesis is that the loss of this balance by stem cells can lead to unregulated self-renewal, a hallmark of cancer. Therefore, tumor cells may arise from stem cells. Alternatively, differentiated cells may acquire a mutation that reactivates a self-renewal program. This concept is supported by experiments that showed that minor, but specifi c, genetic alterations of differentiated cells can produce induced pluripotent cells (Takahashi et al. , 2007 and others). That is, differentiated cells can be modifi ed to create stem cell-like cells. Both of these proposals, that cancer can initiate either in a stem cell that has lost regulation of self-renewal or in a differentiated cell that has obtained the ability to self-renew, are supported by the identifi cation of cancer stem cells. These are rare cells within a tumor that have the ability to self-renew and to give rise to phenotypically diverse cancer cells. Some evidence suggests that cancer stem cells drive tumorigenesis.

It has been shown in several types of cancer that tumors are maintained in a growing cancerous state by only a small fraction of particular tumor cells. These cells have surface proteins called markers, which are characteristic of the stem cell normally present in the tissue. For example, it has been established that only about one in a million acute myeloid leukemia cells can develop into new leukemias when transferred in vivo and that these cells expressed the same markers (CD34+, CD38−) as normal hematopoietic stem cells. Also, brain cancer stem cells display normal neural stem cell markers. Interestingly, the proportion of brain cancer stem cells identifi ed in a variety of brain cancers correlates with the course of the disease, or prognosis. Fast-growing tumors such as glioblastomas had more brain cancer stem cells than slow-growing tumors like astrocytomas. Evidence for the existence of breast cancer stem cells was obtained by testing whether human breast cancer cells could give rise to new tumors when grown in immunocompromised mice (Al-Hajj, 2003). A minority subpopulation of breast cancer stem cells was isolated based on the expression of cell surface markers (CD44+, CD24−/low) and these cells showed a 10- to 50-fold increase in ability to form tumors in animals compared with the bulk of breast tumor cells. Furthermore, these cells were not only able to demonstrate the ability to self-renew but were also able to give rise to cells with different characteristics or phenotypes that made up the bulk of the tumor. These observations support the concept that these cells are breast cancer stem cells. Colon cancer stem cells and pancreatic cancer stem cells have also joined the list (O’Brien et al. , 2006; Ricci-Vitiani et al. , 2006; Chenwei et al. , 2007). Colon cancer stem cells, along with prostate and brain cancer stem cells, over-express the cell surface antigen CD133.

Pancreatic cancer stem cells and breast cancer stem cells both express

8 . 1 S T E M C E L L S A N D C A N C E R 177

CD44. More recently, there has been a debate over exact defi nitions of cancer stem cells and confl icting results in different mouse/human model systems. Rosen and Jordan (2009) suggest that this is to be expected in such “inherently unstable conditions as cancer.”

Mammary stem cells react to physiological cues, such as hormones, to provide a source of proliferation and differentiation during pregnancy for the creation of a milk-generating breast. A major factor that protects women from breast cancer is an early fi rst full-term pregnancy (Chapter 11). It is suggested that the depletion of stem cells as a result of the burst of differentiation that occurs during pregnancy is the reason why pregnancy is protective against breast cancer. There may be fewer breast stem cells that have the potential of becoming breast cancer stem cells over time in women who have had children in early adulthood.

In summary, a small minority of cancer stem cells may drive tumorigenesis in some cancers, similar to the small number of adult stem cells that drive the growth of normal tissues.

Molecular mechanisms of self-renewal

Let us examine the molecular mechanisms of self-renewal. The molecular mechanisms that regulate self-renewal of stem cells are beginning to be understood. There is evidence that the Wnt signaling pathway, which is important for regulating pattern formation during development, is

involved in the self-renewal process of stem cells during development in the adult, and also in cancer. When the Wnt-regulated transcription factor Tcf (see following section) is deleted in mice by gene knock-out procedures, the resulting phenotype is a lack of stem cells in the intestines. In addition, hematopoietic stem cells respond to Wnt signaling in vivo and require Wnt signaling for self-renewal (Reya et al. , 2003). Data from DNA arrays show that the gene expression pattern in response to Wnt signaling is similar between colon stem cells and colon cancer cells, but differs in differentiated colon cells, suggesting that Wnt signaling plays a role in stem (cancer) cell self-renewal. The Hedgehog signaling pathway, which is also important for regulating pattern formation in the embryo, has also been implicated in the process of stem cell self-renewal. Both the Wnt and Hedgehog signaling pathways will be discussed next.

The Wnt signaling pathway



Wnt proteins (of which there are more than 19 members) are secreted intercellular signaling molecules that act as a ligand to trigger a specifi c signal transduction pathway (Figure 8.2). It is easiest to examine the cell in the absence of Wnt ligand fi rst (Figure 8.2a). In this state, several proteins associate together in the cytoplasm to form a degradation complex.

178 8: STEM CELLS AND DIFFERENTIATION

(a) No Wnt

P

Axin

APC

u

LRP

CKI

Ubiquitin

GSK3

β-catenin

Tcf/

β

Lef

ligase

degradation

Groucho

P

Proteosomes

Frizzled

β-catenin

P

(b) Wnt

Pygopus

Bcl9

LRP

P Axin

APC

Tcf/

GSK3

β-catenin

Lef

CKI

β

Target genes

Frizzled

e.g. c-myc

cyclin D 1

Figure 8.2 The Wnt signaling

The degradation complex consists of axin, adenomatous polyposis coli pathway. See text for details.

(APC) protein, glycogen synthase kinase (GSK3β), and casein kinase I (P) and (u) mark events of

(CKI). Axin and APC form a structural scaffold for GSK3β and CKI

phosphorylation and

ubiquitination.

which are serine/threonine kinases. An important transcriptional co-activator, called β-catenin (Figure 8.2a, red triangular shape), is modifi ed by this complex via sequential phosphorylation by CKI and GSK3β.

β-catenin is further modifi ed by ubiquitination via newly recruited ubiquitin ligase. Ubiquitin acts as molecular fl ag that targets β-catenin for degradation by proteosomes. As β-catenin is not available to associate with PAUSE AND THINK

the Tcf/LEF (T-cell factor/lymphoid enhancing factor) family of transcription factors in unstimulated cells, target genes under the regulation of There are several molecular simi-

β-catenin–Tcf are repressed (shown by a red “x”). In the absence of larities and differences between

β-catenin, Tcf associates with the transcriptional repressor Groucho.

this signaling transduction path-

Upon binding of Wnt ligand to its seven-pass transmembrane receptor, way and the others previously

Frizzled, and co-receptor LRP (low-density lipoprotein receptor related described. What are they? Phos-protein), the cytoplasmic tail of LRP is phosphorylated and axin is phorylation is an important regulatory process in many signaling

recruited to the phosphorylated co-receptor LRP. This disrupts the assem-transduction pathways (e.g. bly of the degradation complex (Figure 8.2b). In addition, an inhibitor of EGF), but in the case of the Wnt

GSK3β, dishevelled protein, is activated via phosphorylation (not shown).

pathway, it recruits a ubiquitin

These events allow β-catenin to escape degradation and move into the ligase and is tied closely to pro-nucleus where it can act as a co-activator of the Tcf/LEF family of tran-tein degradation. Also, similar to

scription factors to regulate specifi c target genes (e.g. c-myc, cyclin D, and the transcription factor, E2f,

genes that code for adhesion molecules from the EPH family). Activation β-catenin is prevented from act-of target genes also depends on nuclear proteins Bcl9 (also known as leg-ing until a specifi

c signal is

less) and Pygopus (see Pause and Think).

received: phosphorylation of RB

is the signal in the case of E2F and

Wnt pathway activation is the

Self-test Close this book and try to redraw Figure 8.2. Check your answer. Correct your signal in the case of β-catenin.

work. Close the book once more and try again.

8 . 1 S T E M C E L L S A N D C A N C E R 179

Wnt signaling and cancer

Wnt1 was one of the fi rst proto-oncogenes discovered. Viral integration induced oncogene activation and subsequent cancer of the mammary

gland. Mutations that constitutively activate the Wnt signaling pathway have been identifi ed in several types of cancer.

Mutations that result in the constitutive activation of the Wnt pathway are responsible for 90% of colorectal cancer. This translates in human terms to 50,000 lives per year in the USA alone. Most of the mutations inactivate the function of APC or activate β-catenin, but rarely alter the ligand Wnt. Colorectal cancer can be classifi ed into two forms: familial forms and sporadic forms. Patients with the inherited cancer predisposition syndrome, familial adenomatous polyposis coli (FAP), carry a germline mutation in the APC gene and develop high numbers of polyps in the colon (polyposis) in early adulthood. As a result of having many polyps, PAUSE AND THINK

these patients have an increased risk of colorectal cancer. The APC gene What is the ultimate molecular

acts as a true tumor suppressor gene in that both copies of the APC gene consequence of having inactivat-are inactivated in colorectal tumors. Most mutations occur in the coding ing mutations in APC? Constitu-sequences for the central region of the APC protein (codons 1250–1500), tive activation of Tcf transcription

referred to as the mutation cluster region, in both germline and somatic factors.

cases (Figure 8.3) (see Pause and Think).

The small intestine/colon is a well-studied model system for examining the link between stem cells, the Wnt pathway, and cancer. Intestinal tissue is highly regenerative; stem cells and epithelial progenitors, also called transit-amplifying cells that reside in the crypts give rise to more differentiated cells that migrate up along the villi (see Plate 6a and Figure 8.4).

The stem cells renew over the lifespan of the individual, while progenitor cells have a limited self-renewal capacity (about four divisions). Upon reaching the top of the villi, fully differentiated cells undergo apoptosis.

The intestinal epithelium is renewed within a few days. Normally, Wnt signaling is required to maintain the stem cells and progenitors of the crypt. Lgr5, encoding a G protein-coupled receptor, is one target gene of the Wnt pathway that is restricted to the stem cells of the intestine. Colorectal cancer seems to follow a sequence of progression from benign polyps or adenoma (see Plate 6b) to carcinoma in situ, and fi nally invasive carcinoma. The sequence is paralleled by the accumulation of mutations.

The location of the initial event, the cell of origin of adenomas, induced by constitutively active Wnt signaling, has shown to be the stem cell of the Truncating mutations

β-catenin

Axin-

Mutation cluster

binding

binding

region

domains

domain

Figure 8.3 The mutation cluster

1

1250

1500

Codons

region of APC.

180 8: STEM CELLS AND DIFFERENTIATION

Apoptotic cells

Villi

Deletion of Apc in

transit-amplifying cells

No tumor

entiated cells

fer

Dif

Deletion of Apc in

stem cells

Tumor

Figure 8.4 Schematic

Transit-

representation of the cells of the

amplifying

cells

Paneth

intestinal crypts and villi. Tumors

Stem cells

cell

initiate from stem cells, and not

transit-amplifying cells.

Crypt

small intestine (Barker et al. , 2009). Barker and colleagues deleted the Apc gene in long-lived intestinal stem cells using genetically engineered mice that allow examination of oncogenes/tumor suppressor genes in different cellular compartments (see Activity, at the end of the chapter). Adenomas were induced within several weeks. They also showed that deletion of the Apc gene in progenitor transit-amplifying cells or differentiated cells does not trigger tumor formation (Figure 8.4). Therefore, their data supports the cancer stem cell concept that a small subset of cells is able to self-renew and maintain a tumor.

Mutations in the Wnt signaling cascade also promote other types of cancers. Activating mutations of β-catenin that affect the regulatory sequences essential for its targeted degradation can lead to skin tumors. Mutations in the axin gene are found in hepatocellular carcinoma. Many of the axin gene mutations lead to protein truncations that delete the axin–β-catenin binding sites. Therefore, these observations suggest that some transforming mutations may function to reactivate the self-renewal pathway. The cells carrying these mutations can be thought of as de novo stem cells, that is cells that have acquired stem cell characteristics as a result of mutation, and were not produced from self-renewal of other stem cells.

The Hedgehog signaling pathway

The Hedgehog (Hh) signaling pathway also plays important roles in

embryonic development, tissue self-renewal, and carcinogenesis. It is essential for pattern formation in many tissues, including the neural tube, skin, and gut. Similar to Wnt proteins, Hh proteins (three members: Sonic, Desert, and Indian) are secreted intercellular signaling molecules that act as a ligand to trigger a specifi c signal transduction pathway (Figure 8.5).

Two transmembrane proteins, Patched and Smoothened (related to

8 . 1 S T E M C E L L S A N D C A N C E R 181

(a)

No Hh

Smoothened

Sufu

PKA

Gli

Target genes

Patched

Microtubule

Nucleus

complex

(b)

Hh

PKA

Smoothened

Sufu

Gli

Patched

Gli

Target genes

Figure 8.5 The Hedgehog

signaling pathway. See text for

Nucleus

details.

Frizzled described earlier), are responsible for signal transduction by Hh.

In the absence of Hh (Figure 8.5a), Patch inhibits Smoothened and thus suppresses the pathway. Upon binding of Hh to Patched (Figure 8.5b), inhibition of Smoothened is relieved. The signal is transduced into the cell and causes a large protein complex to dissociate and release the zinc fi nger transcription factor Gli (shaded red) so that it can be translocated to the nucleus and regulate the expression of its target genes. Hh target genes include Gli, which amplifi es the initial Hh signal at the transcriptional level. Although Hh target genes may be cell-type specifi c, they may include: Cyclin Ds; Bcl2; VEGF, and Snail (the last two are important for angiogenesis and metastasis respectively—see Chapter 9). The signaling events downstream of Smoothened are not well defi ned in mammals but the suppressor of fused (Sufu) and protein kinase A (PKA) have been identifi ed as negative regulators that reside in the protein complex.

Self-test Close this book and try to redraw Figure 8.5. Check your answer. Correct your work. Close the book once more and try again.

A LEADER IN THE FIELD . . . of differentiation: Cliff Tabin

Cliff Tabin once told me that he never really wanted a science career that required only working at the bench; he preferred to formulate hypotheses about molecular developmental biology and to teach. He is now renowned worldwide for his discovery of the protein Sonic Hedgehog, and the many functional studies of this protein that have followed.

Drosophila larvae that carry mutations in a specifi c gene have a phenotype characterized by bristles. Hence, the name given to the protein product of that gene was hedgehog. The vertebrate homolog was named Sonic Hedgehog by the Tabin laboratory after the character from a British comic book. Coincidently their scientifi c paper describing the cloning of the ¼

182 8: STEM CELLS AND DIFFERENTIATION

¼ vertebrate gene came out in the same year as the US release of the Sega Sonic the Hedgehog video game. Scientists do have fun at play.

Cliff carried out his PhD in Robert Weinberg’s laboratory at MIT, Boston. His postdoctoral tenure was carried out at the Department of Biochemistry at Harvard University and the Department of Molecular Biology at Massachusetts General Hospital. Cliff is currently a Professor of Genetics at the Harvard Medical School in Boston.

Hedgehog signaling and cancer

Patched is defi ned as a tumor suppressor gene; patients with Gorlin’s syndrome carry a germline mutation in one copy of Patched and have a predisposition to develop skin, cerebellar, and muscle tumors (basal cell carcinoma (BCC), medulloblastomas, and rhabdomyosarcomas, respectively). Inactivating mutations in Patched and activating mutations of Smoothened were identifi ed in sporadic (opposed to familial) human BCC

tumors and Gli-1 expression was found in nearly all BCCs. In fact, all sporadic BCCs possess an activated Hh signaling pathway.

It has been suggested that as BCC are tumors that include hair follicle differentiation, they may originate from a source of stem cells that reside in a structure of the hair follicle, called the hair follicle bulge, which has acquired an aberrant Hh signaling pathway. These cancer

stem cells could self-renew and give rise to the differentiated hair follicle cells observed in BCC tumors. Similarly, it has been proposed that

medulloblastoma, the most common childhood malignant brain tumor,

arises from neuron precursors that possess an inappropriately activated Hh pathway. Activation of this pathway by mutation is observed in

30% of sporadic medulloblastomas. Molecular evidence of an activated Hh pathway was also reported for gliomas. Gli was originally identifi ed as an amplifi ed gene in cultured glioma cells. Unlike Wnt, where mutations involved in carcinogenesis rarely affect this ligand, Hh is overexpressed in upper gastrointestinal tumors. Pre-clinical studies also point to paracrine signaling such that secreted, tumor-derived Hh stimulates Gli expression in the tumor- associated stroma but not in the tumor itself. Stromal feedback to the tumor is suggested to promote tumor growth.

The role of Hh signaling has been extended to chronic myeloid leukemia (CML). Zhao et al. (2009) have demonstrated that loss of Smoothened inhibits hematopoietic stem cell renewal and decreases the induction PAUSE AND THINK

of CML by the oncogenic bcr-abl chromosomal translocation. They also show that inhibition of the Hh pathway inhibits the growth of Gleevec™-

Does Smoothened act as a tumor

resistant mouse and human CML. This has direct implications for a new suppressor gene or an oncogene?

It is an oncogene as acti

vating

approach to the development of drugs for Gleevec™-resistant cancers.

mutations have been isolated.

Taken together, it is apparent that the Hh signal pathway is relevant for several types of human cancer.

8 . 1 S T E M C E L L S A N D C A N C E R 183

Additional properties of stem cells and tumor cells

Cancer stem cells, in addition to being able to self-renew, also have the ability to give rise to more differentiated cell types with limited proliferative capacity. Teratocarcinoma is an obvious example whereby the tumor contains undifferentiated stem cells and non-proliferative differentiated cells such as bone and cartilage. Although the degree of differentiation for other cancers is less obvious, cancer stem cells from other cancers have been shown to generate more cells with different phenotypes. The cell heterogeneity present in a tumor may be derived from cancer stem cells that can not only self-renew but can simultaneously give rise to more differentiated cells. A striking demonstration has suggested that tumor cells can be reprogrammed to become normal and totipotent during experimental manipulation (like fully differentiated cells during cloning experiments). When placed in early mouse embryos, teratocarcinoma cells can mimic stem cells and can contribute to normal development. In addition, the degree of differentiation of a cell may also affect the outcome of oncogene activation. The use of selective gene promoters to drive the expression of a Ras oncogene in different cell populations with different degrees of differentiation (e.g. stem cells or committed progeny cells) resulted in PAUSE AND THINK

tumors with different malignant potential (i.e. malignant carcinomas versus benign papillomas). Although additional studies are needed, this sug-Do you think that the proportion

gests that the activation of an oncogene may be carcinogenic in some of cancer stem cells in different

states of differentiation and not in others within a particular cell lineage.

tumors can help explain differ-

Another feature of stem cells that is shared with tumor cells is the abil-ences in the ability of the tumor

to spread or metastasize? Yes,

ity to migrate to other tissues of the body. In contrast, most differentiated the success of metastasis may be

cells remain localized to a specifi c tissue. Transplantation of stem cells has based on the number of cancer

demonstrated the migratory nature of stem cells. For example, bone mar-stem cells in the primary tumor;

row stem cells migrate to several non-hematopoietic tissues such as the non-tumorigenic cancer cells

brain, liver, and lung. Metastasis of tumor cells from a primary site to may not have the ability to form

secondary sites is a characteristic that makes cancer lethal (details are dis-new tumors at distant sites.

cussed in Chapter 9).

It has been proposed that the origin of the transformed cell determines the potential for metastasis: tumors arising from a stem cell are more likely to metastasize than tumors arising from more differentiated cells which are less likely to spread. The inherent ability of a stem cell to migrate may cause these cells to be aggressively metastatic, if transformed.

The myeloid leukemias support this view: transformed stem cells are likely to be malignant while transformed committed progenitor cells are likely to be benign.

Moreover, telomerase activity (discussed in Chapter 3), which is necessary for tumor proliferation and progression and is present in 90% of human cancers, is present in normal stem cells and proliferative cells. This supports the hypothesis that cancer cells are derived from normal stem cells.





184 8: STEM CELLS AND DIFFERENTIATION

Summary

This discussion leads to the question of the nature of the cell that initiates carcinogenesis. It may be hypothesized that tumors arise from stem cells within a tissue or alternatively from more differentiated cells that acquire the stem cell quality of self-renewal. There is supporting evidence for both. Alternatively, a continuum of target cells relative to different states of differentiation may exist: stem cells, progenitor cells, and terminally differentiated cells may all be targets for transformation. Further, the stage of differentiation of the target cell may affect the malignant potential and severity of the cancer.

8.2 Differentiation and the regulation of transcription

We have thus far discussed one of the two defi ning properties of stem cells, that is their ability to self-renew. Next, let’s examine the ability of stem cells to generate differentiated progeny. The process of differentiation is dependent upon the expression of a specifi c subset of genes that defi nes a particular type of cell. Regulation of gene expression can include both inhibitory and inductive mechanisms. The polycomb group of protein repressors and hematopoietic lineage-specifi c transcription factors are two examples of important regulatory mechanisms involved in a stem cell’s ability to form differentiated progeny.

Polycomb proteins silence gene expression in stem cells and cancer The polycomb group (PcG) of proteins represses the transcription of specifi c sets of genes by epigenetic modifi cations (see Chapter 3). PcG proteins do not have the ability to bind to specifi c DNA motifs, but they are thought to be recruited to genes by transcription factors and/or long non-coding RNAs (e.g. HOTAIR) which can bind to genomic DNA in a

sequence-specifi c manner. As p53 has been nicknamed the “guardian of the genome,” the polycomb group proteins have been nicknamed the

“guardians of stemness.” This is because the target genes that they repress include a large number of developmental regulators that promote differentiation (Figure 8.6). Transcription factors, such as the homeobox proteins of the Dlx and Pax family and the Fox, Sox family that are crucial during development, are among the hundreds of target genes identifi ed by mapping of PcG proteins to human DNA. Thus, polycomb group proteins are implicated in stem cell maintenance. In addition, they also repress key tumor suppressor pathways. This can be seen by repression of the genetic locus INK4a/ CDKN2A that encodes the cdk inhibitor INK4a (p16), and

8 . 2 D I F F E R E N T I AT I O N A N D T H E R E G U L AT I O N O F T R A N S C R I P T I O N 185

Polycomb group (PcG) proteins

‘Guardian of stemness’

Genes that

Figure 8.6 Polycomb group

control

proteins repress the expression of

development

many developmental regulators

and transcription Hox

Fox

Pax

Pou

Sox

(only a sample is shown). The role

Tumor

suppressor

of PcG proteins in stem cell

Stem cell maintenance

genes

maintenance and in repressing

?

tumor suppressor genes suggests

Oncogenic

that they may have oncogenic

potential

potential.

ARF (p14), an inducer of p53, and suggests that the polycomb group proteins have oncogenic potential.

The mechanism of epigenetic regulation involves the formation of two PcG repressive complexes, PRC2 and PRC1. PRC2 consists of proteins EED, EZH1, EZH2, and SUZ12. This complex contains histone methyltransferase activity and targets lysine 27 (and lysine 9) of histone H3. The trimethylated histone H3 may serve as an anchor for PRC1. It is proposed that repression involves direct inhibition of the transcriptional machinery, recruitment of methyltransferases, and chromatin compaction.

Upon differentiation, there is de-repression of PcG target genes. Al though the mechanism for the de-repression is unknown, some evidence suggests that PcGs are removed from the promoter regions of their target genes and/

or a specifi c histone lysine demethylase is involved in reversing the epigenetic modifi cations initiated by the PcG proteins.

PcG proteins and cancer

The ability of polycomb group proteins to suppress the differentiation of stem cells implicates them in oncogenesis as abnormal regulation of differentiation can lead to cancer. In acute myeloid leukemia, most leukemic cells have a limited capacity for proliferation but are replenished by rare leukemic stem cells (see Section 8.1). Therefore, the ability of stem cells to self-renew is important in the maintenance of this disease.

A PcG protein repressor, Bmi-1, has been demonstrated to be essential for the control of self-renewal in hematopoietic stem cells and in leukemic stem cells (Lessard and Sauvageau, 2003). In vitro, leukemic stem cells that lack Bmi-1 show growth arrest in the G1 phase of the cell cycle and begin to differentiate. In vivo, mice with a Bmi-1 gene knock-out show a progressive depletion of all blood cells indicating the essential role of Bmi-1 in hematopoietic stem cells. In addition, in mouse models using leukemic stem cells lacking Bmi-1, smaller numbers of leukemic cells are detected in the peripheral blood compared with controls, indicating that these cancer stem cells have proliferative defects. This is an

186 8: STEM CELLS AND DIFFERENTIATION

example of how a common gene can regulate self-renewal in both nor-

mal and cancer stem cells. Bmi-1 normally exerts its effects partially by repressing the expression of two cdk inhibitors p16 and p14 via chromatin remodeling. The role of Bmi-1 as a human oncogene is supported by the identifi cation of Bmi-1 gene amplifi cation in some lymphomas.

Several other PcG proteins are linked to oncogenesis: SUZ12 is overexpressed in breast and colon cancers and EZH2 is over-expressed in lymphoma and breast and prostate tumors. This evidence supports the theory that cells with stem cell properties drive tumor formation and progression. PcG proteins may contribute to carcinogenesis by both the silencing of tumor-suppressing pathways and by inducing and maintaining the stem cell state (Figure 8.6).

Role of lineage-specifi c transcription factors in differentiation and cancer

The induction of lineage-specifi c gene transcription is dependent on lineage-specifi c transcription factors. Acute myeloid leukemia serves as an important paradigm for examining how disruption of the function of a transcription factor can interfere with differentiation and lead to cancer.

Acute myeloid leukemia (AML) is a disease characterized by a block in the differentiation of the granulocyte or monocyte lineage (Figure 8.7).

There are several subtypes of acute myeloid leukemia. The classifi cation system of this disease is still evolving but should eventually refl ect molecular features at the point of the differentiation block. The lineage is organized as a hierarchy that begins with pluripotent hematopoietic stem cells (HSCs). These cells self-renew and form progenitor cells. The Lymphoid pathway

Pro-T

Pre-T

T cell

Pro-B

Pre-B

Pu.1

B Cell

CLPs

AML1

GMPs

Pu.1

Figure 8.7 Hematopoietic

HSCs

Monocyte

lineages: disruption in the

granulocyte or monocyte lineage

C/EBPα

(shown in red) leads to AML.

Granulocyte

Pu.1

From Tenen, D.G. (2003)

Disruption of differentiation in

CMPs

human cancer: AML shows the

Megakaryocyte

way. Nat. Rev. Cancer 3: 89–101.

Myeloid pathway

Copyright 2003, with permission

Erythrocyte

from D.G. Tenen.

MEPs

8 . 2 D I F F E R E N T I AT I O N A N D T H E R E G U L AT I O N O F T R A N S C R I P T I O N 187

progenitor cells differentiate into several types of precursor cells, including myeloid precursor cells. Myeloid precursor cells are common to both the monocyte and granulocyte lineages. Several transcription factors have been identifi ed to be important in the development of hematopoietic lineages. One factor, AML1, is involved in almost all lineages. Others are lineage-specifi c factors (differentiation factors), such as PU.1 and CCAAT/enhancer-binding protein α (C/EBPα). Lineage-specifi c transcription factors activate a particular set of lineage-specifi c genes and/or inhibit the cell cycle for terminally differentiated cells. Focus on the myeloid pathway. PU.1 is involved in the differentiation of the common myeloid progenitor (CMP) cell and, later on, in the differentiation of monocytes/macrophages. Most myeloid-specifi c genes have PU.1 sites in their promoters. C/EBPα, a zinc fi nger transcription factor, functions in the differentiation of granulocytes.

Many mutations that are typically found in acute myeloid leukemia

affect specifi c transcription factors; both chromosomal translocations (e.g. t(8;21)) and coding region mutations are common. The gene for the AML1 transcription factor is disrupted in the t(8;21) translocation and this translocation leads to acute myeloid leukemia. The chromosomal translocation t(8;21) is identifi ed in both hematopoietic stem cells and more differentiated cells in patients, thus providing additional evidence that the transforming mutations of acute myeloid leukemia occur in

hematopoietic stem cells.

Mutations in lineage-specifi c transcription factors are found in patients with acute myeloid leukemia subtypes that are consistent with their role in normal hematopoiesis. PU.1 mutations are found in the earliest stage (M0: very immature leukemia) and in monocytic leukemias refl ecting PU.1′s early role in myeloid precursor cells and in the development of monocytes/

macrophages. Approximately 10% of patients with acute myeloid leukemia carry a mutation in c/EBPα, and most of these cases are associated with the granulocytic subtype refl ecting the role of c/EBPα in granulocyte differentiation. Thus, mutation of transcription factors involved in differentiation is an important mechanism behind oncogenesis.

Acute promyelocytic leukemia, a subtype of acute myeloid leukemia,

is most often characterized by the chromosomal translocation t(15;17), that results in the fusion of the PML gene with the retinoic acid receptor alpha (RARα) gene to create a hybrid protein, PML–RAR, with altered functions. As described in Chapter 3, RARs (α, β, and γ) are members of

the steroid hormone receptor superfamily and act as ligand-dependent transcription factors that are important effectors of the essential role of retinoic acid in cell differentiation. The wild-type receptors bind to the retinoic acid response element in target genes as RAR–RXR heterodimers. In the absence of retinoic acid (RA), the receptors associate with HDAC–co-repressor complexes that silence target genes by histone

188 8: STEM CELLS AND DIFFERENTIATION

HDAC

(a) No RA

RXR

RAR

target genes

(b) Physiological [RA]

Co-activator

RXR

RAR

target genes

(c) Physiological [RA]

PML-RAR

HDAC

PML-RAR

target genes

(d) Pharmacological [RA]

Co-activator

Figure 8.8 The activity of the

RAR and the PML–RAR fusion

protein in varying conditions of

PML-RAR

PMLRAR

retinoic acid concentration.

Expression of target genes leads

to differentiation.

target genes

deacetylation and subsequent chromatin compaction (Figure 8.8a).

Upon binding of RA, the receptor undergoes a change in shape that

causes the receptor to dissociate from the HDAC–co-repressor complex and allows the receptor to interact with co-activators in order to transcriptionally induce its target genes and promote differentiation (Figure 8.8b). Co-activators recruit HATs and also mediate interactions with the basal transcriptional machinery. The oncogenic fusion protein

(shown in red) maintains both the DNA-binding domain and the ligand-binding domain of the RARα receptor. It has a higher affi nity for HDAC

and does not dissociate in the presence of physiological concentrations of RA (Figure 8.8c). In addition, the ability of the fusion protein to form homodimers is essential for the development of the disease, suggesting that they act in a dominant negative manner by blocking wild-type

RAR–RXR heterodimers or by recruiting novel co-repressors. The nor-

mal role of the PML protein may also be disrupted in the fusion protein.

PML protein is normally found in nuclear organelles called nuclear bodies and, as a co-activator of p53, acts as a pro-apoptotic protein. Thus, although altered gene expression of retinoic acid target genes is most likely the predominant mechanism of the oncogenic effect of PML–

RAR, additional possibilities, such as affecting PML function, exist (Salomoni and Pandolfi , 2002).





8 . 2 D I F F E R E N T I AT I O N A N D T H E R E G U L AT I O N O F T R A N S C R I P T I O N 189

Therapeutic strategies

The concept of cancer stem cells has important implications for the design PAUSE AND THINK

and testing of new cancer drugs. First, as cancer stem cells support the growth and migration of the tumor, drugs need to target this small subset Consider the possible side-effects

of cells within the tumor. Many existing conventional drugs give hopeful of drugs that target cancer stem

initial responses that are followed by disappointing latter reoccurrences.

cells. Such drugs may destroy

normal stem cells. Depend ing on

Drugs targeted at cancer stem cells may prevent reoccurrence and actually the tissue, this may or may not

cure metastatic cancer.

be acceptable. For example, the

The best scenario would be to fi nd a drug that would target cancer stem loss of breast stem cells may

cells without affecting normal stem cells of the same tissue. In fact, there is be acceptable for most patients

evidence that suggests this may be possible (Yilmaz et al. , 2006). It has as breast cancer usually strikes

been demonstrated in mice that deletion of PTEN (a tumor suppressor after child-bearing years and the

phosphatase protein) resulted in leukemia-initiating cells that could trans-breast is not a vital organ. How-

fer disease upon transplantation to irradiated mice but also caused initial ever, destruc

tion of skin stem

proliferation and later depletion of normal hematopoietic stem cells.

cells would result in serious

Thus, a distinction was made between the cancer stem cells and normal problems as the skin would be

stem cells of the hematopoietic system: PTEN deletion promotes the gen-unable to self-renew.

eration of leukemia-initiating cells but the depletion of normal stem cells.

A drug that is able to reverse the downstream effects of PTEN deletion would lead to a depletion of leukemia-initiating cells and prevent the depletion of normal stem cells.

The effi cacy of such new drugs should be determined by their effect on the cancer stem cell population and not on overall tumor regression.

Drugs may be successful at killing all of the cells of a tumor except cancer stem cells, so that measuring tumor regression would not refl ect the fact that the most dangerous tumor cell types remained unaffected.

Differences in drug resistance between cancer stem cells and other

tumor cells is a possible explanation for such a scenario. Stem cells express high levels of ATP-binding cassette (ABC) transporters (e.g.

P-glycoprotein), members of the multi-drug-resistance gene family (see Chapter 2). The ability of the ABC transporters in stem cells to inhibit the accumulation of the fl uorescent dyes Hoechst 33342 and rhoda-mine 123 provides a means of helping to sort stem cells. The populations of tumor cells that do not accumulate these dyes are referred to as

“side-population” cells. Stem cells are predominantly found in this population. This is a property that protects these long-living cells from foreign toxins and is not usually maintained upon differentiation.

A side-population of cells with high effl ux capacity has also been identifi ed in tumor cells. This suggests that cancer stem cells have inherent drug resistance and may be an alternative mechanism to the acquired drug resistance discussed in Chapter 2. Therefore, therapeutic strategies





190 8: STEM CELLS AND DIFFERENTIATION

involving the administration of ABC inhibitors along with chemotherapies are being investigated.

The rarity of cancer stem cells in tumor cell populations and the diffi culty of propagating them in culture made it diffi cult to use high-throughput screening approaches to search for new drugs. However,

the knowledge that stem-like cells can be produced by induction of the epithelial–mesenchymal transition (see Chapter 9) in epithelial cells has provided a new resource that can be used for high-throughput screening for cancer stem cell-specifi c drugs. Gupta et al. (2009), report the success of such an approach.

Next are several examples of drug strategies that target self-renewal or differentiation pathways.

8.3 Inhibitors of the Wnt pathway

The importance of the Wnt pathway in several cancers, particularly colo-PAUSE AND THINK

rectal cancer, suggests that the molecular components of this pathway are What molecules would you tar-good targets for new therapeutics (see Pause and Think).

get in this pathway?

Disruption of the protein–protein interaction between β-catenin and the Tcf transcription factors (Figure 8.9) is one strategy that has been investigated (Lepourcelet et al. , 2004). This interaction occurs downstream of the APC degradation complex and is the endpoint effect of Wnt signaling. Drugs acting at this stage would counter both inactivating mutations in APC, axin, and GSK3β, and activating mutations in

β-catenin that cause inappropriate formation of β-catenin–Tcf com-

plexes. The observation that Tcf inhibition induces the differentiation of colorectal cancer cells into epithelial villi is evidence that supports this approach. From a high-throughput screen Lepourcelet et al. (2004) β-catenin

Self-renewal

Tcf

β-catenin

Differentiation

Figure 8.9 Drug strategy to inhibit

Tcf

the β-catenin–Tcf interaction.





8 . 4 I N H I B I TO R S O F T H E H h PAT H WAY 191

identifi ed three natural compounds that acted as inhibitors of the β-catenin–Tcf interaction. Also, these compounds that share a core

chemical structure inhibited the expression of two Tcf target genes and inhibited proliferation of colorectal cancer cells. Although in its early stages, this strategy holds promise for the development of new cancer therapeutics. As these drugs target a molecular pathway that is important in self-renewal, they have a greater chance of tumor eradication rather than just tumor regression.

8.4 Inhibitors of the Hh pathway

Inhibitors of the Hh signaling pathway are being investigated as cancer therapeutics (Figure 8.10). The fi rst Hh pathway inhibitor, cyclopamine, a steroidal alkaloid, was isolated from wild corn lilies. (Its name comes from the cyclopic effects—formation of a single eye—observed

from its action as a teratogen. Pregnant sheep that ingested high quantities of wild corn lilies gave birth to cyclopic lambs. There are obvious implications for treating women of child-bearing age with this teratogen.) Cyclopamine suppresses the Hh pathway by inhibiting the activity of the transmembrane protein, Smoothened. As a result of the

inhibition of Smoothened, transcription of target genes is repressed. In medulloblastoma cell lines (see “How do we know that?” box), cyclopamine treatment blocked the growth of medulloblastoma cells and

affected the regulation of genes involved in differentiation (Berman et al. , 2002). Expression of a neuronal stem cell marker, neurofi lament nestin, was decreased while expression of a marker of neuronal differentiation, Neuro D, was increased. Although promising pre-clinical

results were demonstrated, cyclopamine does not possess appropriate GDC-0449

LDE225

BMS-833923

IPI-926

PF 04449913

LEQ506

TAK-441

Smoothened

Figure 8.10 Inhibitors of

Hh

smoothened in clinical trials.

Patched

Target genes

Inhibition of Smoothened

represses the expression of target

genes. Information obtained by

ClinicalTrials.gov.





192 8: STEM CELLS AND DIFFERENTIATION

? HOW DO WE KNOW THAT?

Pre-clinical testing of anti-tumor activity

study, growth inhibition by cyclopamine was examined in allo-

grafts of these tumors and cell lines originating from the allo-Examine the method of investigation used in the Berman et al.

grafts. Allografts involve the transplantation of tissue from one

(2002) study and in the Romer et al. (2004) study discussed ear-individual to another. In this case, tumor cells from the medullo-

lier and compare the two.

blastomas were taken from the transgenic mice and transplanted

In the studies by both Berman et al. (2002) and Romer et al.

subcutaneously in nude mice. In Romer’s study, the effect on

(2004), a transgenic mouse model that mimicked the molecular

tumor growth by a small-molecule inhibitor, HhAntag-691 (a

defect of human tumors was created. The mice were heterozy-

benzimidazole derivative), that can enter the brain, was exam-

gous for the Ptc1 gene and null for the p53 gene. These mice have ined in vivo.

a 100% incidence of developing medulloblastoma. In Berman’s

PAUSE AND THINK

drug characteristics (e.g. poor bioavailability, suboptimal pharmaco-kinetics). Later, small-molecule inhibitors were identifi ed, some with a The choice of experimental

model for developing an anti-

100-fold increase in potency compared to cyclopamine.

cancer drug is vital for predict-

A small-molecule inhibitor of Smoothened, HhAntag-691, has shown

ing the outcome in patients.

promise in a transgenic mouse model (Romer et al. , 2004). Treatment Which do you suppose pro-resulted in the reduction of expression of several genes associated with the duces the strongest evidence for

Shh pathway, a decrease in tumor growth, and an increase in apoptosis.

proceeding to clinical trials?

Genentech and collaborators are involved in the development of small-Ex vivo analysis (xenografts,

molecule antagonists and Hedgehog-blocking antibodies as means of

allografts) remove the tumor

inhibiting the Hh pathway for new cancer treatments. One of these drug from its normal environment

candidates has been tested in clinical trials. An orally active small-and cell culture lines may not

molecule inhibitor of smoothened called GDC-0449 (vismodegib) showed truly represent the disease in

anti-tumor activity in patients with advanced basal-cell carcinoma in a humans. Romer’s study exam-Phase 1 clinical trial (Von Hoff et al. , 2009). Several other Smoothened ines the effects of a drug on a

tumor located in its normal ana-

inhibitors (Figure 8.10) are being tested in over 40 clinical trials (Ng and tomical location.

Curran, 2011). Some groups are attempting to develop drugs that target Gli but, as yet, there are none in clinical trials.

8.5 Leukemia and differentiation therapies

Differentiation therapy aims to promote the maturation and differentiation of cells such that a malignant phenotype changes into a benign phenotype. The mechanisms may include the induction of growth arrest and apoptosis via gene regulation. The use of differentiation therapy for the treatment of acute promyelocytic leukemia (APL), a subtype of AML, has been one of the great success stories of the last few decades. Retinoid treatment, using all-trans retinoic acid (ATRA), has transformed a deadly leukemia into one of the most treatable forms of cancer. Retinoid therapy along with chemotherapy results in complete remission with 80%

8 . 5 L E U K E M I A A N D D I F F E R E N T I AT I O N T H E R A P I E S 193

survival at 5 years. Note that treatment with retinoic acid alone causes retinoic acid syndrome in 10–15% of patients but administration with chemotherapy reduces this side-effect. The high concentration of retinoids administered “push” RA binding to the ligand-binding domain of the RARα–PML fusion protein (Figure 8.8d). This results in a conformational change that induces the exchange of the HDAC–co-repressor complex for a co-activating complex. Consequently, the target genes of RARα

are expressed and the block of differentiation is overcome. The gene encoding the differentiation specifi c transcription factor C/EBP is one of the targets of retinoid treatment. Another strategy for developing a new therapy may be to inhibit homodimerization of the fusion proteins, an idea that is supported by the work of Kwok et al. (2006).

■ CHAPTER HIGHLIGHTS—REFRESH YOUR MEMORY

•

Stem cells provide a source of cells for differentiation.

•

A germline mutation in the Patched gene causes Gorlin’s

•

Stem cells are characterized by their ability to self-

syndrome.

renew and to form more differentiated progeny,

•

Both stem cells and malignant tumor cells migrate to

simultaneously.

other tissues in the body.

•

Self-renewal is a characteristic that is shared with tumor

•

The degree of differentiation of the transformed founder

cells.

cell may determine metastatic potential.

•

Stem cells are more likely to accumulate mutations com-

•

Cancer may originate from stem cells or may involve reac-

pared with other cells.

tivation of the self-renewal process.

•

Cancer stem cells are rare cells within tumors that self-

•

The polycomb group of proteins are nicknamed the

renew and drive tumorigenesis.

“guardians of stemness.”

•

Evidence suggests that the Wnt signaling pathway is

•

Polycomb group proteins act as epigenetic gene silencers

involved in self-renewal.

and maintain the stem cell state.

•

The transcriptional co-activator, β-catenin, is stabilized in

•

AML is an important paradigm for the role of

the presence of Wnt.

differentiation in cancer.

•

Mutations that inappropriately activate the Wnt signaling

•

Lineage-specifi c transcription factors are commonly

pathway promote carcinogenesis, particularly colon

mutated in AML.

cancer.

•

Drugs that target the self-renewal pathways of cancer

•

A germline mutation in the APC gene causes familial ade-

stem cells are more likely to achieve a cure.

nomatous polyposis coli.

•

Interference with both the Wnt and Hh signaling

•

The Hedgehog (Hh) signaling pathway is also implicated

pathways is a recent therapeutic strategy that is being

in self-renewal.

explored.

•

Hh signaling exerts its effects via the Gli zinc fi nger

•

Retinoid therapy is successful as a differentiation therapy

transcription factors.

for APL.

•

Inappropriate activation of the Hh pathway is linked

to many cancers.

■ ACTIVITY

1. Stem cells of the intestinal crypt have been identifi ed as the cells-of-origin for cancer of the intestine (Barker et al. , 2009).They used a genetically engineered inducible cre mouse in vivo system to examine Apc deletions in different cell compartments of the intestine.

194 8: STEM CELLS AND DIFFERENTIATION

Learn and describe the details of the cre-mouse system (start with the website: http://cre.

jax.org/introduction.html). Draw a diagram to summarize your fi ndings. Refer back to the paper by Barker et al. , 2009 and try to understand their experimental approach.

■ FURTHER READING

Bracken, A.P. and Helin, K. (2009) Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat. Rev. Cancer 9: 773–784.

Dean, M., Fojo, T., and Bates, S. (2005) Tumour stem cells and drug resistance. Nat.

Rev. Cancer 5: 275–284.

Freemantle, S.J., Spinella, M.J., and Dmitrovsky, E. (2003) Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 22: 7305–7315.

Giles, R.H., van Es, J.H., and Clevers, H. (2003) Caught up in a Wnt storm: Wnt signaling in cancer. Biochem. Biophys. Acta 1653: 1–24.

Lee, T., Jenner, R., Boyer, L., Guenther, M., Levine, S., Kumar, R., et al. (2006) Control of developmental regulators by polycomb in human embryonic stem cells. Cell 125: 301–313.

Owens, D.M. and Watt, F.M. (2003) Contribution of stem cells and differentiated cells to epidermal tumors. Nat. Rev. Cancer 3: 444–451.

Pardal, R., Clarke, M.F., and Morrison, S.J. (2003) Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer 3: 895–902.

Perez-Losada, J. and Balmain, A. (2002) Stem-cell hierarchy in skin cancer. Nature Rev. Cancer 3: 434–443.

Radtke, F. and Clevers, H. (2005) Self-renewal and cancer of the gut: two sides of a coin. Science 307: 1904–1909.

Reya, T. and Clevers, H. (2005) Wnt signaling in stem cells and cancer. Nature 434: 843–850.

Reya, T., Morrison, S.J., Clarke, M.F., and Weissman, I.L. (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105–111.

Scales, S.J. and de Sauvage, F.J. (2009) Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharm. Sci. 30: 303–312.

Smalley, M. and Ashworth, A. (2003) Stem cells and breast cancer: a fi eld in transit.

Nat. Rev. Cancer 3: 832–844.

Sparmann, A. and van Lohuizen, M. (2006) Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 6: 846–856.

Tenen, D.G. (2003) Disruption of differentiation in human cancer: AML shows the way. Nat. Rev. Cancer 3: 89–101.

Vescovi, A.L., Galli, R., and Reynolds, B.A. (2006) Brain tumor stem cells. Nat. Rev.

Cancer 6: 425–436.

Vries, R.G.J., Huch, M., and Clevers, H. (2010) Stem cells and cancer of the stomach and intestine. Mol. Oncol. 4: 373–384.

Werner, E. (2011) Cancer Networks: A general theoretical and computational framework for understanding cancer. http://asxiv.org/abs/1110.5865: 1–121.

■ WEB SITE

Wnt homepage http://www.stanford.edu/group/nusselab/cgi-bin/wnt/

8 . 5 L E U K E M I A A N D D I F F E R E N T I AT I O N T H E R A P I E S 195

■ SELECTED SPECIAL TOPICS

Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., and Clarke, M.F.

(2003) Prospective identifi cation of tumorigenic breast cancer cells. Proc. Natl.

Acad. Sci. USA 100: 3983–3988.

Barker, N., Ridgway, R.A., van Es, J.H., van de Wetering, M., Begthel, H., van den Born, M., et al. (2009). Crypt stem cells as the cells-of-origin of intestinal cancer.

Nature 457: 608–611.

Berman, D.M., Karhadkar, S.S., Hallahan, A.R., Pritchard, J.I., Eberhart, C.G., Wat-kins, D.N., et al. (2002) Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297: 1559–1561.

Chenwei, L., Heidt, D.G., Dalerba, P., Burant, C.F., Zhang, L., Adsay, V., et al.

(2007) Identifi cation of pancreatic cancer stem cells. Cancer Res. 67: 1030–1037.

Gupta, P.B., Onder, T.T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R.A., et al.

(2009) Identifi cation of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138: 645–659.

Kwok, C., Zeisig, B.B., and So, C.W. (2006) Forced homo-oligomerization of RARalpha leads to transformation of primary hematopoietic cells. Cancer Cell 9: 73–74.

Lepourcelet, M., Chen, Y.-N.P., France, D.S., Wang, H., Crews, P., Petersen, F., et al.

(2004) Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 5: 91–102.

Lessard, J. and Sauvageau, G. (2003) Bmi-1 determines the proliferative capacity of normal and leukemic stem cells. Nature 423: 255–260.

Ng, J.M.Y., and Curran, T. (2011) The Hedgehog’s tale: developing strategies for targeting cancer. Nat. Rev. Cancer 11: 493–501.

O’Brien, C.A., Pollett, A., Gallinger, S., and Dick, J.E. (2006) Identifi cation of a human colon cancer cell capable of initiating tumour growth in immunodefi cient mice. Nature 445: 106–110.

Reya, T., Duncan, A.W., Ailles, L., Domen, J., Scherer, D.C., Willert, K., et al. (2003) A role for Wnt signaling in self-renewal of haematopoietic stem cells. Nature 423: 409–414.

Ricci-Vitiani, L., Lombardi, D.G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., et al. (2006) Identifi cation and expansion of human colon-cancer-initiating cells.

Nature 445: 111–115.

Romer, J.T., Kimura, H., Magdaleno, S., Sasai, K., Fuller, C., Baines, H., et al. (2004) Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1+/− p53−/− mice. Cancer Cell 6: 229–240.

Rosen, J.M. and Jordan, C.T. (2009) The increasing complexity of the cancer stem cell paradigm. Science 324: 1670–1673.

Salomoni, P. and Pandolfi , P.P. (2002) The role of PML in tumor suppression. Cell 108: 165–170.

Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fi broblasts by defi ned factors. Cell 131: 861–872.

Von Hoff, D.D., Lo Russo, P.M., Rudin, C.M., Reddy, J.C., Yauch, R.L., Tibes, R., et al. (2009) Inhibition of the Hedgehog pathway in advanced basal-cell carcinoma.

N. Engl. J. Med. 361: 1164–1172.

196 8: STEM CELLS AND DIFFERENTIATION

Yilmaz, O.H., Valdez, R., Theisen, B.K., Guo, W., Ferguson, D.O., Wu, H., et al.

(2006) Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441: 475–482.

Zhao, C., Chen, A., Jamieson, C.H., Fereshteh, M., Abrahamsson, A., Blum J., et al.

(2009). Hedgehog signaling is essential for maintenance of cancer stem cells in myeloid leukemia. Nature 458: 776–779.





Chapter 9

Metastasis

Introduction

Most cells of the body normally remain resident within a particular tissue or organ (though hematopoietic stem cells are a notable exception). Liver cells remain in the liver and cannot be found in the lung and vice versa. Organs have well-demarcated boundaries defi ned by surrounding basement membranes. Basement membranes are acellular structures made up of a fabric of extracellular matrix (ECM) proteins: predominantly laminins, type IV collagen, and proteoglycans. Cancer is distinctly characterized by the spreading of tumor cells throughout the body. The process by which tumor cells from a primary site invade and migrate to other parts of the body is called metastasis. Metastasis is the fundamental difference between a benign and malignant growth and represents the major clinical problem of cancer. A primary tumor can be surgically removed relatively easily, whereas once hundreds or more metastases have been established throughout the body they are practically impossible to remove. Sadly, many solid tumors have metastasized at the time of diagnosis.

The spread of cells throughout the body results in physical obstruction, competition with PAUSE AND THINK

normal cells for nutrients and oxygen, and invasion and interference with organ function.

Why is the spread of cells

Interestingly, specifi c cancers metastasize to particular sites. Many of the preferences throughout the body lethal?

observed for the spread of specifi c cancers to specifi c metastatic locations can be explained by the directionality of blood fl ow. As the bloodstream is the predominant means of long-distance transport, organs in close proximity “en route” are likely to be main sites of metastasis for a particular primary tumor. However, about one-third of the locations of frequent metastases is puzzling in this regard. For example, a particular kidney cancer often metastasizes to the thyroid, a relationship that cannot be explained simply by anatomy. One explanation of this observation was described over 100 years ago in the “seed and soil” theory proposed by Stephen Paget. It described cancer cells as “seeds” requiring a match with optimal environments or “soils” to succeed. The ability of cancer cells to metastasize is dependent on the interactions of their cell surface molecules with the microenvironment, including neighboring cells and the extracellular matrix. Recent molecular evidence suggest that receptors lining the capillaries in the organs to which cancer spreads infl uence the destination of metastasized cells, and these fi ndings support the “seed and soil” theory.

This theory is also supported by the concept of the establishment of a pre-metastatic niche, a site of future metastasis that is altered in preparation for the arrival of tumor cells. Further studies are needed to discover the factors needed for a tumor cell to be successful in metastasis. Although cancers are largely successful in metastasizing in the long run, on the cellular level, only 1 in 10,000 metastasizing cells survives transport.





198 9: METASTASIS

9.1 The process of metastasis

Tumor cells undergo several major steps during metastasis: invasion, intravasation, transport, extravasation, and metastatic colonization (Figure 9.1). An additional layer of complexity must be added to this model because a tumor cannot be viewed simply as an isolated mass of cancer cells, but instead as a tissue that recruits and receives signals from surrounding normal cells, called the tumor microenvironment or tumor-associated stroma. The interaction of tumor cells with the tumor microenvironment affects the metastatic ability of individual cancer cells: not all cells of a primary tumor contain the same ability to metastasize. The subpopulation of cancer stem cells in a primary tumor also affects metastatic potential. The interaction of the primary tumor with distant locations via signaling molecules to create a future site of metastasis has also been demonstrated (see later in the chapter). Thus, both individual tumor cells and the tumor microenvironment play a role in the process of metastasis. The interactions between cancer cells and their microenvironment are complex but they are beginning to be understood. As we examine each of the major steps take note of the contributions made by the tumor microenvironment. Also, try to evaluate the molecular components as possible therapeutic targets and think about strategies that may be used to Invasion

Intravasation

Transport

Extravasation

Metastatic

colonization

Angiogenesis

Figure 9.1 Steps of metastasis.





9 . 2 TO O L S O F C E L L I N VA S I O N : C E L L A D H E S I O N M O L E C U L E S, I N T E G R I N S, A N D P R OT E A S E S 199

develop new drugs. Examples of therapeutic strategies will be described at the end of the chapter.

9.2 Tools of cell invasion: cell adhesion molecules,

integrins, and proteases

Cell adhesion molecules

In order for cells of the primary tumor to invade into their local environment (top right, Figure 9.1), cells must break free from the normal molecular constraints that link adjacent cells to each other. Cell adhesion molecules (CAMs) and cadherins are two families of proteins that mediate homotypic (same cell type) and heterotypic (different cell types) recognition. They “hook” cells into place extracellularly (Figure 9.2). Cadherins (Figure 9.2a) are calcium-dependent transmembrane glycoproteins that interact, via catenins (Figure 9.2b), with the cytoskeleton (Figure 9.2c).

Catenins also bind to transcription factors and induce gene expression in the nucleus. Thus, intercellular interactions are networked to mediators of intracellular functions.

c

c

a

b

a

b

n

n

d

d′

e

e

f

f

a – Cadherins

b – Catenins

c – Actin cytoskeleton

d – Integrin receptors (d′ represents different subunits)

e – Collagen

Figure 9.2 Cell adhesion

f – Fibronectin

molecules and associated

n – Nucleus

components.

200 9: METASTASIS

Several lines of evidence support the role of cadherins in metastasis. It has been suggested that the gene encoding the predominant cell adhesion molecule in epithelial cells, E-cadherin, acts as a tumor suppressor that normally functions to secure cell–cell adhesion and suppresses metastasis of tumor cells to distant sites. Cells treated with antibodies that block the PAUSE AND THINK

function of E-cadherin became invasive in collagen gels, indicating an increased metastatic potential. Transfection of the E-cadherin gene into Classify the types of evidence premetastatic epithelial cells can render them non-invasive. Mutations in the sented here that support the idea

extracellular domain and methylation in the promoter region of the

that E-cadherin is a tumor sup-

E-cadherin gene, have been identifi ed in gastric and prostate carcinomas, pressor gene, using the descrip tion

as expected for a tumor suppressor gene (see Pause and Think).

of types of evidence presented in

the Chapter 1 “How do we know

Cell behaviors are infl uenced by specifi c cadherin family members. Cad-that?” box.

herin switching plays a role in gaining a migratory phenotype characteristic of the epithelial–mesenchymal transition described in a later section.

Integrins

Cells must also break free from the normal molecular constraints by the α1

α2

ECM. Integrin receptors (Figure 9.2d) are a family of more than 24 hetero-

α3

dimers made up of a range of α and β subunits (Figure 9.3) that mediate α4

α5

cell–ECM interactions and intracellular signal transduction. The recogni-

α6

β1

tion of the different components of the ECM, for example collagen (Fig-

α7

ure 9.2e), fi bronectin (Figure 9.2f), or laminin, depends on the α and β

α8

α9

subunit composition. Many ligands for integrin receptors contain the α10

three-amino acid sequence: Arg(R)–Gly(G)–Asp(D) (where the letter in α11

parenthesis represents the single letter abbreviation for the corresponding αv

amino acid) that is involved in integrin binding. Upon ligand binding, the αD

integrins cluster in the membrane and affect the cytoskeleton through αL

β2

interaction with actin-binding proteins and specifi c kinases, such as focal αM

adhesion kinase (FAK). In contrast to most transmembrane receptors, the αX

cytoplasmic tail of integrins does not exhibit any catalytic activity (e.g.

α11b

kinase activity) itself. Data suggest that FAK mediates cell motility α

β3

v

through recruitment of Src and activation of the RAS pathway (discussed in Chapter 4). In addition to this typical outside of the cell to inside of the α6

β4

cell signaling, integrins also mediate “inside–outside” signaling. Intracellular signals mediated at the cytoplasmic domain of integrins induce a αv

β5

conformational change in the extracellular domain and thus regulate the αv

β6

affi nity of the integrins for their ECM ligands. Integrins also have a role in anoikis—apoptosis triggered in response to lack of ECM ligand binding αE

β7

and loss of cell adhesion. Integrins without suitable ECM ligands recruit α4

caspase-8 to the membrane and trigger apoptosis. Thus, integrin-dependent αv

β8

cell anchorage is crucial for survival of the cell.

Altered integrin receptor expression in tumor cells can enable the

Figure 9.3 The integrin family: α

and β subunit heterodimers.

mobility and invasion of metastasizing cells by modifying membrane

9 . 2 TO O L S O F C E L L I N VA S I O N : C E L L A D H E S I O N M O L E C U L E S, I N T E G R I N S, A N D P R OT E A S E S 201

distribution and/or allowing adherence to different ECMs. Regulation by the cancer cell must result in precise intermediate strengths of adhesion to produce the maximum rate of cell migration, allowing cells to advance their leading edge and to release their lagging edge. The role of integrins in motility is obvious in melanoma cells in which their invasive front edge shows a strong pattern of expression of integrin αvβ3 that is absent in preneoplastic melanomas. An altered expression of a specifi c integrin heterodimer may be permissive for invasion. For example, an increase of α6β4, a laminin-binding integrin, promotes invasion through the basement membrane and the laminin matrix often secreted by epithelial tumors. Further still, altered integrin expression may facilitate invading cells to overcome anoikis.

Proteases

Invasion of tumor cells into the surrounding tissue requires the action of specifi c proteases that degrade a path through the ECM and stroma. Ser-



ine proteases and matrix metalloproteinases (MMPs) are two families that are important. Although some tumor cells can synthesize MMPs,

more often tumor cells induce surrounding stromal cells to produce

MMPs. One appropriately named protein, called extracellular matrix

metalloprotease inducer (EMMPRIN), is upregulated on the membrane

of tumor cells and induces production of MMP in adjacent stromal cells.

The family of MMPs can not only degrade structural components of the ECM, but also cleave other proteins residing on the outside of cells (e.g.

endothelial cell growth factors), and thus are likely to play an important role in metastasis, including angiogenesis (see Sections 9.6 and 9.7). Normally, these zinc-dependent proteinases are tightly regulated at several levels in addition to gene expression. First, they are synthesized as latent enzymes and require proteolytic cleavage to be activated. Also, endogenous tissue inhibitors (TIMPs) regulate their function. A tip in the balance between MMPs and TIMPs can signal invasion. MMPs are upregulated in almost all tumors and their expression profi le can indicate the degree of tumor progression in some cancers.

The epithelial–mesenchymal transition

The acquisition of the characteristics needed for invasion may be orchestrated by a mechanism called the epithelial–mesenchymal transition (EMT) which involves the conversion of a sheet of closely connected epithelial cells into highly mobile mesenchymal cells. This process is common in early embryogenesis. The early embryo requires cell invasion and motility during early development to orchestrate pattern formation. For example, gastrulation requires coordinated cell movement and detachment and

202 9: METASTASIS

invasion from/into adjacent tissue. Many of the processes/cell behaviors that are active in early embryogenesis are reactivated in cancer cells. There are molecular similarities between EMT and metastasis. EMT is characterized by loss in cell polarity, downregulation of epithelial markers such as E-cadherin, upregulation of mesenchymal proteins such as N-cadherin, and secretion of MMPs. These molecular characteristics are also observed in migrating tumor cells.

Signals from the tumor stroma (e.g. growth factors HGF, EGF, PDGF,

and TGF-β) induce EMT in neighboring tumor cells via their specifi c receptors (MET, EGFR, PDGFR, and TGFR, respectively) and signal

transducers, ultimately activating specifi c transcription factors (e.g. Snail, Slug, ZEB1, Twist, Goosecoid, FOXC2). These transcription factors control sets of genes needed to trigger EMT (Figure 9.4). In a comparison of tumors derived from cell lines with varying capabilities for metastasis, gene expression profi ling revealed the transcription factor, Twist, as one of the most differentially expressed genes. Inhibition of Twist resulted in the loss of several steps of metastasis, including intravasation. Twist expression has been documented for several human tumors (e.g. metastatic melanoma). These fi ndings suggest that Twist is a key regulator of metastasis.

The relationships between cancer cells and stem cells were discussed in Chapter 8. Evidence, such as the induced expression of stem cell markers, Epithelial-like tumor cells

EMT-inducing

signals

E-cad

e.g. TGFβ

TGFβR

HGF

MET

EMT-TFs e.g. Twist

EMT

Tumor stroma

N-cad

MMPs

Mesenchymal-like tumor cell

Figure 9.4 The epithelial–mesenchymal transition (EMT). Cells of the stroma release EMT-inducing signals such as TGFβ and HGF. These signals activate their corresponding receptors TGFβR and MET on tumor cells and is signaling transduced to the nucleus. This leads to the activation of EMT transcription factors such as Twist, which in turn regulate a set of genes whose products direct EMT. Mesenchymal cells express N-cadherin (N-cad) and secrete proteases such as MMPs.





9 . 4 T R A N S P O R T 203

suggests that EMT produces stem cell-like cells (Mani et al. , 2008). Thus, EMT not only enables tumor cells to acquire a migratory phenotype but also promotes their self-renewal capability, qualities that are essential for metastasis, including successful colonization.

9.3 Intravasation

Intravasation is the entry of a tumor cell into a blood or lymphatic vessel.

The process requires several steps: the tumor cell must attach to the stromal face of the vessel, degrade the basement membrane (absent in lymphatic vessels) using MMPs and serine proteases, and pass between the endothelial cells (transendothelial migration) into the bloodstream. The structural features of tumor-associated blood vessels infl uence the mechanics of intravasation. New blood vessels stimulated by the tumor are leaky and tortuous allowing easy access compared with blood vessels in normal tissues. Direct visualization in animal models by multiphoton microscopy has established that the process of intravasation is assisted by tumor-associated macrophages which “guide” tumor cells to vessels (Wyckoff et al. , 2007—videos are freely available in supplementary data online). This process involves the CSF1 (colony-stimulating factor 1) receptor on macrophages and EGFR on tumor cells. Macrophages associate with blood vessels and are a source of EGF, and tumor cells produce CSF1 leading to chemotaxis-mediated co-migration. Antibodies that block CSF1 receptor function decreased intravasation compared to controls. Further research to understand additional molecular events involved in this process will be needed to develop therapeutic strategies that target intravasation.

9.4 Transport

Transport through the bloodstream is “one-way”. Tumor cells travel singly or as clumps with platelets, called emboli, in the direction of blood fl ow. Emboli may protect tumor cells from sheer forces inside the bloodstream. Specifi c cancers have favored sites of metastasis and for some cancers this is explained by the concept of the fi rst-pass organ. The fi rst-pass organ is the fi rst organ en route via the bloodstream that lies downstream from the primary tumor site. The large size of tumor cells (20–30 μm) relative to the diameter of capillaries (about 8 μm) suggests that a large fraction of tumor cells get trapped in the fi rst capillary beds that they encounter. The lung is the fi rst pass organ for cells of the breast via the superior vena cava that also receives drainage from the lymphatic vessels.

Thus, the lung is a common site of metastasis from breast cancer. The liver





204 9: METASTASIS

is the fi rst-pass organ for cells via the hepatic portal vein and is particularly vulnerable because of sinusoids, areas where blood is in direct contact with hepatocytes. Overall, only a very small proportion of tumor cells that enter the blood stream are successful in setting up a metastatic colony.

9.5 Extravasation

Extravasation is the escape of a tumor cell from a blood or lymphatic vessel. The steps involved are similar to intravasation but in reverse (although there are some differences, mentioned in this section): the tumor cell must attach to the endothelial side of the blood vessel, pass through the endothelial cells and basement membrane, and migrate into the surrounding stroma.

Tumors cells are arrested in the circulation as a result of mechanical entrapment, as mentioned earlier, or by molecular adhesion to blood vessel cells. Note that macrophages that supported intravasation are unlikely to be involved in extravasation. Members of the selectin family of adhesion molecules, particularly E-selectin, are specifi cally expressed on endothelial cells and are important for the attachment of cancer cells to the endothelium. They are calcium-dependent transmembrane receptors that mediate interactions with cancer cells by binding to various glycoprotein ligands presented on adhering cells. Endothelial selectins are differentially expressed on the vasculature of different organs and may support the “seed and soil” theory discussed previously. E-selectin expression in liver sinusoidal cells is triggered by Lewis lung carcinoma cells and may explain the preference of these cells to metastasize to the liver. Signaling between the selectins and their ligands appears to be bidirectional, in that signal transduction in both participating cells has been demonstrated.

That is, signaling initiates from both the selectin cytoplasmic tails and from their activated ligands. For example, cross-linking of E-selectin induces tyrosine phosphorylation in endothelial cells and also modifi es endothelial cell shape. In contrast, stress-activated protein kinase-2

(SAPK2/p38), an isoform of MAPK, is induced in cancer cells upon binding of E-selectin (on endothelial cells) and is necessary for transendothelial migration.

This suggests that binding to E-selectin on the endothelium by cancer cells not only mediates adhesion to the endothelium but also triggers a signal transduction cascade that is important for transendothelial migration by the cancer cells. Note that the structural features of a blood vessel at a distant site from the primary tumor differ from the new vasculature induced by the tumor where intravasation occurs and thus extravasating cells require additional mechanisms compared with intravasating cells.





9 . 6 M E TA S TAT I C C O L O N I Z AT I O N 205

9.6 Metastatic colonization

The words in the term “metastatic colonization” have been precisely chosen to describe the last stage of metastasis. Let us examine the “familiar” concept of colonization. The British established distant colonies in the New World, the growth of which was dependent on the environment, including the surrounding waterways and harbors. As the settlers moved west, some of the new environmental conditions were unfavorable for growth. Other locations encouraged the development of a new means of water access and resulted in a fl ourishing settlement. Metastatic colonization is the establishment of a progressively growing tumor at a distant site, involving the formation of new blood vessels as an essential process to provide nutrients and oxygen. It is important to contrast this process with the situation of metastasized tumor cells that do not expand and remain dormant for years as micrometastases. Micrometastases

maintain an overall balance between proliferation and apoptosis and do not demonstrate progressive growth. In some cases, this may be due to a period of time before angiogenesis. Metastatic colonization identifi es the last, and often rate-limiting, step of metastasis that can be targeted to halt the complete clinical cancer phenotype.

Metastasis suppressor genes

A new class of genes, called metastasis suppressor genes, have been identifi ed by their low expression in metastatic cells compared with non-metastatic tumor cells. They are defi ned by their ability to inhibit overt metastasis without affecting the growth of the primary tumor. Many

products of these genes are involved in the regulation of growth of metastatic cells at secondary sites and may maintain these cells as stable, non-proliferating dormant cells. Thus, loss of function (analogous to the mechanism of tumor suppressor genes) increases the metastatic propen-sity of a cancer cell. Approximately 23 metastasis suppressor genes have been identifi ed since the discovery of the fi rst, NM23. The protein product of the NM23 gene functions as a nucleoside diphosphate kinase and a histidine kinase, and it is suggested that the latter may contribute to its metastasis inhibitory effects. MKK4 (mitogen-activated protein kinase kinase 4) is a metastasis suppressor gene whose protein product affects metastatic colonization. It is hypothesized that MKK4 protein induces apoptosis in response to the stress of a new microenvironment and thus suppresses metastatic colonization. Both NM23 and MKK4 appear to

promote dormancy of micrometastatic colonies. The mechanism of action of metastasis suppressor proteins includes regulation of common signal-transduction pathways (e.g. MAPK) and gap–junction communication,

although these are only beginning to be elucidated. In addition, a new





206 9: METASTASIS

class of microRNAs that suppress metastasis, called metastasis suppressor microRNAs, have been identifi ed and include miR-335 and miR-126 (see Section 3.6).

The pre-metastatic niche

The “seed and soil” theory states that metastases selectively colonize specifi c organs because of a “match” between the migrating tumor cell and a

“suitable” environment. The concept of a pre-metastatic niche, a site of future metastasis that is altered as a result of factors released by the primary tumor, in preparation for the arrival of tumor cells supports the “seed and soil” theory. Evidence for the pre-metastatic niche was presented in a ground-breaking paper (reviewed by Kaplan et al. (2006) and Oppenheimer (2006)). The migration of green fl uorescently-labeled bone marrow-derived cells in mice was examined after the inoculation of specifi c red fl uorescently-labeled mouse tumor cells. The data demonstrated that green-labeled cells arrive at common sites of metastasis and form clusters before the arrival of red-labeled tumor cells (Plate 7). The bone-marrow-derived cells express VEGFR1 (discussed later in the chapter) and integrin VLA-4 that binds to fi bronectin-rich environments induced by tumor-PAUSE AND THINK

specifi c growth factors, facilitating cell clustering. Importantly, further Exosomes are small vesicles (40–

experiments showed that factors released by the primary tumor orches-100 nm) that carry protein and

trate the formation of the pre-metastatic niche in selective locations (see nucleic acids, and are derived

Pause and Think). Conditioned media from one type of tumor was able to from late endosomes. They are

redirect the location of metastatic colonization of another tumor type. For constitutively released from cells

example, melanoma-conditioned media reprogrammed the metastatic

via fusion with the cell mem-

profi le of lung cancer cells to locations normally colonized by melanoma brane. Peinado et al. have

cells. Similar results were obtained when human cancer cells were tested.

recently proposed that tumor-

As discussed in Oppenheimer (2006) and Kaplan et al. (2006), these data derived exosomes may act as

suggest that tumor-type specifi c factors released from the primary tumor systemic factors that “educate”

facilitate changes to the microenvironment of a distant and future coloni-bone-marrow derived cells to

zation site before tumor cells arrive. Bone marrow cells respond to these mobilize to a pre-metastatic

niche (Peinado et al. 2011).

systemic factors by migrating to the pre-metastatic niche and are involved Watch this space . . .

in preparing a favorable environment for the cancer cells to colonize (for more on migrating bone marrow cells and cancer see also page 242).

9.7 Angiogenesis

As alluded to earlier, metastatic colonization cannot be successful without the formation of new blood vessels. Angiogenesis is the process of forming new blood vessels from pre-existing ones by the growth and

migration of endothelial cells in a process called “sprouting.” Although

9 . 7 A N G I O G E N E S I S 207

this process is common during embryogenesis it rarely occurs in the adult, being reserved for wound healing and the female reproductive cycle. With respect to cancer, angiogenesis is essential for metastasized tumors as all cells must be within 100–200 μm of a blood vessel (the diffusion limit of oxygen) in order to receive essential oxygen and nutrients.

Sprouting of pre-existing vessels requires major reorganization involving destabilization of the mature vessel, proliferation and migration of endothelial cells, and maturation. It is regulated by the interaction of soluble mediators and their cognate receptors. Malignant cells in culture and host stromal cells induced by a tumor in vivo have been shown to be sources of these soluble mediators. The neovasculature that is formed in cancer is unlike that formed in wound healing. It is leaky and tortuous and provides direct entry, allowing cells easy access to the circulation.

The neovasculature is also different at the molecular level from resting endothelium. For example, the integrins αvβ3 and αvβ5 are upregulated in angiogenic vessels compared with mature vessels. The proliferating endothelial cells of the sprouting vessel need to interact with components of the ECM that it is invading. Factors that promote angiogenesis induce the expression of these integrins. Molecular differences are not limited to the endothelium as the supporting pericytes and ECM show specifi c

angiogenic markers (e.g. NG2 and oncofetal fi bronectin, respectively).

Therefore, many components of angiogenic vasculature are molecularly distinct from normal vessels.

The angiogenic switch

The regulation of angiogenesis is dependent upon the dynamic balance of angiogenic inducers and inhibitors. Increasing the activity of the inducers or decreasing the activity of the inhibitors tips the balance of A LEADER IN THE FIELD . . . of angiogenesis: in memory of Judah

Folkman

Judah’s pioneering discoveries into the mechanism of angiogenesis opened up a new fi eld of cancer research and supported his ground-breaking idea that tumors are dependent on angiogenesis. His laboratory identifi ed the fi rst angiogenic inhibitor and carried out clinical trials of anti-angiogenic therapies. He also investigated the observation that some tumors remain dormant, sometimes indefi nitely, because of the production by the tumor of an angiogenic inhibitor, but can become angiogenic when production of the inhibitor decreases.

Judah received his BA from Ohio State University and his MD from Harvard Medical School.

He made advancements in a range of fi elds, including the development of the fi rst atrioven-tricular implantable pacemaker and implantable polymers for controlled release of contraceptive. He was the Director of Surgical Research and Professor of Cell Biology at Harvard Medical School, Children’s Hospital in Boston.

208 9: METASTASIS

Anti-angiogenic factors

Pro-angiogenic factors

• Angiostatin

• Vascular endothelial

growth factor (VEGF)

• Endostatin

• Fibroblast growth factor

• Prolactin (16kD)

(FGF (acidic and basic))

• Protein 53 (p53)

• Hepatocyte-derived

growth factor (HGF)

• Thrombospondin–1,–2

Blood vessel

• Epidermal growth

Figure 9.5 The angiogenic switch:

factor (EGF)

examples of anti-angiogenic

factors and pro-angiogenic factors

Angiogenic switch

discussed in the text.

the “angiogenic switch” to the “on” position, and vice versa. We will focus on only a few of these (Figure 9.5).

Angiogenic inducers

Growth factors, both non-specifi c (e.g. EGF, FGF, HGF, PDGF) and

endothelial-specifi c (VEGF), are examples of angiogenic inducers. Although the non-specifi c growth factors (e.g. FGF) affect many cell types, they are still important for angiogenesis. Three families of vascular-endothelium-specifi c growth factors and their transmembrane receptors have been iden-

tifi ed: vascular endothelial growth factors (VEGFs) and VEGF receptors (VEGFRs), angiopoietins and Tie receptors, and ephrins and ephrin receptors. All of these receptors are tyrosine kinase receptors.

VEGF is the star player involved in the initiation of angiogenesis, while PAUSE AND THINK

angiopoietins and ephrins are important for subsequent maturation. The Could VEGFRs, Tie receptors,

VEGF family currently consists of fi ve family members (VEGFA–E)

and ephrin receptors be addi-

which transmit their signal via three VEGF receptor tyrosine kinases tional targets for kinase inhibi-

(VEGFR-1, VEGFR-2, and VEGFR-3). VEGFA is secreted by a range of

tor therapeutics?

tumor cells. The tumor cells also affect the surrounding stromal cells, and induction of the VEGF promoter in surrounding non-transformed cells has been demonstrated suggesting a collaboration between normal and transformed cells. Also, reserves of VEGF are found in the ECM and are released by MMPs. Not only does VEGF induce endothelial cell proliferation but it can also induce permeability and leakage. This feature may be important for the initiation of angiogenesis as it has been suggested that the existing mature vessels must be destabilized before sprouting begins. VEGFR-2 mediates the endothelial effects of VEGF, while

VEGFR-1 is inhibitory and VEGFR-3 is vital for lymphatic vessels.

Although many of the details of the signal transduction pathway of

VEGFs have yet to be elucidated, the VEGFA signal transduction

pathway (Figure 9.6) appears to be very similar to the signal transduction

9 . 7 A N G I O G E N E S I S 209

VEGF

VEGFR

VEGFR

PIP3

PIP3

PIP2

e.g.

RAS

PI3K

P

P

ScK

PDK-1 AKT

VRAP

GTP

PLCγ

AKT

P

RAF

Src

Caspase 9

eNOS

BAD

NO production

MEK

Apoptosis

Vascular

permeability

MAPK

MAPK

P

Transcription

factor

Gene expression

Figure 9.6 The VEGFA signal transduction pathway. One molecule of VEGFA binds to two VEGFR2 receptors facilitating dimerization and autophosphorylation. Proteins containing SH2 domains (shaded in gray) bind to the phosphorylated receptor and trigger activation of the RAS–Raf–MAP kinase cascade. In addition, PI3K is activated. AKT

leads to inhibition of apoptosis. AKT also stimulates endothelial nitric oxide synthase and stimulates vascular permeability via nitric oxide (NO) production. Src is one of several other molecules that are activated by VEGFR2.

pathways for EGFs (compare with Figure 4.2): dimerization, autophosphorylation, creation of high-affi nity binding sites for proteins with SH2

domains (e.g. VEGFR-associated protein (VRAP), Sck, and phospholi-

pase Cγ), and subsequent activation of the RAS, Raf, MAP kinase cascade. VEGF-responsive genes include the EGFR ligand, epiregulin,

COX2, and matrix-metalloproteinases MMP1 and MMP2. In addition, a PI3K-dependent pathway is triggered. This activates AKT and leads to a block in apoptosis and, via nitric oxide production, to increased vascular permeability. Several other important intracellular molecules, such as Src, are also implicated.

Angiogenic inhibitors

Angiogenic inhibitors normally found in the body (endogenous inhibitors) maintain the angiogenic switch in the “off” position by inhibiting endothelial cell migration and proliferation. Some angiogenic inhibitors

are stored as cryptic parts within larger proteins that are not themselves

210 9: METASTASIS

MMPs

MMPs

NH3

COOH

PLASMINOGEN

Angiostatin

Figure 9.7 Cryptic angiogenic

inhibitors.

inhibitors (Figure 9.7). Plasminogen can be cleaved by proteinases, including several MMPs, to release the angiogenic inhibitor, angiostatin.

Angiostatin binds to its endothelial cell surface receptor, annexin II, to

exert its inhibitory effects. Endostatin is a fragment of collagen XVIII and can be proteolytically released by elastase and cathepsin. It blocks MAPK activation in endothelial cells and also MMPs.

It has been observed that sometimes, when a tumor is removed by surgery or irradiation, dormant metastases are often activated and growth and angiogenesis are initiated. This phenomenon has been termed “concomitant resistance.” Evidence suggests that the production of angiogenic inhibitors, such as angiostatin and endostatin, by certain tumors prevents the growth of remote micrometastases via the blood. When the primary tumor is removed so are these inhibitors, and the angiogenic switch is activated for the micrometastases. Also, surgery is known to cause induction of angiogenic growth factors and thus may exacerbate malignant disease through this mechanism (Ian Judson, personal communication).

The angiogenic switch is regulated in two ways during tumorigenesis.

First, as a tumor grows it creates conditions of hypoxia (low oxygen concentration), and this induces angiogenesis via the hypoxia-inducible factor-1α (HIF-1α). One target of HIF-1α that is important for angiogenesis is the VEGF gene. HIF is actually a heterodimeric transcription factor comprising one HIF-1α and one HIF-1β subunit. The activity of HIF is regulated by oxygen concentration, not at the level of mRNA

expression as both subunit mRNAs are constitutively expressed, but

rather at the protein level of HIF-1α (Figure 9.8). Under normoxic conditions (20% oxygen) HIF-1α is rapidly degraded. The von Hippel–Lindau (VHL) tumor suppressor protein is an important regulator of HIF-1α degradation (Kim and Kaelin, 2003). The fi rst step in targeting HIF-1α for degradation under normoxic conditions is modifi cation (hydroxylation) by the enzyme prolyl 4-hydroxylase (shown in red in Figure 9.8). This enzyme directly binds and links molecular oxygen to specifi c proline

9 . 7 A N G I O G E N E S I S 211

Normoxic conditions

Hypoxic conditions

O2

Low O2

Prolyl

Inactive

4 hydroxylase

prolyl

4 hydroxylase

OH

HIFα

No hydroxylation

No VHL binding

OH VHL

No ubiquitin

U

HIFα

No HIFα degradation

Figure 9.8 The induction of

HIFα degradation

angiogenesis by hypoxia.

α

β

PAUSE AND THINK

No transcription

VEGF

Allow me to interject at this

HRE

point to share a personal story

of how I have come to appreci-

ate the importance of this path-

No angiogenesis

Angiogenesis

way. I wear contact lenses and

was told when I purchased

residues on HIF-1α, and thus acts as a direct oxygen sensor in this path-them that I could wear them

during sleep. I received a shock

way. VHL binds to hydroxylated HIF-1α and activates a complex of pro-during the next visit with my

teins responsible for the addition of ubiquitin (indicated by a “U” in a red optometrist when he told me

diamond, Figure 9.8) that target HIF-1α for proteosomal degradation. In that my eyes were not receiving

the absence of HIF-1α, HIF-1α target genes cannot be transcriptionally enough oxygen during the night

activated and angiogenesis does not occur.

and blood vessels had begun

Under hypoxic conditions the enzyme prolyl 4-hydroxylase is inacti-

to grow out into the eye. He

vated, HIF-1α is not hydroxylated, and VHL cannot bind and target

explained that my eyelid alone

HIF-1α for proteosomal degradation. HIF-1α is rapidly stabilized and reduces the amount of oxygen

transported to the nucleus. The heterodimeric HIF transcription factor to the eye during sleep and that

can then activate its target genes. As previously mentioned, the most nota-the addition of a contact lens

ble target is the VEGF gene that contains a hypoxia response element created a hypoxic condition. The

(HRE) in its promoter region.

hypoxia was sensed and trig-

gered angiogenesis to supply

Second, oncogenic proteins and loss of tumor suppressors contribute to more oxygen to the eye rather

the modifi cation of the angiogenic switch. In contrast to the well known then allow the tissue to become

direct contribution of oncogenes and tumor suppressors to proliferation, damaged. I no longer wear con-apoptosis, and differentiation, direct roles in angiogenesis are now recog-tact lenses during sleep, and

nized. Approximately 30 oncoproteins have been shown to tip the bal-have an appreciation of the regu-

ance towards angiogenesis. Aberrant production of growth factor, in lation of prolyl 4-hydroxylase.

addition to acting in an autocrine manner to stimulate proliferation of





212 9: METASTASIS

tumor cells, can also act in a paracrine manner to stimulate the growth of endothelial cells. “Star” oncogenic proteins including receptor tyrosine kinases (e.g. EGFR), intracellular tyrosine kinases (e.g. Src), intracellular transducers (e.g. Ras), and transcription factors (e.g. Fos, Jun), have been shown to upregulate the “star” angiogenic inducer, VEGF. Some tumor suppressor proteins normally upregulate/increase angiogenic inhibitors, but when these are mutatated, anti-angiogenic activity decreases.

For example, the transcription factor, p53, normally binds to and activates the promoter of the thrombospondin-1 gene. Mutations in the p53

gene, commonly associated with the cancer phenotype, result in a

decrease of the angiogenic inhibitor so that the angiogenic switch favors angiogenesis.

9.8 Other means of tumor neovascularization

Recent evidence has suggested that, in addition to angiogenesis, vasculogenic mimicry and vasculogenesis contribute to the formation of tumor vessels (Figure 9.9a–c). Vasculogenic mimicry describes the process whereby tumor cells (e.g. melanoma cells; shown as gray circles in Figure 9.9) act as endothelial cells and form vascular-like structures (Figure 9.9b, red arrow).

Vasculogenesis involves the differentiation and proliferation of endothelial cells from endothelial progenitor cells. Studies have demonstrated that up to 40% of tumor endothelial cells originated from circulating endothelial progenitor cells (CEPs; shown as a red circle) derived from the bone marrow. Angiogenic factors from the tumor, such as VEGF, are involved in the recruitment of these cells that express VEGFR-2. After reaching the tumor, CEPs differentiate and contribute to the tumor neovasculature (Figure 9.9c, red ovals). It seems likely that different cancers may differ in their requirement for CEP contributions to the new tumor vasculature. It is known that they are necessary for lymphomas and colon cancer.

Therapeutic strategies

Perhaps, in theory, one could envisage a therapy targeted at each of the major steps of metastasis. Protease and integrin inhibitors are obvious molecular targets to block invasion, but the development of such drugs has been met with mixed success. More recently, EMT pathways are providing new targets for diagnostics, prognostics, and therapeutics. Therapies aimed at the tumor vasculature designed either to halt the angiogenic





9 . 9 M E TA L L O P R OT E I N A S E I N H I B I TO R S ( M P I s ) 213

(a) Angiogenesis

CEP

(b) Vasculogenic mimicry

(c) Vasculogenesis

Figure 9.9 Tumor

(a)

(b)

(c)

neovascularization.

process (anti-angiogenic drugs) or to destroy the tumor vasculature which has already been formed (vascular targeting) have been developed. Some examples of therapies that target the processes of metastasis are discussed in the following sections. However, success in practical terms is more diffi -

cult as patients often show signs of metastasis upon diagnosis. We await the development of new drugs that target already metastasized cells instead of merely attempting to block escape.

9.9 Metalloproteinase inhibitors (MPIs)

There was a rapid response by pharmaceutical companies to develop metalloproteinase inhibitors because of the evidence of the role of MMPs in metastasis. These molecules appear to function in several steps of metastasis, including invasion and metastatic colonization. The initial wave of clinical trials proved to be disappointing although informative for future trials. The development of drugs exceeded the rate at which basic research was able to uncover the details of the MMP family. First, about 24 different family members have been identifi ed. The knowledge of temporal and spatial expression patterns, functional roles, and roles in different cancers of the individual family members, lagged behind the initial development of small-molecule inhibitors and natural product drugs. The trials were hindered by unexpected side-effects (musculoskeletal pain) and poor





214 9: METASTASIS

design. There was diffi culty in measuring effi cacy and the drugs were administered only to patients with advanced disease, even though pre-clinical evidence suggested that administration at early stages of disease was crucial. No MPIs have received approval as a cancer therapy thus far.

Targeting membrane-bound MMPs by selective therapeutic antibodies is a more recent strategy for the development of the next generation of MMP

inhibitors (Devy and Dransfi eld, 2011) and promises to improve upon the severe toxicities associated with the broad-spectrum inhibitors developed earlier.

9.10 Strategies for restoring metastasis suppressors

Similar to drug development strategies that aim to reactivate tumor suppressor genes, drug development strategies that reactivate metastasis suppressor genes are also being developed. Gene analysis has revealed that mutations in the coding region of the NM23 gene are rare and this suggests that gene expression is inhibited in cancer cells. Therefore, agents that could reactivate gene expression may be drug candidates.

The promoter of the NM23 gene is regulated by the glucocorticoid response pathway. Medroxyprogesterone acetate (MPA), a progesterone and gluco corticoid agonist, was shown to induce expression of the NM23 promoter. A Phase II trial (NCT00577122) is currently testing MPA with and without chemotherapy in metastatic breast cancer. Other strategies for reactivating metastasis suppressor genes that are being tested in pre-clinical trials include administration of recombinant metastasis suppressor proteins and gene therapy approaches (Smith and Theodorescu, 2009).

9.11 Anti-angiogenic therapy and vascular targeting

Anti-angiogenic therapy is designed to prevent the formation of new blood vessels. Rather than target the tumor cells directly, the aim of anti-angiogenic therapy is to interfere with the responsiveness of endothelial cells that is essential to the tumor’s survival. Drugs may be designed to prevent the cells from responding to pro-angiogenic signals or may be targeted to block the activity of the inducers (Figure 9.10). Overall, these drugs are cytostatic rather than cytotoxic, and therefore may need long-term continuous administration. Anti-angiogenic therapies, together with vascular targeting (discussed in the next section), differ from the therapies discussed previously, and the differences have several implications. First,

9 . 1 1 A N T I - A N G I O G E N I C T H E R A P Y A N D VA S C U L A R TA R G E T I N G 215

Avastin

VEGF

SU5416

Sunitinib

Sorafenib

VEGFR

Thalidomide

Vitaxin

Figure 9.10 Anti-angiogenic

Endostatin

therapies and their molecular

Cilengitide

targets. Endothelial cells are

shown as black ovals. Therapeutic

α ν β3

agents are shown in red and

integrin

cellular targets are indicated by a

() symbol. Clinical development

of SU5416, the fi rst VEGFR

tyrosine kinase inhibitor to enter

clinical trials, has been stopped

(shown by a red cross).

as angiogenesis only occurs on occasion in the adult, drugs that inhibit it are predicted to cause minimal side-effects. More importantly, the target endothelial cells recruited during angiogenesis are genetically stable, unlike the tumor cells that have accumulated mutations, and are therefore less likely to develop drug resistance rapidly. There are approximately 95

clinical trials that are currently testing anti-angiogenic cancer drugs (some are listed in Table 9.1). Examples of several different strategies that have been employed are described next.

One strategy involves targeting angiogenic factors such as VEGF. Avastin™ (bevacizumab), a recombinant human monoclonal antibody that

PAUSE AND THINK

recognizes all VEGF isoforms, has been tested in clinical trials (for example see Yang et al. , 2003) and approved for treatment of colorectal cancer.

AvastinTM for breast cancer was

Interestingly, the drug failed to show a response (life extension) in an ini-approved by the FDA in 2008

tial breast cancer trial. Why was there a different response observed in the via the accelerated program

that allows provisional approval

two different cancers? The answer lies in the angiogenic switch: colon subject to further confi rmation.

tumors are more dependent on VEGF for the induction of angiogenesis This approval was revoked in

while this is true only for early stages of breast cancer. Advanced breast 2011 after follow-up studies

cancer utilizes a broader arsenal of angiogenic inducers, thus inhibition of and concern for potential seri-just one activator does not have an effect.

ous side-effects. Drug develop-

Small-molecule tyrosine kinase inhibitors have been used to target the ment has its ups and downs.

VEGFR. Semaxanib (SU5416) was the fi rst VEGFR inhibitor to enter

216 9: METASTASIS

Table 9.1 Angiogenesis inhibitors in clinical trials

Drug

Company

Mechanism

Phase of trial

Drugs that block activators of angiogenesis and their receptors

SU5416

Sugen

Blocks VEGFR signaling

Withdrawn

SU6668

Sugen

Blocks VEGFR, FGFR, PDGFR

Withdrawn

Sorafenib (BAY 43–9006)

Bayer

Blocks VEGFR, PDGFR, FLT3, KIT, and Raf

Approved

Sunitinib (SU-11248)

Pfi zer

VEGFR, PDGFR, FLT3, KIT

Approved

Avastin™ (bevacizumab)

Genetech

Monoclonal Ab to VEGF

Approved

Recentin™ (AZD2171)

AstraZeneca

VEGFR1/2 tyrosine kinase inhibitor

III (failed for CRC but ongoing for other cancers)

Zactima™ (ZD6474) (vandetanib)

AstraZeneca

VEGFR1/2 tyrosine kinase inhibitor

Approved orphan drug/III

VEGF-Trap (afl ibercept)

Regeneron Pharm

Soluble decoy VEGFR

II/III

Drugs that inhibit endothelial-specifi c integrin signaling

Vitaxin II

MedImmune

Inhibitor of αvβ3 integrin

II

Cilengitide

Merck KGaA

Antagonist of integrins αvβ3 and αvβ5

II/III

Drugs that inhibit endothelial cells

Thalidomide

Celgene

Unknown

Approved

Endostatin

EntreMed

Inhibition of endothelial cells

II (approved in China, 2005)

Angiostatin

EntreMed

Inhibition of endothelial cells

I

ABT-510

Abbott Labs

Thrombospondin-1 analog

II

Drugs that block matrix

breakdown

Marimastat

British Biotech

Inhibitor of MMPs

Withdrawn

Neovastat

Aeterna Zentaris

Inhibitor of MMPs

Withdrawn

BMS-275291

Bristol Myers

Inhibitor of MMPs

Withdrawn

Squibb

Miscellaneous

Combretastatin

Oxigene

Binds to tubulin; disrupts the cytoskeleton

I/II

Ab, antibody; CRC, colorectal cancer.

Phase III clinical trials. Its mechanism of action is that it inhibits receptor autophosphorylation. Although semaxanib demonstrated promising

results in patients with Kaposi’s sarcoma, signifi cant toxicity and poor responses in patients with colorectal cancer led to the withdrawal of the drug. Its further development was also discontinued as a result of

unfavorable phar macology, namely a particularly short half-life of only

9 . 1 1 A N T I - A N G I O G E N I C T H E R A P Y A N D VA S C U L A R TA R G E T I N G 217

several hours. As a result of the short half-life of the drug, effective doses were unable to be maintained even after bi-weekly intravenous administration. Similarly, the drug SU6668, which has a similar mode of action to semaxanib and is orally active, was also withdrawn. However, this strategy has proved successful by the approval of two multi-targeted tyrosine kinase inhibitors, sunitinib and sorafenib, for the treatment of advanced renal cell carcinoma in 2006. Sunitinib targets VEGF receptors, as well as PDGFR, KIT, and FLT3. Sorafenib targets VEGF receptors, PDGFR, KIT, FLT3, and Raf kinase (as mentioned in Chapter 4) (see Pause and Think).

Administration of recombinant human endogenous inhibitors is

PAUSE AND THINK

another anti-angiogenic treatment strategy that held much promise but which thus far has not delivered the expected results. Endostatin, which Do you remember another

was discovered in 1996, was the fi rst to enter clinical trials. Although it example where a small molecule

inhibitor was used to target a

was demonstrated to be non-toxic, no clinical response was observed.

tyrosine kinase receptor? Hint,

This negative result may, again, be due to suboptimal design of the clinical see Chapter 4.

trial rather than ineffi cacy of the drug, as patients with advanced solid tumors were selected despite pre-clinical success with early stage cancer models. The company (EntreMed Inc., Rockville, MD) has announced

that it will halt production of endostatin because of fi nancial diffi culties.

Antagonists to integrins αvβ3 and αvβ5 would block endothelial

integrin–ECM interactions and specifi cally induce apoptosis of angiogenic vessels with little effect on mature vessels. Two integrin inhibitors have entered clinical trials: Vitaxin™ is a humanized monoclonal antibody against αvβ3 and cilengitide is a synthetic cyclic peptide antagonist that mimics the Arg–Gly–Asp “ligand” sequence and inhibits integrins αvβ3, and αvβ5 (Tucker, 2006; Reardon et al. , 2008).

Thalidomide, a drug cursed in the past as being teratogenic and causing truncated limbs, is one of the most effective drugs for treating patients with multiple myeloma. It has been shown to inhibit angiogenesis induced by bFGF or VEGF, and reduced plasma levels of these proteins correlate with the effi cacy of thalidomide treatment. However, the anti-angiogenic activity of thalidomide is linked to its teratogenicity; limb defects are a result of anti-angiogenic effects during limb formation. Thus, patient education regarding pregnancy is crucial. Derivatives of thalidomide with enhanced anti-angiogenic effects and less toxicities are being developed.

Anti-angiogenic effects may be “side-effects” of other cancer therapies.

Cancer therapies targeted at oncogene products often affect angiogenesis.

Herceptin™ (the antibody directed against ErbB2, see Chapter 4) has been shown to be anti-angiogenic by inhibiting the production of angiogenic inducers (e.g. TGF-α and angiopoietin-1) by tumor cells and upregulating angiogenic inhibitors (e.g. thrombospondin). Chronic frequent administration of conventional chemotherapy at doses of one-tenth to one-third of the MTD, known as metronomic scheduling, has also resulted in anti-angiogenic effects.



218 9: METASTASIS

Vascular targeting

Vasculature targeting is a therapeutic approach designed to destroy the existing neovasculature in order to starve the tumor of oxygen and nutrients and lead to tumor regression. This approach is possible owing to the identifi cation of molecular differences between tumor and normal vasculature. Combretastatin, fi rst isolated from the African bushwillow, Com-bretum caffrum, is selectively toxic to neovasculature and combretastatin and recently developed derivatives are being tested in clinical trials (Griggs et al. , 2001; Marrelli et al. , 2011). Combretastatin compounds bind tubulin and disrupt the cytoskeleton. Their effects have been explained by the hypothesis that immature endothelium may have a more intrinsic need for a tubulin cytoskeleton to maintain its shape than stable mature vasculature which is fi rmly supported by a basement membrane. Loss of shape and rounding up of the endothelial cells in new blood vessels block blood fl ow and/or lead to vascular collapse thereby depriving the tumor of oxygen and nutrients (Figure 9.11; compare images before (a) and after (b) treatment with combretastatin A4). As a result, necrosis occurs at the core of the tumor. Unfortunately, a ring of tumor cells at the periphery remain viable (Figure 9.11b) and indicate the need for combination therapy.

Other mechanisms of action responsible for the cell death effects of combretastatins are also probable. Anti-vascular effects are seen at doses of one-tenth of the MTD. ZD6126 is another vascular targeting agent in clinical trials that targets the tubulin cytoskeleton. ZD6126 was well-tolerated and anti-vascular effects were demonstrated in a Phase I trial (a)

(b)

Figure 9.11 Effects of combretastatin on tumor neovasculature. Anti-vascular effects were analyzed by magnetic resonance imaging. The image intensity indicates tumor vasculature.

A primary tumor before (a) and after (b) treatment with combretastatin A4. Strong anti-vascular effects are seen in the core of the tumor after treatment but a small viable rim of tumor tissue can be seen at the periphery. Reprinted from Beauregard, D.A. et al. (1998) Magnetic resonance imaging and spectroscopy of combretastatin A(4) prodrug induced disruption of tumor profusion and energetic status. Br. J. Cancer 77: 1761–1767, Copyright (1998), with permission from Nature Publishing Group.

9 . 1 1 A N T I - A N G I O G E N I C T H E R A P Y A N D VA S C U L A R TA R G E T I N G 219

(LoRusso et al. , 2008). We must be aware for long-term administration that both drugs are selective for all neovasculature and are not only tumor specifi c.

Nanoparticle technology, gene therapy, and vascular targeting have

come together in an exciting report with hints at future applications.

Knowledge of several biochemical areas has been combined specifi cally to target an anti-angiogenic gene to the neovasculature of tumors in mice (Hood et al. , 2002) (Figure 9.12). Lipid-based nanoparticles (Figure 9.12, shaded red) were coated with a ligand to a neovasculature-specifi c receptor, integrin αvβ3. This integrin is not only specifi c to newly growing vessels but also internalizes viruses and small particles and can thus facilitate gene delivery. A mutant form of the Raf gene (Figure 9.12, marked by an asterisk) was coupled to the nanoparticles and was used to inhibit the Raf pathway critical for angiogenesis in vivo. Systemic delivery to mice resulted in apoptosis of tumor endothelial cells and concentric rings of apoptotic tumor cells around the targeted vessels. Regression of primary and metastatic tumors was demonstrated. As viruses were not used for gene delivery, the disadvantages of viral delivery (e.g. risk of further carcinogenesis and an immunogenic response) were bypassed.

integrin

ανβ3

*

raf

*

*

*

Angiogenic blood vessel

Figure 9.12 Vascular targeting by

nanoparticle technology.





220 9: METASTASIS

9.12 Targeting several steps of metastasis at once

As we have seen in this chapter, there are several steps involved in the metastasis of a cell from a primary tumor to a secondary site. Recently, sets of genes or “gene signatures” that are associated with primary tumor growth and risk of metastasis have been identifi ed. Gupta et al. (2007) analyzed the function of four genes of a lung metastasis gene signature (the EGFR ligand epiregulin, COX2, and MMP1 and MMP2) in human cancer cells. The experimental approach involved using the technique of short hairpin RNA interference to generate cells that simultaneously targeted four genes for reduced expression. Biological parameters of tumor progression and metastasis were then examined in mouse models. Their results demonstrated that when all four genes were inactivated tumor growth and lung metastasis were inhibited. Thus, the four genes mediate the processes of tumor growth, angiogenesis, migration, intravasation, and extravasation in mice (Gupta et al. , 2007). More interesting from a therapeutic context, a combination of existing drugs (cetuximab, an anti-EGFR antibody, celecoxib, a COX inhibitor, and GM6001, a MMP

inhibitor) was also able to target the protein products of the four genes and demonstrated inhibition of growth and metastasis. These results hold great potential for the future because if we can catch cancer early and block metastasis we have a hope of managing cancer.

? HOW DO WE KNOW THAT?

In vivo tumor growth and metastasis assays to effects of these drugs on intravasation, the presence of human analyze the effects of drugs that target four cells in the blood of mice was examined by the detection of specifi c gene products (see Gupta et al., 2007)

human-specifi c GAPDH expression using real-time PCR. Look

at Figure 4c of Gupta et al. , 2007. Did a combination of treat-The experimental system was as follows: human cancer cells

ments cause a decrease in the number of circulating tumor

(originally obtained from cells that had metastasized to the

cells? To assess extravasation and colonization of the lung, cry-

lung in a breast cancer patient) were injected into the mam-

osections of lung tissue were analyzed by immunohistochemis-

mary fat pad of immunosuppressed mice. After allowing 24

try using a human-specifi c fl uorescent antibody to detect

days for primary tumor growth, mice were treated with the

tumor cells and DAPI (4,6-diamidino-2-phenylindole) stain to

named drugs, and tissues were harvested from mice at speci-

detect all nuclei (see Figure 4d of Gupta et al. , 2007). The meta-fi ed times.

static burden (number and size distribution of metastases) is

In vivo assays: to assess the effects on primary tumor growth, calculated as the area of fl uorescence normalized to the area of

tumor volume was measured and compared with controls.

DAPI staining. Look at Figure 4f of Gupta et al. (2007). Did the Look at the data in Figure 4b of Gupta et al. (2007). Was pri-results show that a combination of drugs inhibited lung metas-

mary tumor growth inhibited with a combination of treat-

tasis? In summary, primary tumor growth and metastasis

ments? Results are attributed to tumor cell apoptosis. How do

was inhibited by specifi c drugs in the mouse model described

they know that? You will need to refer to the online supple-

earlier.

mentary information associated with the article. To assess the

9 . 1 2 TA R G E T I N G S E V E R A L S T E P S O F M E TA S TA S I S AT O N C E 221

■ CHAPTER HIGHLIGHTS—REFRESH YOUR MEMORY

•

The major steps involved in metastasis of a tumor cell are:

•

Loss of function of metastasis-suppressor genes results in

invasion, intravasation, transport, extravasation, and met-

an increase in metastatic capability. Many metastasis sup-

astatic colonization.

pressor genes play a role in dormancy.

•

Complex interactions between primary tumor cells and

•

Evidence suggests that primary tumors can release long-

the tumor-associated stroma affect the ability of individ-

range signals that prepare a future site of metastasis,

ual cells to metastasize.

called a pre-metastatic niche.

•

Different cancers metastasize to specifi c locations. This

•

Members of the VEGF family are specifi c endothelial cell

may be explained either by anatomy with respect to the

growth factors that are key players in angiogenesis. Their

direction of blood fl ow from the primary tumor or match-

signals are mediated through transmembrane tyrosine

ing with “tumor-receptive” environments as described by

kinase receptors.

the “seed and soil” hypothesis.

•

Hypoxia-inducible factor is a heterodimeric transcription

•

Integrins are receptors that mediate cell–ECM interac-

factor that regulate genes important for angiogenesis,

tions and, with respect to the exterior and interior of a

such as VEGF.

cell, mediate bidirectional signaling.

•

The angiogenic switch is regulated by the dynamic

•

The steps involved in intravasation and extravasation are

balance of pro- and anti-angiogenic factors.

similar (with some exceptions) but are the reverse of each

•

Vasculogenic mimicry and vasculogenesis also contribute

other.

to neovascularization of tumors.

•

Metastatic colonization is characterized by progressive

•

Anti-angiogenic therapy is designed to prevent the for-

growth of a tumor at a distant site and requires angio-

mation of new blood vessels while vasculature targeting

genesis.

is designed to destroy the neovasculature.

•

Micrometastases do not show net growth and may stay

dormant for years.

■ ACTIVITY

1. The tyrosine kinase receptor MET (mesenchymal-epithelial transition factor; also know as the hepatocyte growth factor receptor) and its ligand hepatocyte growth factor (HGR) play a role in EMT that is important for motility and invasion of cancer cells, in addition to other processes important in carcinogenesis. Discuss the clinical and experimental evidence that supports a role of MET/HGF in cancer. Suggest strategies that could target MET using your knowledge of similar molecular targets (see Liu et al. , 2009; Cecchi et al. , 2010).

2. Using the web sites on page 223, update Table 9.1. Have certain drugs progressed to advanced clinical trials? Have some been terminated? Have new drugs been added? Can you think of any additional strategies not mentioned? Can you think of any strategies that target HIF-1α?

■ FURTHER READING

Baeriswyl, V. and Christofori, G. (2009) The angiogenic switch in carcinogenesis.

Semin. Cancer Biol. 19: 329–337.

222 9: METASTASIS

Bourboulia, D. and Stetler-Stevenson, W.G. (2010). Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin. Cancer Biol. 20: 161–168.

Bridges, E.M. and Harris, A.L. (2011). The angiogenic process as a therapeutic target in cancer. Biochem. Pharmacol. 81: 1183–1191.

Chaffer, C.L. and Weinberg, R.A. (2011). A perspective on cancer cell metastasis.

Science 331: 1559–1564.

Cook, K.M. and Figg, W.D. (2010). Angiogenesis inhibitors: Current strategies and future prospects. CA Cancer J. Clin. 60: 222–243.

Cook, L.M., Hurst, D.R., and Welch, D.R. (2011) metastasis suppressors and the tumor microenvironment. Semin. Cancer Biol. 21: 113–122.

Cross, M.J., Dixelius, J., Matsumoto, T., and Claesson-Welsh, L. (2003) VEGF-receptor signal transduction. Trends Biochem. Sci. 28: 488–494.

Desgrosellier, J.S. and Cheresh, D.A. (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10: 9–22.

Ellis, L.M. and Hicklin, D.J. (2008) VEGF-targeted therapy: mechanisms of antitumor activity. Nature Rev. Cancer 8: 579–591.

Folkman, J. (2006) Antiangiogenesis in cancer therapy-endostatin and its mechanism of action. Exp. Cell Res. 312: 594–607.

Geiger, T.R. and Peeper, D.S. (2009) Metastasis mechanisms. Biochem. Biophys. Acta 1796: 293–308.

George, D.J. and Moore, C. (2006) Angiogenesis inhibitors in clinical oncology.

Update Cancer Ther. 1: 429–434.

Horak, C.E., Lee, J.H., Marshall, J.-C., Shreeve, S.M., and Steeg, P.S. (2008) The role of metastasis suppressor genes in metastatic dormancy. APMIS 116: 586-601.

Kalluri, R. and Weinberg, R.A. (2009). The basics of epithelial-mesenchymal transition. J. Clin. Oncol. 119: 1420–1428.

Kaplan, R.N., Rafi i, S., and Lyden, D. (2006) Preparing the ‘Soil’: the premetastatic niche. Cancer Res. 66: 11089–11093.

Langley, R.R. and Fidler, I.J. (2007). Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr. Rev. 28: 297–321.

Lyden, D., Welch, D.R., and Psaila, B. (2011) Cancer Metastasis, Biologic Basis and Therapeutics. Cambridge University Press, Cambridge.

McCarty, M.F., Liu, W., Fan, F., Parikh, A., Reimuth, N., Stoeltzing, O., and Ellis, L.M. (2003) Promises and pitfalls of anti-angiogenic therapy in clinical trials.

Trends Mol. Med. 9: 53–58.

Oppenheimer, S.B. (2006) Cellular basis of cancer metastasis: a review of fundamentals and new advances. Acta Histochem. 108: 327–334.

Roy, R., Yang, J., and Moses, M.A. (2009). Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 27: 5287–5297.

Ruegg, C., Hasmim, M., Lejeune, F., and Alghisi, G.C. (2006) Antiangiogenic peptides and proteins: from experimental tools to clinical drugs. Biochim. Biophys. Acta 1765: 155–177.

Ruoslahti, E. (2002) Specialization of tumour vasculature. Nat. Rev. Cancer 2: 83–90.

Valastyan, S. and Weinberg, R.A. (2011) Tumor metastasis: molecular insights and evolving paradigms. Cell 147: 275–292.

9 . 1 2 TA R G E T I N G S E V E R A L S T E P S O F M E TA S TA S I S AT O N C E 223

Yang, J., Mani, S.A., and Weinberg, R.A. (2006) Exploring a new twist on tumor metastasis. Cancer Res. 66: 4549–4552.

Yilmaz, M., Christofori, G., and Lehembre, F. (2007) Distinct mechanisms of tumor invasion and metastasis. Trends Mol. Med. 13: 535–541.

■ WEB SITES

The Angiogenesis Foundation http://www.angio.org/

Clinical trials http://www.cancer.gov/clinicaltrials

■ SELECTED SPECIAL TOPICS

Cecchi, F., Rabe, D.C., and Bottaro, D.P. (2010). Targeting the HGF/Met signaling pathway in cancer. Eur. J. Cancer 46: 1260–1270.

Devy, L. and Dransfi eld, D.T. (2011). New strategies for the next generation of matrix metalloproteinase inhibitors: selectively targeting membrane-anchored MMPs with therapeutic antibodies. Biochem. Res. Int. Article ID 191670, 11 pages.

Griggs, J., Metcalfe, J.C., and Hesketh, R. (2001) Targeting tumor vasculature: the development of combretastatin A. Lancet Oncol. 2: 82–87.

Gupta, G.P., Nguyen, D.X., Chiang, A.C., Bos, P.D., Kim, J.Y., Nadal, C., et al. (2007) Mediators of vascular remodeling co-opted for sequential steps in lung metastasis.

Nature 446: 765–770.

Hood, J.D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R.A., Xiang, R., et al.

(2002) Tumor regression by targeted gene delivery to the neovasculature. Science 296: 2404–2407.

Kim, W. and Kaelin Jr, W.G. (2003) The von-Hippel-Lindau tumor repressor protein: new insights into oxygen sensing and cancer. Curr. Opin. Genet. Dev. 13: 55–60.

Liu, X., Newton, R.C., and Scherle, P.A. (2009). Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol. Med. 16: 37–45.

LoRusso, P.M., Gadgeel, S.M., Wozniak, A., Barge, A.J., Jones, H.K., DelProposto, Z.S., et al. (2008) Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest. New Drugs 26: 159–167.

Mani, S.A., Guo, W., Liao, M.-J., Eaton, E.N., Ayyanan, A., Zhou, A., et al. (2008).

The epithelial-mesenchymal transition generates cells with properties of stem cells.

Cell 133: 704–715.

Marrelli, M., Conforti, F., Statti, G.A., Cachet, X., Michel, S., Tillequin, F., et al.

(2011) Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin a-4. Curr. Med. Chem. 18: 3035–3081.

Peinado, H., Lavotshkin, S., and Lyden, D. (2011) The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin. Cancer Biol.

21: 139–146.

224 9: METASTASIS

Reardon, D.A., Nabors, L.B., Stupp, R., and Mikkelsen, T. (2008) Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin. Investig. Drugs 17: 1225–1235.

Smith, S.C. and Theodorescu, D. (2009) Learning therapeutic lessons from metastasis suppressor proteins. Nat. Rev. Cancer 9: 253–264.

Tucker, G.C. (2006) Integrins: molecular targets in cancer therapy. Curr. Oncol. Rep.

8: 96–103.

Wyckoff, J.B., Wang, Y., Lin, E.Y., Li, J., Goswami, S., Stanley, E.R., et al. (2007) Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 67: 2649–2656.

Yang, J.C., Haworth, L., Sherry, R.M., Hwu, P., Schwartzentruber, D.J., Topalian, S.L., et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody for metastatic renal cancer. N. Engl. J. Med. 349: 427–434.





Chapter 10

The immune system,

infections, and infl ammation

Introduction

The function of the immune system is to protect the host from environmental agents, including infectious agents, and it is also involved in repair. All types of white blood cells have roles in immune responses. Perhaps surprisingly, the immune system plays a dual role in cancer: it has both anti-tumor and pro-tumor effects. On one hand, immune cells can recognize and eliminate tumor cells, including the killing of viral-infected cells. However, escape from the immune response is a hallmark of cancer (see Chapter 1). On the other hand, some immune responses, such as long-term infl ammation, can promote carcinogenesis. An infl ammatory microenvironment is characteristic of all tumors and tumor-promoting infl ammation has been named as an emerging hallmark of cancer (see Chapter 1). Overall, the role of the immune system is infl uenced by the tumor and the tumor is affected by the immune system.

One-sixth of all cancers are caused by infectious agents and infl ammation. This may be a surprising fact, and suggests the logical question: “Can we ‘catch’ cancer?” The answer to this question is not straightforward. One does not “catch” cancer in the same way as one “catches a cold.” Exposure to an infectious agent does not immediately trigger cancer. However, we now know that long-term exposure to specifi c infectious agents, some causing chronic infl ammation, can lead to cancer. In addition, there is evidence that chronic infl ammation, in the absence of an infectious agent, leads to an increased risk of cancer. This is good news for cancer prevention and treatment, as we have learned a lot about the prevention and treatment of some types of infection related to other diseases and also about prevention and treatment of chronic infl ammation. Infection and infl ammation may be major preventable causes of human cancer.

Infectious agents involved in carcinogenesis include DNA and RNA viruses and bacteria.

DNA viruses contain viral genes that do not have cellular homologs. As we discussed in Chapter 6 (Figure 6.9), they act by producing proteins that interact and inhibit tumor suppressor genes (e.g. p53 and Rb) to promote cell proliferation. RNA viruses, or retroviruses, carry altered forms of cellular genes, called oncogenes, or disrupt normal gene expression via insertional mutagenesis (discussed in Chapter 4). The mouse mammary tumor virus (MMTV), an oncogenic retrovirus, is an important model system that induces breast cancer in mice through insertional mutagenesis. However, confl icting evidence for a role of MMTV-like sequences in human breast cancer has been reported.





226 10: THE IMMUNE SYSTEM, INFECTIONS, AND INFLAMMATION

Infl ammation is a physiological response against infectious agents and injury, and is a consequence of wound healing. Under normal conditions it is highly regulated and short lived: such acute infl ammation typically resolves itself with the help of anti-infl ammatory factors. By contrast, recent evidence suggests that it is lingering, chronic infl ammation that plays an important role in causing cancer. Some viral and bacterial infections induce a chronic infl ammatory response that contributes to the process of carcinogenesis. Infl ammation caused by an external agent is often referred to as extrinsic infl ammation. Cancer has been referred to as a “wound that never heals.” The body responds to a tumor by creating an infl ammatory microenvironment around it. This type of infl ammation is often referred to as intrinsic infl ammation. Infl ammatory cells, growth factors, and reactive oxygen/nitrogen species characterize the site of the infl ammatory response. These factors of infl ammation set the stage for cell proliferation, mutagenesis, angiogenesis, and metastasis. This chapter will begin with a review of the immune system and its roles in cancer. Afterwards, infectious agents that are considered to be carcinogens will be identifi ed and several modes of action of these infectious agents will be discussed. The molecular mechanisms of chronic infl ammation (in the presence or absence of an infectious agent) that contribute to carcinogenesis will also be described.

Finally, the chapter will conclude with a report on the major therapeutic applications of this knowledge.

10.1 The immune system and cancer

The immune system as a whole plays a dual role in cancer: it can both suppress tumor growth and promote it. The immune system is a network of cells, signals, and organs that helps protect against foreign invaders, infectious agents, and cancer. Before examining the roles of the immune system in cancer, a review of the main players are described in Table 10.1.

Cells of the immune system are derived from hematopoetic stem cells (HSC) in the bone marrow. As illustrated in Figure 8.7, the immune cells arise from two types of progenitor cells: myeloid progenitor cells and lymphoid progenitor cells. Immune cells that respond early and non-specifi cally to infection are part of the innate immune response and include neutrophils, eosinophils, basophils, dendritic cells, natural killer cells, and macrophages derived from monocytes (important in infl ammation as we will see later). Immune cells that respond later during infection and specifi cally to antigens presented by antigen presenting cells (APCs; e.g. dendritic cells and macrophages) are involved in the adaptive immune response and include B cells and T cells (helper T cells and cytotoxic T cells).

Here, we will focus on lymphocytes (B and T cells), cells of specifi c immunity. The main function of B cells is to synthesize and secrete antibodies. The aspect of immunity mediated by antibodies is called humoral immunity. Antibodies contain an antigen-binding domain (an antigen

1 0 . 1 T H E I M M U N E S YS T E M A N D C A N C E R 227

Table 10.1 Immune cell function in cancer: a short guide

Cell type

Function

B cells

Production of tumor-specifi c antibodies; can trigger cell lysis

T cells:

CD4+

Helper cells for cytotoxic T cell response → tumor rejection

CD8+

Principal effector cells for cytotoxic T cell response → cell lysis Treg

Immunosuppression → tumor promoting

Dendritic cells

Antigen presenting cells (APCs)

Macrophages

Important phagocytic cells of the infl ammatory response; also APCs Natural killer cells

Innate immune cells → rejection of viral-infected cells and tumor cells; release cytotoxic enzymes or secrete cytokines (e.g. interferon- γ)

Neutrophils

Innate immune cells →

Eosinophils

respond early and non-specifi cally to infection

Basophils

can be defi ned as any molecule that is able to generate an immune

response). Antibodies can recognize almost any antigen encountered by the immune system. As many B cells respond to an antigen, a mixture of antibodies is produced by many clones (polyclonal). Experimentally, we can grow a single clone of a specifi c B lymphocyte by creating a hybrid-oma, a hybrid cell formed by fusing a B cell with a B-cell cancer cell (myeloma), in order to produce quantities of a specifi c, monoclonal antibody.

Once they have recognized an antigen, antibodies can activate cell-mediated cell lysis.

T cells, mainly CD4+ helper T cells and CD8+ effector T cells, are the principal cells responsible for cell-mediated immunity. Maturation of T

cells occurs in the thymus—thus the “T” in T cells. T cells coordinate an immune response and eliminate virally-infected cells and tumor cells.

Cytokines, small secreted proteins, are the major cell signaling proteins of both B and T cells (e.g. interferon-γ, interleukins, chemokines). Note that T regulatory (Treg) cells suppress the function of immune cells and are important regulators of the immune response.

The tumor suppressive roles of the immune system

The immune system protects against cancer in three ways. Most obvi-

ously, it protects us from viral and bacterial infection that may be causative agents of cancer. It also helps resolve infl ammation, a promoter of

228 10: THE IMMUNE SYSTEM, INFECTIONS, AND INFLAMMATION

cancer (discussed later). And most directly, it can recognize and kill tumor cells. The concept that the immune system recognizes cancer cells as foreign agents and eliminates them is called immunosurveillance and was fi rst hypothesized in the mid-20th century. In support of this hypothesis, the use of mouse models has shown that mice lacking interferon-γ responsiveness or adaptive immunity (that is mice lacking B cells, T cells, and natural killer T cells), were more susceptible to both spontaneous and carcinogen-induced cancer. In humans, it was noticed that immunodefi -

cient patients and patients who received organ transplants and where prescribed immunosuppressive drugs had a higher incidence of cancer than the general population. Thus, the immune system can act as a tumor suppressive defense (reviewed in Vesely et al. , 2011).

The immune system can recognize tumor-specifi c antigens (molecules that are unique to cancer cells) or tumor-associated antigens (molecules that are differentially expressed in cancer and normal cells) and it is because of these antigens that cancer cells can be distinguished from

“self.” These types of antigens arise because of mutations that either produce altered protein products or result in mis-regulated gene expression, respectively. Examples include mutant p53 peptides and HER2

(over-expressed cellular protein). There is an ongoing effort to identify tumor-specifi c antigens for therapeutic purposes. Also, tumors caused by viruses exhibit viral antigens. These antigens can be presented to T

cells via the major-histocompatibility complex on antigen-presenting cells (dendritic cells and macrophages, see also Figure 13.1). This presentation occurs with the T-cell receptor, the primary trigger of activation. Upon activation, T cells release molecules such as perforin and granzymes, and express ligands for death receptors on the target cell.

These events have been described as the kiss of death. The cytotoxic T-cell response is one of the most important anti-tumor defenses of the body.

Cancer immunoediting

However, the immune system is not always successful in inhibiting tumor formation and, in fact, the immune system can also promote tumor formation by selecting for tumor cells that are best adapted to survive in an immunocompetent host or by creating conditions within the tumor’s

microenvironment that facilitate tumor growth. The concept of cancer immunoediting integrates the immune system’s dual role in cancer.

Immunoediting is the term used to describe how the host immune system shapes tumor immunogenicity and clonal selection and the way that cancer cells constantly modulate and “edit” the host antitumor immune system. Immunoediting may go through three distinct phases (the three

“Es” of immunoediting):

1 0 . 1 T H E I M M U N E S YS T E M A N D C A N C E R 229

(1) elimination of the cancer

(2) equilibrium, the selection of less immunogenic tumor cells during an antitumor response

(3) escape, whereby the tumor evades the immune system.

The process begins with the elimination phase. During the elimination phase, the immune system is alerted to a developing tumor, most likely by cytokines that are induced during early tumor development. As a consequence, an anti-tumor immune response, carried out by both innate and adaptive immunity, is initiated. If the immune system is successful at eliminating the tumor cells, then the host is cancer free and the next phase is not initiated. Immunoediting is complete. But if only a portion of tumor cells are eliminated, then the process enters a phase of equilibrium between the immune system and the developing tumor. During equilibrium, rare tumor cell variants that escape the elimination are kept at bay by the adaptive immune response. This may account for decades of immune dormancy. The immune system may also help shape the immunogenicity.

This phase may provide pressure to select for tumors cells that acquire immunoevasive mutations, leading to lower quantities or tumor antigens or less potent antigens. These tumors cells may then enter the fi nal phase, escape.

Mechanisms of avoiding immune destruction

As discussed in Chapter 1, avoiding immune destruction is a new emerging hallmark of cancer. Mechanisms for tumor evasion include loss of tumor antigens, downregulation of antigen-presenting molecules, and tumor resistance to cytotoxic pathways including over-expression of anti-apoptotic molecules.

Several factors in the tumor microenvironment have been shown to

play a role in tumor escape. Tumors secrete immunosuppressive mole-

cules such as transforming growth factor β (TGFβ), interleukin-10 (IL-10), VEGF, and indolamine-2,3-dioxygenase (IDO). TGF-β binds to

the TGF-β receptors on lymphocytes and can alter their phenotype and cytokine secretion profi les. They have been implicated in the generation of T regulatory cells that actively inhibit other T cells. IL-10, a cytokine, exerts its effects by binding to its cell surface receptor expressed on immune cells. The signal transduction pathway involves tyrosine kinase phosphorylation and activation of the STAT transcriptions factors

leading to the upregulation of hundreds of genes. IL-10 is able to prevent the maturation of dentritic cells, the most important antigen-presenting cell involved in primary immune responses. In addition, IL-10

has a direct effect on CD4+ T cells; it inhibits their proliferation and their production of cytokines. IDO was fi rst known for its role in





230 10: THE IMMUNE SYSTEM, INFECTIONS, AND INFLAMMATION

maternal tolerance to antigens from the fetus and is thus involved in evading the immune response. Pre-clinical studies suggest that inhibitors of IDO may restore immunity and permit immune destruction of

the tumor. We explore the use of immunotherapy in cancer in detail in Chapter 13.

Evidence for cancer immunoediting

Supporting evidence that the immune system can affect the immunogenicity of a tumor is that tumors formed in a defi cient immune system are more immunogenic and are hence described as “unedited” whereas

tumors formed in immunocompetent hosts are termed “edited.” External factors such as stress, aging, and medical intervention can also affect the process.

The strongest evidence for cancer immunoediting in humans comes

from the studies that show that the profi le (quantity, type, and location) of tumor-infi ltrating lymphocytes correlate with patient survival and prognosis for several different cancers. For example, melanoma patients with high levels of CD8+ cell infi ltration survive longer than those with tumors containing low numbers of these cells. Conversely, tumor infi ltration by immune inhibitory cells such as Tregs, have a negative prognosis.

In fact, some studies report that the type and density of tumor-infi ltrating lymphocytes was a more accurate prognostic indicator than tumor stag-ing by pathology and analysis of oncogene expression. In addition, as mentioned earlier, patients with immunodefi ciencies or who have had organ transplants and are taking immunosuppressive drugs, are more

likely to develop some types of cancer (see Roithmaier et al. , 2007 as one example).

10.2 Identifying infectious agents as carcinogens

In order to identify which infectious agents actually cause cancer several general criteria are applied. First, there must be a consistent association between infection and the cancer that is supported by either epidemiological or molecular evidence. In addition, cell transformation or induction of tumors in animal models by the infectious agent must be demonstrated. In some instances, infectious agents may not reside in the transformed cells but may cause cancer indirectly, through infl ammation and chronic tissue injury or paracrine growth stimulation (see “Kaposi’s sarcoma-associated herpesvirus” section). A list of some of the infectious agents that are known to be carcinogenic is shown in Table 10.2 and discussed in the following sections.

1 0 . 2 I D E N T I F Y I N G I N F E C T I O U S AG E N T S A S C A R C I N O G E N S 231

Table 10 .2 Infectious agents and their role as cancer-causing agents (data from Pagano et al. , 2004)

Infectious agent

Type

Presence in

Type of cancer

Causative

Major

tumor

effector

Human

DNA virus

100%

Cervical

Yes

E6, E7

papillomaviruses

Epstein–Barr virus

DNA virus

100%

Nasopharyngeal

Yes

carcinomas

98% (endemic)

Burkitt’s

No

LMP1

lymphoma

Kaposi’s sarcoma-

DNA virus

>95%

Kaposi’s sarcoma

Yes

LANA

associated herpesvirus

100%

Primary effusion

Yes

LANA

lymphoma

Human T-cell leukemia

RNA virus

100%

T-cell leukemia

Yes

Tax protein

virus

Hepatitis B virus

DNA virus

100%

Hepatocellular

Yes

HBV X

carcinoma

Helicobacter pylori

Bacterium

+ / − Gastric

cancer

Yes

CagA

Epstein–Barr virus (EBV)

Epstein–Barr virus, a DNA virus, is a good starting point for examining the role of infectious agents as carcinogens. Upon close evaluation it has been shown to act as a causative factor in B-cell lymphoproliferative diseases and probably nasopharyngeal carcinoma. However, it is thought to be only a contributing factor for a type of cancer called Burkitt’s lymphoma (Pagano et al. , 2004). Let’s look at the evidence. In support of a causative role of EBV in the former two cancers, it has been demonstrated that EBV can transform lymphoid cells in culture and documented that all cases of nasopharyngeal carcinoma are associated with EBV infection, regardless of geographical location. In contrast, Burkitt’s lymphoma is not always associated with EBV although Burkitt’s lymphoma is associated with EBV in geographical regions that are also endemic for malaria (Table 10.2). This suggests that EBV may be an important co-factor along with malaria for the disease. Thus, epidemiological evidence is lacking to support a causative role for EBV in Burkitt’s lymphoma. Further studies examining the role of EBV, perhaps in subtypes of Burkitt’s lymphoma, are required.

Epstein–Barr virus encodes several viral proteins that affect host gene expression. One of these, oncoprotein LMP1, is able to transform cells in

232 10: THE IMMUNE SYSTEM, INFECTIONS, AND INFLAMMATION

culture. Its multi-functional effects include the activation of genes that are important for promoting cell proliferation (e.g. EGFR) and inhibiting apoptosis (e.g. Bcl-2). It also activates a nuclear transcription factor called NF-κB. As we will see later, activation of cell growth pathways and anti-apoptotic pathways, as well as activation of the key player, NF-κB, are important molecular themes that run throughout this chapter.

Human papillomavirus (HPV)

Human papillomavirus infection is strongly associated with cervical can-LIFESTYLE TIP

cer: virtually 100% of all cervical cancer cells contain HPV. There is a lag Cancer is a rare but possible con-time between HPV infection and cervical cancer of at least 10 years. Geni-sequence of contracting a sexu-

tal HPV may be the most common sexually transmitted viral infection, ally transmitted disease. This may

and the risk of infection increases with the number of sexual partners.

be one reason to consider neces-

This DNA virus requires access to the proliferating cells of the cervical sary precautions.

epithelium. It uses entry points created by micro-erosion of the overlying cell layers to reach the basal layer of the epithelium, where stem cells and progenitor cells reside. The development of cancer involves expression of viral genes, integration of viral DNA into the host chromosomes, and changes to host cell genes and gene products. The HPV gene products E6

and E7 are major players in carcinogenesis that target tumor suppressor proteins in the host cell. E7 binds to and triggers the degradation of RB, thus preventing the sequestration of E2F. This leads to the constitutive expression of E2F responsive genes, including cyclin A and cyclin E that are important for cell cycle progression. E6 forms a complex with a ubiquitin ligase. The complex binds p53, and p53 degradation is triggered (see Chapter 6). E6 and E7 can also induce genomic instability by targeting telomerase, γ-tubulin (a centrosome regulator), and proteins involved in DNA damage pathways. Both E6 and E7 have been shown to induce

DNA damage. Viral products E6 and E7 are able to transform cultured human cells and induce tumors in mice.

Note that only a subset of the total of 130 types of HPV that have been identifi ed is considered “high risk” for cervical cancer (see Figure 10.1).

High-risk HPVs also contribute to over 40% of oral cancers and some penile, vulvar, and anal cancers. HPV16 and HPV18 account for about 70% of the global distribution of HPV types in cervical cancer. Viral genotype analysis, distinguishing between the different types, was crucial in establishing the link with cervical cancer; if all HPVs were considered as one agent the link would not have been established.

Human T-lymphotropic virus type-1 (HTLV-1)

Almost all cases of adult T-cell leukemia exhibit molecular evidence for the presence of HTLV-1. This is the only virus known to have a causal link

1 0 . 2 I D E N T I F Y I N G I N F E C T I O U S AG E N T S A S C A R C I N O G E N S 233

HPV 16

21%

HPV 18

2%

HPV 45

2%

HPV 31

55%

2%

HPV 52

3%

HPV 33

4%

HPV 58

Figure 10.1 A pie chart showing

11%

HPV others

the distribution of HPV types in

cervical cancer (data from Munoz

et al. , 2003.)

to human leukemia. Also, it is the only retrovirus that is linked to human cancer. HTLV-1 infection is prevalent in Japan, the Caribbean, South America, and Central Africa. About 2–5% of infected individuals develop T-cell leukemia/lymphoma.

Transmission of the virus is through intimate contact and includes

transmission through breast milk, semen, unscreened blood, and contaminated needles among drug users. In Japan, breast-feeding for more than six months has been discouraged; as a result, transmission of HTLV-1 to infants has been greatly reduced.

As a retrovirus, HTLV-1 genomic RNA is copied into DNA by reverse

transcriptase before viral proteins are synthesized by the host cell’s machinery. The TAX protein of HTLV-1 is a key player in the mechanism of HTLV-1-induced carcinogenesis. TAX exerts its functions by

protein–protein interactions with over a hundred cellular proteins generating a plethora of effects, including stimulation of cell growth, inhibition of DNA repair, and alteration of the cell cycle by activating cyclin-dependent kinases (Boxus and Willems, 2009). It is a molecule that activates host cell genes through the transcription factors NF-κB

(see later section) and AP1, and interferes with several tumor suppressor proteins (e.g. p53) to promote cell proliferation and, ultimately, leukemia.

Hepatitis B virus (HBV) and liver cancer



There is a strong association between hepatitis B virus infection and liver cancer (hepatocellular carcinoma). Hepatitis B, a DNA virus, is a potent carcinogen, as demonstrated by the fact that HBV carriers have a 10–25-fold greater risk of developing hepatocellular carcinoma than uninfected individuals (see Pagano et al. , 2004). Host–viral interactions evoke an immune response that results in liver necrosis, infl ammation, and regeneration. These effects are sustained in the 10% of adults who develop chronic infections. It has been proposed that increased proliferation

234 10: THE IMMUNE SYSTEM, INFECTIONS, AND INFLAMMATION

Note that hepatitis C virus

and/or oxidative stress from infl ammation may lead to oncogenic muta-is also a risk factor for

tions. Infl ammation caused by hepatitis B virus is important for the devel-hepatocellular carcinoma

opment of hepatocellular carcinoma, in a manner that parallels

but details will not be

mechanisms observed in gastric cancer (see later section).

included here.

The multifunctional viral protein, HBV X, is thought to be important for HBV-induced carcinogenesis and it was shown to induce liver cancer in transgenic mice. It is thought to function by activating proto-oncogenes via various signaling cascades, including many kinase cascades (e.g. the RAS–RAF–MAPK pathway, Chapter 4); interacting with NF-κB (see

later); and binding to and inactivating p53.

Kaposi’s sarcoma-associated herpesvirus (KSHV)

Kaposi’s sarcoma-associated herpesvirus (KSHV; also known as herpesvirus 8 (HHV8) is a DNA virus. It is causally linked with a vascular tumor of heterogeneous cell composition usually associated with the skin, called Kaposi’s sarcoma (>95%), and primary effusion lymphomas (100%). The virus is thought to infect circulating endothelial precursor cells or endothelial cells. Although Kaposi’s sarcoma is associated frequently with AIDS

patients, there are types found in different populations where AIDS is not prevalent. Classic Kaposi’s sarcoma is seen in elderly men of Mediterranean or eastern European Jewish ancestry while an endemic type is prevalent in parts of Central and Eastern Africa described before the HIV

pandemic. Kaposi’s sarcoma is also seen in immunosuppressed patients who have received an organ transplant. It is thought that immunodefi -

ciency is the main mechanism by which HIV infection acts as a co-factor for KSHV. KSHV infection in the general population rarely leads to Kaposi’s sarcoma.

KSHV is thought to contribute to tumorigenesis through several mechanisms. Firstly, several viral gene products have been shown to drive cell proliferation and prevent apoptosis. KSHV produces viral cyclin, viral anti-apoptotic proteins (e.g. vBcl-2), viral-encoded miRNAs, and a viral protein called LANA that interferes with the function of RB and p53.

LANA’s mechanism of targeting two crucial tumor suppressor proteins is shared with HPV viral proteins.

However, note that Kaposi sarcoma cells are not fully transformed in that they are not able to induce tumors in nude mice like other tumor cells and they require external growth factors and cytokines to grow in vitro. It has been suggested that KSHV tumorigenesis involves a paracrine process, (coined paracrine neoplasia), whereby KSHV-infected cells induce neighboring uninfected cells to produce cytokines and growth factors that are necessary as autocrine and paracrine factors for driving tumorigenesis.

1 0 . 2 I D E N T I F Y I N G I N F E C T I O U S AG E N T S A S C A R C I N O G E N S 235

Helicobacter pylori infection and gastric cancer



Helicobacter pylori is a bacterium capable of inducing chronic infl ammation in the stomach and initiating carcinogenesis. It has been identifi ed as a carcinogen for humans by the International Agency for Research on Cancer (IARC)/World Health Organization. However, less than 1%

of those infected will develop gastric cancer. Gastric carcinogenesis depends on the bacterial strain, host response, and environmental factors. It is a multi-step process where infl ammation is considered the initial and required step in the process: Helicobacter pylori infection→chronic superficial gastritis→atrophic gastritis→intestinal dysplasia→gastric carcinoma.

Gastric atrophy is characterized by the loss of normal glandular cells and results in a decrease of acid production. These conditions allow additional bacteria to colonize the stomach and trigger an infl ammatory response.

Epidemiological studies show that the prevalence of gastric cancer corresponds with the prevalence of particular strains of H. pylori in specifi c geographical locations and that gastric cancer develops in H. pylori-

infected individuals and not in uninfected individuals. Overall, it is estimated that 60–90% of all gastric cancers are caused by H. pylori infection.

Experimental evidence includes the induction of gastric cancer in animals by H. pylori infection and reduction in gastric cancer risk and the prevention of pre-cancerous lesions by eradication of H. pylori infection.

Let’s examine the proposed mechanism by which this bacterium can

LIFESTYLE TIP

cause cancer. Many high risk strains of H. pylori code for a protein called cytotoxin-associated antigen A (CagA). Epidemiological studies show Indications of a stomach ulcer

that CagA-positive strains are predominant in regions with a high preva-should be brought to the atten-

lence of gastric cancer. The bacterial CagA protein is an effector protein tion of a doctor. Early eradication

of H. pylori infection, especially

that is injected into cells by the bacterial secretion system to elicit cellular in high-risk locations such as east

effects, such as stimulation of cell growth (Figure 10.2a). Integrin recep-Asian countries, may help pro-

tors on host cells represent a portal of entry for CagA injection. CagA is tect against gastric cancer.

phosphorylated by cellular tyrosine kinases that are members of the Src family of kinases. Phosphorylated CagA interacts with SH2 domain-containing proteins such as SHP-2 (an oncogenic tyrosine phosphatase, see Chapter 4) and Grb2. SHP-2 normally maintains an inactive conformation by a mechanism similarly described for Src (see Figure 4.6): an amino-SH2 domain of SHP-2 blocks substrate access by an intramolecular interaction. Binding of CagA may cause a conformational change that relieves the intramolecu lar inhibition and leads to the stimulation of SHP-2 phosphatase activity (note the change in shape of SHP-2, shown in red in Figure 10.2a). Thus, CagA binding of SHP-2 mimics a gain-of-function oncogenic mutant form of SHP-2. A signal transduction pathway is initiated that affects cell mitosis, migration, and adhesion (Figure

236 10: THE IMMUNE SYSTEM, INFECTIONS, AND INFLAMMATION

(a)

(b)

mitosis

H. pylori

cell migration

transformation

Cag A

SHP2

cell adhesion

gastritis

apoptosis

increased:

Cag A

• cell turnover

Src family

• DNA replication

of kinases

• mutation

Cag A

P

PTP

PTP

SH2

Figure 10.2 Molecular mechanisms involved in H. pylori

Inactive

SH2

infection that contribute to carcinogenesis. (a)

SHP2

Active

Phosphorylated cytotoxin-associated antigen A (CagA)

SHP2

causes a conformational change and activates an oncogenic

protein tyrosine phosphatase (PTP) called SHP-2. (b)

Transformation

Cellular effects of SHP-2 activation that may lead to

transformation.

10.2b). Sustained activation of SHP-2 by CagA leads to apoptosis in cell culture, most likely as a result of it causing an imbalance of mitogenic signals. Long-term apoptosis of the gastric mucosal cells may be the cause of gastritis and also lead to increased cell turnover. Increased DNA replication increases the risk of mutation and may lead to transformation. Also, CagA induces the nuclear accumulation of β-catenin, an

important host transcriptional regulator of genes that are required for the development of metaplasia. Another H. pylori protein linked with gastric malignancy is VacA. VacA is a secreted protein that induces vacu-olation and apoptosis by inserting into in gastric epithelial cell and mitochondrial membranes.

In addition to the effect of bacterial proteins on cell signaling and cell biology, other mechanisms seem to be involved in carcinogenesis caused by H. pylori. These include effects of chronic infl ammation and stem cell recruitment (see page 242). In addition to CagA, H. pylori also delivers proteins to cells that induce pro-infl ammatory mediators through the NF-κB pathway. Helicobacter pylori-induced infl ammation stimulates DNA methyltransferases and results in epigenetic changes by hypermethylation. Infl ammation may induce oxidative stress and ultimately increase the rate of mutations. Helicobacter pylori may also induce oxidative stress by production of superoxide and reduction of the antioxidant vitamin C.

Note that although causality has not yet been proven, associations

between other bacterial infections and cancer have been noted. These include Salmonella typhi infection and gall bladder cancer, Streptococcus





1 0 . 3 I N F L A M M AT I O N A N D C A N C E R 237

bovis and colon cancer, Bartonella and vascular tumors, and Chlamydia PAUSE AND THINK

pneumoniae and lung cancer.

Try to make a list of the infec-

tious agents discussed in this

section and describe how their

10.3 Infl ammation and cancer

major effector molecule(s) exert

its (their) effects. Check your

answers with Table 10.2.

The link between infl ammation and cancer is clearly illustrated by the association of chronic infl ammation in both hepatitis B virus and H.

pylori-induced cancers, as seen in Section 10.2. Furthermore, infl ammation plays a causative role, independent of infection. There are a number of chronic infl ammatory conditions caused by non-infectious agents that are associated with cancer.

• In addition to being a tumor initiator because of its 81 carcinogens, tobacco smoke also acts as a tumor promoter by virtue of its ability to induce chronic infl ammation (Takahashi et al. , 2010). (Tumor promotion is the process of tumor growth from a single initiated cell into a primary tumor.)

• It has been proposed that asbestos acts as an infl ammatory stimulus in the lungs, predisposing individuals to bronchial carcinoma.

• Similarly, esophageal refl ux causes injury of the esophagus and may induce an infl ammatory response that increases the risk of esophageal carcinoma.

• Infl ammatory bowel disease greatly increases the risk of colorectal cancer.

• In an animal model prototype of infl ammation-associated cancer, genetically altered mice that develop liver infl ammation also subsequently develop cancer (this animal model is used in the study by Pikarsky et al. (2004) discussed in the “How do we know that?” box).

Let’s examine the molecular and cellular events of the infl ammatory response. Oncogenes, activated upon cancer initiation, also regulate the expression of tumor-promoting infl ammatory cytokines generating an infl ammatory microenvironment for tumors that do not develop from an infl ammatory environment. RAS and myc are two examples of important oncogenes that induce infl ammatory cytokines.

The key cells of a chronic infl ammatory response are macrophages.

These cells produce tumor necrosis factor-alpha (TNF-α), a cytokine that

helps orchestrate the infl ammatory response by inducing a range of effector molecules, some of which help perpetuate the infl ammatory response.

In addition, leukocytes produce reactive oxygen and nitrogen species (ROS and NOS, respectively) to help fi ght infection, but these products (via the formation of peroxynitrite) also cause DNA damage. Chronic infl ammation is associated with an increased production of ROS and NOS, increased risk of DNA damage, and therefore increased mutation rates. Tissue regeneration and cell renewal induced by hepatitis B virus

238 10: THE IMMUNE SYSTEM, INFECTIONS, AND INFLAMMATION

and H. pylori infections, respectively, involve cell division, during which DNA is most susceptible to damage. Thus, the interplay between infection and an immune response can be seen.

Several pro-infl ammatory products, such as TNF-α, interleukins, and chemokines, mediate processes known to be critical in carcinogenesis: proliferation, apoptosis, angiogenesis, and metastasis. The expression of the genes that code for these products is regulated by the transcription factor NF-κB. As NF-κB is induced by carcinogens, including oncogenic viral products, it is an important link between infl ammation and cancer and will be discussed in detail later in this chapter.

Once a tumor has developed, the immune response continues to play a role in tumor progression. Both the tumor cells and non-malignant cells residing in or near the tumor are involved in the process of infl ammation-associated malignant progression (Figure 10.3). Chemoattractive molecules, called chemokines, are involved in the recruitment and the infi ltration of leukocytes, including tumor-associated macrophages (TAMs), into the tumor. The expression of growth factors, cytokines, and chemokines, by both the TAMs and the tumor cells, impacts on the cells in that location and promotes proliferation and survival. TNF-α produced by TAMs and a variety of tumor cells is a key player in the infl ammatory response, as mentioned above, and, when unregulated, can act as a tumor promoter. TNF-α

can affect cell motility and tumor metastasis. The enzyme, inducible nitric oxide (NO) synthase, is one target stimulated by TNF-α. This enzyme is implicated in several stages of carcinogenesis including cell transformation and growth of transformed cells. The cytokine interleukin-6 (IL-6), produced by liver macrophages, has been shown to be important in hepatocarcinogenesis (Naugler et al. , 2007) and it is the downregulation of IL-6

by macrophages in response to estrogen that is responsible for females being less susceptible to liver cancer. Production of IL-6 requires the activation of transcription factor NF-κB (see following section). In addition to their role in recruiting leukocytes to the site of infl ammation, chemokines Figure 10.3 Molecular events of

TAM

the infl ammatory response at the

site of a tumor. Tumor cells (red)

ROS

secrete chemokines that recruit

Cytokines

Cytokines

NOS

leukocytes including tumor-

(e.g. TNF α)

associated macrophages (TAMs).

Chemokines

TAMs produce cytokines and

reactive oxygen/nitrogen species

(ROS/NOS, respectively) which

can mutate DNA (shown by the

asterisk). Tumor cells also

produce cytokines. Chemokines

promote angiogenesis.

Tumor

Angiogenesis

1 0 . 3 I N F L A M M AT I O N A N D C A N C E R 239

play an important role in the angiogenic switch. Chemokines signal via G-protein-coupled receptors, and this results in the transcription of target genes. Pro-infl ammatory chemokines promote angiogenesis.

NF-κB is a key player in the infl ammatory response



A key mediator of the infl ammatory response is the transcription factor NF-κB. It is induced by several cell types, such as macrophages, target cells of infl ammation, and cancer cells. Figure 10.4 shows some of the upstream activators of NF-κB in both macrophage and cancer cells (see Aggarwal, 2004; Karin, 2006). NF-κB is activated by specifi c macro phage products (e.g. TNF-α), H. pylori CagA protein, viral proteins (e.g. KSHV), carcinogens (cigarette smoke), stress, and chemotherapeutic agents. In addition to infl ammation, NF-κB has other downstream effects that contribute to tumorigenesis, such as the inhibition of apoptosis and the promotion of metastasis and angiogenesis (Figure 10.4). Thus, NF-κB provides a molecular link between infl ammation and cancer. Oncogenic activation of the NF-κB gene has also been identifi ed in human tumors, including multiple myeloma, acute lymphocyte leukemia, prostate, and breast cancers.

Inflammatory

Bacteria

Carcinogens

agents

• endotoxin

• cigarette

• cytokines

• cagA protein

smoke

(e.g. TNF α)

Viruses

• EBV

Stress

• HTLV-1

Upstream

• hypoxia

• HBV

• KSHV

NF-κB

Downstream

Inhibition

Metastasis

Inflammation

of apoptosis

Angiogenesis

Tumorigenesis

Figure 10.4 Upstream activators

and downstream effects of NF-κB.

240 10: THE IMMUNE SYSTEM, INFECTIONS, AND INFLAMMATION

Let’s describe the molecular regulation of the NF-κB pathway (Figure 10.5). NF-κB (shown in red) is a dimeric transcription factor made up of hetero- or homodimers of protein members in the NF-κB family. The fi ve NF-κB family members are placed into two groups. The fi rst group consists of p65 (RelA), Rel B, and c-Rel. The second group consists of NF-κB 1

(p50), and NF-κB 2 (p52). The fi rst group of proteins are synthesized as mature products, whereas the second group of proteins must be proteolytically processed to produce the mature p50 and p52 proteins. Only the fi rst group contains transactivation domains and therefore proteins of the second group cannot activate transcription on their own. The most pre-PAUSE AND THINK

dominant NF-κB dimer activated by the classical pathway is p65–p50.

(Note: an important fi nding linking NF-κB to carcinogenesis was the dis-Can you remember similar types

covery that c-rel is the proto-oncogene of the v-rel oncogene.) Normally, of molecular mechanisms regu-NF-κB is sequestered in the cytoplasm by an inhibitor of NF-κB (IκB).

lating other transcription fac-

Upon cell activation, the kinase IκB kinase (IKK), phosphorylates IκB and tors? Hint: one is an important

targets it for degradation via a ubiquitin ligase complex. This causes the transcription factor involved in

release and translocation of NF-

angiogenesis and another is

κB to the nucleus. Here, NF-κB can tran-

involved in an important develop-

scriptionally regulate its target genes at NF-κB DNA response elements mental program.

(GGGRNNYYCC). NF-κB regulates more than 200 genes to elicit its

varied effects.

Stimulus

Cell membrane

IKK

P

IκB NF-κB

P

u

IκB

NF-κB

Nucleus

Degradation

NF-κB

Target genes:

Bcl-XL

c-Flip

Cox-2

MMP9

VEGF

cytokines (IL6, TNF α) etc.

Figure 10.5 Regulation of the

Inhibition

Inflammatory

Metastasis

NF-κB pathway. See text for

of apoptosis

response

Angiogenesis

details.

1 0 . 3 I N F L A M M AT I O N A N D C A N C E R 241

One of the most important cellular effects of activation of NF-κB is the inhibition of apoptosis via the induction of anti-apoptotic gene expression (e.g. induction of Bcl-XL, cellular inhibitor of apoptosis (c-IAP), cFLIP). In this way NF-κB prevents an important tumor suppressing

mechanism and promotes carcinogenesis.

? HOW DO WE KNOW THAT?

Functional knock-out mice

tory cells controlled the activation of NF-κB in the hepatocytes.

PCR analysis of cell fractions showed that the source of TNF-α

The role of NF-κB in tumorigenesis was investigated in a mouse

was in the non-hepatocyte fraction of the liver. A block in

model system whereby the mouse strain develops hepatitis and

NF-κB activation was demonstrated by using an anti-TNF-α

is prone to hepatocellular carcinoma (Pikarsky et al. , 2004).

antibody to block TNF-α function. Thus, NF-κB in the liver is

Transgenic animals containing a hepatocyte-inducible NF-κB

controlled through a paracrine manner via TNFα produced by

inhibitor, IκB, were examined as a means of creating an equiva-

infl ammatory cells.

lent of a NF-κB knockout.

This work supported the fi ndings from another laboratory

Why and how was this hepatocyte-inducible (Greten et al. , 2004) that also used knock-out transgenic mice regulation accomplished?

to ablate (knock out) NF-κB activity. An essential activator of

As NF-κB is involved in many crucial cellular responses, a total

NF-κB, called IKKβ, was ablated in intestinal epithelial cells in a eradication of activity would lead to embryonic lethality. An

mouse model of colon cancer. These mice showed an 80%

experimental system that can be turned on and off would allow

reduction in tumor incidence relative to control animals. Tumor

for normal development and investigation of the role of NF-κB

size was not affected. Analysis of the colon revealed that apo-

in one tissue-specifi c context.

ptosis was not inhibited by NF-κB in these altered mice. Thus,

The IκB gene was linked to a tetracycline-regulated promoter

apoptosis acts as an important tumor-suppressing mechanism

so that IκB was only expressed in the presence of a tetracycline

in the absence of NF-κB activation. Ablation of IKKβ in myeloid

transactivator. The gene for the transactivator was under the

cells in this mouse model reduces the expression of cytokines

control of a hepatocyte-specifi c promoter so that it was only

that infl uence tumor growth and results in a decrease in tumor

expres sed in liver cells. In the presence of the tetracycline deriv-size. Thus, inhibition of the NF-κB pathway in these two cell

ative, doxycycline, the tetracycline-controlled transactivator types affects tumorigenesis in two different ways (Table 10.3).

could not bind to its target DNA sequences (sequences of the

Table 10.3 Summary of NF-κB pathway

tetracycline operon) and transcription of IκB was blocked.

inhibition experiments

Treatment of mice with the doxycycline suppressed the

transgene (in this case, the inhibitor of NF-κB). So, doxycycline-

Deletion of IKKβa

Intestinal

Myeloid

epithelial

cells

treated transgenic mice contained active NFκB, while untreated

cells

mice contained inactive NF-κB owing to the expression of its

inhibitor (see Pause and Think).

Tumor incidence

Decrease

The results showed that when NF-κB is inactive, only a small

percentage (10%) of pre-cancerous adenomas progressed to

Tumor size

No effect

Decrease

carcinoma compared with controls. Blocking NF-κB activity

Production of

Decrease

induced hepatocyte apoptosis as detected by antibody staining

for activated caspase-3 and also led to a dramatic decrease in

pro-infl ammatory

tumor progression as shown by magnetic resonance imaging

cytokines

and histological analysis. In addition, they showed that the

infl ammatory factor, TNF-α, produced by residing infl amma-

aFunctionally equivalent to inactive NF-κB

242 10: THE IMMUNE SYSTEM, INFECTIONS, AND INFLAMMATION

PAUSE AND THINK

Other roles of NF-κB

See if you can sketch a diagram

NF-κB activates the cyclin D1 gene and thus plays a role in regulating the that shows the transgene (labe-cell cycle. In addition, NF-κB activates the expression of pro-infl ammatory ling promoter and coding

genes (e.g. the COX-2 gene and cytokine genes) and metastasis and angio-sequences), the transactivator,

genic genes (e.g. MMP9, chemokine receptors, VEGF). COX-2 is an

and the consequences of no

enzyme that is involved in the synthesis of prostaglandin, PGE-2, a potent treatment versus doxycycline

pro-infl ammatory molecule (see section 10.7). A NF-κB DNA-binding ele-treatment. Check your answer

ment has been identifi ed in the MMP9 gene. Thus, NF-κB helps maintain with Figure 10.6.

the infl ammatory response and promotes metastasis. It is important to note that NF-κB also has anti-tumorigenic effects in certain tissues (e.g.

skin) and so complexities of cell context exist and must be kept in mind when considering therapeutic strategies. Note, STAT3 and AP-1 are two other transcription factors that are activated in tumor and infl ammatory cells and orchestrate gene programs involved in infl ammation and tumor promotion. STAT3 is required for the maintenance of NFkB in tumors.

Infl ammation and tissue injury in gastric cancer recruits bone

marrow stem cells

In Chapter 8 we discussed that cancer may arise from cancer stem cells and reviewed the data in support of tissue-specifi c cancer stem cells. An alternative proposal suggests that the stem cells that contribute to cancer may originate from a different tissue. The environment of tissue injury and infl ammation has been linked to the recruitment of bone marrow-derived stem cells. Bone marrow-derived stem cells respond to infl ammatory Transgenic mouse:

All cells in the animal

contain the transgene

TA is only expressed

in liver cells of the

Hepatocyte-

TA

transgenic animal

specific

promoter

Doxycycline

IκB NFκB

Figure 10.6 Hepatocyte-inducible

regulation of a transgene used to

–

TA

TET

IκB

Inactive

experimentally control NF-κB

activity. TA, transactivator; IκB,

inhibitor of NF-κB; TET,

+

TA

NFκB

tetracycline-regulated promoter

Active

sequence.

TET

IκB





1 0 . 3 I N F L A M M AT I O N A N D C A N C E R 243

mediators and tissue injury, and because of their demonstrated plasticity may serve as a backup when tissue-specifi c stem cells are damaged. In a mouse model of gastric cancer induced by chronic infection with H. pylori, bone marrow-derived stem cells were shown to be recruited to the stomach and to contribute to gastric cancer (Houghton et al. , 2004). Acute infl ammation and/or injury did not cause recruitment of these stem cells.

In summary, as can be seen from the preceding discussions, several mechanisms of infection and infl ammation are involved in the process of cancer initiation and promotion. We have seen examples of infectious agents that carry oncogenes or produce products that inhibit tumor suppressors. Many infective agents trigger chronic infl ammation and this plays a part in their mechanism of action. However, chronic infl ammation, even in the absence of an infectious agent, plays its own role in carcinogenesis. Key cells of the infl ammatory response produce factors that infl uence major processes involved in carcinogenesis and, as reported more recently, trigger the migration of stem cells that may themselves contribute to cancer.

Therapeutic strategies

Cancers caused by infections could be prevented if infections could be eradicated. The impact of this can be fully appreciated by looking at some numbers: there are 405,000 deaths per year worldwide from gastric carcinoma and 35,000 women per year die from cervical cancer in the USA and Europe.

Infections are implicated in the occurrence of these diseases. Wouldn’t it be extraordinary if we could prevent the suffering and death of these people?

What follows is a discussion of several strategies targeted against infection and infl ammation for the prevention of cancer (Figure 10.7). Some of NSAIDS

Vaccines

– Celebrex

– Gardasil

Antibiotics

– Vioxx (withdrawn)

– Cervarix

– HBV vaccine

Cox 2

Bacteria

Viruses

Inflammation

– H. pylori

– HPV

IKK

– Hepatitis B

Gastric cancer

IKK inhibitors

Cervical cancer

– PS –1145

(and some head and

Figure 10.7 Cancer prevention

neck/anal cancers)

strategies targeted against

Liver cancer

infection and infl ammation.





244 10: THE IMMUNE SYSTEM, INFECTIONS, AND INFLAMMATION

these are used today, others have just been approved or are on our

doorstep, and one has been tried but is no longer administered because of severe side-effects.

10.4 A national vaccination program against hepatitis B

virus in Taiwan

In Taiwan, in 1982, 15–20% of the population were carriers of hepatitis B

virus. In addition, 20% of all cancer deaths were a result of hepatocellular carcinoma, and more than 80% of these cases were caused by chronic

hepatitis B infection. As a result of this public health problem, a nation-wide hepatitis B vaccination program was initiated in 1984. In the fi rst two years, infants born to carrier mothers were vaccinated. Two years later, all newborns were vaccinated, and from 1987 pre-school children were vaccinated. Later adolescents and adults were also vaccinated. The incidence of hepatocellular carcinoma in children decreased signifi cantly (Figure 10.8), demonstrating that a majority of cases of hepatocellular carcinomas in children can be prevented by hepatitis B vaccination.

10.5 Eradication of H. pylori and the relationship to

prevention of gastric cancer

Wong et al. (2004) examined the effects of H. pylori eradication on the prevention of gastric cancer in a randomized, controlled trial. Participants (1630 healthy carriers of H. pylori from a high-risk region of China) were randomly divided into two groups: approximately half

received a two-week course of triple therapy (omeprazole, amoxicillin plus clavulanate potassium, and metronidazole) and half received a placebo. They were followed up for 7.5 years from 1994–2002. The study found that the incidence of gastric cancer was similar between the two groups. However, eradication of H. pylori resulted in a signifi cant decrease of the incidence of gastric cancer in the group of H. pylori 1.00

0.80

0.60

0.40

0.70

0.57

0.20

0.36

Annual average

incidence 100,000

Figure 10.8 Graph showing the

0.00

effects of HBV vaccination on

1981–1986 1986–1990 1990–1994

liver cancer in children.

Year





1 0 . 6 C A N C E R VAC C I N E S TO P R E V E N T C E R V I C A L C A N C E R 245

carriers who did not have pre-cancerous lesions. Thus, these results suggest that eradication of H. pylori should be considered in all patients without pre-cancerous lesions in high-risk areas.

10.6 Cancer vaccines to prevent cervical cancer

The world’s fi rst cervical cancer vaccine called Gardasil™ (Merck), was PAUSE AND THINK

approved in June 2006 by the US Food and Drug Administration (FDA).

The hope is that, over time, after implementation of vaccination strate-Why were these four HPV types

gies, the number of women diagnosed with cervical cancer in the world chosen for the production of

Gardasil™? We can see from

(currently about 470,000 cases per year) will decrease dramatically.

Figure 10.1 that HPV types 16

The major capsid protein, L1, from four HPV types (6, 11, 16, 18) was and 18 account for approxi-used to form virus-like particles (VLPs) for the production of this quadri-mately 70% of cases of cervical

valent vaccine. When the capsid protein is expressed in eukaryotic cells cancer. What is not shown on

using recombinant DNA techniques, the L1 capsid protein self-assembles the graph is that HPV6 and -11

into particles that mimic the virus. These particles, along with an cause approximately 90% of

adjuvant, are administered as the vaccine. The vaccine has been demon-genital warts and give rise to

strated to prevent cervical cancer caused by HPV16 and HPV18 and also lesions that are clinically indis-pre-cancerous lesions and warts caused by HPV6, -11, -16, and -18, in tinguishable from pre-cancerous

clinical trials (Villa et al. , 2005). As the ideal time to administer a preven-lesions caused by HPV16 and

tative vaccine is before infection, Gardasil™ has been approved for

-18. Abnormal lesions called by

administration in adolescent girls/young adults, aged 9–26 years, and HPV6 and -11 lead to false-positives and trigger additional

more recently in males for the prevention of genital warts and anal can-investigations. Thus, by elimi-

cers. The vaccine is likely to help ease the HPV-associated head and neck nating these lesions, abnormal

cancer epidemic (Marur et al. , 2010). Cervarix™ (GlaxoSmithKline), a Pap results (see “A little lesson

HPV16 and HPV18 bivalent vaccine, also showed benefi cial results

about Pap and HPV DNA

against cervical cancer in clinical trials (Harper et al. , 2004), was chosen screening” box) will be easier to

for use in the UK national vaccination program, and was approved by interpret.

the FDA (2009).

A little lesson about Pap and HPV DNA screening

LIFESTYLE TIP

The most common method of screening for cervical cancer is the Papanicolaou cytology Although we now have a HPV

technique or Pap smear test. Cells from the cervix are harvested for microscopic analysis vaccine to help prevent against

and examined for changes in cell morphology that may represent pre-cancerous cell cervical cancer, screening pro-changes called cervical intra-epithelial neoplasia (CIN) or cancer. Limitations of this tech-grams are still important for

nique include poor sample collection and/or slide preparation leading to abnormal cell detecting cervical cancer caused

morphology, and errors of interpretation by the laboratory scientist. However, routine Pap by HPV strains not covered by the

screening in some countries has resulted in a substantial reduction in cervical cancer mor-vaccine or for previously infected

tality. Signifi cantly, cervical cancer mortality rates in the UK have decreased over 60% in women.

the last 30 years (http://info.cancerresearchuk.org/cancerstats/types/cervix/mortality/). ¼





246 10: THE IMMUNE SYSTEM, INFECTIONS, AND INFLAMMATION

¼The addition of testing for HPV DNA may be a great aid to screening procedures in the near future. The value of HPV testing in both primary cervical screening and in the management of abnormal cervical cytology has been stated in recommendations from the IARC

and/or in US/European guidelines (Cox and Cuzick, 2006). The Hybrid Capture 2 (hc2) high-risk HPV DNA test (Digene) is a diagnostic test that has been approved by the FDA. In this test, RNA probes are used to detect the genomic DNA of 13 high-risk HPV types. Specifi c RNA–DNA hybrids are formed in solution and captured by specifi c antibodies coated at the bottom of a microtiter plate. Additional antibodies that generate a luminescent product in the presence of hybrids are used to detect the captured hybrids, and a specialized instrument called a luminometer analyzes the signal. Note that the majority of HPV

infections will be transient (clearance time 6–18 months) and conclusions from these tests need to take this fact into account.

LEADERS IN THE FIELD . . . of cancer vaccines: Douglas Lowy and John Schiller

The work of Douglas Lowy and John Schiller laid the foundation for the development of a preventative vaccine against cervical cancer. Their work investigated the role of papillomavirus in cervical cancer and showed that the capsid proteins of the virus could elicit an immune response. They also supervised the Phase I clinical trials of the vaccine, leading to FDA approval of the fi rst HPV vaccine in 2006. Their work exemplifi es the translation of basic research to applications in public health. They were presented with the Landon Award at the 100th year anniversary of the American Association for Cancer Research in 2007.

Dr Lowy received his MD from New York University School of Medicine. Dr Schiller received a PhD from the University of Washington in Seattle. Both are currently working at the Center for Cancer Research at the National Cancer Institute.

10.7 Inhibition of infl ammation

Non-steroidal anti-infl ammatory drugs (NSAIDs), such as aspirin, have been shown to decrease cancer risk and may be used for the treatment of cancer. For example, a dose and duration-dependent protective effect of aspirin on colorectal cancer incidence was demonstrated in an over

30-year ongoing prospective observational study of 121,000 women

called the Nurses’ Health Study.

One mechanism of action of NSAIDs in inhibiting infl ammation is by inhibiting cyclo-oxygenase (COX) activity. There are two COX isoforms: COX-1 is constitutively active and COX-2 is inducible. These enzymes catalyze the synthesis of prostaglandins from arachidonic acid. Thus,

1 0 . 7 I N H I B I T I O N O F I N F L A M M AT I O N 247

inhibition of COX results in the decrease of prostaglandin synthesis.

Prostaglandin synthesis produces mutagenic metabolites, and prostaglandins induce the production of cytokines and stimulate cell proliferation.

NSAIDs may also act via inhibition of NF-κB.

The use of aspirin is not without side-effects; it can cause severe stomach irritation and ulcers. As COX-1 was found to have protective effects on the stomach lining, selective COX-2 inhibitors were developed to eradicate these side-effects. However, this avenue of drug discovery is not without problems. Vioxx (Merck; http://www.merck.com/), a COX-2 inhibi-

tor, had to be withdrawn from the market in 2004 owing to an increased risk of heart attacks and stroke.

Another COX-2 inhibitor, celecoxib (Celebrex™; Pfi zer; http://www.

pfi zer.com/), has been approved for the disease called familial adenomatous

polyposis (Chapter 8). As you may remember from Chapter 8, patients with this disease carry a germline mutation in the APC gene and have almost a 100% risk of colon cancer. One study has demonstrated a 30%

reduction in the number of polyps in these patients after treatment with celecoxib (Steinbach et al. , 2000). Additional trials of celecoxib for cancer prevention/treatment (see Kismet et al. , 2004; Meyerhardt, 2009) are continuing, although under high doses, side-effects similar to those induced by Vioxx have been reported. Again, tumor profi ling may be important for drug testing as the results of a trial for non-small cell lung cancer reported that celecoxib benefi ted patients with increased COX-2

expression. Risk-benefi ts will need to be examined for specifi c subpopula-tions of patients.

Antagonists of TNF-α have demonstrated disease stabilization and

some partial responses in early clinical trials. Other cytokine antagonists, for example antagonists of IL-6, are currently being tested in clinical trials.

PAUSE AND THINK

What other strategies can be

Inhibiting the NF-κB pathway

used to inhibit the NF-κB path-

Many research groups are focusing on strategies that selectively inhibit way? Think about the molecular

IKK activity as the most promising and effective approach to inhibit mechanisms involved and how

NF-κB activation. Numerous compounds have been identifi ed by large-NF-κB exerts its effects.

You may have thought of

scale screening and combinatorial chemistry and include ATP-competi-compounds that interfere with

tive and allosteric inhibitiors of IKK (Lee and Hung, 2008). One of NF-κB binding to DNA; block

these compounds, PS-1145, was developed from a β-carboline natural

nuclear translocation; block

product and was shown to prevent NF-κB activation and inhibit the

degradation of IκB, or inhibit

growth of multiple myeloma cells. Further along, pyridyl cyanoguanigene expression of IKK by anti-

dine compounds have been reported to act as anti-tumor agents in clini-sense oligonucleotides or siRNA.

cal trials.

248 10: THE IMMUNE SYSTEM, INFECTIONS, AND INFLAMMATION

■ CHAPTER HIGHLIGHTS—REFRESH YOUR MEMORY

•

Infectious agents and chronic infl ammation account for

•

The CagA protein is implicated in the mechanism of the

15–20% of all cancers.

induction of gastric cancer by the bacterium H. pylori.

•

Some infectious agents are classifi ed as carcinogens.

•

CagA is a phosphoprotein that interferes with kinase

•

Specifi c DNA and RNA viruses and bacteria have been

signaling and regulation in the cell.

classifi ed as carcinogens.

•

Chronic infl ammation, even in the absence of infection, is

•

The immune system plays a dual role in cancer: it can

characteristic of most tumors and is considered a hall-

both suppress and promote tumor growth.

mark of cancer.

•

Immunosurveillance is the concept that the immune sys-

•

The site of chronic infl ammation is characterized by

tem can recognize tumor-specifi c and tumor associated

cytokines, chemokines, and reactive oxygen/nitrogen spe-

antigens as “foreign” and can eliminate cancer cells.

cies that can act as a carcinogen.

•

Immunoediting includes that the concept that the

•

The transcription factor NF-κB is an important mediator

immune system can shape the immunogenicity of a

between infl ammation and cancer.

tumor.

•

Bone marrow stem cells migrate to sites of infl ammation

•

One hundred per cent of cervical cancers are associated

and injury and may contribute to gastric carcinogenesis.

with human papillomavirus. This virus is also a causative

•

Gardasil™ (Merck), the fi rst preventative cervical cancer

agent for several other cancers.

vaccine, was approved in 2006.

•

Common mechanisms of infectious agents and chronic

•

Current HPV vaccines are not able to protect against all

infl ammation in carcinogenesis include:

HPV infection. Therefore, screening procedures must be

– induction of growth factors/signaling programs (auto-

maintained.

crine or paracrine)

•

Vaccination programs have been, and will continue to be,

– inactivation of tumor suppressor genes

important preventative measures for some cancers.

– activation of nuclear transcription factor NF-κB.

■ ACTIVITY

1. It is well-established that tobacco smoke contains tumor-initiating carcinogens. New evidence suggests that tobacco smoke is also a tumor promoter and that this role depends on infl ammation. Look at the 2010 article by Takahashi et al. ( Cancer Cell 17: 89–97).

Describe the model system, experimental procedure and the methods of analysis that provided in vivo evidence that tobacco smoke promotes lung tumorigenesis by inducing infl ammation. What possible role may anti-infl ammatory therapy play in lung cancer?

■ FURTHER READING

Aggarwal, B.B. (2004) Nuclear factor-κB: the enemy within. Cancer Cell 6: 203–208.

Aggarwal, B.B., Shishodia, S., Sandur, S.K., Pandey, M.K., and Sethi, G. (2006) Infl ammation and cancer: how hot is the link? Biochem. Pharmacol. 72: 1605–1621.

Colotta, F., Allavena, P., Ica, A, Garlanda, C., and Mantovani, A. (2009) Cancer-related infl ammation, the seventh hallmark of cancer: links to genetic instability.

Carcinogenesis 30: 1073–1081.

1 0 . 7 I N H I B I T I O N O F I N F L A M M AT I O N 249

Escarcega, R.O., Fuentes-Alexandro, S., Garcia-Carrasco, M., Gatica, A., and Zamora, A. (2007) The transcription factor Nuclear Factor-kappa B and cancer.

Clin. Oncol. 19: 154–161.

Farazi, P.A. and DePinho, R.A. (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6: 674–687.

Grivennikov, S.I., Greten, F.R., and Karin, M. (2010) Immunity, infl ammation, and cancer. Cell 140: 883–899.

Hatakeyama, M. (2004) Oncogenic mechanisms of the Helicobacter pylori CagA protein . Nat. Rev. Cancer 4: 688–694.

Huang, K.-Y. and Lin, S.-R. (2000) Nationwide vaccination: a success story in Taiwan.

Vaccine 18: S35–S38.

Karin, M. (2006) Nuclear factor-κB in cancer development and progression. Nature 441: 431–436.

Li, Q., Withoff, S., and Verma, I.M. (2005) Infl ammation-associated cancer: NF-κB is the lynchpin. Trends Immunol. 26: 318–325.

Lowy, D.R. and Schiller, J.T. (2006) Prophylactic human papillomavirus vaccines. J.

Clin. Invest. 116: 1167–1173.

Mantovani, A., Allavena, P., Sica, A., and Balkwill, F. (2008) Cancer-related infl ammation. Nature 454: 436–444.

Matysiak-Budnik, T. and Megraud, F. (2006) Helicobacter pylori infection and gastric cancer. Eur. J. Cancer 42: 708–716.

Mesri, E.A., Cesarman, E., and Boshoff, C. (2010) Kaposi’s sarcoma and its associated herpesvirus. Nat. Rev. Cancer 10: 707–719.

Moody, C.A. and Laimins, L.A. (2010) Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer 10: 550–560.

Munoz, N., Bosch, F.X., de Sanjose, S., Herrero, R., Castellsague, X., Shah, K.V., et al.

(2003) Epidemiologic classifi cation of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348: 518–527.

Pagano, J.S., Blaser, M., Buendia, M.-A., Damania, B., Khalili, K., Raab-Traub, N., et al. (2004) Infectious agents and cancer: criteria for a causal relation. Semin. Cancer Biol. 14: 453–471.

Polk, D.B. and Peek, R.M. Jr (2010) Helicobacter pylori: gastric cancer and beyond.

Nat. Rev. Cancer 10: 403–414.

Rayburn, E.R., Ezell, S.J., and Zhang, R. (2009) Anti-infl ammatory agents for cancer therapy. Mol. Cell Pharmacol. 1: 29–43.

Schreiber, R.D., Old, L.J., and Smyth, M.J. (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331: 1565–1570.

Swann, J.B. and Smyth, M.J. (2007) Immune surveillance of tumors. J Clin. Invest.

117: 1137–1146.

Tan, T.-T. and Coussens, L.M. (2007) Humoral immunity, infl ammation and cancer.

Curr. Opin. Immunol. 19: 209–216.

Vogelmann, R. and Amieva, M.R. (2007) The role of bacterial pathogens in cancer.

Curr. Opin. Microbiol. 10: 76–81.

Zhang, X., Zhang, H., and Ye, L. (2006) Effects of hepatitis B virus X protein on the development of liver cancer . J. Lab. Clin. Med. 147: 58–66.

250 10: THE IMMUNE SYSTEM, INFECTIONS, AND INFLAMMATION

zur Hausen, H. (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2: 342–350.

■ WEB SITES

Gardasil™, Merck www.merck.com/newsroom/press_releases/product/2007_0509.html

UK Cervical Cancer Statistics http://info.cancerresearchuk.org/cancerstats/types/cervix/

mortality/

Understanding the immune system http://www.cancer.gov/cancertopics/understandingcan-

cer/immunesystem

■ SELECTED SPECIAL TOPICS

Boxus, M. and Willems, L. (2009) Mechanisms of HTLV-1 persistence and transformation. Br. J. Cancer 101: 1497–1501.

Cox, T. and Cuzick, J. (2006) HPV DNA testing in cervical cancer screening: from evidence to policies. Gynecol. Oncol. 103: 8–11.

Greten, F.R., Eckmann, L., Greten, T.F., Park, J.M., Egan, L.J., Kagnoff, M.F., et al (2004) IKKb links infl ammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 118: 285–296.

Harper, D., Franco, E., Wheeler, C., Ferris, D., Jenkins, D., Schuind, A., et al. (2004) Effi cacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women, a randomized controlled trial. Lancet 364: 1757–1765.

Houghton, J., Stoicov, C., Nomura, S., Rogers, A.B., Carlson, J., Li, H., et al. (2004) Gastric cancer originating from bone marrow-derived cells. Science 306: 1568–

1571.

Kismet, K, Akay, M.T., Abbasoglu, O., and Ercan, A. (2004) Celocoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect. Prev. 28: 127–142.

Lee, D.-F., and Hung, M.-C. (2008) Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin. Cancer Res. 14: 5656–5662.

Marur, S., D’Souza, G., Westra, W.H., and Forastiere, A.A. (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 11: 781–789.

Meyerhardt, J.A. (2009) COX-2 inhibitors and colorectal cancer: The end or just a new beginning. Update Cancer Ther. 3: 154–156.

Naugler, W.E., Sakurai, T., Kim, S., Maeda, S., Kim, K.H., Elsharkawy, A.M., et al.

(2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317: 121–124.

Pikarsky, E., Porat, R.M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., et al. (2004) NF-κB functions as a tumour promoter in infl ammation-associated cancer. Nature 431: 461–466.

Roithmaier, S., Haydon, A.M., Loi, S., Esmore, D., Griffi ths, A., Bergin, P., et al.

(2007) Incidence of malignancies in heart and/or lung transplant recipients: a single institution experience. J. Heart Lung Transplant. 26: 845–849.

1 0 . 7 I N H I B I T I O N O F I N F L A M M AT I O N 251

Steinbach, G., Lynch, P.M., Phillips, R.K.S., Wallace, M.H., Hawk, E., Gordon, G.B., et al. (2000) The effect of Celecoxib, a cyclooxygenease-2 inhibitor, in familial adenomatous polyposis. N. Engl J. Med. 342: 1946–1952.

Takahashi, H., Ogata, H., Nishigaki, R., Broide, D.H., and Karin, M. (2010) Tobacco smoke promotes lung tumorigenesis by triggering IKKβ- and JNK1-dependent infl ammation. Cancer Cell 17: 89–97.

Vesely, M.D., Kershaw, M.H., Schreiber, R.D., and Smyth, M.J. (2011) Natural innate and adaptive immunity to cancer. Annual. Rev. Immunology 29: 235–271.

Villa, L.L., Costa, R.L., Petta, C.A., Andrade, R.P., Ault, K.A., Giuliano, A.R., et al.

(2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II effi cacy trial. Lancet Oncol. 6: 271–278.

Wong, B.C.-Y., Lam, S.K., Wong, W.M., Chen, J.S., Zheng, T.T., Feng, R.E., et al.

(2004) Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. J. Am. Med. Assoc. 291: 187–194.

This page intentionally left blank





Chapter 11

Nutrients, hormones, and gene

interactions

Introduction

Does our diet infl uence whether we are the one out of three people who get cancer? Diet plays a signifi cant role in cancer incidence. Many epidemiological studies provide evidence to support the role of diet in both causation and prevention of cancer. Approximately one-third of the variations in cancer incidence between different populations are due to differences in diet. For example, the Japanese diet has changed radically between the 1950s and 1990s, including a seven-fold increase in meat consumption (Key et al. , 2002). This coincides with a fi ve-fold increase in colorectal cancer over the same period. The knowledge gained from investigations into the role of diet in cancer and cancer prevention should be integrated into lifestyle modifi cations in order to reduce the occurrence of the disease.

In this chapter we will see that some components of diets act as cancer-causative factors and others act as cancer-preventative factors. Diet and exercise also affect cell metabolism. The reprogramming of energy metabolism associated with tumor cells, an emerging hallmark of cancer, will be described. Upon examination of the mechanisms of action of nutrients it will become clear that some of these mechanisms parallel the mechanism of action of growth factors and others parallel the mechanism of action of hormones. The chapter will conclude with a discussion of the role of hormones in carcinogenesis.

Let us examine why we eat food (Figure 11.1). The basic food groups of carbohy-drates, fats, and proteins provide us with glucose, fatty acids, and amino acids, respectively, which can be metabolized to produce energy. Food also provides precursors for biosynthetic reactions. For example, proteins provide a source of nitrogen needed for the synthesis of the nitrogenous bases of DNA. Vitamins and minerals provide co-factors that are essential for the function of many enzymes. Additional biologically active microconstituents have been identifi ed in the foods we eat (Table 11.1). Many biologically active microconstituents act as antioxidants, compounds that signifi cantly inhibit or delay the damaging action of ROS (see Chapter 2), often by being oxidized themselves. Plants require many phytochemicals as a defense against excess energy and oxidative damage as they absorb solar energy for photosynthesis. Many of these phytochemicals provided in the diet are important for the protection of human cells.

254

1 1 : N U T R I E N T S, H O R M O N E S, A N D G E N E I N T E R AC T I O N S

Carbohydrates

Fats

Protein

Glucose

Fatty acids

Amino acids

Energy

Precursors for biosynthetic reactions

Gene expression

Enzyme function

Vitamins

Minerals

Gene expression

Protection from free radicals

Gene expression

Antioxidants

Figure 11.1 Provisions of food.

Phytochemicals

Although humans can synthesize some required antioxidants others must be obtained by eating fruit and vegetables. The four major groups of dietary antioxidants–phytochemicals are vitamin C, isoprenoids (e.g. vitamin E), phenolic compounds (fl avonoids), and organosulfur compounds. These will be discussed later in this chapter. Lastly, specifi c nutrients and microconstituents have been shown to affect gene expression (Figure 11.1).

Information gained about the role of microconstituents in cancer prevention could PAUSE AND THINK

be applied to the development of chemopreventative supplements, extra sources of dietary components taken in addition to food. However, unraveling the individual Propose a hypothesis to explain

contributions of microconstituents as preventative agents against cancer is a chal-these seemingly confl icting

lenge for the future. Epidemiological studies strongly suggested that diets rich in results. The most likely explana-

β-carotene-containing fruits and vegetables reduced lung cancer risk. Animal studies tion is that alternative micro-also generated supportive evidence. This led to the β-Carotene and Retinol Effi cacy constituents in β-carotene-rich

Trial (CARET) and the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study vegetables and fruits may be the

(ATBC) which tested the effect of β-carotene supplements on smokers and those active ingredient in reducing

exposed to asbestos. Surprisingly, β-carotene supplementation increased lung cancer lung cancer risk, or perhaps

in these high-risk individuals and had no effect on healthy individuals. The results of β-carotene works in a synergistic

these trials do not support the initial hypothesis formulated on pre-clinical fi ndings manner with other microconstit-

(see Pause and Think).

uents not present in the supple-

ments. Interactions between

Only recently have molecular approaches been used to investigate the molecular mech-different dietary constituents

anisms of dietary constituents involved in the causation or prevention of cancer. One of must be considered for a com-the most signifi cant insights gained is that components in foods regulate gene expression.

plete picture.

The power of food has begun to be revealed. This chapter will include a sample of these fi ndings.





1 1 . 1 C AU S AT I V E FAC TO R S 255

Table 11.1 Microconstituents. Reprinted from Manson, M.M. (2003) Cancer prevention—

the potential for diet to modulate molecular signaling. Trends Mol. Med. 9: 11–18, Copyright (2003), with permission from Elsevier

Food source

Class of compound

Chemical

Cruciferous vegetables

Isothiocyanate

Benzyl isothiocyanate, phenethyl

isothiocyanate, sulforaphane

Cruciferous vegetables

Dithiolthione

Ohipraz

Cruciferous vegetables

Glycosinolate

Indole-3-carbinol,

3,3′-diindoylmethane, indole-3-

acetonitrile

Onions, garlic, scallions, chives

Allium compound

Diallyl sulfi de, allylmethyl

trisulfi de

Citrus fruit (peel)

Terpenoid

D-Limonene, penllyl alcohol,

geraniol, menthol, carvone

Citrus fruit

Flavonoid

Tangeretin, nobiletin, ratin

Berries, tomatoes, potatoes, broad

Flavonoid

Quercetin

beans, broccoli, squash, onions

Radish, horseradish, kale, endive

Flavonoid

Kaempferol

Tea, chocolate

Polyphenol

Epigallocatechin gallate,

epigallocatechin, epicatechin,

catechin

Grapes

Polyphenol

Resveratrol

Turmeric

Polyphenol

Curcumin

Strawberries, raspberries, blackberries,

Polyphenol

Caffeic acid, ferulic acid, ellagic

walnuts, pecans

acid

Cereals, pulses (millet, sorghum,

Isofl avone

Genistein

soya beans)

Orange vegetables and fruit

Carotenoid

α- and β-carotene

Tomatoes

Carotenoid

Lycopene

Tea, coffee, cloa, cacao (cocoa and

Methylxanthines

Caffeine, theophylline,

chocolate)

theobromine

11.1 Causative factors

Three main aspects of our diet can be considered as causative factors of cancer. First, any given food is a very complex substance that can carry harmful factors in addition to nutritional value. The consumption of food provides a route for chemical carcinogens to be delivered to the body.

256

1 1 : N U T R I E N T S, H O R M O N E S, A N D G E N E I N T E R AC T I O N S

Genotoxic agents present as microconstituents in food act as dietary carcinogens. Second, lack of a particular essential nutrient may enhance the risk of cancer. Third, worldwide health issues such as obesity and chronic alcohol consumption cause cancer. In this section we will examine carcinogenic contaminants, nutritional defi ciencies, obesity, and chronic alcohol consumption as dietary cancer-causative factors.

Carcinogenic contaminants

The carcinogenic effect of one particular food can be variable. Salmon, rich in omega-3 polyunsaturated fatty acids, and known to be an important component of a healthy diet, is one example. Salmon, being fatty carnivorous fi sh, accumulate pollutants and can pass genotoxic contaminants through the food chain to humans. A study of farmed and wild

salmon from around the world found that in some geographical regions (e.g. Scotland), polychlorinated biphenols (PCBs) and other pesticides are present in quantities that suggested that eating farmed salmon more than once a month could increase cancer risk (Hites et al. , 2004). Risk was calculated based on the assumption that the risks of individual carcinogens are additive. This study raises many issues. First, it underscores that differences in the source of food can have varying consequences; farmed salmon has more contaminants than wild salmon and farmed

salmon from Scotland contains signifi cantly more contaminants than farmed salmon available in North American cities. Perhaps the results have a broader implication and point to the suggestion that the source of all food should be properly labeled to allow for consumer choice and to create competition for the production of good products. Data from

this study suggested that fi sh feed (fi sh meal and fi sh oils) may be a distinguishing factor for the carcinogenicity of salmon, suggesting that improvements in feed composition are needed. Evaluating cancer risk associated with more than one contaminant at a time, in addition to the benefi ts of other microconstituents of a particular food, is an area that requires further study. Overall, the study described here underlines the complications that occur when analyzing the relationship between diet and cancer.

Food preparation can contribute to the cancer-causing properties of PAUSE AND THINK

our diet. Heterocyclic amines produced by cooking meat at high tempera-Suggest an experiment to

tures were discussed as carcinogens in Chapter 2. After metabolic activa-examine whether the nutri-

tion, their mechanism of action involves the formation of DNA adducts, tional benefi t of a particular

resulting in base substitutions and thus mutations. Similarly, toxins pro-food outweighs its risk as a

duced by molds that contaminate food form DNA adducts and thus are

carcinogen.

genotoxic. Afl atoxin B, a fungal product of Aspergillus fl avus, is a well-known contaminant found on peanuts, and fumonisin B is found on corn.

Afl atoxin induces GC→TA transversions and is thought to be involved in

1 1 . 1 C AU S AT I V E FAC TO R S 257

hepatocellular carcinoma. Food preservatives, such as sodium nitrite, are regulated by government agencies because they, too, are a risk factor producing carcinogenic N-nitroso compounds.

Dietary defi ciencies

Evidence is accumulating that supports the concept that micronutrient defi ciencies also contribute to cancer risk. The most compelling fi ndings suggest that a defi ciency in folate increases the risk of colorectal cancer.

Folate, one of the B vitamins, can accept or donate one-carbon units in metabolic reactions. Folate is a critical co-enzyme for nucleotide synthesis and DNA methylation, and these processes can affect carcinogenesis. The enzyme methylenetetrahydrofolate reductase (MTHFR) regulates the balance between nucleotide synthesis and DNA methylation by affecting

the relative quantities of 5,10-methylenetetrahydrofolate (5,10-methylene THF) and methyl-tetrahydrofolate (5-methyl THF), the respective precursors of these distinct processes (Figure 11.2a). MTHFR irreversibly converts 5,10methylene THF to 5-methyl THF. 5,10-Methylene THF and

deoxyuridylate (dUMP) are reactants for the enzyme thymidylate syn-

thase used for the production of deoxythymidylate (dTMP). 5-Methyl

THF and homocysteine are reactants used to produce methionine, which regenerates S-adenosylmethionine (SAM), the methyl donor for DNA methylation.

The depletion of folate may contribute to tumor development by interfering with both nucleotide synthesis and DNA methylation. A disruption in DNA synthesis leads to DNA instability and fuels mutation, while disruption in DNA methylation may cause genomic hypomethylation

(Figure 11.2b). Deoxythymidylate synthesis is inhibited in conditions of low folate and the imbalance of the nucleotides results in the incorporation of uracil into DNA. DNA strand breaks occur as a result of attempts to repair this DNA and these breaks increase cancer risk. Both uracil mis-incorporation and DNA strand breaks are observed in folate-defi cient humans, and both defects are reversed by folate administration. Remember that genomic hypomethylation and specifi c tumor suppressor gene promoter hypermethylation is characteristic of the epigenetic changes observed in cancer cells (Chapter 3). As the methyl groups used for DNA methylation are supplied by folate, a lack of folate causes a decrease in the synthesis of methionine, and subsequently genomic hypomethylation of DNA. Genomic hypomethylation is observed in folate-defi cient humans and is reversed upon folate repletion. Hypermethylation at specifi c 5′ gene loci have also been observed during studies of folate depletion. In addition, dietary methyl defi ciency has been shown to alter hepatic DNA methylation patterns and induce hepatocarcinogenesis in the absence of a carcinogen in rodents.

258

1 1 : N U T R I E N T S, H O R M O N E S, A N D G E N E I N T E R AC T I O N S

(a)

N5N10 Methylene

MTHFR

5N-methyl

tetrahydrofolate

tetrahydrofolate Homocysteine

dUMP

Methionine

Thymidylate synthetase

SAM

dTMP

CH3

DNA synthesis

CH3

DNA methylation

(b)

Folate deficiency

Figure 11.2 (a) Role of folate

Mutation

Hypomethylation

derivatives in DNA synthesis and

DNA methylation. (b) Role of

folate defi ciency in cancer.

Cancer

Obesity

Obesity, classifi ed as a risk factor for several cancers by the International Agency for Research on Cancer (IARC), is the excessive accumulation of fat that leads to a body weight that is greater than skeletal and physical requirements. Those with a body mass index [weight (in kg)/height (in m) squared]

greater than 30 (kg/m2) are considered obese. It has become a signifi cant problem in the USA, affecting 25% of the population, and it has been suggested that 15–20% of all cancer deaths in the USA can be attributed to being overweight and obese. Based on epidemiological evidence, obesity increases the risk of cancer of the colon, breast, endometrium, kidney, pancreas, liver, and esophagus. Adipose tissue is an endocrine organ that can affect other tissues: it can release free fatty acids, peptide hormones, and steroid hormones. Several mechanisms of action of obesity as a cancer risk factor or tumor promoter have been suggested. Evidence from mice demonstrate that obesity causes a chronic infl ammatory response with increases in tumor-promoting cytokines such as Il-6 and TNF and acts as a bona fi de liver tumor promoter (Park et al. , 2010). Indirectly, obesity is associated with acid refl ux, which damages the esophageal epithelium and leads to adenocarcinoma of the esophagus. Obesity results in high fat deposits in adipose cells. The deposits may be used for the synthesis of estrogen from





1 1 . 2 P R E V E N TAT I V E FAC TO R S : M I C R O C O N S T I T U E N T S O F F R U I T S A N D V E G E TA B L E S 259

androgen by aromatase and may contribute to the risk of breast cancer (see Section 11.6). Also, food metabolism is linked with oxidation and an increase in ROS production can cause an increase in mutations. Lastly, obesity leads to chronically increased levels of plasma insulin as a result of the release of large amounts of free fatty acids from adipose tissue. Subsequent tumorigenic effects (e.g. promotion of cellular proliferation and inhibition of apoptosis) are mediated through insulin receptors and additional growth factors (e.g. insulin-like growth factor).

Chronic alcohol consumption

Two billion people consume alcohol. Because of this statistic and the recent classifi cation of alcohol as a carcinogen by the International Agency for Research on Cancer in 2007, there is a great need to publicize the cancer-causing nature of alcohol in order to prevent specifi c cancers. The mechanism of how alcohol causes cancer is linked to its metabolism in the body (Seitz and Stickel, 2007). Alcohol is metabolized by the enzyme alcohol dehydrogenase to form acetaldehyde that can directly bind to DNA forming DNA adducts that cause mutations. Acetaldehyde DNA

adducts have been found in alcohol consumers. Additional acetaldehyde can be made by bacteria in saliva such that concentrations can be 10–100

times higher than in blood, accounting for the increased risk of mouth cancer. Acetaldehyde is oxidized in the body by the enzyme acetaldehyde dehydrogenase. A single nucleotide polymorphism of the gene for this enzyme, common in Asians, is responsible for low enzyme activity

and consequently, alcohol intolerance. Carriers of the inactive aldehyde dehydrogenase allele are at increased risk for alcohol-related esophageal cancer. The association of alcohol consumption with increased risk of breast cancer is thought to be because of its link with estrogen (see Section 11.6). Overall, 3.6% of cancers worldwide, including 7–19% of oral

cancers, are attributable to drinking alcohol.

11.2 Preventative factors: microconstituents

of fruits and vegetables

The intake of fruits and vegetables as a means of reducing cancer risk is supported by epidemiological studies but these are not easy studies to perform as it is diffi cult to control for other behavioral variables. One report published in 2007 by the World Cancer Research Fund and American

Institute for Cancer Research called: Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective, summarizes an evaluation of a mass of scientifi c publications with respect to cancer risk.

260

1 1 : N U T R I E N T S, H O R M O N E S, A N D G E N E I N T E R AC T I O N S

In their report, they conclude that there is probable evidence which supports that intake of fruits and some vegetables decreases the risk of specifi c cancers. The European Prospective Investigation into Cancer and Nutrition (EPIC) analyzed over 400,000 people and recently concluded that there is a very small but statistically signifi cant inverse association between intake of total fruits and vegetables and cancer risk (Boffetta et al. , 2010). But caution is needed in the interpretation of these latter results because this analysis examined overall cancer risk. It did not examine correlations to specifi c cancers. This is an area of research that needs more data from carefully designed studies.

The ability to block DNA damage caused by ROS and/or carcinogens is the most direct strategy for preventing the initiation of cancer and for slowing down the progression of disease. It is here that microconstituents found in fruits and vegetables play an important role. This is accomplished either directly by free radical scavengers (see following section) or indirectly by regulating the expression of Phase I (oxidative) and Phase II (conjugative) metabolizing enzymes in the body.

The modulation of Phase I and Phase II metabolizing enzymes is a major defense mechanism against xenobiotics (foreign substances). The cytochrome P450 family of Phase I drug-metabolizing enzymes catalyzes the hydroxylation/oxidation of many drugs which often has a harmful effect by converting pro-carcinogenic molecules into ultimate carcinogens.

Phase I products are often highly electrophilic (e.g. epoxides) and can damage DNA but at the same time induce enzymes required for Phase II.

Phase II enzymes, such as UDP-glucuronosyltransferases or glutathione S-transferases, catalyze conjugation reactions of Phase I products to hydrophilic moieties, thus making them more water soluble and aiding in their innocuous removal from the cell.

? HOW DO WE KNOW THAT?

Analysis of DNA damage by the Comet assay oxidized pyrimidine bases and subjected to electrophoresis.

(see Bub et al., 2003)

Comet-like images indicating single-strand breaks and resulting

from the extension of DNA into the agarose were computer-

The molecular effects of fruit polyphenols in humans were investi-

analyzed after neutralization and ethidium bromide staining.

gated by analyzing DNA damage in blood samples taken before,

The data showed signifi cantly lower levels of DNA base oxidation

during, and after treatment. A precise schedule of fruit juice

for both juices over the last treatment period (see Figure 1 in Bub consumption (330 ml/day; over two, 2-week periods) in healthy

et al. , 2003). That is, the effect was observed after the second men was executed. Two juices were tested; both contained apple,

two-week period of consumption but not the fi rst. The effect

mango, and orange juice but one was enhanced with berries rich

was not permanent as levels returned to baseline when tested

in anthocyanin and the other with green tea, apricot, and lime,

11 weeks after the experiment was terminated. The time delay

rich in fl avanols. The single-cell microgel electrophoresis, or

indicated by this experiment suggests that ROS scavenging is not

Comet, assay was used to detect oxidized DNA bases. Blood cells

the prime mechanism and that protective detoxifying enzymes

were embedded onto agarose-coated slides, lysed, treated with

(described in a later section) are induced.

alkali (for unwinding) and a specifi c endonuclease (III) to detect

1 1 . 2 P R E V E N TAT I V E FAC TO R S : M I C R O C O N S T I T U E N T S O F F R U I T S A N D V E G E TA B L E S 261

Figure 11.3 illustrates the modifi cations of the carcinogen afl atoxin B1

PAUSE AND THINK

(AFB1) made by Phase I and II metabolizing enzymes. First, afl atoxin B1undergoes oxidation by Phase I cytochrome P450 to form the potent In general, how would you

genotoxic metabolite AFB

modify Phase I and II enzyme

1–8,9-epoxide. AFB1–8,9-epoxide is conjugated

activity to reduce tumor forma-

to glutathione by the Phase II enzyme, glutathione S-transferase to pro-tion? Inhibit Phase I and induce

duce AFB1-glutathione. This leads to detoxifi cation and facilitates easy Phase II.

excretion.

O

O

O

O

O

OCH3

aflatoxin B1

Phase I

O

O

O

DNA adducts

O

O

O

OCH3

ABF1 -8, 9-Epoxide

GSH

Glutathione

Phase II

Oltipraz

S-transferase

O

O

O

HO

O

O

GS

OCH3

Figure 11.3 Effects of Phase I and

AFB1-glutathione

II enzymes on afl atoxin B1. GS,

glutathione. Oltipraz is a

synthetic agent that can induce

Phase II enzymes and is discussed

Excretion

in “Therapeutic strategies.”

262

1 1 : N U T R I E N T S, H O R M O N E S, A N D G E N E I N T E R AC T I O N S

PAUSE AND THINK

Free radical scavenging

Several microconstituents in fruits and vegetables act as antioxidants that Is the hydroxyl radical described

in Chapter 2 likely to be scav-

scavenge ROS. Water-soluble vitamin C (see Figure 11.4a) can donate an enged by these microconstitu-electron to a free radical directly, thus inhibiting its reactivity and block-ents? No. In fact the menacing

ing free radical chain reactions. Oxidized vitamin C forms an ascorbyl reactive hydroxyl radical is

radical that is fairly stable and unreactive because of electron delocaliza-unlikely to be scavenged by

tion or resonance. An enzyme called vitamin C reductase can regenerate these microconstituents because

vitamin C from the ascorbyl radical for reuse, or the ascorbyl radical may of its extremely rapid reaction

lose another electron and become degraded. Consequently, vitamin C

time. It would take exceptionally

reserves need to be replenished daily. Lipid-soluble vitamin E (Figure high concentrations to prevent

11.4b) acts as a free radical scavenger in a similar manner. A resonance-such interactions with molecules

stabilized structure called the α-tocopheryl radical is produced after vita-immediately surrounding it.

min E donates an electron to a free radical (e.g. singlet oxygen) and helps to terminate chain reactions of free radicals in membranes.

Regulation of genes that code for drug-metabolizing and

antioxidant enzymes

“You are what you eat” is a common expression. It has been given greater signifi cance recently by its translation into molecular terms and the study of nutrigenomics: some dietary constituents can affect the expression of our genes. The molecular mechanisms employed are common to those discussed in previous chapters. The crucial link between some dietary constituents and their role in preventing DNA damage via gene expression was made by the identifi cation of an antioxidant response element (ARE) (5′-

A/G TGA C/T NNNGC A/G-3′) in the promoter region of several genes

encoding detoxication and antioxidant enzymes (e.g. glutathione S-transferase and NADPH:quinine oxidoreductase1). The ARE conferred antioxidant-dependent regulation of target genes. In fact, the ARE is transcrip-

tionally activated not only by food antioxidants such as isothiocyanates (e.g. sulforaphane) in cruciferous vegetables and EGCG in green tea but also in response to reactive electrophilic intermediates and H2O2.

Antioxidant vitamins

HO

H

CH3

C

CH2 OH

O

HO

C

H

H

H3C

CH

3

HO

OH

CH

3

3

Figure 11.4 The structure of the

CH3

antioxidant vitamins, vitamin C

and vitamin E.

Vitamin C

Vitamin E

1 1 . 2 P R E V E N TAT I V E FAC TO R S : M I C R O C O N S T I T U E N T S O F F R U I T S A N D V E G E TA B L E S 263

Activation of gene expression through the ARE is mediated by the transcription factor Nrf2 and co-activator Maf, a member of the basic leucine zipper family. KEAP1 is an important repressor of Nrf2. Evidence suggests that in non-stressed cells, KEAP1 constitutively enters the nucleus, promotes Nrf2 ubiquitylation, and shuttles Nrf2 into the cytoplasm to proteosomes for degradation (Figure 11.5a). Inactivation of KEAP1 leads to the stabilization of Nrf2. KEAP1 contains cysteines that are important for its inactivation. It is these cysteines that normally act as sensors of the redox status in the cell. Electrophiles or ROS can react with these cysteines and inactivate KEAP1 resulting in the stabilization of Nrf2 and induction of gene expression via the ARE (Figure 11.b). This is an important molecular mechanism that the cell possesses to limit damage from oxidative and xenobiotic stresses: these stresses stimulate induction of enzymes that will make them less toxic and modify them for excretion.

Some food components can also inactivate KEAP1 (Figure 11.5c). As

mentioned earlier, sulforophane found in broccoli also activates Nrf2-regulated transcription. Sulforophane (a hydrolysis product of sulfur-containing glucosinolates) contain sulfydryl groups that are able to react (a) Non-stressed cells

(b) Electrophiles E

(c)

Green tea

Broccoli

EGCG

Sulforophane

KEAP1

EGCG*

cys

KEAP1

KEAP1

cys

cys

E

cys

Proteosome

cys

cys

Nrf2 degradation

u

KEAP1

Nrf2

Nucleus

Nucleus

Phase II

Phase II

Nrf2

Maf

Nrf2

Detoxifying enzymes

Detoxifying enzymes

A/GTGAC/TNNNGCA/G

A/GTGAC/TNNNGCA/G

ARE

ARE

Figure 11.5 The Nrf-2-antioxidant response element signaling pathway. (a) In non-stressed cells, KEAP1 (shaded in red) constitutively enters the nucleus, promotes Nrf2 ubiquitylation, and shuttles Nrf2 into the cytoplasm to proteosomes for degradation. (b) Dangerous electrophiles interact with cysteine (cys) residues present in KEAP1 causing a conformational change and KEAP1 inhibition. This results in the stabilization of Nrf2. Nrf2 can bind to the ARE, heterodimerize with its coactivator MAF, and stimulate transcription of detoxication enzymes. (c) Several dietary constituents regulate gene expression via the transcription factor Nrf2. Broccoli is a rich source of sulforophane. Sulforophane reacts with the cysteine residues in KEAP1

causing a conformational change and its inhibition. This results in the stabilization of Nrf2. Nrf2 can bind to the ARE, heterodimerize with its coactivator MAF, and stimulate transcription of detoxication enzymes. Also, green tea contains EGCG.

It has been suggested that an electrophilic metabolite of EGCG (EGCG*) may bind and inactivate KEAP1. As a result, Nrf2 is stabilized and is able to induce transcription of detoxication enzymes via the ARE.

264

1 1 : N U T R I E N T S, H O R M O N E S, A N D G E N E I N T E R AC T I O N S

with cysteine residues within the Nrf2 repressor, KEAP1. The direct interaction of sulforophane with the cysteine residues of KEAP1 causes a conformational change in KEAP1 that blocks its action and leads to the stabilization of Nrf2. Nrf2 is then able to bind to the ARE, dimerize with Maf, and induce the expression of genes encoding Phase II detoxication enzymes.

Epigallocatechin-3-gallate (EGCG), the major polyphenol found in

LIFESTYLE TIP

green tea, is another dietary constituent that activates the Nrf2 pathway.

We should use the knowledge

Several possibilities for its mode of action have been proposed (Na and that we have gained about the

Surh, 2008): KEAP1 may be inhibited by metabolites of EGCG or by

preventative role of particular

ECGC-generated ROS (Figure 11.5c). Alternatively, evidence suggests foods and beverages to make

that EGCG may activate a distinct MAPK signal transduction pathway

better choices about what we

(not shown). Similar to the induction of this pathway by growth factors ingest. Green tea is the second

(Chapter 4), intracellular kinases may lead to phosphorylation of Nrf2

most popular beverage in the

and its subsequent stabilization resulting in gene expression.

world, after water. A high intake

of green tea is associated with a

Therefore, some dietary microconstituents mimic carcinogenic ROS or low incidence of several cancers

electrophiles that inactivate KEAP1 and stabilize Nrf2. This molecular (e.g. gastric and colorectal can-pathway is important for protecting the cell from DNA damage caused by cer). Green tea is a better choice

oxidants by regulating the expression of genes that code for detoxication than soda.

enzymes.

Additional mechanisms of dietary microconstituents

Current evidence suggests several mechanisms for the cancer-preventative role of fruits and vegetables. As we have seen earlier, one mechanism is the ability to decrease oxidative DNA damage by free radical scavenging or inducing protective enzymes. Two other mechanisms for the role of particular vegetables in cancer prevention are modulation of apoptosis and/

or cell proliferation. The microconstituents of garlic utilize all three mechanisms. The antioxidant properties of organosulfur compounds in garlic include the induction of Phase II enzymes and scavenging. Ajoene, a major compound in garlic, has been shown to induce apoptosis of leukemic cells in patients with leukemia. Particular caspases (3 and 8) and transcriptional regulators (IκB) are activated and peroxide is produced. Allicin, another major compound in garlic, has been shown to inhibit the proliferation of human mammary, endometrial, and colon cancer cells. It is suggested that some of these effects are mediated via inhibition of the NFκB

signaling pathway (Chapter 10).

Another protective mechanism of EGCG found in green tea is its ability to bind to the catalytic site of DNA methyltransferase, blocking entry of cytosine and preventing methylation. This may be able to reverse the inactivation of key tumor suppressor genes. By this mechanism, EGCG blocks telomerase activity (Li and Tollefsbol, 2010). Paradoxically the hTERT

promoter is highly methylated and active in most tumor cells and in this





1 1 . 3 R E P R O G R A M M I N G E N E R G Y M E TA B O L I S M I N T U M O R C E L L S — A N E M E R G I N G H A L L M A R K O F C A N C E R 265

unusual case, demethylation represses activity. The inhibition of telomerase limits the replicative capacity of cells (see Chapter 3) and in this study correlates with a decrease in tumor size in mouse models.

Although fi ber is usually included in discussions of preventative agents of cancer, I have chosen to omit this topic here owing to the inconsisten-cies of recent large studies (see references within Key et al. , 2002). However, the fi rst key publication of EPIC shows a strong protective effect of dietary fi ber against colorectal cancer (Bingham et al. , 2003). The data suggest that preventative effects were not seen in some previous studies because the range of fi ber intake was much lower than those in the EPIC

study (see Activity 2 at the end of this chapter).

In conclusion, a brief examination of several different foods demonstrates that the molecular mechanisms by which nutrients affect carcinogenesis are beginning to be revealed.

11.3 Reprogramming energy metabolism in tumor

cells—an emerging hallmark of cancer

The digestion of food provides many of the compounds required for

metabolism, the sum of the biochemical reactions in the body. Thus, diet (and exercise) affect cellular metabolism. Reprogramming energy metabolism is an emerging hallmark of cancer (Chapter 1). Some tumors cells seem to be addicted to increased glucose uptake and glycolysis. The observation that cancer cells carry out aerobic glycolysis, converting glucose to lactate in the presence of oxygen, was made in the 1920s and is called the Warburg effect. This metabolic alteration differs from both anaerobic (without oxygen) glycolysis and aerobic metabolism used by differentiated cells that proceeds through the Krebs cycle and electron-transport chain (see box “A quick review about glucose metabolism”). This area of study has recently been revived, and differing viewpoints have not yet settled. Some suggest that 60–90% of tumors shift to glycolysis; others propose that the shift is time-dependent, and others again suggest it may be cell-type-dependent (stem cells versus differentiated cells). It has been proposed that the metabolism of cancer cells resembles the metabolism of PAUSE AND THINK

proliferating cells. Both are adapted to meet the anabolic needs of prolif-You may remember from Chap-

eration. Making new cells requires proteins, nucleotides, and lipids. Aero-ter 9 that hypoxia-inducible fac-

bic glycolysis provides anabolic substrates and ATP from enhanced

tor (HIF), is composed of two

glucose uptake. Regardless of these different views, it is of interest that the subunits; the α-subunit is regu-Warburg effect is the basis for an important imaging technique used to lated at the protein level via

detect tumors in the clinic. Positron emission tomography (PET) scans regulated degradation and the

work on the basis that tumor cells exhibit a greater uptake of glucose than β-subunit is constitutive.

most normal cells. A glucose analog, [18F]fl uoro-2-deoxyglucose (FDG),

266

1 1 : N U T R I E N T S, H O R M O N E S, A N D G E N E I N T E R AC T I O N S

is injected into the bloodstream and is converted by the glycolytic enzyme hexokinase to FDG-phosphate, which can be visualized (see Plate 11).

Data suggest that both genetic alterations (oncogenes and tumor sup-

pressor genes) and a response to hypoxia via HIF-1α contribute to the altered metabolism observed in cancer cells. Let’s examine evidence for both mechanisms.



Understanding of the pathway of a key metabolic enzyme, AMP-

activated protein kinase (AMPK), is uncovering links between energy metabolism and cancer. AMPK senses the energy state of a cell and is activated under conditions of increased AMP and decreased ATP in

response to starvation, hypoxia, and exercise. It is composed of an α

catalytic subunit and β and γ regulatory subunits. In the current model of AMPK activation (Figure 11.6), AMP binds to the γ subunit of AMPK

and causes a conformational change exposing a potential phosphorylation site within the α subunit of AMPK. The serine/threonine kinase LKB1 phosphorylates (Thr172) and activates AMPK. AMPK, also a

serine/threonine kinase, exerts its effects through the regulation of target enzymes and transcription factors. In general, ATP-generating pathways are stimulated (e.g. fatty acid oxidation, glycolysis) and ATP-consuming pathways are inhibited (e.g. fatty acid synthesis). A link between AMPK

and cancer comes from the fi nding that LKB1 and a downstream effector called TSC2 are tumor suppressor genes (Figure 11.7). Both have been identifi ed as germline mutations in syndromes that predispose patients to cancer (Peutz–Jeghers syndrome and tuberous sclerosis,

respectively). Although more studies are required, inhibition of growth P

AMP

LKB1

α

β

δ

α

β

δ

α

δ AMP

α

γ AMP

Inactive AMPK

Binding to AMP

β

β

Conformational change

Active AMPK

Enzymes

Transcriptional

regulators

• Increase ATP synthesizing reactions

• Decrease ATP consuming processes

Figure 11.6 Activation of AMP-activated protein kinase, AMPK. When the energy of a cell decreases, AMP increases. AMP

binds to inactive AMPK and causes a conformational change that allows phosphorylation of the α catalytic subunit by LKB1.

The activating phosphate is shown in red.

1 1 . 3 R E P R O G R A M M I N G E N E R G Y M E TA B O L I S M I N T U M O R C E L L S — A N E M E R G I N G H A L L M A R K O F C A N C E R 267

Exercise

Oncogenic

Starvation

Hypoxia

mutations

AMP

LKB1

AMPK

HIF - 1α

p53

TSC2

Glycolytic

Krebs and

enzymes

oxidative phosphorylation

enzymes

Cell

Glycolysis

mTOR

cycle

arrest

Figure 11.7 Pathways of

Cell growth

metabolic regulators AMPK and

Cell survival

HIF-1α (shown in red).

has been reported for tumor cells in culture upon activation of AMPK.

In addition, AMPK activates the “star” tumor suppressor, p53. In this capacity, p53 acts as a metabolic checkpoint and induces cell cycle arrest in response to low cellular energy.

Target genes of tumor suppressor p53 include inhibitors of glycolysis (e.g. TIGAR) and stimulators of oxidative phosphorylation (e.g. cytochrome c oxidase 2) (Matoba et al. , 2006). Thus, mutations in p53 that drive cancer also cause altered metabolism that leads to the Warberg effect. (Note: in contrast to the effect of p53 in inhibiting of glycolysis, one report suggests that AMPK stimulates glycolysis in some cell types, and thus the role of AMPK in the regulation of glycolysis requires further study.)

Both hypoxia and oncogenic mutations in the absence of hypoxia can

activate HIF-1α (Figure 11.7). The inactivation of the tumor suppressor VHL stabilizes HIF-1α in the presence of oxygen. Also, HIF-1α is

increased in cells transformed with oncogenes such as Src and Ras.

In addition to regulating VEGF transcription, HIF-1α upregulates

the expression of nearly all of the core enzymes of glycolysis and inhibits the expression of some enzymes involved in the Krebs cycle and oxidative phosphorylation. Thus, the increased glycolysis observed in some tumors is regulated by a specifi c transcriptional program, rather than only a lack of oxygen.

Warburg’s original hypothesis implied a dysfunction of mitochondria in cancer cells but we now know that most cancer cells do not have defects in mitochondrial metabolism (with some rare exceptions: succinate





268

1 1 : N U T R I E N T S, H O R M O N E S, A N D G E N E I N T E R AC T I O N S

dehydrogenase and fumarate hydratase; germline mutations in both can lead to cancer). Rather, complex metabolic pathways such as those discussed earlier underlie the Warburg effect. Further investigations regarding the mechanism of this long-observed phenomenon are needed and

may have additional therapeutic implications.

A quick review of glucose metabolism

In normal cells, the glycolysis pathway involves the breakdown of glucose in the absence of oxygen (anaerobic metabolism) and the production of pyruvate. Pyruvate is converted into lactate by the enzyme lactate dehydrogenase. In the presence of oxygen, pyruvate from glycolysis is shuttled through the Krebs cycle, and NADH and FADH are generated. These 2

electron carriers shuttle their electrons through the electron transport chain located in the inner mitochondrial membrane. Oxygen is the terminal electron acceptor. The resulting proton motor force generates ATP.

11.4 Genetic polymorphisms and diet

It seems that some people can do all the “wrong things” such as drink excessive amounts of alcohol and smoke heavily and still live long

healthy lives. We often hear that this is due to an individual’s metabolism. Cancer risk associated with diet is infl uenced by an individual’s metabolism. Metabolic reactions are catalyzed by enzymes. Enzyme

activities may vary among individuals because of small variations,

often single nucleotide changes, in the genes that code for them. The study of genetic polymorphisms that alter the response to a particular dietary constituent is called nutrigenetics. Here are two examples. A polymorphism (C→T transition at nucleotide 677) in the MTHFR gene reduces its enzyme activity and homozygotes for this polymorphism

have a 50% decreased risk of colorectal cancer compared with those

with wild-type alleles. These individuals have an increased availability of 5,10-methylene THF and a lower chance of disrupting nucleotide

and subsequently DNA synthesis; these conditions deter mutation and carcinogenesis (see Figure 11.2). However, the polymorphism increases the risk of cancer if these individuals become defi cient in folate. Under these conditions, methyl-THF becomes depleted and DNA methylation

is altered in a manner that is characteristic of carcinogenesis. Note: chronic alcohol consumption is the most common cause for impair-ment of folate uptake. Recommendation of higher intake of folate and lower intake of alcohol is especially important for those who are

homozygous for the T allele at nucleotide 677 of the MTHFR gene





1 1 . 5 V I TA M I N D : A L I N K B E T W E E N N U T R I E N T S A N D H O R M O N E AC T I O N 269

(Kim, 2007). Polymorphisms in the gene that codes for N-acetyltransferase modify the risk of specifi c cancers in response to the consumption of red meat. This enzyme is involved in the metabolic activation of carcinogenic heterocyclic amines produced by cooking meat at high

temperatures. Individuals with the “rapid variant” of the enzyme (a fast acetylator) who consume large amounts of red meat have an

increased risk of colon cancer compared with those who have this variant and do not consume much red meat, or those who possess the “slow variant” polymorphism who do. Therefore, the response to red meat

intake with respect to an increased risk of cancer depends on a person’s genotype in combination with exposure to carcinogens that result from cooking.

Inherited metabolic diseases can illustrate a more obvious role of

metabolism in carcinogenesis. Here are two examples resulting from

blocks in tyrosine metabolism pathways. Albinos have an inherited defi -

ciency of the enzyme tyrosinase and are unable to produce melanin, causing the characteristic lack of pigment in their skin. The lack of pigment causes albinos to be more sensitive to the sun and results in an increased risk of skin carcinoma. Tyrosinemia type I, another disorder of tyrosine metabolism, results from a defi ciency of fumarylacetoacetate hydrolase.

As a result of this metabolic block, the metabolites fumarylacetoacetate and maleylacetate accumulate. Both are alkylating agents and cause DNA mutations and tumorigenesis. In brief, tyrosinemia type I is characterized by the synthesis and accumulation of carcinogens.

11.5 Vitamin D: a link between nutrients and

hormone action

A precursor, or pre-vitamin, to biologically active vitamin D can be obtained through the diet (fortifi ed dairy products and seafood) or produced in the skin from 7-dehydrocholesterol upon exposure to sunlight.

LIFESTYLE TIP

The pre-vitamin, regardless of its source (skin or diet), must be metabolized fi rst in the liver to form 25-hydroxyvitamin D (biologically inert) Vitamin D defi ciency is now a

and then in the kidney to form the biologically active form, 1,25-dihy-worldwide problem. Most

droxyvitamin D. Synthesis of the pre-vitamin in the skin upon UV expo-experts recommend 1000 IU of

vitamin D is needed daily in the

sure accounts for 90–95% of an individual’s requirement for vitamin D; absence of sun exposure to

very few foods (except oily fi sh) naturally contain vitamin D. This is one maintain healthy blood levels of

reason why some countries fortify milk and other foods.

the pre-vitamin. Exposure to a

Epidemiological evidence has demonstrated that there is an increased

“sensible” amount of sunlight

risk of several cancers (particularly prostate, colon, and breast; note that (depending on skin type) is also

prostate, colon, and breast cells contain the enzyme needed to produce encouraged.

1,25-dihydroxyvitamin D) in people living at higher latitudes (van der

270

1 1 : N U T R I E N T S, H O R M O N E S, A N D G E N E I N T E R AC T I O N S

Rhee et al. , 2006; see also Holick, 2006). It has been proposed that vitamin D defi ciency underlies this effect, although additional effects of sun exposure may also play a role. One study evaluated the growth of colon cancer cells in xenografts (human cells implanted in the backs of the immunodefi cient mice) in vitamin D-defi cient versus vitamin D-suffi cient mice (Tangpricha et al. , 2005). Tumors were 80% larger on average in mice that were defi cient in vitamin D compared with vitamin D-suffi cient mice. Collectively, epidemiological and in vivo evidence suggest a link between vitamin D defi ciency and increased cancer risk.

A little lesson about the history of vitamin D fortifi cation of milk Rickets, a debilitating bone-deforming disease, affected more than 80% of children living in industrialized cities in the northeastern USA and northern Europe at the beginning of the 20th century. Vitamin D fortifi cation was introduced to try to reduce the incidence of rickets. In the USA, milk, orange juice, and some cereals are fortifi ed with vitamin D. In Europe, fortifi cation of foods was carried out until the late 1940s. Over-fortifi cation of milk caused an outbreak of vitamin D intoxication in Great Britain and led to regulations that ablated vitamin D fortifi cation throughout Europe. These remain active today. Over-fortifi cation most likely resulted from human error or inaccurate food analysis. As food analysis has become more reliable over the last 50 years, should vitamin D fortifi cation be reconsidered in northern Europe and elsewhere?

The link between nutrients and gene expression became apparent upon the discovery that the receptors for vitamin A and D are members of the steroid hormone receptor superfamily.

Let us examine the molecular mechanisms of vitamin D action. The

PAUSE AND THINK

active form of vitamin D (1,25-hydroxyvitamin D) acts as a ligand for the How do steroid hormone recep-cytoplasmic vitamin D receptor, a member of the steroid hormone receptors function? Remember from

tor superfamily. This receptor recognizes the vitamin D response element Chapter 3 that they are ligand-in gene promoter regions and regulates transcription of its target genes.

dependent transcription factors.

Current data suggest that vitamin D is a chemopreventative agent that inhibits growth and induces differentiation and apoptosis through several molecular targets. Here are a few examples: vitamin D can act as a dominant negative ligand for EGFR (epidermal growth factor receptor, Chapter 4). That is, vitamin D can bind to the ligand-binding domain of EGFR

instead of EGF and prevent the binding of EGF to EGFR. As a result, vitamin D can inhibit growth. Secondly, upon binding to the vitamin D

receptor, the active form of vitamin D can directly activate specifi c tumor suppressor genes such as BRCA1 and p21 through a vitamin D response element in their promoter regions. You may recall that the p21 protein is an inhibitor of cyclin-dependent kinase and that it can induce cell cycle arrest. Vitamin D promotes apoptosis through mitochondrial signaling independent of caspase activation. It induces the redistribution of two





1 1 . 6 H O R M O N E S A N D C A N C E R 271

pro-apoptotic proteins BAK and BAX from the cytosol to the mitochondria. These two proteins form channels in the mitochondrial membrane and facilitate the release of cytochrome c and apoptosome assembly (see Chapter 7). Simultaneously, Bcl-2 and IAPs, inhibitors of apoptosis, are downregulated.

11.6 Hormones and cancer

There is group of cancers linked by a common mechanism of carcinogenesis that involves endogenous hormones as initiators rather than chemicals, viruses, or radiation. The hormone-related cancers include breast, endometrium, ovary, prostate, testis, and thyroid cancer. We will examine breast cancer as a paradigm for hormonal carcinogenesis. (Note: links between hormones and some other hormone-related cancers are not as

straightforward.)

Breast cancer is the most common type of cancer in women. Estrogens



(estradiol and estrone) appear to play a central role in the initiation and progression of breast cancer. Life events that prolong exposure to estrogens are considered risk factors for breast cancer (Figure 11.8). Early menarche (the start of the menstrual cycle) and late menopause indicate an extended length of time when the ovaries are producing estrogen. Pregnancy affects the exposure time to estrogens. The principal site of estrogen synthesis in the body changes with increased age: the ovaries are the main source in pre-menopausal women and adipose tissue (fat) is the main source in post-menopausal women. Obesity in post-menopausal

women is a risk factor because adipose cells are the primary source of estrogen at this stage in life. Obese women have an increased number of fat cells and therefore produce increased amounts of estrogen. Adipose cells use the enzyme aromatase to produce estrogen from androgens.

Thus, obesity increases the risk of breast cancer through increased estrogen production. It is thought that alcohol consumption increases the risk of breast cancer because of its association with increased concentrations of estrogen. The mechanism for the increase in estrogen concentration is not fully known, but it is known that alcohol dehydrogenase can also metabolize estrogens. It has been suggested that alcohol may compete with estrogens in this metabolic pathway and lead to an increase in estrogen concentration. Some data suggest that one alcoholic drink per day causes a 7% increase in the risk of breast cancer. The use of exogenous hormones in oral contraceptives and in hormone replacement therapy has also been linked to increased risk of breast cancer. Conversely, factors that interrupt the menstrual cycle, such as pregnancy, lactation, and physical activity, are considered protective factors. Although a rare event, breast

272

1 1 : N U T R I E N T S, H O R M O N E S, A N D G E N E I N T E R AC T I O N S

Breast cancer risk factors

Alcohol

consumption

Oral

contraception

Age of 1st pregnancy >30 yrs

Hormone

Early menarche

Late menopause

replacement

Post-menopausal

therapy

obesity

Figure 11.8 Risk factors for breast

cancer.

Increased estrogen exposure

cancer can occur in men. Men also produce some amounts of estrogen

and those with high levels appear to be more at risk.

Two predominant models for the mechanisms by which estrogens exert

their effects have been proposed (Figure 11.9). It is likely that both mechanisms contribute to breast cancer.

One model is that estrogens promote cell proliferation of the breast and the high division rate allows less time for DNA repair, thus creating an opportunity for errors to occur during DNA replication. The increase in error rate translates into an increase in somatic mutations that lead to carcinogenesis. This model contrasts chemical- and radiation-induced carcinogenesis, as no specifi c initiator other than errors in replication is required. Estrogen does indeed act as a mitogen for cells in the breast that contain estrogen receptors. During pregnancy, estrogen levels increase and cause the mammary ducts to grow and the breasts to nearly double in

size. Effects of estrogen are mediated through estrogen receptors (ERs), estrogen receptor-α and estrogen receptor-β, members of the steroid hormone receptor superfamily (see Chapter 3). The receptors bind as dimers to the estrogen response element (ERE) and regulate estrogen-responsive

1 1 . 6 H O R M O N E S A N D C A N C E R 273

Estrogen

ER

BRCA

*

estradiol-

3,4-quinone

*

ERE

Mitogenic genes

G

T

C

Cell proliferation

Abasic site

T

C

Errors during DNA

replication

Mutations

Figure 11.9 Carcinogenic

mechanisms of estrogens:

Breast cancer

mitogenic and/or genotoxic.

genes. In addition to this genomic pathway, non-genomic signaling pathways outside the nucleus have also been documented (Revankar et al. , 2005). The expression of the estrogen receptor isoforms changes during carcinogenesis of the breast. Estrogen receptor-α is signifi cantly upregulated and estrogen receptor-β is downregulated in the majority of breast cancers. The reasons for these alterations are unknown at present. However, as we shall see in Section 11.9, blocking ER function has proved to be a successful strategy for the treatment of breast cancer.

The involvement of estrogen signaling in increasing susceptibility to breast cancer is supported by studies of the breast cancer susceptibility genes ( BRCA s). About 5–10% of all cases of breast cancer are a result of an inherited predisposition, 85% of which result from germline mutations in either the BRCA1 or BRCA2 gene. The BRCA gene products are nuclear tumor suppressor proteins that play a role in transcriptional regulation, DNA repair, and regulation of the cell cycle. BRCA1 inhibits the transcriptional activation activity of estrogen receptors and this suggests that it suppresses the proliferating effects of estrogen signaling. It has been





274

1 1 : N U T R I E N T S, H O R M O N E S, A N D G E N E I N T E R AC T I O N S

suggested that the loss of modulation of estrogen signaling contributes to the increased risk to breast cancer in patients with an inherited mutation of BRCA1.

Another model suggests that estrogen and its metabolites are geno-

toxic. This model is consistent with the mechanism by which chemicals, viruses, and radiation initiate carcinogenesis. Estradiol is metabolized to form estradiol-3,4-quinone in cells. This metabolite covalently binds to adenine or guanine bases. The resulting adducts destabilize the bonds linking the base to the DNA backbone and result in an abasic site and, ultimately, mutations. (Note: as adenine and guanine are purines, abasic sites that involve the loss of adenine or guanine are referred to as apurinic sites.) Estradiol quinones are present in human breast tissue. Estrogen receptor knock-out mice were used as an animal model to test the effect of estrogen in the absence of estrogen receptors. Results demonstrated that genotoxic effects occurred in the absence of estrogen receptors (Yue et al. , 2003). Data obtained from human breast epithelial cells in vitro indicated that metabolites of estrogen induce transformation in vitro and also induce loss of heterozygosity at chromosomal regions that have been reported to be affected in primary breast tumors (Russo et al. , 2003).

These genotypic changes were not blocked by inhibitors of the estrogen receptor, showing that this effect was not receptor-mediated. Together, these results support the concept that estrogen metabolites contribute to breast carcinogenesis.

For this second model, predispositions to breast cancer may involve germline mutations in genes involved in estrogen biosynthesis and metabolism. Loss of the BRCA tumor suppressor proteins may leave breast cells more susceptible to the genotoxic effects of estrogen metabolites because of the normal role of BRCA tumor suppressor proteins in DNA repair.

A third model combines the two models just described and suggests

that the estrogen receptor acts as a “Trojan Horse” and carries carcinogenic estrogen metabolites directly to estrogen sensitive genes (Bolton and Thatcher, 2008).

Therapeutic strategies

11.7 “Enhanced” foods and dietary supplements

for chemoprevention

Chemoprevention is the use of naturally occurring or synthetic agents to prevent, inhibit, or reverse the process of carcinogenesis in pre-malignant

1 1 . 7 “ E N H A N C E D ” F O O D S A N D D I E TA RY S U P P L E M E N T S F O R C H E M O P R E V E N T I O N 275

cells. Foods are not yet widely accepted as preventative agents against cancer. However, as we learn more about the important role of nutrients in cancer and as our skills for manipulating food composition increase, this concept is set to change. The development of enhanced food products (foods that have altered levels of particular microconstituents), derived in some cases from genetically modifi ed crops, will begin to fl ood the market. Foods have already been produced to have increased levels of antioxidants and may be used in future chemopreventative diets. Tomatoes have been classically bred to be bright red for consumer appeal and as a result contain more lycopene. They have also been engineered to contain increased levels of zeaxanthin by over-expressing enzymes utilized in its synthesis. Recently, broccoli, containing high levels of glucosinolates (which are hydrolyzed to isothiocyanates including sulforophane; discussed in Section 11.2), has been developed by a traditional plant-breeding program and licensed to Seminis Inc., the world’s largest developer and grower of vegetable and fruit seeds. A balance of potential advantage from enhanced foods must be tempered by the likelihood that we may have adverse reactions to food constituents at abnormally high concentrations.

Although we discussed the disappointing results of β-carotene supplementation with respect to lung cancer, an interesting observation resulting from the ATBC trial prompted further study into the effects vitamin E supplementation on the risk of prostate cancer. A signifi cantly decreased rate of prostate cancer was observed in patients taking vitamin E (11.7 versus 17.8%) in the ATBC trial. A similar observation was observed for selenium in a separate study. The Selenium and Vitamin E Cancer Prevention Trial (SELECT), a Phase III randomized placebo-controlled trial, has recruited over 35,000 male participants to test the effects of selenium and vitamin E supplements after a minimum of 7 years. Again, the results were disappointing in that they found that dietary supplementation with vitamin E increased the incidence of prostate cancer by 17% (see website reference at the end of the chapter). This supports the World Cancer Research Fund recommendation not to use supplements to protect against cancer.

The synthetic agent oltipraz holds promise as a chemopreventative

agent. Similar to sulforophane, it induces Phase II enzymes via transcription factor Nrf2 and brings about the detoxifi cation of afl atoxin (Figure 11.2). The effects of oltipraz as a chemopreventative agent were tested in Phase I and IIa trials in Qidong, China, an area where afl atoxin contributes to a high incidence of hepatocellular carcinoma. Results demonstrated an increase in afl atoxin detoxifi cation products, suggesting that there was a change in the metabolic phenotype of patients as a result of the induction of Phase II enzymes. Although this agent provides evidence for proof of concept, food-based approaches (e.g. using broccoli sprout teas) may be better alternatives, and these are also being investigated.





276

1 1 : N U T R I E N T S, H O R M O N E S, A N D G E N E I N T E R AC T I O N S

As we learn more about the role of nutrients in cancer prevention, it is certain that the list of trials for testing the effects of diet and supplements as chemopreventative agents will expand.

11.8 Drugs that target energy pathways

Although a fairly new strategy, the potential of targeting energy pathways may be worth exploring (Gatenby and Gillies, 2007). As some tumor cells exhibit increased aerobic glycolysis (the Warburg effect), one obvious approach is to target hexokinase, the enzyme that catalyzes the fi rst, and rate-limiting, step in glycolysis. Pre-clinical experiments testing the effects of a hexokinase inhibitor, 3-bromopyruvate (3-BrPA), have demonstrated anti-tumor effects. Numerous approaches that inhibit HIF are being

developed. The small-molecule inhibitor PX-478 is one example that is due to be tested in clinical trials. Metformin is widely used for the treatment of type 2 diabetes. It activates AMPK via LKB1. Results from a pilot study have suggested that cancer risk is reduced in type 2 diabetics taking metformin (Evans et al. , 2005). Additional studies are ongoing. See Vander Heiden (2011) for a table of strategies to target metabolic enzymes for cancer therapy.

11.9 Drugs that target estrogen

There are two strategies for the design of drugs that target estrogen action (Figure 11.10). The fi rst is to design drugs that antagonize the actions of estrogens by interacting with estrogen receptors in order to block growth in “estrogen-receptor-positive” tumors. These compounds are

called anti-estrogens. Tamoxifen, used in the clinic for over 30 years, is the most widely used anti-estrogen to treat estrogen-receptor-positive, post-menopausal breast cancer. Tamoxifen is a competitive inhibitor that alters the folding of the ligand-binding domain of the estrogen receptor and blocks its ability to transactivate and initiate transcription of its target genes. Recently, the principle of a potentially new strategy for interfering with estrogen receptor function has been tested. Several electrophilic agents have been shown to target the estrogen receptor zinc fi nger domain and selectively block the receptor’s DNA-binding activity. Furthermore, the progression of breast carcinoma was inhibited in mouse models by these drugs (Wang et al. , 2004). These drugs may act as lead compounds for the development of new breast cancer therapies.

1 1 . 9 D R U G S T H AT TA R G E T E S T R O G E N 277

Aromatase

inhibitors

Aromatase

Androgens

Estrogens

Tamoxifen

ER

Target genes

Figure 11.10 Drugs that target

estrogen action (shown in red).

Electrophilic

Molecular targets are indicated

agents

by a () symbol.

The second strategy for blocking the function of estrogen in breast cancer is to design drugs that interfere with estrogen synthesis. Drugs that target aromatase, the enzyme that converts androgens into estrogens in post-menopausal women have been developed. Targeting this enzyme does not interfere with the synthesis of other steroids but is rate-limiting for estrogen production. Aromatase is the main source of estrogen production in post-menopausal women because the ovaries no longer pro-

duce it. Aromatase inhibitors can be prescribed to reduce the level of estrogen in the body of post-menopausal breast cancer patients, making it appropriate for over 50% (estrogen-receptor-positive and post-menopausal) of all breast cancers. These drugs are not an option for pre-menopausal patients as aromatase is not the major estrogen producer (see Pause and Think).

Three aromatase inhibitors have gone through clinical trials and have PAUSE AND THINK

been approved in the USA: exemestane, anastrozole, and letrozole. Exemestane (Aromasin™) is a steroidal compound that competes with endogenous How would you design an aro-androgens for enzyme binding. Intermediates are formed upon binding to matase inhibitor? One way is to

aromatase. These intermediates bind irreversibly and block enzyme func-model your compound on

androstenedione, the endoge-

tion. Anastrozole (Arimidex™) and letrozole (Femara™) are non-steroidal nous substrate for the enzyme.

compounds that bind reversibly to the active site of aromatase (Hiscox These drugs should interact and

et al. , 2009). A 10-year large-scale trial called the ATAC trial (Arimidex, inactivate the steroid-binding

Tamoxifen Alone or in Combination) compared anastrozole and tamoxifen domain of aromatase.

as adjuvant treatment (treatment given after surgery to prevent recurrence) for early-stage breast cancer. Results supported long-term superior effi cacy and safety of anastrozole over tamoxifen as initial adjuvant therapy for post-menopausal women with early-stage breast cancer (Cuzick et al. ,

278

1 1 : N U T R I E N T S, H O R M O N E S, A N D G E N E I N T E R AC T I O N S

2010). The result from the ATAC trial is to be expected when considering the two proposed mechanisms of action of estrogen. Tamoxifen blocks estrogen-receptor-mediated effects only. Aromatase inhibitors reduce total estrogen concentrations and therefore block both estrogen receptor mechanisms and non-receptor-mediated genotoxic events. Molecular knowledge advances drug design.

Tamoxifen has potent chemopreventative activity that may be greater than its therapeutic activity. Several studies have demonstrated that the incidence of invasive breast cancer is reduced by 49%. As a result, the US

FDA has approved tamoxifen for breast cancer risk reduction. However, the perceived risk of taking tamoxifen for the recommended fi ve years (increased risk for endometrial cancer and stroke) and its associated side-effects has not made it a popular option. The estrogen receptor modulator raloxifene has shown equivalent effi cacy to tamoxifen and has fewer side-effects, and thus may become a better alternative. Future chemopreventative strategies need to consider the risk–benefi t ratio and also improved means for the identifi cation of high-risk individuals.

■ CHAPTER HIGHLIGHTS—REFRESH YOUR MEMORY

•

Diet plays a role in both the causation and the prevention

•

The Warburg effect describes the increase in aerobic

of cancer.

glycolysis that occurs in some tumor cells.

•

In contrast to the association of a β-carotene-rich

•

Genetic polymorphisms can interact with nutrient status

diet with reduced lung cancer incidence, β-carotene sup-

and affect cancer risk.

plementation increases lung cancer in smokers.

•

Vitamin D is a nutrient that acts through a member of the

•

Diet contributes to carcinogenesis by the delivery of carci-

steroid hormone receptor family.

nogenic contaminants.

•

Breast cancer is a paradigm for hormonal

•

Folate defi ciency affects nucleotide synthesis and DNA

carcinogenesis.

methylation.

•

Estrogen acts as a mitogen for cells in the breast.

•

Obesity and chronic alcohol drinking are also causative

•

Estrogen and its metabolites may damage DNA directly to

factors in cancer.

initiate carcinogenesis.

•

Nutrients may work as chemopreventative agents by

•

Dietary factors such as obesity and alcohol intake increase

blocking DNA damage via scavenging or the induction of

breast cancer risk by increasing estrogen production.

metabolizing enzymes, inducing apoptosis, or inhibiting

•

Germline mutations in the BRCA1 and BRCA2 genes pre-cell proliferation.

dispose patients to breast cancer.

•

The antioxidant response element (ARE) is found in the

•

Enhanced food and dietary supplements are being inves-

gene promoters of detoxifying and antioxidant enzymes.

tigated as chemopreventative agents.

•

Some dietary constituents regulate gene expression of

•

Tamoxifen is a breast cancer drug that acts as an “anti-

detoxifying enzymes via the transcription factor NRF2 and

estrogen” and blocks estrogen binding to its receptor.

AREs.

•

Aromatase inhibitors, such as anastrozole, act by inhibit-

•

The major polyphenol of green tea, epigallocatechin gal-

ing the enzyme aromatase that converts androgens to

late, inhibits telomerase.

estrogen.

1 1 . 9 D R U G S T H AT TA R G E T E S T R O G E N 279

■ ACTIVITY

1. Record what you ate and drank for dinner last night. Give a critical account of how the meal contributed either to reducing or enhancing your cancer risk. Bon appetit!

2. By reviewing the literature and using experimental evidence critically discuss the role of fi ber as a cancer-preventative factor in our diet.

■ FURTHER READING

Aggarwal, B.B. and Shishodia, S. (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 71: 1397–1421.

Calle, E.E. and Kaaks, R. (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 4: 579–589.

Choi, S.-W. and Mason, J.B. (2002) Folate status: effects on pathways of colorectal carcinogenesis. J. Nutr. 132: 2413S–2418S.

Kensler, T.W., Egner, P.A., Wang, J.-B., Zhu, Y.-R., Zhang, B.-C., Lu, P-X., et al.

(2004) Chemoprevention of hepatocellular carcinoma in afl atoxin endemic areas.

Gastroenterology 127: S310–S318.

Key, T.J., Allen, N.E., Spencer, E.A., and Travis, R.C. (2002) The effect of diet on risk of cancer. Lancet 360: 861–868.

Lamprecht, S.A. and Lipkin, M. (2003) Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. Nat. Rev. Cancer 3: 601–614.

Levine, A.J. and Puzio-Kuter, A.M. (2010) The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330: 1340–1344.

Nguyen, T. and Nioli, P., and Pickett, C.B. (2009) The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem. 284: 13291–13295.

Pool-Zobel, B., Veeriah, S., and Bohmer, F.-D. (2005) Modulation of xenobiotic metabolizing enzymes by anticarcinogens – focus on glutathione S-transferases and their role as targets of dietary chemoprevention in colorectal carcinogenesis. Mut.

Res. 591: 74–92.

Qi, R. and Wang, Z. (2003) Pharmacological effects of garlic extract. Trends Pharmacol. Sci. 24: 62–63.

Ross, S.A. (2010) Evidence for the relationship between diet and cancer. Exp. Oncol.

32:137–142.

Shaw, R.J. (2006) Glucose metabolism and cancer. Curr. Opin. Cell Biol. 18: 1–11.

Surh, Y.-J. (2003) Cancer chemoprevention with dietary phytochemicals. Nat. Rev.

Cancer 3: 768–780.

Vander Heiden, M.G. (2009) Understanding the Warburg Effect: the metabolic requirements of cell proliferation. Science 324: 1029–1033.

Venkitaraman, A.R. (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108: 171–182.

World Cancer Research Fund/American Institute for Cancer Research. (2007) Food, Nutrition, Physical Activity and the prevention of Cancer: a Global Perspective.

AICR, Washington DC. http://www.dietandcancerreport.org

Yager, J.D. and Davidson, N.E. (2006) Estrogen carcinogenesis in breast cancer. N.

Engl. J. Med. 354: 270–282.

280

1 1 : N U T R I E N T S, H O R M O N E S, A N D G E N E I N T E R AC T I O N S

■ WEB SITES

Key fi ndings of the EPIC study http://epic.iarc.fr/keyfi ndings.php

World Cancer Research Fund http://www.wcrf.org/

Selenium and Vitamin E Cancer Prevention Trial (SELECT) http://www.cancer.gov/

clinicaltrials/digestpage/SELECT/allpages

■ SELECTED SPECIAL TOPICS

Bingham, S.A., Day, N.E., Luben, R., and Ferrari, P. (2003) Dietary fi bre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 361: 1496–1501.

Boffetta, P., Couto, E., Wichmann, J., Ferrari, P., Trichopoulos, D., Bueno-de-Mesquita, H.B., et al. (2010) Fruit and vegetable intake and overall cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) J. Natl.

Cancer Inst. 102: 529–537.

Bolton, J.L. and Thatcher, G.R.J. (2008) Potential mechanisms of estrogen quinone carcinogenesis. Chem. Res. Toxicol. 21: 93–101.

Bub, A., Watzl, B., Blockhaus, M., Briviba, K.L., Liegibel, U., Muller, H., et al. (2003) Fruit juice consumption modulates antioxidative status, immune status, and DNA damage. J. Nutr. Biochem. 14: 90–98.

Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., et al. (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10 year analysis of the ATAC trial. Lancet Oncol. 11: 1135–1141.

Evans, J.M., Donnelly, L.A., Emslie-Smith, A.M., Alessi, D.R., and Morris, A.D.

(2005) Metformin and reduced risk of cancer in diabetic patients. Br. Med. J. 330: 1304–1305.

Gatenby, R.A. and Gillies, R.J. (2007) Glycolysis in cancer: a potential target for therapy. Int. J. Biochem. Cell Biol. 39: 1358–1366.

Hiscox, S., Davies, E.L., and Barrett-Lee, P. (2009) Aromatase inhibitors in breast cancer. Maturitas 63: 275–279.

Hites, R.A., Foran, J.A., Carpenter, D.O., Hamilton, M.C., Knuth, B.A., and Schwa-ger, S.J. (2004) Global assessment of organic contaminants in farmed salmon.

Science 303: 226–229.

Holick, M.F. (2006) Vitamin D: its role in cancer prevention and treatment. Prog. Biophys. Mol. Biol. 92: 49–59.

Kim, D.-H. (2007) The interactive effect of methyl-group diet and polymorphism of methylenetetrahydrofolate reductase on the risk of colorectal cancer. Mutation Res.

622: 14–18.

Li, Y. and Tollefsbol, T.O. (2010) Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Curr. Med. Chem. 17: 2141–2151.

Matoba, S., Kang, J.-G., Patino, W.D., Wragg, A., Boehm, M., Gavrilova, O., et al.

(2006) P53 regulates mitochondrial respiration. Science 312: 1650–1653.

1 1 . 9 D R U G S T H AT TA R G E T E S T R O G E N 281

Na, H.K. and Surh, Y.-J. (2008) Modulation of Nrf2-mediated antioxidant and detoxifying enzyme induction by the green tea polyphenol EGCG. Food Chem. Toxicol.

46: 1271–1278.

Park, E.J., Lee, J.H. Yu, G.-Y., He, G., Ali, S.R., Holzer, R.G., et al. (2010) Dietary and genetic obesity promote liver infl ammation and tumorigenesis by enhancing Il-6 and TNF expression. Cell 140: 197–208.

Revankar, C.M., Cimino, D.F., Sklar, L.A., Arterburn, J.B., and Prossnitz, E.R. (2005) A transmembrane intracellular estrogen receptor mediates rapid cell signaling.

Science 307: 1625–1630.

Russo, J., Lareef, M.H., Balogh, G., Guo, S., and Russo, I.H. (2003) Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J. Steroid Biochem. Mol. Biol. 87: 1–25.

Seitz, H.K. and Stickel, F. (2007). Molecular mechanisms of alcohol-mediated carcinogenesis. Nat. Rev. Cancer 7: 599–612.

Tangpricha, V., Spina, C., Yao, M., Chen, T.C., Wolfe, M.M., and Holick, M.F. (2005) Vitamin D defi ciency enhances the growth of MC-26 colon cancer xenografts in Balb/c mice. J. Nutr. 135: 2350–2354.

van der Rhee, H.J., de Vries, E., and Coebergh, J.W.W. ( 2006) Does sunlight prevent cancer? A systematic review. Eur. J. Cancer 42: 2222–2232.

Vander Heiden, M.G. (2011) Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov. 10: 671–684.

Wang, L.H., Yang, X.Y., Zhang, X., Mihalic, K., Fan, Y.-X., Xiao, W., et al. (2004) Suppression of breast cancer by chemical modulation of vulnerable zinc fi ngers in estrogen receptor. Nat. Med. 10: 40–47.

Yue, W., Santen, R.J. Wang, J.-P., Li, Y., Verderame, M.F., Bocchinfuso, W.P., et al.

(2003) Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J. Steroid Biochem. Mol. Biol. 86: 477–486.

This page intentionally left blank





Chapter 12

The cancer industry:

drug development,

pharmacogenomics,

and clinical trial design

Introduction

The goal of cancer research is to develop new effective and non-toxic cancer therapies. In this chapter, the process of drug development is reviewed. The development of the drug Gleevec™, one of the most successful cancer therapies of recent years, is used to illustrate the process. The understanding of both the mechanism of action of this drug and the development of drug resistance is being used to produce “second-generation” therapeutics. Investigations of the variable responses of individuals to another drug, Iressa™, will also be described. The chapter ends with a description of how to initiate a career in cancer research—just in case I have caught your interest.

12.1 Strategies of drug development

Drug development follows a series of stages (see Figure 12.1) and people with different expertise (e.g. biochemists, cell biologists, chemists, clinicians) may carry out the different stages at different facilities. In the preceding chapters we have seen many examples of important molecular targets and strategies to manipulate them (e.g. kinase inhibitors). Once a potential drug has been identifi ed and prepared as a fi nal product for in vivo delivery (drug formulation), subsequent studies can be divided into pre-clinical and clinical studies. Pre-clinical studies test a drug in animal models and gather data on safety and effi cacy for proof of concept. These studies are required before administration of the drug to humans in clinical trials (discussed in Section 1.5). The concept of validating a drug target is often used in drug

284 12: THE CANCER INDUSTRY: DRUG DEVELOPMENT, PHARMACOGENOMICS, AND CLINICAL TRIAL DESIGN

Molecular target

Screen for inhibitors or activators

or

Design a specific inhibitor or activator

Optimization and formulation

Pre-clinical studies

Clinical trials

Figure 12.1 Stages of drug

Regulatory approval

development.

discovery. True cancer drug target validation occurs when a therapeutic agent is shown to act via the molecular target it was designed against and proved to be clinically effective. However, a more current use of the term

“target validation” refers only to the experimental evaluation of the role of a given gene or protein in cancer and its potential as a therapeutic target; that is, target validation may occur before clinical testing.

In order to develop a new targeted therapy, a three-step approach has been proposed for development of the drug before it goes to the clinic: identify the molecular targets/pathways that drive tumor growth; create a genetically equivalent, high-incidence animal model where tumors of interest develop in their correct anatomical locations and at a developmentally relevant time; and screen for, or design, inhibitors to block the molecular pathway and test their effects in the animal models (Romer and Curran, 2005).

Molecular targets and target validation

There are several different types of molecular target that may be identifi ed and studied for drug development. The most popular are genetic lesions that have a causal role in cancer. The products of these lesions are oncogenic proteins or mutated tumor suppressor proteins. Targets include these aberrant proteins or components of the pathways they affect. Another type of molecular target may involve tissue-specifi c characteristics and/or differentiation pathways. For example, estrogen acts as a mitogen for the breast and inhibitors of estrogen action (e.g. tamoxifen) are effective in the

1 2 . 1 S T R AT E G I E S O F D R U G D E V E L O P M E N T 285

treatment of breast cancer. Similarly, knowledge of the differentiation pathways of the hematopoietic lineage has been applied for the treatment of acute promyelocytic leukemia by differentiation therapy (see Section 8.5). Another type of molecular target affects host processes rather than tumor biology. For example, molecular regulators of angiogenesis are good therapeutic targets (e.g. VEGF, VEGFR; Section 9.11).

Validating a molecular target may involve several strategies that

PAUSE AND THINK

together provide data for evaluation. Genetic validation of a specifi c genetic lesion is obtained by investigating the patterns of somatic mutation What pattern of somatic

in a particular tumor (see Pause and Think).

mutation would you expect to

Once a specifi c pathway is identifi ed, downstream effectors may also observe? One feature to expect

is that the genetic lesion is

prove to be important therapeutic targets. For example, EGFR has proved tumor-specifi c and occurs early

to be a validated drug target and its downstream effectors RAF and MEK

in tumor development. Absence

are also validated targets. Cell-based systems are also valuable methods in healthy tissue would also be

used for target validation. Transformation assays that rely on the intro-expected.

duction of putative oncogenes into normal cells are an example and have been instrumental in the fi eld. RNA-interference techniques in cells are also important approaches to test target validation. However, perhaps the most valuable strategy is the use of transgenic animals, whereby a target may be analyzed in the context of a tumor in situ.

Let’s look at an example. Raf, a component of the EGF signal transduction pathway (Chapter 4), is an important regulator of cell proliferation.

Oncogenic mutations resulting in constitutive activation of Raf have been identifi ed in cancers, especially melanomas and thyroid cancers. Evidence was needed to support the hypothesis that Raf is a potential therapeutic target. The results from an experiment utilizing Raf antisense oligonucleotides demonstrated growth inhibition in human tumor xenografts in

mice. This provided proof of concept that Raf is a valid target for future drug development. (See the Activity at the end of the chapter for a discussion of an approved drug targeted against Raf.)

Animal models

There is diffi culty in fi nding a cancer model that can reliably predict the effect of a new drug in human patients. A tumor is similar to an organ with tumor cells interacting with host cells, the immune system, blood vessels, and the extracellular matrix. The obvious diffi culty in testing new drugs in cultured cells is that the system is far from replicating a true tumor environment. The next step up from cells in culture is the use of organ cultures and organotypic cultures, as these systems possess a three-dimensional aspect.

Organ cultures are made of tissue slices. Organotypic cultures are made of cells grown in a specifi c matrix to mimic the tissue of interest.

The most common model systems used in drug discovery are in vivo mouse models. There are several approaches for using a mouse model system. The

286 12: THE CANCER INDUSTRY: DRUG DEVELOPMENT, PHARMACOGENOMICS, AND CLINICAL TRIAL DESIGN

older approach is to use high doses of a single carcinogen, often with little relationship to the etiology and/or molecular defect of the tumor of interest. The most widely used approach is the creation of human tumor xenografts. Xenografts are generated by injecting human cancer cells under the skin of immunodefi cient (nude) mice (the use of nude mice is necessary to avoid rejection of human cells by the immune system of the mouse). Disadvantages of this system are that reactions of the immune system cannot be monitored and that the environment, although in vivo, is foreign to the tumor. An improvement to this model is to inject human cells into the organ of the mouse from which they were derived (orthotopic). Injecting tumor cells of mice into mice (syngeneic tumor) is another alternative. The approach that offers a better alternative are genetically altered mice, created by transgenic, knock-out, or RNAi technologies. For example, the multiple intestinal neoplasia (min) mouse carries a germline truncation of the adenomatous polyposis coli gene. The min mouse develops multiple adenomas and is used to study colon carcinogenesis. Tissue-specifi c and inducible promoters can be used in these models to better mimic the etiology/molecular defect of the disease and the anatomical and temporal characteristics of human cancer. Also, “instability models” creating mice with defective DNA repair, telomere dysfunction, impaired DNA damage

checkpoints, etc. generates “instability models” of cancer. The resultant genome instability gives rise to tumors with a level of complexity compara-ble to human tumors and thus is an important tool for further studies of carcinogenesis (see Maser et al. , 2007 and references within). It must be remembered that species differences exist and results from any of these models may give very different results in the clinic.

Drug screening

High-throughput screening is a common approach to selecting lead compounds for drug development (Figure 12.2). It permits the testing of millions of compounds in a short period of time. Plates containing hundreds of wells of biological material (e.g. cells) are used to test various chemical compounds for a desired biological effect (e.g. apoptosis). Robotics can be deployed to prepare plates and to analyze up to 100,000 compounds per day. Many screening protocols use synthetic molecules synthesized via combinatorial chemistry—methodologies that rapidly and systematically assemble molecular entities to synthesize a large number of different but structurally related compounds. Note that many successful drugs are based on natural compounds that have also been used in screening procedures. Another approach for selecting lead compounds for development is virtual screening. In this approach, computer analysis is used to select compounds that will bind to a molecular target based on the previously known three-dimensional structural information about the target





1 2 . 2 D E V E L O P M E N T O F I M AT I N I B 287

Combinatorial chemistry

Library of

Robotic plate preparation

synthetic

compounds

Assay for biological effect

Analysis

Identification of

Figure 12.2 High-throughput

lead compound

screening. See text for details.

(e.g. crystal structure). As this is an in silico approach, consumables are not required and the compounds examined may not necessarily exist.

Studies suggest that high-throughput screening and virtual screening are complementary approaches, each yielding potentially promising results.

12.2 Development of imatinib

Let us look at the development of imatinib (Gleevec™, USA; Glivec™, UK, Europe) in relation to the stages of drug development (Capdeville et al. , 2002). It began with the understanding of a genetic lesion: the chromosomal translocation that is characteristic of chronic myelogenous leukemia. The identifi cation of the molecular consequence of this translocation pointed to the resulting fusion protein, BCR–ABL, as a molecular target. As the translocation results in elevated tyrosine kinase activity that is crucial for transformation, the obvious strategy was to develop a specifi c tyrosine kinase inhibitor. A lead compound (a compound that shows a desired activity, e.g. kinase inhibition) was elucidated from a chemical screen. In this case, kinase inhibition was demonstrated by the inhibition of protein kinase C. Optimization of the lead compound by the addition of small chemical groups (Figure 12.3) produced a drug that inhibited BCR–ABL tyrosine kinase activity (instead of protein kinase C) and showed good bioavailability. Bioavailability relates to

the ability of the drug to reach its site of action after administration.

Pre-clinical testing demonstrated fairly selective inhibition of BCR–ABL

kinase activity and induction of apoptosis in cell culture experiments and





288 12: THE CANCER INDUSTRY: DRUG DEVELOPMENT, PHARMACOGENOMICS, AND CLINICAL TRIAL DESIGN

H

H

H

H

N

N

N

N

N

N

N

R1

N

N

N

O

Lead compound

Inhibits protein kinase C

N

N

(a) Improved cell activity

(b) Improved inhibition of BCR-ABL

H

H

H

H

N

N

N

N

R1

N

N

N

N

N

O

N

O

H3C

H3C

N

N

(c) Decreased specificity for protein kinase C

(d) Increased solubility and oral bioavailability

Figure 12.3 Optimization of a lead compound leading to production of Gleevec™. Small chemical modifi cations are shown in red.

(a) The addition of a 3′-pyridyl group enhances cellular activity. (b) An amide group conferred BCR-ABL tyrosine kinase inhibition. (c) A methyl group abolished unwanted protein kinase C activity. (d) A N-methyl piperazine moiety enhanced oral bioavailability and solubility.

in leukemic cells from patients. Inhibition of tumor growth was also observed in animal models. Clinical trials (see Table 1.1 for phases of clinical trials) documented safety and effi cacy. Results from a Phase I dose-escalation study were extremely positive: 53 out of 54 patients (98%) achieved a complete hematological response with minimal side-effects, usually within the fi rst 3 weeks of treatment (Druker et al. , 2001).

Positive results continued to be demonstrated for Phase II and Phase III PAUSE AND THINK

trials. Approval by the US Food and Drug Administration (FDA) was

CML involves a block in differen-

given on May 2001, and subsequent approval for use in Europe and Japan tiation that leads to an increase

followed shortly afterwards. The European Medicines Evaluation Agency in white blood cells. A complete

(EMEA) and the Japanese Ministry of Health and Welfare, together with hematological response is the FDA, are working towards an internationally harmonized system for defi ned as a reduction in white

drug approval that will facilitate the delivery of drugs to more patients, blood cell count to less than

more quickly.

10,000 per cubic millimeter (the

upper limit of a normal white

blood cell count) and platelet

count to less than 450,000 per

cubic millimeter maintained for

12.3 Second- and third-generation therapeutics

at least 4 weeks.

Initial drug treatment can select for cancer cells that are resistant to the treatment and, consequently, new drugs are required when the initial

1 2 . 3 S E C O N D - A N D T H I R D - G E N E R AT I O N T H E R A P E U T I C S 289

A LEADER IN THE FIELD . . . of drug discovery: Brian Druker

Brian Druker was a major contributor to the development of Gleevec™ and thus has helped revolutionize drug discovery and, ultimately, the treatment of leukemia. In addition to being involved in pre-clinical studies, he also conducted the fi rst clinical studies of Gleevec™.

During early studies of Gleevec™, several of Brian’s collaborators at Novartis observed that the side-effects were minimal and were disappointed as they thought this indicated that the drug would not be effective. To everyone’s delight, the drug was effective and showed minimal side-effects. Brian has emphasized that the connection to cancer patients through his work at the clinic is a major motivational force behind his work.

Brian Druker received a BA in Chemistry and an MD from the University of California, San Diego. Currently, he is a Howard Hughes Medical Institute Investigator working at the Oregon Health and Science University. Brian is a member of the National Academy of Sciences and, among other honors, has received the Medal of Honor from the American Cancer Society.

treatment is no longer effective. Although imatinib is a highly successful treatment for the treatment of CML in early phase disease, patients with later-phase (accelerated and blast stage) disease often develop resistance to imatinib. New drugs called second-generation inhibitors have been developed to block the progression of CML in those who are resistant to imatinib. Strategies in the development of these new second-generation inhibitors often rely on structural biology data that analyze drug binding (see Plate 8; it shows the binding of Gleevec™ to Abl).

Point mutations in the Bcr– Abl gene that interfere with the binding of imatinib but maintain a functional tyrosine kinase domain are the most common mechanism involved in imatinib resistance. Mutations may

affect physical bonding/contact points or cause changes in shape that ster-ically obstruct binding. Alternatively, mutations may destabilize the inactive conformation, the conformation to which imatinib binds.

Although more than 50 different mutations associated with imatinib

resistance have been identifi ed, only 6 account for 60–70% of all mutations. One of these six, a mutation at Thr315 (T315I; a substitution by isoleucine; Gorre et al. , 2001), is noteworthy because it has proved to be resistant to many second-generation inhibitors. Dasatinib (Figure 12.4a) is a second-generation inhibitor that, unlike imatinib (Figure 12.4b), binds to the active conformation of the ABL kinase and therefore inhibits many mutant forms of BCR–ABL. The FDA and the European Medicines

Agency approved dasatinib for the treatment of imatinib-resistant CML.

Nilotinib is another second-generation inhibitor that has been approved.

Unfortunately, the T315I mutation noted earlier confers both dasatinib and nilotinib resistance.

A potent aurora kinase and JAK2 inhibitor called MK-0457 (VX-680,

Merck) was the fi rst agent to show activity in patients with the BCR-ABL

T315I mutation. However, owing to cardiac toxicity further development has been stopped.





290 12: THE CANCER INDUSTRY: DRUG DEVELOPMENT, PHARMACOGENOMICS, AND CLINICAL TRIAL DESIGN

(a)

H

N

N

S

O Cl

N

N

HN

N

N

HO

(b)

N

H

H

N

N

N

N

CH3

N

O

Figure 12.4 An example of a

second-generation inhibitor of

BCR–ABL: (a) dasatinib.

N

Compare with (b) imatinib.

New agents are being developed for patients who have failed sequential therapy with imatinib and a second-generation tyrosine kinase inhibitor.

These are called third-generation tyrosine kinase inhibitors (including other aurora kinases). Many have shown potent activity against the T315I mutation and some are in clinical trials (Quintas-Cardama et al. , 2010).

The origin of resistance is still not completely understood. Some data suggest that all mutant Bcr–Abl clones may exist before imatinib treatment and that clones carrying these may grow in response to selective pressure of imatinib. When a patient initially responds to a second-generation inhibitor but subsequently develops resistance with a second mutation, the new mutation responsible for the resistance is not found in addition to the fi rst mutation but instead is identifi ed on the original Bcr–Abl background.

Thus, the clone carrying the new mutation may grow as a result of selective pressure of the second-generation inhibitor. Combinations of inhibitors may be effective in preventing the expansion of drug-resistant clones; thus, such strategies are being examined.

12.4 Pharmacogenomics

Pharmacogenomics is the study of the infl uence of the genome on an individual’s response to a drug. Gene variability in both the individual and in the tumor may lead to differences in drug response among individuals.

1 2 . 4 P H A R M AC O G E N O M I C S 291

Iressa™ (gefi tinib; AstraZeneca), a tyrosine kinase inhibitor targeted against the EGF receptor (see Section 4.3), was reported to have mixed clinical responses. Initially approved in the USA and Japan for the treatment of non-small-cell lung cancer, Iressa™ causes impressive and successful tumor regression but, curiously, in only a select 10% of patients.

As non-small-cell lung cancer accounts for 80% of all lung cancers, the number of patients that respond to Iressa™ (10%) is signifi cant. It has now been demonstrated that the patients who respond to Iressa™ carry specifi c mutations in the EGFR gene (Lynch et al. , 2004; Paez et al. , 2004).

Clinical trials showed that Japanese people are three times more likely to respond to Iressa™ than Americans. Scientists screened for mutations in the EGFR gene in two groups of non-small-cell lung cancer tumor samples: one set from a Japanese hospital and another set from an American hospital. Somatic mutations in the EGFR gene were found more often in Japanese patients. The mutations were either missense mutations or small deletions that were located in the coding region for the receptor tyrosine kinase active site, a region near the binding site for Iressa™. Scientists then asked whether the mutations correlated with treatment response.

The analysis of a small set of patients showed that those who responded to Iressa™ also carried the identifi ed mutations.

The mutations produce an altered protein that increases the amount

and duration of EGF-induced signal transduction compared with wild-

type receptors. In other words, the receptors are hyperactive but not constitutive. These mutations that underlie aberrant tyrosine kinase signaling and drive carcinogenesis also make the tumor more susceptible to Iressa™

because they cluster in the sequences that code for the region where Iressa™ binds. This suggests that knowing the particular molecular characteristics of a tumor (e.g. mutations of the EGFR gene) is important for selecting the best treatment for an individual.

In contrast to the earlier example where a mutation enables a drug

PAUSE AND THINK

response, there are examples where a mutation blocks the ability of a tumor to respond to a drug. Tumor DNA that carries a mutation in the Why are these particular muta-KRAS gene blocks the effect of Erbitux™. Recalling the details of the EGF

tions in the EGFR gene more

signaling pathway (Chapter 4) helps to understand why patients with common in Japanese than

Americans? It may be due to a

KRAS mutations will not respond. If the EGFR is the oncogenic signal lifestyle factor such as exposure

then blocking it will be a successful strategy. But if a molecule further to a specifi c carcinogen or a

downstream in the pathway is the oncogenic signal, then blocking EGFR

genetic predisposition, or a mix-

will be in vain. The KRAS gene is mutated in about 40% of colorectal ture of both.

cancer patients. In 2009, the US Food and Drug Administration (FDA) updated the Erbitux™ label to include a recommendation on screening for the KRAS mutation. This is one of the fi rst cases where pharmacogenomic information is included on a drug label. Recommendation for KRAS screening is also included for the drug panitumumab (Vectibix™).





292 12: THE CANCER INDUSTRY: DRUG DEVELOPMENT, PHARMACOGENOMICS, AND CLINICAL TRIAL DESIGN

It is important to remember that the gene profi le of a tumor lies against a background of an individual’s inherited genome. Genetic variations among individuals can defi ne subsets of a population that respond differently to drugs. A strong determinant of drug response is variation in drug metabolizing enzymes (Wu, 2011). Genetic variation in the enzyme thiopurine methyltransferasse (TPMT) is one example. TPMT-defi cient patients accumulate certain chemotherapies, such as 6-mercaptopurine and 6-thioguanine used to treat some leukemias and this can lead to severe toxicity.

Successful treatment of these patients can occur with 10–15-fold lower dosage upon identifi cation using pharmacogenic tests. Other patients may clear a drug from the body more effi ciently and require higher doses of a particular drug. In the future, the dose of a drug may be adjusted for an individual based on their genomic information.

The discussed examples and similar observations illustrate the concept that knowing the genetic profi le of a tumor, in addition to inherited genomic information, helps doctors to choose the best treatment for an individual.

12.5 Improved clinical trial design

There are some fl aws in the design of clinical trials performed today that result in an infl ated number of unsuccessful drug results. A problem that is diffi cult to overcome is that many new drugs are tested on older patients who have advanced cancer and who have not responded to a range of conventional therapies. Drugs that may be effective in early stage cancer may fail to have an effect on late-stage cancer in clinical trials. The development of such drugs would be wrongly discontinued. Ethically acceptable suggestions are needed on how we can move forward. The inclusion of controls is strongly recommended, but surprisingly they have not been included in a majority of Phase II oncology trials in the past. Modifi cations are being made to the classical Phase I, II, and III trials. The FDA has approved Phase 0 Trials. Phase 0 trials allow the testing of small doses of experimental drugs in people for seven days or less. They aim to gather data on drug targeting, action, and metabolism in the body. Initially, only small batches of a drug are required to be produced for these studies. In addition, Phase IV trials may be carried out after a drug has been approved and licensed. The purpose of Phase IV trials is to further investigate side-effects, safety, and/or long-term risks and benefi ts. They are also useful to help develop new applications for a given drug. Phase IV trials for the HPV vaccine Gardasil™ (discussed in Section 10.6) are planned to test different vaccination policies in Nordic countries and to monitor effectiveness and the occurrence of rare adverse events.

It is expected that sample size calculations for a clinical trial should be carried out properly and reported in associated publications. This is

1 2 . 5 I M P R OV E D C L I N I C A L T R I A L D E S I G N 293

important for trial evaluation and the production of statistically meaning-ful results. Many researchers use computer software programs for this task. However, it may be informative to describe a basic formula (Schulz and Grimes, 2005). For trials with two outcomes (e.g. patient remains ill or patient becomes well), four components are required for calculating sample sizes. They are: type I error (α), power, event rate in the control group, and event rate in the treatment group (treatment effect). Type I error is the probability of concluding that two treatments (e.g. treatment versus placebo) differ, when, in fact, they do not; i.e. the chance of a false-positive result. Power is derived from type II (β) error: P = 1 − β. Type II error is the opposite of type I: it is the probability of not detecting a statistically signifi cant difference when a difference actually exists. It is the chance of a false-negative result: the treatment is different from the control but the difference is not detectable. Therefore, power is the probability of detecting a statistically signifi cant difference when a difference really exists. Investigators would usually like less than a 5% chance of making a false-positive error, and thus, by convention, α is usually set to 0.05. Similarly, if investigators want less than a 10% chance of making a false-negative error they will set β to 0.10. In this case, power will be 1 − 0.10 = 0.90.

The following equation illustrates a simple formula for calculating sample size for a case with two possible outcomes, assuming α = 0.05, power = 0.90 and an equal sample size in the two groups:

10.51[ R

(

)

1

p

2

2 R

(

)

1 ]

n =

+

−

+

,

2



p 2(1 − R)

where n is sample size, p 1 is the event rate in the treatment group, p 2 is the event rate in the control group, and R is the risk ratio ( p 1/ p 2).

Defi ning the target population and clinical endpoints requires special attention in clinical trial design. Important lessons have been gained recently about defi ning the target population for clinical trials. The results previously discussed that illustrated variable response rates among two different populations to the drug Iressa™ argue for the benefi t of including geographically and genetically diverse populations in clinical trials. Molecular profi ling of the tumor prior to and/or during clinical trials is also important in order to gain a true measure of drug effi cacy. However, obtaining tumor tissue for analysis may be diffi cult, as in the case of the lung.

Patient selection (i.e. choosing patients who have the molecular defect that a drug is designed to target) is important so that drugs are shown to be effi -

cient when tested on the “right” patients. Otherwise, a variable response will be observed and the observed effi cacy will not be accurate. For example, as we saw earlier with Iressa™, if a drug acts on tumor cells that contain a mutated receptor, the effi cacy of the drug should be tested on patients whose tumor contains these mutations. For other drugs, patients may be selected on

294 12: THE CANCER INDUSTRY: DRUG DEVELOPMENT, PHARMACOGENOMICS, AND CLINICAL TRIAL DESIGN

the basis of gene copy number rather than mutation. Digital karyotyping is a method that allows determination of DNA copy number on a genomic scale.

When designing drug trials it is important to defi ne parameters that will indicate the effectiveness of the drug. How will we know if the drug is working? Before the initiation of the trial, clinical endpoints must be defi ned. Tumor shrinkage is commonly used to indicate a response, but it may not necessarily correlate with survival. In particular, cytostatic drugs inhibit tumor growth and/or metastasis and thus progression-free survival time is a more suitable endpoint, rather than tumor regression. The classical endpoints used are survival, improved time to progression, plus improvement in symptoms or quality of life.

A novel trial design is the randomized discontinuation trial design. In this design patients receive one or two cycles of a cytostatic drug and, upon completion, those who have stable disease are then randomized to placebo or to continue the same treatment. The aim of this design is to enrich the patient population with those with slowly progressive cancer and eliminate those with rapidly progressive cancer.

In addition to clinical endpoints, clinical trials that evaluate new molecular therapeutics warrant defi ned molecular endpoints. Molecular endpoints involve the evaluation of molecular target inhibition and are important to ensure that the drug is eliciting its effects in the expected manner. For example, testing whether Gleevec™ inhibits BCR–ABL

tyrosine kinase activity was an important molecular endpoint (data shown in Druker et al. , 2001). A phosphorylated substrate of Abl tyrosine kinase was used as a biomarker. A biomarker is a biochemical or genetic feature that can be used to measure disease progression or the effect of treatment.

They may include the measurement of specifi c molecules (prostate-specifi c antigen, PSA), genetic alterations, gene expression profi les, cell-based markers (circulating cells), and single-nucleotide polymorphisms (SNPs).

The measurement of a biomarker has important implications for the

administered dose, as maximal tolerated dose, often prescribed for conventional chemotherapies, may not be necessary. In the earlier example, the dose of imatinib required to inhibit substrate phosphorylation would be appropriate to test in clinical trials. Also, some studies have shown that expression levels of drug targets can change during progression of the disease, and therefore drug response may be expected to change during the course of the disease.

A new and novel paradigm for a personalized approach to lung cancer clinical trials was demonstrated in The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial (Kim et al. , 2011). Mandatory fresh tumor biopsies informed future treatment later in the trial. For instance, after an initial period of equal randomiza-tion, patients who did not respond to chemotherapy were adaptively randomized to targeted therapies based on relevant molecular biomarkers





1 2 . 6 A C A R E E R I N C A N C E R R E S E A R C H 295

? HOW DO WE KNOW THAT?

Clinical trial terms and clinical endpoints

Multicenter: participants were recruited from Brazil, Europe, and the USA. Several criteria were set including age (16–23

Let’s examine some of the characteristics of the Phase II trial of

years old) and aspects of previous medical history.

Gardasil™ reported by Villa et al. (2005). As the title of the Phase II: a dose-escalation study involving several hundred article states, it is a randomized, double-blinded, placebo-participants was used to assess safety, immunogenicity, and

controlled, multicenter, phase II study. Each term will be

effi cacy. Methods used to monitor effi cacy included gyneco-

explained.

logical examination, Pap test, PCR analysis to detect HPV, serum

Randomized: treatment parameters (dose and type:

samples, and biopsies of any lesions.

treatment or placebo) were assigned to participants using

The primary endpoint assessed was persistent infection by

computer-randomized schedules.

HPV6, -11, -16, or -18 or disease of the cervix or external geni-

Double-blinded: neither participants, nor hospital staff, nor tals. Cervical cancer was not used as an endpoint because cer-investigators knew which participants received treatment

vical cancer can be prevented by the treatment of pre-cancerous

versus placebo.

lesions identifi ed by screening. Identifying pre-cancerous

Placebo-controlled: the placebo consisted of the same

lesions and allowing them to progress without treating them

adjuvant used for the vaccine, so that participants in the control

would be unethical. Furthermore, long-term studies would be

group received exact the same treatment as the participants in

required because of the lag time between infection and cancer.

the treatment group except they did not receive the vaccine.

analyzed in fresh biopsied material. Overall, the conclusions supported the idea that targeted drugs are superior to chemotherapy for patients with specifi c activating mutations in targeted molecules. There is a need for a shift from population-based unselected approaches to this type of biomarker adaptive and hypothesis testing clinical trial, as we move forwards towards personalized medicine (de Bono and Ashworth, 2010).

12.6 A career in cancer research

People are the most important asset in cancer research and drug discovery. There are several avenues to pursue for a career in cancer research.

The road most often traveled is to obtain a PhD in an area that interests you. Interest is important for several reasons: fi rst, you will be spending many hours reading and thinking about your subject; second, you will spend many hours in the laboratory conducting experiments which

focus around your topic; third, one can never predict in which area a big breakthrough will occur, so there is no sense in trying to guess. Research can be frustrating at times because you are trying to fi gure out something that no one knows or has really done before and progress tends to be in small steps. However, many small steps made by many individuals drive the fi eld. It can be most rewarding to know that you have made contributions to relieving suffering and saving lives. PhD studentships are posted in the back of the leading scientifi c journals, such as Nature

296 12: THE CANCER INDUSTRY: DRUG DEVELOPMENT, PHARMACOGENOMICS, AND CLINICAL TRIAL DESIGN

and Science and on internet sites, such as http://www.fi ndaphd.com/, but a

personal approach by letter to the head of a laboratory in which you are interested in working can also be successful. Alternatively, cancer research can be pursued in a pharmaceutical company with entry levels at different stages of education. In fact, working in a research laboratory after obtaining a BSc degree is another valid path for a career in cancer research.

Cancer research is expensive and requires appropriate facilities

equipped with high-tech equipment. These facilities are available in uni-versities, research institutes, hospitals, and in biotechnology and pharmaceutical companies (see Appendix 2). The relationship between these types of research providers has recently grown to be symbiotic; a close association leads to mutual benefi t. Several organizations and funding agencies create opportunities that help foster collaborations between uni-versities and industry. Such organizations also provide commercial busi-ness training for academics. A career in cancer research promises to be interesting and rewarding. You are guaranteed to meet and work with interesting, intelligent, and talented people!

■ CHAPTER HIGHLIGHTS—REFRESH YOUR MEMORY

•

Drug development follows a series of stages from defi n-

•

The study of the infl uence of the genome on a patient’s

ing a molecular target through to approval.

response to a drug is called pharmacogenomics.

•

Target validation refers to the experimental evaluation of

•

Iressa™ has shown favorable responses in patients who

the role of a given gene or protein in cancer and its

carry specifi c mutations in the EGFR gene.

potential as a therapeutic target.

•

Phase 0 and Phase IV clinical trials have been added to the

•

Combinatorial chemistry in conjunction with high-

three conventional phases of clinical trials, Phases I, II, and

throughput screening are common methodologies used

III.

in drug discovery.

•

Defi ning the target population and clinical endpoints are

•

The development of Gleevec™ (imatinib) is a paradigm for

two important aspects requiring careful consideration

drug development of new molecular cancer therapeutics.

during the design of clinical trials.

•

Many patients with late-phase CML often develop resist-

•

A biomarker is a biochemical or genetic feature that can

ance to Gleevec™.

be used to measure disease progress or the effect of

•

Only six mutations in the Bcr–Abl gene account for

treatment.

60–70% of mutations that lead to imatinib resistance.

•

Please consider a career in cancer research.

•

Second-generation therapeutics are being developed to

overcome resistance to Gleevec™.

■ ACTIVITY

1. Read the case history of the discovery and development of sorafenib ( Nature Rev. Drug Discov. 5: 835–844). Compare the process with that of imatinib. Pay particular attention to the target population used in the early clinical trials. Note the timescale from discovery to approval.

1 2 . 6 A C A R E E R I N C A N C E R R E S E A R C H 297

■ FURTHER READING

Arteaga, C.L. and Baselga, J. (2003) Clinical trial design and end point for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. Clin. Cancer Res. 9: 1579–1589.

Benson, J.D., Chen, Y.-N.P., Vornell-Kennon, S.A., Dorsch, M., Kim, S., Leszc-zyniecka, M., et al. (2006) Validating cancer drug targets. Nature 441: 451–456.

Druker, B.J. (2002) STI571 (Gleevec™) as a paradigm for cancer therapy. Trends Mol.

Med. 8: S14–S18.

Klebe, G. (2006) Virtual ligand screening: strategies, perspectives, and limitations.

Drug Discov. Today 11: 580–594.

Schiller, J.H. (2004) Clinical trial design issues in the era of targeted therapies. Clin.

Cancer Res. 10: 4281S–4282S.

Strausberg, R.L., Simpson, A.J.G., Old, L.J., and Riggins, G.J. (2004) Oncogenomics and the development of new cancer therapies. Nature 429: 469–474.

Weisberg, E., Manley, P.W., Cowan-Jacob, S.W., Hochhaus, A., and Griffi n, J.D.

(2007) Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukemia. Nature Rev. Cancer 7: 345–356.

■ SELECTED SPECIAL TOPICS

Capdeville, R., Buchdunger, E., Zimmermann, J., and Matter, A. (2002) Glivec (STI571, Imatinib), a rationally developed, targeted anticancer drug. Nature Rev.

Drug Discov. 1: 493–502.

De Bono, J.S. and Ashworth, A. (2010) Translating cancer research into targeted therapeutics. Nature 467: 543–549.

Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., et al.

(2001) Effi ciency and safety of a specifi c inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344: 1031–1037.

Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N., et al.

(2001) Clinical resistance to STI-571 cancer therapy caused by Bcr-Abl gene mutation or amplifi cation. Science 293: 876–880.

Kim, E.S., Herbst, R.S., Wistuba, I.I., Lee, J.J., Blumenschein Jr, G.R., Tsao, A., et al.

(2011) The BATTLE Trial: Personalizing Therapy for Lung Cancer. Cancer Discov.

1: 44–53; CD-10-0010.

Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefi tinib. N. Engl. J. Med.

350: 2129–2139.

Maser, R.S., Choudhury, B., Campbell, P.J., Feng, B., Wong, K.-K., Protopopov, A., et al. (2007) Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447: 966–971.

Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to Gefi tinib therapy. Science 304: 1497–1500.

Quintas-Cardama, A., Kantarjian, H., and Cortes, J. (2010) Third-generation tyrosine kinase inhibitors and beyond. Semin. Hematol. 47: 371–380.

298 12: THE CANCER INDUSTRY: DRUG DEVELOPMENT, PHARMACOGENOMICS, AND CLINICAL TRIAL DESIGN

Romer, J. and Curran, T. (2005) Targeting medulloblastoma: small-molecule inhibitors of the sonic hedgehog pathway as potential cancer therapeutics. Cancer Res.

65: 4975–4978.

Schulz, K.F. and Grimes, D.A. (2005) Sample size calculations in randomized trials: mandatory and mystical. Lancet 365: 1348–1353.

Villa, L.L., Costa, R.L., Petta, C.A., Andrade, R.P., Ault, K.A., Giuliano, A.R., et al.

(2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II effi cacy trial. Lancet Oncol. 6: 271–278.

Wu, A.H.B. (2011) Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance. Clin. Proteomics 8: 12.





Chapter 13

Cancer in the future: focus on

cancer vaccines and

technology

Introduction

This concluding chapter will address two issues: fi rst is the question of whether cancer will exist in the future and, second, if the answer is “yes,” what changes in cancer treatment and management are likely to be implemented? As discussed in Chapter 11, chemoprevention of cancer, based on strategies that use dietary microconstituents or target hormonal signaling pathways, hold potential for reducing the incidence of some cancers in the future. Overall, however, evidence suggests that cancer will “always be around”

because mutation underlies carcinogenesis and we cannot escape from mutations.

Although we may be able to avoid certain carcinogenic agents (e.g. tobacco) and processes (e.g. sunbathing), we certainly cannot avoid all of them. Furthermore, cancer is associated with aging and life expectancies are increasing. As a consequence of people living longer, the incidence of cancer is increasing.

However, maybe there is a lesson to be learnt from the history of medicine. In the past, PAUSE AND THINK

there were dreaded infectious diseases, such as smallpox, which are now preventable What are examples of cellular pro-through vaccination. Could vaccination be used to eradicate cancer? The observation that cesses that can induce mutations?

the immune system could recognize and respond to tumors following bacterial infection was One example is DNA replication,

made over 100 years ago. As discussed in Chapter 10, effector cells of the immune system which is associated with errors

can recognize tumor-associated antigens and kill tumor cells. This endogenous mechanism caused by the incorporation of

of protection against tumor cells by the immune system, called immunosurveillance, sug-incorrect nucleotides. Two other

gests that boosting the immune system by vaccination against tumor cells may be possible.

examples are normal cellular respi-

Alternatively, if we are not able to eradicate cancer, what will it be like having cancer in ration and infl ammation, both of

future decades? It is envisaged that cancer, a disease of the genome at the cellular level, will which are associated with oxygen

be detected much earlier than is possible today because of the rise of genomics and associ-by-products that damage DNA. All

ated technologies and improvements in imaging. Many cancers may become a long-term, three examples are processes that

chronic disease (like arthritis) not linked imminently with death, as it was viewed in the can give rise to mutations.

past. Although a cure is preferred, the complexity of cancer may foster the development of treatments that allow people to live more comfortably with the disease rather than cure it.

In this chapter, we will examine current, far-reaching advancements in the fi elds of immunology and technology in order to form an educated prediction of the future of





300

1 3 : C A N C E R I N T H E F U T U R E : F O C U S O N C A N C E R VAC C I N E S A N D T E C H N O L O G Y

cancer. First we will examine new strategies that utilize cancer vaccines as both therapeutic agents and preventative agents. We will also investigate the application of improved genomic techniques, technologies, and therapeutics that are essential in order to transform cancer into a chronic, rather than a terminal, disease. These include molecular gene expression profi ling for diagnostic and prognostic indicators and cancer classifi cation, personalized medicine and bioinformatics, imaging, and new therapeutic agents that may contribute to the list of approved targeted cancer drugs in the future.

13.1 Cancer vaccines

Our ability to harness the immune system to prevent and/or kill tumor cells is becoming evident. Vaccination is called active immunization because it tries to stimulate the individual’s own immune effector cells. A vaccine is composed of antigen(s) and adjuvant(s). Adjuvants are vaccine additives that enhance the immune response to an antigen. This contrasts passive immunization, which involves the transfer of effectors of the immune system, such as T cells or secreted products of lymphoid cells, into the patient.

Passive immunization

Many early attempts at cancer immunotherapy utilized passive immunization strategies.

Interferon-γ, a cytokine with promising ability to modulate the immune response, was studied extensively in Phase I, II, and III trials. In general, however, poor clinical responses were observed. Tumor necrosis factor also gave disappointing results in clinical trials.

Recently, however, Rosenberg (see Box “Leaders in the fi eld”) and his group have demonstrated promising results after the transfer of autologous tumor-infi ltrating lymphocytes into cancer patients who underwent lympho-depleting chemotherapy (destruction of endogenous lymphocytes by cytotoxic drugs with or without radiation) (Rosenberg, et al. , 2011). Tumor-infi ltrating lymphocytes were expanded in vitro and transferred to patients along with the cytokine adjuvant, interleukin-2, for immunization. Complete tumor regression was observed in 22% of patients with metastatic melanoma.

Here, we focus on vaccinations. Cancer vaccines can either be designed to stimulate the immune system in order to cause tumor regression in a patient with cancer, a therapeutic vaccine or they can prepare the immune system prior to getting cancer for cancer prevention, so-called prophylactic vaccines. Most cancer vaccines are designed to be therapeutic vaccines, though we will consider both types here.

Therapeutic vaccines

The production of a vaccine involves the selection of an appropriate antigen that will stimulate an effective anti-tumor response. Tumor-associated

1 3 . 1 C A N C E R VAC C I N E S 301

antigens may be derived from either degradation and processing of

unfolded intracellular proteins that are shuttled to the surface of the tumor cell or from damaged or dying tumor cells. These may include

oncoproteins arising from oncogenic mutations or chromosomal trans-

locations. As T cells are the main effectors of an anti-tumor response, antigens from the vaccine must be displayed eventually on the surface of other cells, called antigen-presenting cells. A series of cellular events characterize an immune response upon administration of a cancer vaccination (Figure 13.1). Antigen-presenting cells, such as dendritic cells that reside in the tissue, are at the heart of signaling for the mission of eliciting T-cell-mediated immunity. It is the dendritic cells that (1) acquire and (2) process the antigens, and, upon maturation, migrate to the lymphoid organs to (3) present the antigens to the main effector T cells. The uptake of antigens by the dendritic cells is primarily by endocytosis. Antigen processing involves cleavage of the antigen into small peptides by proteases (depicted by scissors in Figure 13.1). The adjuvant in a cancer vaccine induces the maturation of the antigen-presenting cells and their migration to the lymphoid organs. Processed antigen is translocated to the cell surface for presentation in association with proteins from the major histocompatibility complex (MHC; details of which are beyond the scope of this book). It is the CD8+ cytotoxic T cells that recognize the antigen on the tumor cell membrane and proceed to kill the tumor cells by releasing cytotoxic granules or inducing apoptosis.

Cancer vaccines are required to overcome tumor protective mecha-

nisms. As discussed in Chapter 10, tumor cells may undergo immuno-

editing which allows them to evade and suppress the immune system.

+

Vaccine

Antigen

Adjuvant

Lymphoid organ

T cell

Dendritic cell

MHC

i) acquire

ii) process

iii) present

T cell

Tumor

Figure 13.1 Cellular events in an

immune response following

Tumor cell death

vaccination.

302

1 3 : C A N C E R I N T H E F U T U R E : F O C U S O N C A N C E R VAC C I N E S A N D T E C H N O L O G Y

For example, transforming growth factor β obstructs dendritic cell

maturation and interferes with antigen presentation to T cells. Let us examine several strategies used for producing cancer vaccines.

Whole-cell vaccines

PAUSE AND THINK

Vaccines against infectious diseases are composed of bacteria or viruses The term vaccination comes

whose ability to produce disease has been reduced or attenuated by dif-from the Latin word “vacca” or

ferent processes, such as passage through an unnatural host, chemical cow because the fi rst vaccine,

treatment, or irradiation. The fi rst cancer vaccines were composed of reported in 1798 by Edward

irradiated tumor cells, being modeled after successful, attenuated patho-Jenner, used cowpox virus for

gen vaccines.

immunization against small-

All of the antigens expressed by a specifi c tumor are included in the pox. As a doctor in the English

countryside during a smallpox

whole-cell vaccine design. These fi rst cancer vaccines demonstrated outbreak, Jenner noticed that

immune responses in mouse models but were disappointing in clinical milk maids were less likely to

trials, causing either a weak response from the immune system (a weak contract smallpox, although

immunogenic response) or a response against normal cells (autoimmun-these women were often

ity). This may be because of the under-representation of immunogenic exposed to cowpox infection.

antigens relative to the total number of antigens and stimulation against He hypothesized that cowpox

normal gene products, respectively. For example, vitiligo, an autoim-infection was the cause of the

mune disease that targets melanocytes, was observed in studies of a mel-resistance to smallpox and car-

anoma vaccine, suggesting that the induced immune response also

ried out experiments that sup-

targeted normal antigens and thus normal cells. Some modifi cations of ported his hypothesis.

whole-cell vaccines are being pursued. For example, gene-modifi ed

tumor cells that express stimulatory molecules for T cells double as antigens and adjuvants. However, regardless of their degree of success, whole-cell vaccines have been important stepping-stones towards antigen-specifi c vaccines.

Peptide-based vaccines

Another strategy for the development of cancer vaccines is to use tumor-associated antigens to generate an immune response. This involves the identifi cation and characterization of specifi c molecules on the tumor cells PAUSE AND THINK

that are recognized by T cells rather than using whole cells from tumors, What is the difference in methas was described earlier. Tumor-specifi c antigen molecules have qualita-ods between making synthetic

tive or quantitative differential expression patterns in tumor cells com-and recombinant protein? Syn-

pared with normal cells. Many of these antigens elicit an immunogenic thetic peptides are made in the

response without autoimmunity. This has led to the production of

laboratory by linking amino

antigen-specifi c peptide vaccinations. The peptides used are short acids together in a specifi c order

sequences of amino acids that code for a part of the tumor-associated anti-while recombinant proteins are

gen and can be produced as synthetic or recombinant proteins.

synthesized in vivo from geneti-

A growing list of breast tumor antigens, including HER2, mucin1, and cally engineered molecules that

include a DNA sequence encod-

carcinoembryonic antigen (CEA), provide the basis for the production of ing the specifi ed amino acids.

breast cancer vaccines. Several melanoma tumor antigens have also been characterized. A peptide-based vaccine targeting the melanoma-associated

1 3 . 1 C A N C E R VAC C I N E S 303

antigen glycoprotein 100 (gp100) has been developed to treat melanoma patients. The gp100 antigen is an antigen that is expressed in normal melanocytes, melanomas, and pigmented retinal cells. The gp100 peptide vaccine, along with interleukin-2, has been examined in a Phase III clinical trial, and Rosenberg and colleagues reported a higher response rate than interleukin-2 alone.

A LEADER IN THE FIELD . . . of vaccination: Steven A. Rosenberg

In 1999, the Institute for Scientifi c Information reported that Rosenberg was the most cited clinician in the world in the fi eld of oncology for the 17 years between 1981 and 1998.

Rosenberg is the author of over 820 scientifi c articles covering various aspects of cancer research and has written eight books.

Rosenberg helped to develop the fi rst effective immunotherapies for selected patients with advanced cancer. He was also the fi rst person to successfully insert foreign genes into humans, pioneering the development of gene therapy for the treatment of cancer. Along with his research group, he cloned the genes encoding cancer antigens and used these as the basis to develop cancer vaccines for the treatment of patients with metastatic melanoma. His recent studies, involving the transfer of anti-tumor lymphocytes and their repopulation in cancer patients, demonstrated cancer regression.

Rosenberg received his BA and MD degrees at Johns Hopkins University in Baltimore, Maryland and a PhD in Biophysics at Harvard University. After completing his residency training in surgery in 1974, Dr Rosenberg became the Chief of Surgery at the National Cancer Institute, a position he still holds at the present time. Rosenberg is also currently a Professor of Surgery at the Uniformed Services University of Health Sciences and at the George Washington University School of Medicine and Health Sciences in Washington, DC.

Dendritic cell vaccines

Vaccines may also be composed of human dendritic cells, cells that are critical antigen-presenting and stimulatory cells for the induction of a T-cell-dependent immune response. Dendritic cells originate in the bone marrow, and reside in an immature state in peripheral tissues. As described earlier, upon receiving infl ammatory signals, they differentiate or mature and migrate to lymph nodes where antigens are presented and the T-cell response is initiated. In vivo, tumors secrete several factors that suppress dendritic cell differentiation and migration, and may contribute to the immunosuppression observed in cancer patients.

For the purpose of vaccination, dendritic cells must be isolated from an individual patient and cultured in vitro during which time they can be loaded or pulsed with specifi c antigens, DNA, or RNA via their high capacity for endocytosis (Figure 13.2) (or other means of transfection such as electroporation). Subsequently, they are reintroduced into the patient. Thus, dendritic vaccines are labor intensive and expensive. Initial clinical trials using loaded dendritic cells have shown positive clinical

304

1 3 : C A N C E R I N T H E F U T U R E : F O C U S O N C A N C E R VAC C I N E S A N D T E C H N O L O G Y

Figure 13.2 Dendritic cell loading.

responses and no signifi cant toxicity. An antigen-loaded dendritic cell vaccine called Provenge™ (sipuleucel-T; Dendreon Corporation, Seattle, WA) was produced for the treatment of prostate cancer by the following steps:

(1) a dendritic cell precursor-enriched fraction was isolated

(2) the cells were matured in vitro by incubation with a recombinant fusion protein (consisting of prostatic acid phosphatase linked to granulocyte–

macrophage colony-stimulating factor (GM-CSF)) that targets the GM-

CSF receptor present on dendritic cells

(3) the mature dendritic cells, now carrying the prostate cancer antigen, are administered.

After positive Phase I, II, and III trials, Provenge™ (sipuleucel-T) was approved by the US Food and Drug Administration in 2010 (Thara et al. , 2011). Dendritic cell vaccines continue to be actively investigated. CEA (mentioned earlier) is also over-expressed in more than 95% of colorectal cancers and has provided a target for colorectal cancer vaccination. CEA RNA pulsed dendritic cell vaccines are in clinical trials. Ongoing clinical trials for colorectal cancer can be viewed at the National Cancer Institutes web site (http://www.nci.nih.gov/). Expanding and loading dendritic cells in vivo, though not yet possible, is a promising idea for the future that would eliminate the dangers (e.g. contamination) associated with cell transfers and reduce labor and costs.

Overall, the optimization of therapeutic vaccines needs to be pursued.

The correct patient population (i.e. with respect to age, cancer stage, molecular signature of tumors) and timing of vaccine administration needs to be a focus. These vaccines may also become a tool for cancer management as many trials have shown vaccination results more often in a stable disease response rather than a complete curative response. Side-effects of vaccines are usually minimal in contrast to conventional chemotherapies.

Vaccines for cancer prevention

The therapeutic vaccines previously discussed are aimed at the tumor.

Vaccines generated from shared tumor antigens have been successful as prophylactic vaccines in animal models but have not been tested in

1 3 . 1 C A N C E R VAC C I N E S 305

humans. However, there are a few select types of cancer that are caused by pathogenic carcinogens (i.e. bacteria or viruses), and in these cases conventional prophylactic vaccines that target the pathogen can be produced.

As we saw in Chapter 10, human papillomavirus (HPV) is the causative factor of cervical cancer; that is, cervical cancer is 100% attributable to viral infection. The recent approval of vaccines against several HPV

strains (see Chapter 10) will prevent a large proportion of deaths caused by cervical cancer in the near future.

Large strides are being made in the development of prophylactic vaccines for breast cancer. As mentioned earlier, several promising breast-cancer antigens have been characterized. Prophylactic breast cancer vaccines are likely to be an important alternative to prophylactic mastectomies and/or oophorectomies or chemoprevention in women who carry

germline mutations in the BRCA1 and BRCA2 genes (see Section 11.6).

Safety and immune responses have been demonstrated for therapeutic

vaccines in several Phase I and II trials in patients with breast cancer but prophylactic trials are needed. Reluctance to carry out large-scale trials comes from the fear of autoimmunity against normal breast tissue, though autoimmune attack of normal breast tissue may be tolerable and may not have more severe consequences than mastectomies.

Hurdles to jump

There are several problems that need to be overcome for the full potential of vaccine development to be reached. First, the immune system becomes less effective with aging and is suppressed by conventional chemotherapy.

It is rare that pre-clinical studies are performed in old mice or mice that have been pre-treated with chemotherapy and this may help to explain the discrepancies between outcomes in mice and humans; positive immuno-logical responses in mice are often not reproducible in humans. It may be that therapeutic cancer vaccines may be more successful in pediatric cancer patients than older patients. Such comparisons need to be carried out.

Second, many vaccines may be most effective in early stage cancer

patients, although trials using such patients are unlikely to receive approval. In addition, resistance against therapeutic vaccines may arise.

Antigen-negative tumor cell clones evolve as a result of selective pressure exerted by the vaccine. Mutations that alter antigen expression will allow tumor cells to evade the immune response and survive.

Also, vaccines need to be tested in all appropriate contexts. Vaccines against tumor-specifi c antigens are being tested in humans exclusively as therapeutic agents, and not as prophylactics, even though the success of these agents in pre-clinical trials has been demonstrated almost exclusively as prophylactics. Note that as human tumors can only be grown in immune-deprived mice (e.g. nude mice), immunotherapy studies on





306

1 3 : C A N C E R I N T H E F U T U R E : F O C U S O N C A N C E R VAC C I N E S A N D T E C H N O L O G Y

human tumors cannot be performed in existing pre-clinical models and results from animal models may be species-specifi c. We cannot assume that what is successful in mice will be successful in humans because some aspects of physiology between the two are different. Prophylactic vaccines aimed at tumor-specifi c antigens (not including those directed against pathogens, e.g. HPV) have not been tested in clinical trials because the test population will be healthy individuals and the consequences and/or side-effects are unknown. However, at some point, vaccines as prophylactics need to be tested in humans.

13.2 Microarrays and gene expression profi ling

Microarrays and their associated technologies have enabled the expression of up to tens of thousands of genes to be analyzed easily. This technique is a tremendous asset, providing data sets that are not available by other methods. Previous methods could only examine individual genes or, at most, small sets of genes at a time. A group of transcripts associated with a specifi c outcome or phenotype is called a gene signature or profi le.

The applications of microarrays in cancer biology are far-reaching. As cancer is a disease of the genome at the cellular level, the changes in gene expression of genes that are involved in carcinogenesis can be identifi ed.

Different gene expression signatures can be used to identify molecular subtypes of cancers. The data generated may suggest new tumor classifi -

cations and lead to the development of more precise diagnosis. The molecular signatures may also allow for the prediction of disease outcome and prescription of the most effi cient treatment available for a particular tumor type. A futuristic vision is to be able to develop tailor-made therapies for individual patients based on the genetic profi le of their primary tumor.

Experimental procedure

Microarrays are grids, usually made on glass slides or silicon chips. They hold DNA representing thousands of genes that act as probes (i.e.

sequences that are complementary and can hybridize to specifi c RNAs) for RNA. The RNAs that are in a sample indicate genes that are

expressed (transcribed) in that sample. A typical protocol will be

described. Thousands of gene-specifi c hybridization probes are applied to a glass slide or silicon chip (Figure 13.3a). The DNA is usually bound to defi ned locations on the grid by robotic or laser technology. RNA is isolated from a biological sample, such as a tumor, and copied to incorporate fl uorescent nucleotides or a fl uorescent tag (Figure 13.3b). The



1 3 . 2 M I C R OA R R AYS A N D G E N E E X P R E S S I O N P R O F I L I N G 307

(a) Grid preparation

(b) RNA isolation and labelling

*

DNA5

DNA4

DNA3

DNA2

Tumor cells

Tumor RNA

Tumor RNA with

DNA1

fluorescent tag ( )

*

(c) Incubation

(d) Analysis

Laser

* *

* *

+

+

*

Computer

Tumor RNA

Grid

(e) Microarray

Figure 13.3 (a–d) The basic

protocol for microarrays. (e)

Sample microarray. See Plate 9.

chip is then incubated with labeled RNA or complementary DNA

(cDNA) from the tumor sample (Figure 13.3c). Unhybridized RNA is washed off and the microarray is then scanned under a laser and analyzed by computer (Figure 13.3d). A sample microarray image is shown in Figure 13.3e (see also Plate 9). By analyzing the fl uorescent intensities of the RNA or cDNA hybridized to the probes using computerized scanners,

gene expression can be quantifi ed. There are two common types of

microarray: cDNA microarrays and oligonucleotide microarrays. The

difference between the two is due to the nature of the probes. In cDNA microarrays each probe has its own ideal hybridization temperature

(based on factors such as GC content) and thus intensities of a test sample must always be compared with a control sample processed at the

same time. In oligonucleotide microarrays, the synthetic probes are designed such that all the probes have identical hybridization temperatures allowing absolute values of expression to be measured within one sample. Results from microarrays can be visualized in different formats.

One type of data display format is a heat map that uses color to represent levels of gene expression (see Plate 10). Genes may be arranged in rows and time points may be arranged in columns. A red box may be

used to indicate an increase in expression relative to a control; a green





308

1 3 : C A N C E R I N T H E F U T U R E : F O C U S O N C A N C E R VAC C I N E S A N D T E C H N O L O G Y

box may be used to indicate a decrease in expression relative to a control; and a black box to represent no change. Similarities in the patterns of gene expression can then be depicted in clusters in a cluster analysis diagram. Modifi cations of the technique, including protein microarrays and antibody microarrays, demonstrate that the microarray design has far-reaching potential.

Application of microarrays to cancer classifi cation

Let us examine one example of how a microarray was applied to characterize subclasses of a specifi c cancer. The application of a lymphochip, a microarray that screens for genes important to cancer, immunology, and lymphoid cells, helped to defi ne two molecularly distinct forms of a particular lymphoma (Alizadeh et al. , 2000). Diffuse large B-cell lymphoma is clinically heterogeneous, whereby 40% of patients respond to treatment and 60% do not. Results from the lymphochip showed that there

were two distinct patterns of gene expression that were differentiation-stage specifi c and also corresponded to different clinical outcomes (76%

of one subgroup was alive after 5 years, compared with only 16% of the other). The classifi cation of one cancer was refi ned to two distinct cancers. These fi ndings have important implications for cancer management and have stimulated the rethinking of the current treatment strategy. Currently, all patients of diffuse large B-cell lymphoma undergo chemotherapy fi rst. Those who have a poor response are then named candidates for bone marrow transplantation. Perhaps some patients, as defi ned by their molecular signature, should be directed for bone marrow transplantation immediately. DNA arrays are being used to refi ne molecular classifi cations of other cancers, including breast cancer.

13.3 Diagnostics and prognostics

It is well established that early diagnosis of cancer is crucial for a good prognosis. The power of biomarkers is being applied to the fi eld of diagnostics and prognostics. The measurement of a biomarker indicates

whether it falls within either a “normal” or “abnormal” range and this helps to suggest a diagnosis or prognosis. Biomarkers exist in different forms and include mammograms, circulating antigens, and expression

profi les. The future promises new and improved biomarkers.

Let us examine some progress that has been made in the detection of prostate cancer, the second leading cause of cancer-related deaths in men.

Prostate-specifi c antigen (PSA) has been the conventional prostate tumor marker, whereby elevated levels can be detected in blood. However,

1 3 . 3 D I AG N O S T I C S A N D P R O G N O S T I C S 309

improvements are needed to prevent subsequent negative biopsy rates (70–80%). Negative biopsy rates are due to the fact that PSA is not specifi c for prostate cancer. Elevated levels are also detected in benign prostate conditions such as prostatitis. Diagnostics based on genomics are leading to improvements in prostate cancer detection. DD3 PCA3 is a gene that has been identifi ed as the most prostate cancer-specifi c gene described thus far. DD3 PCA3 is only expressed in prostate tissue and is strongly over-expressed (10–100-fold) in more than 95% of prostate tumors.

Urinalysis that detects DD3 PCA3 RNA, using a nucleotide amplifi cation method called quantitative reverse transcriptase-PCR, has been designed for the diagnosis of prostate cancer. The test has been carried out on urine samples collected after prostate massage to help transport tumor cells into the urethra and the results (67% sensitivity) hold great promise as a non-invasive diagnostic tool that may reduce the number of unnecessary biopsies (Makarov et al. , 2009). Cancer blood tests that can provide comprehensive molecular information may one day become a reality with further study focused around the observation that circulating DNA from tumor cell death is released into the bloodstream. Another futuristic idea is that it may become possible to implant a gene chip under the skin to monitor changes in the expression of specifi c genes, thus speeding up diagnosis and facilitating early treatment.

As we saw in Chapter 3, hypermethylation of particular gene promot-

ers is characteristic of specifi c tumors. The promoter regions of two genes, p16 and O-6-methyl-guanine-DNA methyltransferase ( MGMT), are frequently methylated in lung cancer. The p16 gene product is a tumor suppressor that plays a role in the regulation of the cell cycle while the latter is involved in the repair of DNA damage caused by alkylating agents. Methylation-specifi c PCR (see Chapter 3) has been used to detect the aberrant methylation of these two genes in the sputum of patients both at the time of lung cancer diagnosis and up to three years prior to diagnosis. More recently, methylated genes have been examined for detection of lung cancer in blood and exhaled breath condensate (for review see Anglim et al. , 2008). This suggests that aberrant DNA methylation may be an applicable non-invasive molecular diagnostic marker.

Microarrays will play a prominent role in diagnosis. Interestingly, approximately 5% of gene expression distinguishes any normal tissue from its corresponding cancerous tissue. In addition, pre-cancerous lesions can be distinguished from normal and cancerous tissue by expression profi ling. These facts can be applied to diagnostics and prognostics.

One study has reported that the diagnosis of multiple cancers could be achieved solely on the basis of molecular classifi cation from data gathered by DNA microarray analysis (Ramaswamy et al. , 2001). This suggests that in the future DNA microarrays will play a vital role in the molecular diagnosis in the clinic.





310

1 3 : C A N C E R I N T H E F U T U R E : F O C U S O N C A N C E R VAC C I N E S A N D T E C H N O L O G Y

Several groups have used microarrays to identify a number of marker genes whose expression can predict metastasis and/or prognosis (Shipp et al. , 2002; Van’t Veer et al. , 2002). Two gene expression profi ling tests for breast cancer were launched in 2004. Oncotype DX™ (Genomic

Health, Redwood City, CA) and Mammaprint™ (Agendia, Amster-

dam) are tests designed to predict breast cancer recurrence. Sixteen genes selected from a total of 250 and 70 genes from a total of 25,000, respectively, have been identifi ed to indicate good or bad prognosis.

The main purpose of analyzing these selected genes is to identify tumors that are unlikely to metastasize in order to spare patients the trauma of chemotherapy. Only a small proportion of patients whose breast cancer has not spread to the lymph nodes develop metastases (20%) and really require chemotherapy. Most node-negative breast cancer patients are cured by surgery and radiotherapy. Scores of less than 17 (low recurrence score) or scores of 31 and higher (high recurrence score) for the Oncotype DX™ test are being used to predict the benefi t of chemotherapy for breast cancer patients, but ongoing trials for intermediate values are ongoing (TAILORx Breast Cancer Trial). Such gene profi ling tests that may spare patients from receiving unnecessary chemotherapy, routinely given in order to prevent metastasis in the unidentifi ed few for whom it is essential, is a true mark of progress.

Two future potential diagnostic and prognostic indicators include circulating tumor cells (CTCs) and miRNAs. Early studies suggest that overall numbers of CTCs, tumor cells that have intravasated into the blood stream, provide a prognostic indicator of disease outcome for some carcinomas. The use of miRNAs for identifying tumor origins was discussed previously in Chapter 3. Levels of several miRNAs have been correlated to metastatic outcome. We may see new instruments to detect CTCs and miRNA microarrays in the clinic in the future.

13.4 Imaging

In the past, imaging has been restricted mainly to anatomical features.

A brief description of each of the main imaging modalities is shown in Table 13.1. The future of imaging will reside in molecular and functional imaging (MFI), using several techniques (modalities) to investigate molecular pathways and tissue function during routine use in the clinic (Glunde et al. , 2007). Molecular features that may be examined by MFI include over-expression of receptors, gene expression, or cellular location. Functional aspects may include aspects of angiogenesis (e.g. vascular volume, vascular permeability, hypoxia) and metabolism (e.g. glycolytic activity).





1 3 . 5 P E R S O N A L I Z E D M E D I C I N E A N D B I O I N F O R M AT I C S 311

Table 13.1 The main imaging modalities used in cancer medicine Imaging modality

Mechanism

Comments

Computed tomography (CT)

X-rays

Positron-emission tomography

Positrons

Requires radiotracer. Can create

(PET)

a cross-sectional image (see

Plate 11)

Optical imaging

Fluorescent/bioluminescent

probes

Magnetic resonance imaging

Radiofrequency pulse is applied

(MRI)

to tissue in the presence of a

static magnetic fi eld

Ultrasound imaging (US)

High-frequency sound waves

PAUSE AND THINK

So how close are we to being

Molecular and functional imaging promises to have a major impact on able to sequence an individual’s

early diagnosis, as well as on the monitoring of disease progression upon genome? This has already been

treatment. Note, in general, that the detection of early stage (stage 1) can-done in 2007 for one famous

cers is associated with a fi ve-year survival rate of more than 90%. Refi ned person, James Watson the co-imaging may also decrease the number of biopsies taken in the clinic.

discoverer of the structure of

Molecular and functional imaging is another approach that will help DNA. The two-month project

match tumor to therapy. Such imaging will also serve as a guide to the was the result of a collaboration

administration of future molecular therapeutics such as siRNA and nano-between 454 Life Sciences and

and microdevices. One of the main things preventing new imaging tech-the Baylor College of Medicine

Human Genome Sequencing

niques from reaching the clinic is economics.

Center and cost under a million

dollars (to learn how they did it,

see Activity 2 at the end of this

chapter). Thus, the idea is feasi-

13.5 Personalized medicine and bioinformatics

ble but too costly to be routine at

the present time. But technolo-

Physicians currently make decisions about patient treatment on the basis gies are improving all the time

of population-based statistics, but the future holds hope for a time when and companies are helping to

physicians will rely on individual differences instead. Your genome is the drive progress. One company

most personalized “item” you possess. Only cancer patients have a more claims to have the capacity to

personalized “item” and that is the genome of their tumors. The study of sequence and analyze more than

pharmacogenomics has demonstrated that specifi c mutations of a tumor 400 complete human genomes

per month, and expects this

may determine a patient’s response to a cancer drug and several mutation capacity to grow even larger

screening tests for specifi c drugs are currently in use (Section 12.4). The soon. The race is on for the

time will soon come when hospitals and health services will easily be able $1000 genome, and IBM may be

to subject an individual tumor to genomic analysis.

close to performing the task

Such genomic analysis could take place over the course of the tumor’s using nanoscale sequencing on a

known history: upon detection, during, and after treatment (Figure 13.4).

computer-like chip.

This type of information could be pooled from thousands of geographic

312

1 3 : C A N C E R I N T H E F U T U R E : F O C U S O N C A N C E R VAC C I N E S A N D T E C H N O L O G Y

Case 1

Detection

Treatment A

Post-treatment

New York

good response

Expression

Expression

Expression

profile #1

profile #2

profile #3

Case 100

Detection

Treatment A

Poor

Post-treatment B

Japan

response

Good response

Expression

Expression

Expression

Expression

profile #1

profile #2

profile #3

profile #4

Compare

Treatment

international

A or B

profiles

Case 200

1st choice

London

best therapy

Figure 13.4 Cancer

?

Detection

Bioinformatics

bioinformatics: a possible

Expression

application for administration

profile #1

of fi rst-choice best therapy.

locations and thousands of clinical trials, providing an extraordinary tool for future treatment and research. The molecular profi le of an individual patient will be able to be compared and analyzed in order to select the best-known therapy available. Researchers will be able to identify cancer-specifi c molecular targets for drug design more rapidly. Several new bioinformatics initiatives have been launched. The US National

Cancer Institute and the UK National Cancer Institute will collaborate in





1 3 . 6 C A N C E R N A N OT E C H N O L O G Y 313

developing tumor information databases and networks (see “Web sites”

at the end of the chapter). These initiatives will make tissue data, biological contexts or ontologies, and clinical trial information readily available to researchers. Computer capabilities and facilities will need to be expanded and enhanced to handle the enormous number of data generated. Some improvements in image compression have already been made, allowing histological images to be analyzed over the internet.

13.6 Cancer nanotechnology

A multidisciplinary fi eld that promises to make a huge impact on cancer in the future is cancer nanotechnology. Nanotechnology is the study of devices (or their essential components) that are made by humans and have at least one dimension in the 1–1000 nm range. For scale, the size range is similar to the size of a few atoms to the size of subcellular structures.

Nanotechnology has many potential applications in the fi eld of cancer and a selection of these applications will be briefl y described here.

The problem of targeting a cancer drug specifi cally to a tumor must be better addressed in the future. We are all aware of the harsh side-effects observed with conventional therapies which are a result of the exposure of healthy tissue to these agents. Nanostructures that can be fi lled with anticancer drugs and which also contain targeting moieties on their surface are called nanovectors. Nanovectors hold promise in accomplishing effi cient tumor-specifi c drug delivery. Lipid-based nanovectors, called liposomes, were mentioned in Section 9.11 (Figure 9.12) and some are used in the clinic for treatment of Kaposi’s sarcoma and breast cancer. In addition, nanovectors will be used as imaging contrast agents that greatly amplify signals detected by various imaging techniques. It is easy to envi-sion that nanotechnology will refi ne microarrays to greater-capacity

“nanoarrays”.

Lastly, and perhaps most uniquely, nanotechnology will lead to bio-

molecular sensors that are able to detect many biomarkers simultaneously and will be used for refi ned diagnosis, prognosis, and treatment monitoring. Two specifi c designs, the nanocantilever and nanowires, currently show promise. Both can be coated with molecules that bind to biomarkers. Nanocantilevers are defl ected upon binding to a biomarker (in a manner similar to piano keys when they are tapped). Lasers are used to detect the defl ections. Nanowires undergo a change in conductance upon binding and this change is detected electronically. Both may change the way and speed at which cancer is monitored.

In summary, nanotechnology may enable specifi c cancer drug target-

ing, leading to better therapeutic results and fewer toxic side-effects. It





314

1 3 : C A N C E R I N T H E F U T U R E : F O C U S O N C A N C E R VAC C I N E S A N D T E C H N O L O G Y

promises to enhance imaging and biomarker detection for improved

diagnosis. Used as biomolecular sensors, this technology may replace the need for biopsies.

LEADERS IN THE FIELD . . . of nanotechnology: Robert Curl,

Harry Kroto, and Richard E. Smalley

Robert Curl, Harry Kroto, and Richard E. Smalley shared the Nobel Prize for Chemistry in 1996 for the discovery of buckyballs (fullerenes). Full autobiographies of all three can be

found at http://nobelprize.org/.

What I fi nd interesting in reading autobiographies is learning about the varied backgrounds and life events that inspire people to enter a career in science. For example, Richard Smalley claims that his principal impetus for choosing a science career was the success of the Sputnik launch in 1957. This event convinced him that science and technology was going to be where the action was in the future. Indeed, the fi eld of nanotechnology, in which he made enormous contributions, promises to be where the action will be in the future, especially in applications to cancer management. Ironically, Smalley died of cancer at the age of 62.

Smalley received his PhD in Chemistry from Princeton University. He became chair of the chemistry department and a professor in the physics department at Rice University in Texas.

Smalley was also the founding director of the Center for Nanoscale Science and Technology at Rice University.

13.7 Treating cancer symptoms

In order for cancer to become a chronic disease, symptoms that are

associated with it and that contribute to the high mortality rates and poor physiological function must be addressed. The alleviation of cancer pain is one area towards which many pharmaceutical companies are directing their research. Successful drugs will greatly increase the quality of life of cancer patients. Cachexia, a metabolic defect that is characterized by progressive weight loss owing to the deletion of adipose tissue and skeletal muscle, reduced food intake, and systemic infl ammation, is another common symptom of cancer. It is the early loss of skeletal muscle that makes cachexia dissimilar to starvation. In starvation, fat is lost prior to muscle in order to preserve lean body mass. The mechanism for cachexia involves the upregulation of catabolism or a defect in anabolism and infl ammation. Infl ammatory cytokines known to play a role include IL-6, TNF-α, IL-1, and interferon-γ. Therefore, strategies to treat cachexia have included anti-infl ammatory approaches, including cytokine inhibitors (Argiles et al. , 2011). In addition, therapeutic strategies based on anabolic and anticatabolic pathways may be considered. Our current understanding of cachexia suggests that different combinations of treatments may be





1 3 . 8 A R E W E M A K I N G P R O G R E S S ? 315

more successful than a single therapy. New drugs have been developed to help ease the side-effects of chemotherapy. Aranesp™ and Neulasta™ (both developed by Amgen) are used to treat the side-effects of anemia and low white blood cell count, respectively.

13.8 Are we making progress?

Do you think we are making progress? Despite several media articles that raise doubts, the real answer to this question is almost certainly “yes”!

The statistics are available. For example, the overall survival for all stages of prostate cancer combined has increased from 67% to 89% over the

past 20 years. The increased survival is attributable to both earlier and better detection, and advances in therapeutics. Furthermore, cancer death rates decreased in both men and women from 1998 through 2007

in the USA (Siegel et al. , 2011; see Chapter 1) and similar progress has been reported in other parts of the world. Although our knowledge about cancer has grown enormously, there is still so much more to learn. Perhaps there are some secrets held in the heart—literally. Primary cardiac tumors, of which only one-quarter are malignant, are rare (0.02%).

Investigations into why cancer is rare in this particular tissue may lead to knowledge of protective mechanisms that can be applied to other tissues.

You will notice that most of the newly approved therapies, shown in Table 13.2, are directed against molecules that are tyrosine kinases (e.g.

EGFR, VEGFR, ABL). There are several tyrosine kinases that are known to play important roles in carcinogenesis (e.g. fi broblast growth factor receptor, FGFR) but inhibitors that target them, although in clinical trials, have yet to be approved. However, although we can design new cancer therapies against molecular targets, tumor cells may undergo additional mutations that can result in drug-resistant clones. This suggests that combinations of drugs and drug strategies are important for future treatment regimens. The report of the development of a “two-in-one” antibody that interacts with either HER2 or VEGF suggests that the way we administer treatment combinations may change (Bostrom et al. , 2009). Also, a new type of gene therapy is on the horizon. The fi rst in-human phase I clinical trial has demonstrated that systemic administration of siRNAs via targeted nanoparticles to patients with melanoma can reduce both a specifi c mRNA and its associated protein (Davis et al. , 2010). This result may open the door to the development of gene-specifi c therapeutics.

As we saw in previous chapters, there are many potential molecular

strategies, such as angiogenesis inhibitors, anti-endocrine drugs, apoptotic inducers, cell cycle inhibitors, HDAC inhibitors, and inhibitors of cell renewal signaling pathways, in development. (I regret that some

316

1 3 : C A N C E R I N T H E F U T U R E : F O C U S O N C A N C E R VAC C I N E S A N D T E C H N O L O G Y

Table 13.2 A selection of targeted cancer therapeutics approved in 2011

Trademark

Drug

Description

Target

Cancer

Company

Avastin™

Bevacizumab

Humanized mAb VEGF

Colorectal

Genentech

Erbitux™

Cetuximab

Humanized mAb EGFR

Colorectal

Imclone

Gleevec™

Imatinib

Small-molecule

BCR–ABL, KIT,

CML, GIST

Novartis

(USA),

inhibitor

PDGFR

Glivec™

(UK, Europe)

Herceptin™

Trastuzumab

Humanized mAb HER2

Breast

Genentech

Iressa™

Gefi tinib

Small-molecule

EGFR

NSCLC

AstraZeneca

inhibitor

Nexavar™

Sorafenib

Multi-kinase

Raf, VEGFR,

Renal cell

Bayer Pharm

inhibitor

PDGFR, KIT, RET carcinoma

Sprycel™

Dasatinib

Small-molecule

BCR-ABL, Src

Imatinib-resistant Bristol-Myers

inhibitor

family

leukemias

Squibb

Sutent™

Sunitinib

Small-molecule

PDGFR, VEGFR, Renal cell

Pfi zer

(SU11248)

inhibitor

KIT

carcinoma,

GIST

Tarceva™

Erlotinib

Small-molecule

EGFR

NSCLC,

Genetech, OSI

inhibitor

pancreatic

Pharm

Tykerb™

Lapatinib

Small-molecule

EGFR, HER2

Breast

GlaxoSmithKline

inhibitor

Vectibix™

Panitumumab

Human mAb

EGFR

Colorectal

Amgen

Velcade™

Bortezomib

Proteasome

Myeloma

Millennium

inhibitor

Pharm

Xalkori™

Crizontinib

Small-molecule

ALK gene

NSCLC with

Pfi zer

inhibitor

fusion, MET

ALK-gene

fusions

Yervoy™

Ipilimumab

Human mAb

CTLA-4

Melanoma

Bristol-Myers

Squibb

Zactima™

Vandetanib

Small-molecule

VEGFR, EGFR,

Orphan drug for AstraZeneca

(ZD6474)

inhibitor

RET

rare types of

thyroid cancer

Zelboraf™

Vemurafenib

Small-molecule

BRAF V600 E

Melanoma

Genentech

(PLX4032)

inhibitor

Zolinza™

SAHA

Small molecule

HDAC

Non-Hodgkin’s

Merck & Co.

(vorinostat)

(suberoylanilide

inhibitor

lymphoma

hydroxamic acid)

Abbreviations: mAB, monoclonal antibodies; CML, chronic myelogenous leukemia; GIST, gastrointestinal stromal tumor; NSCLC, non-small-cell lung cancer.

1 3 . 8 A R E W E M A K I N G P R O G R E S S ? 317

strategies have not been discussed, e.g. proteasome inhibitors.) For many of these drugs, the therapeutic index is enhanced compared with conventional chemotherapies. We await the elongation of the list of newly approved molecular cancer therapeutics, some of which are shown in

Table 13.2.

■ CHAPTER HIGHLIGHTS—REFRESH YOUR MEMORY

•

Cancer vaccines can be designed to be prophylactic or

•

The genomes of individuals (the fi rst of which was that of

therapeutic.

James Watson) are now able to be sequenced.

•

Therapeutic vaccines use whole-cell, peptide, or dendritic

•

New bioinformatic initiatives have been launched to coor-

cell strategies.

dinate the organization and sharing of data from cancer

•

Conventional prophylactic vaccines can be aimed at can-

studies.

cer caused by pathogens, e.g. the human papillomavirus.

•

Nanovectors are/will be used for tumor-specifi c drug

•

Microarrays analyze the expression of thousands of genes

delivery.

at once.

•

Biomolecular sensors using nanocantilevers and nano-

•

Microarrays have several applications, including identify-

wires are being developed.

ing new oncogenes, helping to refi ne cancer classifi ca-

•

Cachexia, a metabolic defect resulting in the progressive

tions, and predicting cancer prognosis.

loss of fat and protein and infl ammation, is a symptom

•

Gene signature tests can distinguish some breast cancer

associated with cancer and approaches to treat it are

patients into groups that would not or would benefi t

being investigated.

from chemotherapy.

•

We are making progress in the fi eld of molecular cancer

•

Molecular and functional imaging investigates molecular

therapeutics.

pathways and tissue function.

■ ACTIVITY

1. An enzyme involved in the functional activity of phosphorylation sites, called Pin1, has been identifi ed. Discuss the molecular mechanisms of the action of Pin1, its role in oncogenesis, and its use as a molecular diagnostic tool. (Hint: start with Lu, K.P. (2003) Cancer Cell 4: 175.)

2. If you are interested in learning more about DNA sequencing and reading the paper that reported the sequencing of James Watson’s genome see: Metzker, M.L. (2010) Sequencing technologies: the next generation. Nat Rev. Genet. 11: 31-46 and Wheeler, D.A., et al.

(2008) The complete genome of an individual by massively parallel DNA sequencing.

Nature 452: 872–877.

■ FURTHER READING

Antonia, S., Mule, J.J., and Weber, J.S. (2004) Current developments of immunotherapy in the clinic. Curr. Opin. Immunol. 16: 130–136.

318

1 3 : C A N C E R I N T H E F U T U R E : F O C U S O N C A N C E R VAC C I N E S A N D T E C H N O L O G Y

Blattman, J.N. and Greenberg, P.D. (2004) Cancer immunotherapy: a treatment for the masses. Science 305: 200–205.

Chang, J.C., Hilsenbeck, S.G., and Fuqua, S.A.W. (2005) Utility of microarrays in the management of breast cancer patients. Drug Discov. Today: Ther. Strategies 2: 307–311.

Dalton, W.S. and Friend, S.H. (2006) Cancer biomarkers – an invitation to the table.

Science 312: 1165–1168.

Espinosa, E., Fresno Vara, J.A., Sanchez Navvarro, I., Gamez-Pozo, A., Pinto, A., Zamora, P., et al. (2011) Gene profi ling in breast cancer: time to move forward.

Cancer Treat. Rev. 37: 416–421.

Ferrari, M. (2005) Cancer nanotechnology: opportunities and challenges. Nat. Rev.

Cancer 5: 161–171.

Figdor, C.G., de Vries, I.J., Lesterhuis, W.J., and Melief, C.J.M. (2004) Dendritic cell immunotherapy: mapping the way. Nat. Med. 10: 475–480.

Finn, O.J. (2003) Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol.

3: 630–641.

Finn, O.J. and Forni, G. (2002) Prophylactic cancer vaccines. Curr. Opin. Immunol.

14: 172–177.

Frazer, I.H. (2004) Prevention of cervical cancer through papillomavirus vaccination.

Nat. Rev. Immunol. 4: 46–54.

Liu, E.T. (2003) Classifi cation of cancers by expression profi ling. Curr. Opin. Genet.

Dev. 13: 97–103.

Lollini, P.-L., Cavallo, F., Nanni, P., and Forni, G. (2006) Vaccines for tumour prevention. Nat. Rev. Cancer 6: 204–216.

Ma, W.W. and Adjei, A.A. (2009) Novel agents on the horizon for cancer therapy. CA Cancer J. Clin. 59: 111–137.

Schuler, G., Schuler-Thurner, B., and Steinman, R.M. (2003) The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15: 138–147.

Weissleder, R. (2006) Molecular imaging in cancer. Science 312: 1168–1171.

Zeh, H.J. III, Stavely-O’Carroll, K., and Choti, M.A. (2001) Vaccines for colorectal cancer. Trends Mol. Med. 7: 307–313.

■ WEB SITES

Bioinformatics initiatives: Cancer Biomedical Informatics Grid https://cabig.nci.nih.gov/

and NCRI Informatics Initiative http://www.cancerinformatics.org.uk/

Clinical trials: National Cancer Institute http://www.cancer.gov/

US Food and Drug Administration Drug Alerts—American Society of Clinical Oncology

http://www.asco.org/ascov2/Practice+&+Guidelines/Practice+Management+&+Reimbursement/

FDA+Drug+Alerts

1 3 . 8 A R E W E M A K I N G P R O G R E S S ? 319

■ SELECTED SPECIAL TOPICS

Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., et al.

(2000) Distinct types of diffuse large B-cell lymphoma identifi ed by gene expression profi ling. Nature 403: 503–511.

Anglim, P.P., Alonzo, T.A., and Laird-Offringa, I.A. (2008) DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol. Cancer 7: 81–94.

Argiles, J.M., Busquets, S., and Lopez-Soriano, F.J. (2011) Anti-infl ammatory therapies in cancer cachexia. Eur. J. Pharmacol. 668(Suppl 1): S81–S86.

Bostrom, J., Yu, S.-F., Kan, D., Appleton, B.A., Lee, C.V., Billeci, K., et al. (2009) Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323: 1610–1614.

Davis, M.E., Zuckerman, J.E., Choi, C.H.J., Seligson, D., Tolcher, A., Alabi, C.A., et al. (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464: 1067–1070.

Glunde, K., Pathak, A.P., and Bhujwalla, Z.M. (2007) Molecular-functional imaging of cancer: to image and imagine. Trends Mol. Med. 13: 287–297.

Makarov, D.V., Loeb, S., Getzenberg, R.H., and Partin, A.W. (2009) Biomarkers for prostate cancer. Annu. Rev. Med. 60: 139–151.

Ramaswamy, S., Tamayo, P., Rifkin, R., Mukherjee, S., Yeang, C.-H., Angelo, M., et al. (2001) Multiclass cancer diagnosis using tumor gene expression signatures.

Proc. Natl. Acad. Sci. USA 98: 15149–15154.

Rosenberg, S.A. (2001) Progress in human tumor immunology and immunotherapy.

Nature 411: 380–384.

Rosenberg, S.A., Yang, J.C., Sherry, R.M., Kammula, U.S., Hughes, M.S., Phan, G.Q., et al. (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17: 4550–4557.

Shipp, M.A., Ross, K.N., Tamayo, P., Weng, A.P., Kutok, J.L., Aguiar, R.C.T., et al.

(2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profi ling and supervised machine learning. Nat. Med. 8: 68–74.

Siegel, R., Ward, E., Brawley, O., and Jemal, A. (2011). Cancer statistics, 2011. CA: Cancer J. Clin. 61: 212–236.

Thara, E., Dorff, T.B., Pinski, J.K. and Quinn, D.I. (2011). Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas 69: 296–303.

Van’t Veer, L.J., Dai, H., van de Vijver, M.J., He, Y.D., Hart, A.A.M., Mao, M., et al.

(2002) Gene expression profi ling predicts clinical outcome of breast cancer. Nature 415: 530–535.

This page intentionally left blank





■ APPENDIX 1: CELL CYCLE REGULATION

EGF

EGF

EGFR

EGFR

PIP2

PIP3

PIP3

SOS

RAS

RAS

PI3K

PDKI

AKT

P

P

GRB2

SOS

GAPS

GDP

GTP

Active

Autophosphorylation

Inactive

P

AKT

RAF

MEK

MAPK

MAPK

P

Transcription

factor

Cyclin D

M checkpoint

16 hrs/0 hrs

G

G0

2 checkpoint

15 hrs

Mitogens

M

(mitosis)

HDAC

Rb

P

B

Cyclin Ds +

Cyclin D

cdk 4/6

Growth factor

A E2F DP

B

Cdk4

G1 restriction

Cyclin E gene

G2

point

Cyclin E

Cyclin B/A +

G1

G1

A

Rb

P

B

cdk 1

checkpoint

Cdk2

In

P

terphase

Cyclin E +

S phase

cdk2

E2F DP

Cyclin A

Cyclin A+

cdk2

p53

p21

Cyclin

cdK

p21

Figure A1 Key molecular pathways of cell cycle regulation. Growth factor signaling results in the expression of target genes, including cyclin genes. Cyclin proteins are key for progression of the cell cycle and are involved in the regulation of the tumor suppressor protein, RB. The protein product of the p21 gene acts as an inhibitor of cyclin–cdk (cyclin-dependent kinase) complexes. These pathways are discussed in detail in the text.

This page intentionally left blank





■ APPENDIX 2: CENTERS FOR CANCER RESEARCH

Please note that the list which follows is a small sample of cancer research centers and companies in the USA and UK—many others exist.

Web sites

Philadelphia

PA 19140, USA

The National Cancer Institute designated cancer

Tel.: 1215 707 4307

centers: https://cissecure.nci.nih.gov/factsheet/

Fax: 1215 707 1454

FactSheetSearch1_2.aspx

Central E-mail: preddy@sgil.fels.temple.edu

Cancer Careers: http://www.cancercareers.org/

Central URL: http://www.temple.edu/medicine/

departments_centers/research/fels.htm

USA—laboratories/institutes

Fred Hutchinson Cancer Research Center

1100 Fairview Avenue North

Cancer Research Laboratory

Seattle

University of California, Berkeley

WA 98109-1024, USA

447 Life Sciences Addition MC2751

Tel.: 1206 667 5000

Berkeley

Fax: 1206 667 7005

CA 94720-2751, USA

Central E-mail: commrel@fhcrc.org

Tel.: 1510 642 4711

Central URL: http://www.fhcrc.org

Fax: 1510 642 5741

Central E-mail: cslatten@uclink4.berkeley.edu

H. Lee Moffi tt Cancer Center and Research

Central URL: http://biology.berkeley.edu/crl/

Institute

12902 Magnolia Drive

Cold Spring Harbor Laboratory

Tampa

1 Bungtown Road

FL 33612, USA

PO Box 100

Tel.: 1813 972 4673

Cold Spring Harbor

Fax: 1813 972 8495

NY 11724 USA

Central URL: http://www.moffi tt.usf.edu

Tel.: 1516 367 8455

Fax: 1516 367 8496

Ludwig Institute for Cancer Research–San Diego

Central E-mail: pubaff@cshl.org

University of California, San Diego

Central URL: http://www.cshl.edu/

9500 Gilman Drive, Mail Code 0660

La Jolla

Fels Institute for Cancer Research and

CA 92093, USA

Molecular Biology

Tel.: 1858 534 7802

Temple University School of Medicine 3307

Fax: 1858 534 7750

N. Broad Street

Central URL: http://sandiego.licr.org/

324

A P P E N D I X 2 : C E N T E R S F O R C A N C E R R E S E A R C H

Memorial Sloan-Kettering Cancer Center

Central E-mail: herbermanrb@msx.upmc.edu

1275 York Avenue

Central URL: http://www.upci.upmc.edu

New York

NY 10021, USA

University of Texas M. D. Anderson Cancer

Tel.: 212 639 2000

Center

Central URL: http://www.mskcc.org

1515 Holcombe Blvd

Houston

The Ohio State University Comprehensive

TX 77030, USA

Cancer Center

Tel.: 1713 792 2121

The Arthur G. James Cancer Hospital and

Fax: 1713 799 2210

Richard J. Solove Research Institute

Central URL: http://www.mdanderson.org

Suite 519

300 West 10th Avenue

Columbus

UK—laboratories/institutes

OH 43210, USA

Tel.: 1 800 293 5066 (The James Line)

Beatson Institute for Cancer Research

Central E-mail: cancerinfo@jamesline.com

Garscube Estate

Central URL: http://www.jamesline.com

Switchback Road

Bearsden

Salk Institute Cancer Center

Glasgow G61 1BD, UK

10010 North Torrey Pines Road

Tel.: 0141 330 3953

La Jolla

Fax: 0141 942 6521

CA 92037, USA

Central E-mail: beatson@gla.ac.uk

Tel.: 1858 453 4100

Central URL: http://www.beatson.gla.ac.uk/

Fax: 1858 457 4765

Central E-mail: eckhart@salk.edu

Cancer Research UK, National Offi ce

Central URL: http://www.salk.edu/

PO Box 123

Lincoln’s Inn Fields

Shands Cancer Center at the University of Florida

London WC2A 3PX, UK

1600 S. W. Archer Road

Tel.: 020 7242 0200

Box 100286 HSC

Fax: 020 7269 3100

Gainesville

Central URL: http://www.cancerresearchuk.org

FL 32610, USA

Tel.: 1352 395 05 58

Christie Hospital NHS Trust

Fax: 1352 395 05 72

Wilmslow Road,

Central E-mail: gail@surgery.ufl .edu

Manchester M20 4BX, UK

Central URL: http://www.ufscc.ufl .edu/

Tel.: 0845 226 3000

Central URL: http://www.christie.nhs.uk

University of Pittsburgh Cancer Institute

200 Lothrop Street

Gray Institute for Radiation Oncology and Biology

Pittsburgh

University of Oxford

PA 15261, USA

Old Road Campus Research Building

Tel.: 412 692 4670

Off Roosevelt Drive

Fax: 412 692 4665

Churchill Hospital

A P P E N D I X 2 : C E N T E R S F O R C A N C E R R E S E A R C H 325

Oxford OX3 7DQ, UK

London WC1E 6BT, UK

Tel.: 01865 617330

Tel.: 020 7679 6697

Fax: 01865 617334

Central URL: http://www.ucl.ac.uk/cancer/

Central URL: http://www.rob.ox.ac.uk/

The Weatherall Institute of Molecular Medicine

The Institute of Cancer Research

University of Oxford

123 Old Brompton Road

John Radcliffe Hospital

London SW7 3RP, UK

Headington

Tel.: 020 7352 8133

Oxford OX3 9DS, UK

Fax: 020 7370 5261

Tel.: 01865 222443

Central URL: http://www.icr.ac.uk

Fax: 01865 222737

Central URL: http://www.imm.ox.ac.uk

The Institute of Cancer Research

Chester Beatty Labs

Fulham Road

Companies

London SW3 6JB, UK

Amgen Inc.

The Institute of Cancer Research

One Amgen Center Drive

Sutton

Thousand Oaks

15 Cotswold Rd, Belmont

CA 91320, USA

Sutton, Surrey SM2 5NG, UK

Tel.: 1805 447 1000

Fax: 1805 447 1010

Ludwig Institute for Cancer Research Oxford

URL: http://www.amgen.com

Branch

University of Oxford

AstraZeneca UK Ltd

Nuffi eld Department of Clinical Medicine

Horizon Place

Old Road Campus Research Building (off

600 Capability Green

Roosevelt Drive)

Luton LU1 3LU, UK

Headington

Tel.: 01582 836 000

Oxford OX3 7DQ, UK

Fax: 01582 838 003

Tel: 01865 617500

E-mail: medical.informationgb@astrazeneca.com

Fax: 01865 617515

URL: http://www.astrazeneca.co.uk

Central URL: http://www.ludwig.ox.ac.uk/index.htm/

Eli Lilly and Company

The Medical Research Council

Lilly Corporate Center

20 Park Crescent

Indianapolis

London W1B 1AL, UK

IN 46285, USA

Tel.: 020 7636 5422

Tel.: 1317 276 2000

Central URL: http://www.mrc.ac.uk

URL: http://www.lilly.com/

University College London Cancer Institute

Genentech, Inc.

The Paul O’Gorman Building

1 DNA Way

University College London

South San Francisco

Gower Street

CA 94080-4990, USA

326

A P P E N D I X 2 : C E N T E R S F O R C A N C E R R E S E A R C H

Tel.: 650 225 1000

Merck & Co., Inc.

Fax: 650 225 6000

One Merck Drive

URL: http://www.gene.com/

PO Box 100

Whitehouse Station,

Genzyme Ltd, Haverhill Offi ce

NJ 08889-0100, USA

12 Rookwood Way

Tel.: 1908 423 1000

Haverhill

URL: http://www.merck.com

Suffolk CB9 8PU, UK

Tel.: 01440 703522

Novartis Pharmaceuticals UK Ltd

Fax: 01440 707783

Frimley Business Park

URL: http://www.genzyme.co.uk/

Frimley, Camberley

Surrey GU16 5SG, UK

GlaxoSmithKline UK

Tel.: 1276 698 370

Stockley Park West

Fax: 1276 698 449

Uxbridge, Middlesex UB11 1BT, UK

URL: http://www.novartis.co.uk/

Tel.: 020 8990 9000

Fax: 020 8990 4321

Pfi zer Limited

E-mail: customercontactuk@gsk.com

Walton Oaks

URL: http://www.gsk.com

Dorking Road

Tadworth

Hoffmann-La Roche Inc.

Surrey KT20 7NS, UK

340 Kingsland Street

Tel.: 01737 331 111

Nutley, NJ 07110, USA

Fax: 01737 332 507

Tel.: 1973 235 5000

URL: http://www.pfi zer.co.uk, http://www.pfi zer.com

Fax: 1973 235 7605

URL: http://www.rocheusa.com/

Procter & Gamble Pharmaceuticals UK Ltd

Lovett House

ImClone Systems Inc.

Lovett Rd

180 Varick Street

Staines TW18 3AZ, UK

New York, NY 10014, USA

Tel.: 01784 495 000

Tel.: 212 645 1405

Fax: 01784 495 253

Fax: 212 645 2054

URL: http://www.pgpharma.com

URL: http://www.imclone.com/





■ GLOSSARY

Adenocarcinoma a malignant tumor of a gland.

Adjuvant a vaccine additive that enhances the immune response to an antigen.

Afl atoxin a carcinogenic compound produced by the mold Aspergillus fl avus that contaminates some food products such as peanuts.

Alkylating agent a chemical that introduces an alkyl group onto DNA; they act as carcinogens but are also used in chemotherapy.

Allele an alternative form of a gene at the same locus or relative position in a chromosomal pair. One allele may be dominant over the other.

Allograft a transplant of tissue from one individual to another (e.g. a heart transplant).

Angiogenesis the process of forming new blood vessels from pre-existing ones by the growth and migration of endothelial cells in a process called

“sprouting.” The induction of angiogenesis is a hallmark of cancer.

Anoikis apoptosis triggered in response to a lack of extracellular matrix ligand binding.

Antibody a protein produced by lymphocytes in response to an antigen, and which can specifi cally bind the antigen as part of an immune

response.

Antigen a molecule capable of generating an immune response.

Antimetabolite an agent that resembles an endogenous metabolite and blocks a metabolic pathway.

Antioxidant a compound that signifi cantly inhibits or delays the damaging action of reactive oxygen species, often by being oxidized themselves.

Antisense oligonucleotide synthetic nucleotide fragments that hybridize to complementary DNA or RNA in order to inhibit gene expression.

Apoptosis a process of “neat” programmed cell death. It plays a role in tumor suppression; inhibition of apoptosis is a hallmark of cancer.

Attenuated reduced virulence (infectivity) of a pathogenic microorganism.

Autoimmunity a condition in which an individual’s immune system starts reacting against their own tissues, causing disease.

Autophagy a process whereby proteins and organelle components that are no longer required are targeted to the lysosomes for degradation.





328

G L O S S A RY

Excessive autophagy leads to a specifi c type of non-apoptotic cell death program.

Basement membrane an acellular support of endothelial, epithelial, and some mesenchymal cells made up of a complex mix of extracellular

matrix proteins, including laminins, collagens, and proteoglycans. It acts as a passive barrier that separates tissue compartments.

Benign characteristic of a tumor that does not invade surrounding tissues or metastasize.

Bioinformatics the use of computers and information technology to store and analyze nucleotide and amino acid sequences and related information.

Biomarker a biochemical or genetic feature that can be used to measure the progression of disease or the effect of treatment.

Cachexia a metabolic defect often associated with cancer that is characterized by progressive weight loss caused by the depletion of adipose tissue and skeletal muscle.

Cancer stem cells cells within a tumor that have the ability to self-renew and to give rise to phenotypically diverse cancer cells.

Carcinogen a chemical or form of energy that causes cancer.

Carcinogenesis the process of inducing cancer.

Carcinoma a malignant tumor of epithelium.

Caspases specifi c aspartate proteases (that cleave target proteins at aspartate residues) involved in apoptosis.

cDNA the DNA sequence that is complementary (c) to a messenger (m) RNA.

Cell cycle the sequence of stages that a cell passes through between one cell division and the next. The cell cycle can be divided into four main stages: the M phase, when nuclear and cytoplasmic division occurs; the G1 phase; the S phase in which DNA replication occurs; and the G2

phase.

Chemoprevention is the use of naturally occurring or synthetic agents to prevent, inhibit, or reverse the process of carcinogenesis in pre- malignant cells.

Chromatin fi bers made up of DNA, RNA, and protein that form chromosomes.

Chromosome a structure composed of a DNA molecule and associated RNA and protein. Humans have 46 chromosomes in the nucleus of their somatic cells.

Chromothripsis a single catastrophic event in a cell that leads to multiple mutations.





G L O S S A RY 329

Chronic refers to a long-lasting condition; opposite of acute.

Clinical trials involve the testing of a new drug in humans under medical supervision to test for drug safety and effi cacy. Clinical trials proceed in sequential and defi ned phases: Phases I, II, and III.

Clonal originating from one cell.

Coding region the nucleotide sequences of a gene that are transcribed into mRNA, and those coding for exons are translated into protein.

Combinatorial chemistry methodologies that rapidly and systematically assemble molecular entities to synthesize a large number of different but structurally related compounds.

CpG islands regions of DNA that contain clusters of CG dinucleotides.

They are often located in the promoter regions of genes and are not normally methylated. CpG islands of tumor suppressor genes may be

found methylated in cancer cells, resulting in epigenetic gene silencing.

Cytokines small secreted proteins which are the major cell signaling proteins of both B and T cells (e.g. interferon-γ, interleukins, chemokines).

Cytostatic drug a drug that stops cell growth.

Cytotoxic drug a drug that kills cells.

Differentiation the functional specialization of a cell as a result of the expression of a specifi c set of genes.

DNA response elements short sequences of DNA that act as binding sites for transcription factors in gene promoters.

Dominant negative a mutation that produces a protein that interacts with and/or interferes with the function of a wild-type protein.

Downstream refers to DNA sequences that are nearer 3′ as a point of reference. Note that by convention a DNA sequence is read from the 5′ end to the 3′ end.

Dysplastic abnormal development or growth of cells, tissues, or organs.

Electromagnetic radiation a naturally occurring energy that moves as waves resulting from the acceleration of electric charge and the associated electric and magnetic fi elds. The characteristics of the radiation depend on its wavelength.

Electromagnetic spectrum the range of wavelengths over which electromagnetic radiation extends. The longest waves (wavelength

105 − 10−3 m) are radio waves and the shortest are gamma rays (wavelength 10−11 −10−14 m).

Electrophilic molecules that are electron-defi cient and are therefore attracted to compounds with a net negative charge.

Embryonic stem cells cells derived from the inner cell mass of an early embryo. When transferred into another early embryo they combine





330

G L O S S A RY

with the inner cell mass cells of the host and contribute to embryo formation.

Epigenetic refers to inheritable information that is encoded by modifi cations of the genome and chromatin components and affects gene expression. It does not include changes in the base sequence of DNA.

Epithelium–mesenchymal transition (EMT) involves cells leaving an epithelial layer and becoming a loose mass of mesenchymal cells which can migrate individually. EMT is crucial to gastrulation and early development and may also play a role in metastasis.

Estrogens steroid hormones secreted by the ovary, but also produced by adipose cells, that act to maintain female characteristics and as a mitogen for breast cells.

Extravasation the process whereby a cancer cell exits a blood vessel or lymphatic vessel.

First-pass organ the fi rst organ en route via the bloodstream that lies downstream from the primary tumor site.

Gene a region of DNA that occupies a specifi c position on a chromosome and includes the regulatory region and coding region for a protein.

Gene amplifi cation the multiple replication of a section of DNA that results in the production of many copies of the genes involved.

Gene expression the process by which the information encoded by a gene is converted for the making of a protein. In terms of molecular biology, this usually refers to transcription.

Genomics the study of all the genes contained in a set of chromosomes.

Genotoxic the ability of a substance to damage DNA.

Genotype the genetic characteristics of a cell or organism. Also the combination of the alleles at a particular locus.

Germline mutation a mutation in either egg or sperm cell DNA (as opposed to a somatic mutation). Mutations in germ cells only can be passed on to the next generation.

Haploinsuffi ciency occurs with the loss of one (of two) wild type alleles and the single functional copy of the gene is insuffi cient to maintain normal function.

Hematopoietic refers to tissue that can give rise to blood cells in the process of hemopoiesis.

Heterodimer a functional protein that is made up of two different subunits.

Heterozygous having different alleles at a given locus on homologous chromosomes.





G L O S S A RY 331

Histones basic proteins within chromatin that bind DNA at regular intervals.

Homodimer a functional protein that is made up of two identical subunits.

Homozygous having the same two alleles at a given locus on homologous chromosomes.

Hypoxia a state of low levels of oxygen.

Immunoediting the concept that tumor cells modulate the host anti-tumor immune response and the host immune response shapes tumor immunogenicity and clonal selection.

Immunosurveillance a monitoring function of the immune system that recognizes cancer cells as foreign agents and eliminates them.

Incidence the number of new cases of cancer (or other disease) in a defi ned population over a defi ned period of time.

Intravasation the process whereby a cancer cell enters a blood vessel or lymphatic vessel.

Invasion spread of tumor cells into surrounding tissue.

Kinase an enzyme that transfers phosphate groups to a protein at serine, threonine, or tyrosine amino acids.

Knock-out mice mice in which both alleles of a gene have been inactivated experimentally. These mice are often used to study gene function.

Lead compound a compound identifi ed during the development of a drug that shows a desired activity, for example, kinase inhibition.

Leucine zipper a protein domain that mediates dimer formation and is normally adjacent to a basic DNA-binding domain. It is characterized by a pattern of fi ve leucine residues each separated by six residues.

Leukemia a type of cancer characterized by the overproduction of white blood cells or their precursors in the blood or bone marrow.

Ligand an agent that binds to a receptor. A specifi c hormone is a ligand for its corresponding hormone receptor.

Linear energy transfer (LET) rate of energy loss to the surrounding medium, in a radiation track (unit: keV/μm).

Loss of heterozygosity loss of the second allele of a gene.

Lymphoma a solid tumor of T or B lymphocytes in the lymph nodes, thymus, or spleen.

M phase the phase of the cell cycle whereby the cell divides to produce two daughter cells and includes mitosis and cytokinesis.

Malignant characteristic of a tumor that is capable of invading surrounding tissue and of metastasizing to secondary locations.





332

G L O S S A RY

MAP kinases mitogen-activated enzymes that phosphorylate serine and threonine residues on proteins. Also known as extracellular signal-related kinases (ERKs).

Metastasis the process of cancer cells spreading from a primary site to secondary sites in the body.

Metastasis suppressor genes genes that inhibit metastasis but do not affect the growth of the primary tumor.

Microarray (DNA) is a grid of known DNA samples attached to a solid support and probed with cDNA or genomic DNA. It can be used to

monitor gene expression of thousands of genes simultaneously.

MicroRNAs (miRNAs) small non-coding RNAs of 18–25 nucleotides in length that can post-transcriptionally regulate sets of genes. Specifi city of miRNAs is based on Watson–Crick complementarities with the 3′

untranslated region of target mRNAs.

Missense mutation a type of mutation that converts one codon to another, specifying a different amino acid.

Mitogen a substance that can cause cells to divide (i.e. undergo mitosis).

Mitosis the division of the nucleus that occurs in somatic cells. The process maintains a complete set of chromosomes (2 n) for each of the two daughter cells.

Morphology the study of form and structure of organisms.

Mutagen a chemical or form of energy that can cause a mutation.

Mutation a heritable change in the bases of DNA, which may include transitions, transversions, deletions, insertions, or translocations.

Nanotechnology the study of devices (or their essential components) that are made by humans and have at least one dimension in the 1–1000 nm range. For scale, the size range is similar to the size of a few atoms to the size of subcellular structures.

Necrosis a type of cell death characterized by membrane disruption and the release of lytic enzymes. This “sloppy” way of dying contrasts with cell death by apoptosis.

Non-genotoxic carcinogen a substance that causes cancer without damaging DNA.

Nonsense mutation a type of mutation that converts a codon that specifi es an amino acid to one of the “stop” codons, thus signaling termination of translation and the formation of an incomplete polypeptide.

Nude mice immunodefi cient mice (usually hairless) that have no cell-mediated immunity because of the absence of the thymus gland. They

can be used experimentally to grow human tumors.





G L O S S A RY 333

Nutrigenetics the study of the effects of genetic variation on responses to dietary components.

Nutrigenomics the study of the effects of nutrients on gene expression.

Oncogene a gene whose product is capable of transforming a normal cell into a cancer cell. Oncogenes result from the mutation of normal genes (proto-oncogenes).

Oncogene addiction is the dependence of a cancer cell on a specifi c oncogene for its maintenance.

Oncomir a microRNA (miRNA) that can function as an oncogene. Amplifi cation or overexpression of miRNAs that downregulate tumor

suppressor mRNAs are oncogenic.

Ontogeny the development of an individual.

Phagocytosis the process whereby particles or cells are engulfed by cells, such as macrophages. Cells that undergo apoptosis are consumed by

phagocytosis.

Pharmacogenomics the study of the infl uence of the genome on an individual’s response to a drug. Gene variability may lead to differences in drug response among individuals.

Phenotype the observable characteristics of a cell or organism.

Phosphorylation the addition of a phosphate group PO3–

4 to a biomolec-

ule. Phosphorylation may cause conformational changes in proteins or activate particular enzymes.

Polymorphism the occurrence of two or more alleles for a given locus in a population where at least two alleles appear with frequencies of more than 1%. In simple terms: too common to be due merely to new mutation.

Polyp a tumor that projects from an epithelial surface (e.g. polyps of the colon).

Pre-clinical study a study to test a drug or medical treatment in animals and to gather data regarding safety and effi cacy for proof of concept.

Pre-clinical studies are required before clinical trials.

Pre-metastatic niche is the site of future metastasis. Signals from the primary tumor direct the migration of bone marrow cells to these sites where they are involved in altering the local microenvironment before arrival of the tumor cells.

Prognosis a forecast or future outlook for a disease.

Promoter the regulatory region of a gene that initiates transcription; usually DNA sequences located 5′ to the coding sequences but which may be located in other regions such as introns and 3′ sequences.

Protease an enzyme that degrades proteins.





334

G L O S S A RY

Proteasome a complex of proteases in the cytoplasm that degrades proteins marked by covalent modifi cation with ubiquitin.

Proteolysis enzymatic protein degradation involving cleavage of peptide bonds.

Proto-oncogene a normal cellular counterpart of a mutated gene that can cause tumors.

Purine the nitrogenous bases, adenine and guanine, found in DNA.

Pyrimidine the nitrogenous bases, cytosine, thymine, and uracil, found in DNA or RNA.

Radiolysis the use of ionizing radiation to produce chemical reactions.

Reactive oxygen species (ROS) in this book used to classify reactive intermediates of oxygen (e.g. hydroxyl radicals, hydrogen peroxide, and

superoxide radical) although broader defi nitions exist.

Receptor a transmembrane, cytoplasmic, or nuclear molecule that binds to a specifi c factor, such as a growth factor or hormone.

Recessive an allele that is expressed only when present in the homozygous or hemizygous state (i.e. two such alleles must be present).

Relapse reappearance of a disease.

Remission reduction in the severity of cancer as a result of treatment.

Response element a short sequence of DNA within a gene promoter that is recognized by a specifi c protein and contributes to the regulation of the gene.

Retinoblastoma cancer of the retinal cells of the eye. A germline mutation in the retinoblastoma ( Rb) gene is found in familial cases.

S phase the phase of the cell cycle in which DNA synthesis occurs.

Sarcoma a malignant tumor of the mesenchyme, for example, bone cancer.

Self-renewal the process whereby a stem cell (or progenitor cell) gives rise to a daughter cell with equivalent developmental potential. For example, a stem cell divides to give rise to two daughter cells: another stem cell and perhaps another more differentiated cell.

Senescence irreversible cell cycle arrest.

Signal transduction the transfer of information along a pathway of a cell that converts a signal received from the outside of the cell to the inside, to generate a cell response.

Single nucleotide polymorphism (SNP) a single base change in DNA that differs from the usual base at that position. Some cause disease and others are normal variation in the DNA sequence.

Somatic cell all cells other than egg or sperm cells. Mutations in somatic cells cannot be passed on to the next generation.





G L O S S A RY 335

Sporadic cancer is non-hereditary cancer. It arises in the absence of germline mutations that predispose individuals to an increased risk of developing a specifi c cancer.

Stem cell a cell that can self-renew and give rise to more differentiated cell types.

Supplements extra sources of dietary components taken in addition to food.

Telomerase an enzyme that extends telomere length. Elevated levels are observed in many cancer cells.

Telomere repeated DNA sequences and associated proteins that are located at the ends of chromosomes. The structures shorten upon each round of cell replication.

Therapeutic index the difference between the minimum effective dose and the maximum tolerated dose of a drug. The larger the value, the safer the drug.

Transcription the process of transferring the information encoded by DNA into RNA; also refers to the process that occurs when a gene is expressed.

Transfection the transfer of exogenous DNA into cells by experimental procedures such as microinjection or electroporation.

Transformation the changes that occur as a normal cell converts into a cancer cell.

Transgenic mice mice that carry foreign DNA, experimentally introduced, in every cell of their bodies.

Transition a DNA mutation whereby a purine (A or G) is exchanged for another purine (G or A) or a pyrimidine (C or T) is exchanged for

another pyrimidine (T or C).

Translation the process of transferring the information encoded by RNA into protein using the genetic code.

Translocation a DNA mutation whereby the part of one chromosome is transferred to, or exchanged for, another part of a different chromosome.

Transversion a mutation whereby a purine is exchanged for pyrimidine, or vice versa.

Tumor an abnormal growth of cells that can be either benign or malignant.

Tumor suppressor gene a gene whose product performs functions that inhibit tumor formation and therefore loss or mutation of (usually both copies of) these genes leads to tumor formation; also, a gene in which a germline mutation predisposes individuals to cancer.





336

G L O S S A RY

Ubiquitin a small polypeptide (76 amino acids) that is covalently attached to proteins at lysine residues as a marker for protein degradation (proteolysis) by proteosomes.

Upstream refers to DNA sequences that are nearer 5′ as a point of reference. Note that, by convention, a DNA sequence is read from the 5′ end to the 3′ end.

Warburg effect an observation originally made by Otto Warburg that tumor cells utilize glycolysis for glucose metabolism even in the presence of oxygen (aerobic glycolysis).

Wavelength a characteristic of a wave. It is the distance in meters between successive points of equal phase in a wave. For example: the distance between successive peaks.

Xenobiotics substances foreign to living systems.

Xenograft the transfer of tissue from one species to another. A common xenograft model used in cancer research is the transfer of human tumor cells into immunodefi cient mice.





■ INDEX

A

molecular mechanisms 150–9

Bim 155

NFκB 241

bioinformatics 311–13

ABC transporters 189

p53 130, 135, 158–9

biomarkers 294–5, 308

ABT-263 (navitoclax)167

regulating cell numbers 6–7

Bmi-1 185–6

ABT-737 167

therapeutic target 165–8

bone marrow stem cells 242–3

ABX-EGF (Panitumumab; Vectibix) 97

apoptosis-inducing factor (AIF) 163

brain cancer stem cells 176

acetaldehyde 259

apoptosis stimulating proteins of p53

BRCA1 40, 47–8, 64, 124, 125–6, 273–4

acute myeloid leukemia 185, 186–7

(ASPP) 136

BRCA2 40, 47–8, 124, 125–6, 273

acute promyelocytic leukemia 64, 187–8,

apoptosome 156

breast cancer

192–3

Aranesp™ 315

hormones 271–4

adaptor proteins 151–2

Arimidex™ (anastrasole) 277

prognostication 310

adenocarcinomas 2

Aromasin™ (exemestane) 277

protective role of pregnancy 177

adenoviruses 142–3

aromatase inhibitors 277–8

stem cells 176–7

Advexin™ (p53 tumor suppressor

aromatic amines 33

vaccine 305

therapy) 142

asbestos 35, 237

Brugge, J. 87–8

afl atoxin 256–7, 261

aspirin 246–7

Burkitt’s lymphoma 231

Akt 85

AT-101 167

albinos 269

ataxia telangiectasia 40

C

alcohol intake 11–12, 259

ATM 133

alkylating agents 35, 42

atomic bomb survivors 29

c-abl 91–2

all-trans retinoic acid (ATRA) 192–3

ATP-binding cassette (ABC)

C/EBPα 187

AML1 187

transporters 189

c-Flip 152

AMP-activated protein kinase

ATR 133

c-fos 93

(AMPK) 266–7

Aurora kinases 114

c-jun 93

anastrozole (Arimidex TM) 277

cancer 116–17

c-myc 93

aneuploidy 116

inhibitors 118

cachexia 314

angiogenesis 135–6, 206–12

autophagy 163

cadherins 199–200

anti-angiogenic therapy 214–17

Avastin™ (bevacizumab) 215

CagA 235–6

angiopoietins 208

azacitidine 71

calpains 163

angiostatin 210

cancer

animal models 285–6

B

defi nition 2

anti-angiogenic therapy 214–17

disease of genome at cellular level 5–9

anti-EGFR drugs 95–7

B cells 226–7

genomics 17–18

anti-estrogens 276–8

B-Raf 91

hallmarks 2–4

antimetabolites 43–4

bacterial carcinogens 36–7, 235–7

statistics 1

anti-oncogenes 126

basal cell carcinomas 182

treatment of symptoms 314–15

antioxidant response element (ARE) 262–3

base excision repair 38–9

cancer research

antioxidants 129–30, 253–4, 262

base substitutions 23

careers in 295–6

AP-1 transcription factor 55, 57, 83–4, 93

basement membranes 197

centers 323–6

Apaf-1 156, 163

BATTLE trial 294

cancer therapies

APC 124

Bax 155

apoptosis-targeted 165–8

apoptosis 149–71

Bcl-2 family 154–5, 162, 164–5

cell cycle 117–18

cancer 160–4

inhibitors 166–7

differentiation therapies 192–3

chemotherapy 164–5

BCR–ABL 92

DNA-targeted 42–8

cross-talk between intrinsic and extrinsic

“beads on a string” array 59

energy pathway targeting 276

pathways 157–8

benign tumor 4

estrogen-targeted 276–8

described 149

bevacizumab (Avastin TM) 215

future therapies 315–17

extrinsic pathway 151–3

BH3-only proteins 154–5

gene expression 70–3

intrinsic pathway 154–7

Bid 155, 157–8

growth factor signaling 95–100





338

I N D E X

cancer therapies ( Continued)

circulating tumor cells 310

prevention of cancer 259–65

infection-targeted 243–6

cisplatin 42–3

provisions of food 253–4

infl ammation inhibition 246–7

clinical trials 15, 292–5

reprogramming energy metabolism

metastasis-targeted 212–20

colon cancer stem cells 176

265–8

molecular targets 16–18, 284–5

colony-stimulating factor 1 (CSF1) 203

supplements for chemoprevention

p53 pathway 141–5

colorectal cancer

274–6

principles 13–14

infl ammatory bowel disease 237

differentiation 6–7, 173, 174

stem cell-targeted 189–93

nutrigenetics 268–9

stem cells and cancer 174–84

carboplatin 42, 43

Wnt pathway 179–80

transcription regulation 184–8

carcinogens 25–37

combretastatin 218

differentiation therapies 192–3

carcinomas 2

concomitant resistance 210

diffuse large B-cell lymphoma 308

CARD domains 156

contact inhibition 5

dimerization domain 54

careers in cancer research 295–6

continuum model of tumor suppression 139

DNA-binding domains 53–4

β-carotene supplements 254

cooking meat 33, 256

DNA methylation 61–3

casein kinase II 133

correlative evidence 9

cancer 64–6

caspases 150–1, 152, 153, 160–1

COX-2 inhibitors 247

inhibitors 71

activators 165–6

CpG islands 62

DNA methyltransferases (DNMTs)

caspase-8 152, 161–2

CSF1 203

62–3, 65

caspase-9 156

Curl, R. 314

DNA mutations 5–6, 23–5

β-catenin 178

cyclin–cdk complexes 105–6, 111

DNA repair 38–41, 135–6

catenins 199

cyclin D 105, 111, 115–16

DNA replication 68

cathepsins 163

cyclin-dependent kinases (cdks) 104–6

DNA structure and stability 21–51

CDB3 144

cancer 115

DNA tumor viruses 36

Cdc25 tyrosine phosphatases 112

inhibitors 117–18

DNase footprinting 55

cDNA arrays 307

regulation 107–9

domain swap experiments 58

celecoxib (Celebrex™) 247

cyclin E 111

dominant negative mutation 94

cell adhesion molecules (CAMs) 199–200

cyclins 104–6

doxorubicin 44–5

cell cycle 103–12, 321

cancer 115–16

DPC4 124

cancer 114–17

cyclo-oxygenase (COX) activity 246–7

driver mutations 24

check points 105

cyclopamine 191–2

drug development

p53 130, 134

cyclophosphamide 42

imatinib (Gleevec™) 287–8, 289

stages 103

cytochrome c 156

strategies 283–7

therapeutic target 117–18

cytochrome P450 enzymes 31–2

drug resistance 46–7, 164–5, 189

cell number regulation 6–7

cytokines 227

drug screening 286–7

cellular senescence 67

cytotoxin-associated antigen A

Druker, B. 289

Cervarix™ (a HPV bivalent vaccine) 245

(CagA) 235–6

cervical cancer 141, 232

E

screening 245–6

D

vaccines 245–6

E-Cadherin 125

cetuximab (Erbitux™) 97, 291

dasatinib 289

E2F transcription factor 109–11

chemical carcinogens 31–6

DD3PCA3 309

EGF receptor (EGFR; ErbB1 or HER1) 78

chemokines 238–9

death inducing signaling complex

electromagnetic spectrum 25–6

chemoprevention 274–6

(DISC) 152

electrophoretic mobility shift assays

chemotherapy 13–14

death receptors 151–3, 161

(EMSAs) 55

apoptosis 164–5

decitabine 71

end-joining 40

classical therapies 42–5

dendritic cell vaccines 303–4

endogenous carcinogenic reactions 37

drug resistance 46–7, 164–5, 189

dendritic cells 301

endostatin 210, 217

side effects 13, 315

diagnostics 308–9

energy metabolism, reprogramming 265–8

Chk2 133

diet 11, 253–71

“enhanced” foods 274–6

chlorambucil 42

antioxidants 253–4

enhancer elements 22

chromatin 59–60

cause of cancer 255–9

entinostat 72

chromothripsis 21, 24

defi ciencies 257

environmental exposures 10

chronic myeloid leukemia 98–100, 182

“enhanced” foods 274–6

EP300 64

cilengitide 217

fruit and vegetables 254, 259–65

epidermal growth factor (EGF)

Cip/Kip family 108

gene expression 262–4

signaling 77–86

circulating endothelial progenitor cells

genetic polymorphisms 268–9

inhibitors 95–7

(CEPs) 212

microconstituents 253–5, 259–65

epigallocatechin-3-gallate 264





I N D E X

339

epigenetics

gastric cancer 235–6, 242–3, 244–5

histonomic drugs 70–2

carcinogenesis 63–6

GDC-0449 192

homologous recombination 40

transcription regulation 60–3

gefi tinib (Iressa™) 96, 291

hormones 271–4

epigenomic drugs 70–2

gel/band shift assays 55

human papillomavirus (HPV) 36, 141, 232

epithelial–mesenchymal transition 201–3

Genasense™ (oblimersin) 166–7

HPV DNA screening 246

Epstein–Barr virus 36, 231–2

gene amplifi cation 23

human T-lymphotropic virus type-1

ErbB1(HER1) 78

gene expression 22, 53–75

(HTLV-1) 36, 232–3

ErbB2 (HER2) 95–6

diet 262–4

Hunt, T. 106–7

Erbitux™ (cetuximab) 97, 291

profi ling 306–8, 310

hypoxia-inducible factor-1α (HIF-1α)

erionite 35–6

therapeutic target 70–3

210–11, 267

erlotinib (Tarceva TM) 96

gene signatures 220

esophageal refl ux 237

gene structure 22–3

I

estrogen receptor protein 64

gene therapy 141–2, 219

estrogens 271–4

Genedicine™ (p53 gene therapy) 142

imaging 310–11

therapeutic target 276–8

genetic polymorphisms 268–9

imatinib (Gleevec) 98–100, 287–8, 289

evidence, types of 9

germline mutation 6

Imetelstat (telomerase inhibitor) 73

exemestane (AromasinTM) 277

Gleevec™ (Glivec™; imatinib) 98–100,

immune system 225, 226–30

extracellular signal-regulated kinases

287–8, 289

immunoediting 228–9, 230

(ERKs) 83

glucose uptake 265

immunoprecipitation 159

extravasation 204

glycolysis 265

immunosurveillance 228

glycoprotein 100 (gp100) 302–3

in vivo mouse models 285

F

Gorlin’s syndrome 182

indolamine-2,3-dioxygenase (IDO) 229–30

grays 26

inducible nitric oxide synthase 238

familial adenomatous polyposis 179, 247

green tea 264

infectious agents 36–7, 225–6, 230–7

Fas 161

growth 6–7

therapeutic target 243–6

Femara™ (letrozole) 277

growth factors

infl ammation 225–6, 237–43

FHIT 124

angiogenesis 208

inhibitors 246–7

fi ber in diet 265

signaling 77–86

infl ammatory bowel disease 237

fi rst-pass organ 203

therapeutic target 95–100

inherited metabolic disease 269

fl avopiridol 117–18

GX15-070 167

inhibitors of apoptosis proteins (IAPs) 156

fl uorescent in situ hybridization (FISH) 115

INK family 108

fl uorodeoxyuridylate (F-dUMP) 43–4

H

INK4a 124

5-fl uorouracil (5-FU) 43

integrins 200–1

focal adhesion kinase (FAK) 200

H101 143

inhibitors 217

folate defi ciency 257

haploinsuffi ciency 8–9

interleukin-6 238

Folkman, J. 207

Hartwell, L. 106–7

interleukin-10 229

food

Hedgehog signaling pathway 180–2

International Cancer Genome Consortium

contamination 256–7

inhibitors 191–2

(ICGC) 17

“enhanced” foods 274–6

Helicobacter pylori 36–7, 235–6, 243, 244–5

intravasation 203

provisions of 253–4

helix-turn-helix 53–4

ionizing radiation 27–9

see also diet

hepatitis B vaccination 244

Iressa™ (gefi tinib) 96, 291

fos 84

hepatitis B virus 36, 233–4

ispinesib (a kinesin spindle protein

frameshift mutation 23

hepatocellular carcinoma 233–4

inhibitor) 119

free radical 28

HER1–4 (EGFR1-4) 78

fruit and vegetables 254, 259–65

Herceptin™ (trastuzumab) 97, 217

J

hereditary non-polyposis colorectal cancer

G

(HNPCC) 39

JNK 83

heterocyclic amines 33

jun 84

G-3139 166–7

hexokinase inhibitors 276

G proteins 16

HhAntag-691 192

K

G quadruplexes 67

high-throughput screening 286

G0 105

histone acetyltransferases (HATs) 61, 64

Kaposi’s sarcoma 234

G1 checkpoint 105, 109–11

histone core 59–60

Kaposi’s sarcoma-associated herpesvirus

G2 checkpoint 105, 111–12, 116

histone deacetylases (HDACs) 61, 64,

(KSHV) 36, 234

gain-of-function evidence 9

109–11

KEAP1 263–4

Gardasil™ (HPV quadrivalent vaccine) 245

inhibitors 72

kinases 16

garlic 264

histone modifi cation 61, 64

inhibitors 95–100





340

I N D E X

Kinesin spindle protein (KSP) 119

process 198–9

Nurse, P. 106–7

kinome 17

therapeutic target 212–20

nutlins 144

Knudson’s two-hit hypothesis 8, 123

transport 203–4

nutrients, see diet

Korsmeyer, S. 157

vasculogenesis 212

nutrigenetics 268–9

Kroto, H. 314

vasculogenic mimicry 212

metastasis suppressor genes 205–6

O

L

metformin 276

methotrexate 44

obesity 258–9

Lane, D. 140

methylation-specifi c PCR 65

oblimersen sodium (Genasense TM) 166–7

lapatinib (Tyverb TM) 96

microarrays 306–8, 309

olaparib (a PARP inhibitor) 48

letrozole (Femara TM) 277

microconstituents 253–5, 259–65

oligonucleotide microarrays 307

leukemia

micrometastases 205

oltipraz 275

acute myeloid 185, 186–7

microRNAs (miRNAs) 69–70, 206, 310

oncogenes 7, 86–95

acute promyelocytic 64, 187–8, 192–3

mismatch repair 39

angiogenesis 211–12

chronic myeloid 98–100, 182

mitochondria 154–7

infl ammation 237

T-cell 232–3

mitogen-activated protein kinases

oncomirs 70

Li-Fraumeni syndrome 138

(MAPKs) 83

Oncotype DX™ 310

life expectancy 5

mitosis, stages 112–13

one-step repair 38

lifestyle 10–12

mitotic catastrophe 163

Onyx 015 virus 142–3

ligand-binding domain 54

mitotic checkpoint 112–14, 116

organ cultures 285

lineage-specifi c transcription factors 186–8

mitotic spindle inhibitors 118–19

organic drugs 44–5

linear energy transfer 26

MKK4 205

organotypic cultures 285

lipid peroxidation 37

MLH1 125

oxidative respiration 37

liver cancer 233–4

molds 256

LKB1 125

molecular endpoints 294

P

LMP1 231–2

molecular targets 16–18, 284–5

loss-of-function evidence 9

mouse models 286

P-glycoprotein (P-gp) 47

Lowy, D. 246

mRNA regulation 69–70

p14arf 133

lung cancer diagnosis 309

MSH2/6 125

p16ink4a family 108, 116

multiple endocrine neoplasia 2A/B

p21 108, 134, 136

M

(MEN2A/B) 90

p38 83

mustard gas 35

p53 16–17, 31, 124, 137–9

M checkpoint 105

mutations 5–6, 23–5

p53 protein 16–17, 129–36

macrophages 203

mutator phenotype 25

AMPK activation 267

malignant tumor 4

Myc family 84

angiogenesis 135–6, 212

Mammaprint™ 310

antioxidant activity 129–30

MAP kinase cascade 83

N

apoptosis 130, 135, 158–9

markers 176

cancer 137–9, 162

matrix metalloproteinases (MMPs) 201

nanotechnology 219, 313–14

cell cycle arrest 130, 134

Max 84

nasopharyngeal carcinoma 231

continuum model of tumor

MDM2 132

necrosis 149

suppression 139

medroxyprogesterone acetate (MPA) 214

Neulasta™ 315

decision making 136

medulloblastoma 182

Nexavar™ (sorafenib) 97–8, 217

DNA repair 40–1, 135–6

MEK inhibitors 98

NF1/2 124

downstream effects 130, 133–6

melanoma vaccine 302–3

NFκB 156, 238, 239–42

drug resistance 164

metabolic by-products 13

inhibitors 247

MDM2 regulation 132

metalloproteinase inhibitors (MPIs) 213–14

nilotinib (TasignaTM) 289

side-effects of therapy 145

metastasis 197–24

nitrosamides 34

skin cancer 31

angiogenesis 206–12

nitrosamines 34

structure 131

cell invasion 199–203

NKX3.1 124

therapeutic target 141–5

extravasation 204

NM23 205

upstream activators 130, 132–3

fi rst-pass organ 203

non-homologous end-joining 40

viral protein interaction 139–41

gene signatures 220

non-steroidal anti-infl ammatory drugs

paclitaxel 45, 118

intravasation 203

(NSAIDs) 246–7

pancreatic cancer stem cells 176–7

metastatic colonization 205–6

Nrf2 263–4

panitumumab (Vectibix TM) 97

micrometastases 205

nucleotide 22

Pap smear test 245–6

pre-metastatic niche 206

nucleotide excision repair 38

passenger mutations 24





I N D E X

341

passive immunization 300

ras 90–1

sprouting 206–7

Patched 180–1

Ras family 16

SRC 85–6, 91

Patched 182

RAS proteins 82

stem cells 173–4

personalized medicine 311–13

RB1 124

cancer 9, 174–84, 242–3

Pfeifer, G. 33–4

RB protein 109–10, 128–9, 139–41, 153

Hedgehog signaling pathway 180–2

pharmacogenomics 290–2

reactive nitrogen species 237

markers 176

Phase 0 trials 292

reactive oxygen species (ROS) 27–8, 37,

polycomb proteins 184–6

Phase I trials 15

129–30, 237

self-renewal 174, 175–7

Phase II trials 15

recombination repair 40–1

therapeutic target 189–93

Phase III trials 15

red meat 269

Wnt signaling pathway 177–80

Phase IV trials 292

replication-competent adenoviruses

steroid hormone receptors 57–8

Philadelphia chromosome 98

142–3

suberoylanilide hydroxamic acid (SAHA;

phosphatases 16

reproductive life 10

vorinostat) 72, 167

phosphatidylinositol 3-kinase (PI3K) 84

response element 22

sulforophane 263–4

phosphorylation 16

ret 90

sunitinib (Sutent TM) 217

phytochemicals 253–4

retinoblastoma gene ( Rb) 17, 127–9

symptom treatment 314–15

pifi thrin-α 145

retinoblastoma protein (RB) 109–10,

synthetic lethal strategies 47–8

platelet-derived growth factor (PDGF) 89

128–9, 139–41, 153

platinum-based drugs 42–3

retinoic acid receptors (RARs) 58–9, 187

T

PML–RAR 64, 65, 187–8

retinoid therapy 192–3

PMS1/2 125

retroviruses 36, 87–9, 141–2

T-cell leukemia 232–3

poly (ADP-ribose) polymerase (PARP)

reverse transcriptases 67

T cells 227

inhibitors 47–8

rickets 270

Tabin, C. 181–2

polycomb (PcG) proteins 184–6

RNA tumor viruses 36; see also

tamoxifen 276, 278

polycyclic aromatic hydrocarbons 32

retroviruses

Tarceva™ (erlotinib) 96

positron emission tomography 265–6

romidepsin (Istodax TM) 72

target validation 284–5

power 293

Rosenberg, S. A. 303

TATA box 22

PRC2 185

Rous Sarcoma Virus 87

taxol 45, 118

pre-clinical studies 283

telomerase 66–9

pre-metastatic niche 206

S

inhibitors 72–3

PRIMA-1 144

telomeres 66–9

procaspase-9 156

salmon 256

teratocarcinoma 183

prognostics 310

Salmonella enterica serovar Typhi 37

thalidomide 217

promoter region 22

sample size calculation 293

therapeutic index 13

prostate cancer

sarcomas 2

thiopurine methyltransferase 292

diagnosis 308–9

Schiller, J. 246

third-generation tyrosine kinase

vaccine 304

second-generation inhibitors 289

inhibitors 290

prostate-specifi c antigen (PSA) 308–9

seed and soil theory 197

tobacco smoke 32, 237

proteases 201

selectins 204

TPMT defi ciency 292

protein kinases 16

semaxanib (SU5416) 215–17

TRAIL 161, 167–8

proto-oncogenes 7, 88

Ser567 129

transactivation domains 54

Provenge™ (sipuleucel-T) 304

serine proteases 201

transcription factors 53–9

PTC 124

side-population cells 189

lineage-specifi c 186–8

PTEN 124, 126

sieverts 27

transcription regulation

PTEN deletion 189

single nucleotide polymorphisms 17–18

differentiation 184–8

PTPN1 126

skin cancer, UV exposure 30–1

epigenetics 60–3

PU.1 187

skin carcinogenesis 175

transcription factors 53–9

PUMA 158, 159

Smac/DIABLO 156, 157

transforming growth factor β 229

small interfering RNAs (siRNAs) 18

transgenic mice 96

R

Smalley, R. E. 314

trastuzumab (Herceptin™) 97, 217

smoked foods 34

TSC2 124

radiation 25–30

smoking 12, 32

tumor-associated macrophages

radiation therapy 45–6

Smoothened 180–1

(TAMs) 238

Raf 83, 285

Smoothened 182

tumor necrosis factor-α 237, 238

inhibitors 97–8

sodium bisulfate treatment 65

tumor suppressor genes 7–9, 123–7,

randomized discontinuation trial

sorafenib (Nexavar TM) 97–8, 217

211–12

design 294

spindle assembly checkpoint 112–14, 116

TUNEL technique 152–3





342

I N D E X

Twist 202

prostate cancer 304

Vitaxin™ 217

Tykerb™ (lapatinib) 96

therapeutic vaccines 300–4

von Hippel–Landau (VHL) tumor

Type I and Type II error 293

whole-cell vaccine 302

suppressor protein 210, 211

tyrosinemia type I 269

Varmus, H. 88

vorinostat (SAHA) 72, 167

vascular endothelial growth factors

U

(VEGFs) 208–9

W

inhibitors 215–17

ubiquitination 107–8, 178

vascular targeting 218–19

Warburg effect 265–8

ultraviolet radiation 29–30

vasculogenesis 212

Wnt signaling pathway 177–80

vasculogenic mimicry 212

inhibitors 190–1

V

Vectibix™ (panitumumab) 97

Wt1 124

VEGF receptors 208

v-erbA 93–4

inhibitors 215–17

X

v-erbB 89

vemurafenib (Zelboraf TM) 98

v-sis 89

VHL 124

xenografts 286

v-src 87–8

Vidaza™ (azacitidine) 71

xeroderma pigmentosum 38

VacA 236

vinblastine 45, 118

XIAP 156, 163, 166

vaccination 300–6

vincristine 45, 118

breast cancer 305

Vioxx (rofecoxib) 247

Z

cervical cancer 245–6

viral carcinogens 36, 139–41, 231–4

dendritic cell vaccines 303–4

virtual screening 286–7

ZD1839 (Iressa™; gefi tinib) 96, 291

hepatitis B 244

vismodegib (Erivedge TM; GDC0449) 192

ZD6126 218

melanoma 302–3

vitamin C 262

Zelboraf™ (vemurafenib) 98

peptide-based vaccines 302–3

vitamin D 269–71

zinc fi nger 54

prophylactic vaccines 304–5

vitamin E 262, 275

Zolinza™ (SAHA;vorinostat) 72, 167

UPLOADED BY [STORMRG]





Plate 1 Evidence of chromothripsis. The use of fi sh probes marking normal chromosome location labeled with different color dyes (as in (a)) demonstrated massive remodeling of chromosomes (b, derivative chromosome 5). See details in “How do we know that?” on page 24. Reprinted from Stephens, P.J. et al. (2011) Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144: 27–40, Copyright (2011), with permission from Elsevier.

Plate 2 Phosphorylation of EGFR after EGF treatment detected by Phospho-EGF Receptor (Tyr992) Antibody (no. 2235; green). A human epithelial carcinoma cell line was analyzed by confocal immunofl uorescence microscopy. (a) Untreated cells. (b) EGF-treated cells. DNA was stained with a blue fl uorescent dye. Courtesy of Cell Signaling Technology, MA, USA (http://www.cellsignal.com). See Chapter 4.





Plate 3 Cells in the four stages of mitosis: (a)

prophase, (b) metaphase, (c) anaphase, (d)

telophase (all magnifi ed about 2700 times).

DNA (blue); microtubules (red). Coutesy of

Donald A. Levin, University of Texas. See

Chapter 5.

Plate 4 Fluorescent in situ hybridization (FISH) analysis used to detect amplifi cation of the cyclin D1 gene. A tissue section of

non-melanoma skin cancer analyzed by FISH. Directly labeled

DNA probes were used to detect copies of the cyclin D gene

(red) in relation to the number of centromeric regions of

chromosome 11 (green). Described in Section 5.6. (Reprinted

from Figure 1A in Utikal, J., Udart, M., Leiter, U., Kaskel, P.,

Peter, R.U., and Krahn, G. (2005) Numerical abnormalities of

the Cyclin D1 gene locus on chromosome 11q13 in non-

melanoma skin cancer. Cancer Lett. 219: 197–204. Copyright (2005), with permission from Elsevier.) See Chapter 5.

Plate 5 TUNEL staining. The induction of apoptosis in a human neuroblastoma cell line was analyzed by TUNEL staining

(described in the text). Control (a) and induced (b) cells.

Apoptotic cells (red) are detected using an alkaline

phosphataseconjugated anti-fl uorescein antibody. (Reprinted

from Lui, X.-H., Yu, E.Z., Li, Y.-Y., Rollwagen, F.M., and

Kagan, E. (2006) RNA interference targeting Akt promotes

apoptosis in hypoxia-exposed human neuroblastoma cells.

Brain Research 1070: 24–30, Figure 1. Copyright (2006), with permission from Elsevier.) See Chapter 7.





(a)

(b)

villus

crypt

Small intestine

Adenoma in small intestine

Plate 6 Comparison of normal epithelium and adenomas in the small intestine of a mouse. (a) Normal epithelial in the small intestine. Proliferative cells are stained for a cell cycle marker (brown nuclei). (b) An adenoma residing inside the villus in mouse small intestine. Tissue was stained for β-catenin (brown). An accumulation of β-catenin is seen throughout cells in the adenoma and aberrant crypt. (From Radtke, F. and Clevers, H. (2005) Self-renewal and cancer of the gut: two sides of a coin. Science 307: 1904–1909. Reprinted with permission from the AAAS.) See Chapter 8.

Plate 7 Evidence of the premetastatic niche. See Chapter 9, “The pre-metastatic niche,” page 206. Top row: immunohistochemistry to examine the arrival of bone-marrow derived cells (green) and tumor cells (red). Bottom row: a schematic representation of the data shown in the top row. Reproduced from Kaplan, R.N., et al. (2006) Preparing the soil: The premetastatic niche. Cancer Res. 66: 11089–11093, with permission from the American Association for Cancer Research.





Plate 8 Molecular modeling of the binding of the drug

Gleevec™ to its target Abl.

Plate 9 A sample microarray. See Chapter 13, Section 13.2.

Plate 10 A representative heat map. This is a microarray data display format that uses color to represent levels of gene expression. Genes are arranged in rows and time points are arranged in columns. A red box is used to indicate an increase in expression relative to a control; a green box is used to indicate a decrease in expression relative to a control; and a black box represents no change. See Chapter 13, Section 13.2.

Plate 11 A positron-emission tomography (PET) image. Picture courtesy of Siemens Medical Solutions. See Chapters 11 and 13.





Document Outline


Cover

CONTENTS

1 Introduction 1.1 What is cancer?

1.2 Evidence suggests that cancer is a disease of the genome at the cellular level

1.3 Influential factors in human carcinogenesis

1.4 Principles of conventional cancer therapies

1.5 Clinical trials

1.6 The role of molecular targets in cancer therapies





2 DNA structure and stability: mutations versus repair 2.1 Gene structure—two parts of a gene: the regulatory region and the coding region

2.2 Mutations

2.3 Carcinogenic agents

2.4 DNA repair and predispositions to cancer

Therapeutic strategies

2.5 Conventional therapies: chemotherapy and radiation therapy

2.6 Strategies that target DNA repair pathways





3 Regulation of gene expression 3.1 Transcription factors and transcriptional regulation

3.2 Chromatin structure

3.3 Epigenetic regulation of transcription

3.4 Evidence of a role for epigenetics in carcinogenesis

3.5 Telomeres and telomerase

3.6 MicroRNAs (miRNAs) and regulation of mRNA expression

Therapeutic strategies

3.7 Epigenomic and histonomic drugs

3.8 Telomerase inhibitors





4 Growth factor signaling and oncogenes 4.1 Epidermal growth factor signaling: an important paradigm

4.2 Oncogenes

Therapeutic strategies

4.3 Kinases as drug targets





5 The cell cycle 5.1 Cyclins and cyclin-dependent kinases (cdks)

5.2 Mechanisms of cdk regulation

5.3 Progression through the G[sub(1)] checkpoint

5.4 The G[sub(2)] checkpoint

5.5 The mitotic checkpoint

5.6 The cell cycle and cancer

Therapeutic strategies

5.7 Cyclin-dependent kinase inhibitors

5.8 Other cell cycle kinase targets

5.9 Inhibitors of the mitotic spindle





6 Growth inhibition and tumor suppressor genes 6.1 Definitions of tumor suppressor genes

6.2 The retinoblastoma gene

6.3 Mutations in the RB pathway and cancer

6.4 The p53 pathway

6.5 Mutations in the p53 pathway and cancer

6.6 Interaction of DNA viral protein products with RB and p53

Therapeutic strategies

6.7 Targeting of the p53 pathway





7 Apoptosis 7.1 Molecular mechanisms of apoptosis

7.2 Apoptosis and cancer

7.3 Apoptosis and chemotherapy

Therapeutic strategies

7.4 Apoptotic drugs





8 Stem cells and differentiation 8.1 Stem cells and cancer

8.2 Differentiation and the regulation of transcription

Therapeutic strategies

8.3 Inhibitors of the Wnt pathway

8.4 Inhibitors of the Hh pathway

8.5 Leukemia and differentiation therapies





9 Metastasis 9.1 The process of metastasis

9.2 Tools of cell invasion: cell adhesion molecules, integrins, and proteases

9.3 Intravasation

9.4 Transport

9.5 Extravasation

9.6 Metastatic colonization

9.7 Angiogenesis

9.8 Other means of tumor neovascularization

Therapeutic strategies

9.9 Metalloproteinase inhibitors (MPIs)

9.10 Strategies for restoring metastasis suppressors

9.11 Anti-angiogenic therapy and vascular targeting

9.12 Targeting several steps of metastasis at once





10 The immune system, infections, and inflammation 10.1 The immune system and cancer

10.2 Identifying infectious agents as carcinogens

10.3 Inflammation and cancer

Therapeutic strategies

10.4 A national vaccination program against hepatitis B virus in Taiwan

10.5 Eradication of H.pylori and the relationship to prevention of gastric cancer

10.6 Cancer vaccines to prevent cervical cancer

10.7 Inhibition of inflammation





11 Nutrients, hormones, and gene interactions 11.1 Causative factors

11.2 Preventative factors: microconstituents of fruits and vegetables

11.3 Reprogramming energy metabolism in tumor cells—an emerging hallmark of cancer

11.4 Genetic polymorphisms and diet

11.5 Vitamin D: a link between nutrients and hormone action

11.6 Hormones and cancer

Therapeutic strategies

11.7 “Enhanced” foods and dietary supplements for chemoprevention

11.8 Drugs that target energy pathways

11.9 Drugs that target estrogen





12 The cancer industry: drug development, pharmacogenomics, and clinical trial design 12.1 Strategies of drug development

12.2 Development of imatinib

12.3 Second- and third-generation therapeutics

12.4 Pharmacogenomics

12.5 Improved clinical trial design

12.6 A career in cancer research





13 Cancer in the future: focus on cancer vaccines and technology 13.1 Cancer vaccines

13.2 Microarrays and gene expression profiling

13.3 Diagnostics and prognostics

13.4 Imaging

13.5 Personalized medicine and bioinformatics

13.6 Cancer nanotechnology

13.7 Treating cancer symptoms

13.8 Are we making progress?





APPENDIX 1: CELL CYCLE REGULATION

APPENDIX 2: CENTERS FOR CANCER RESEARCH

GLOSSARY A

B

C

D

E

F

G

H

I

K

L

M

N

O

P

R

S

T

U

W

X





INDEX A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

R

S

T

U

V

W

X

Z





